[
  {
    "title": "3 Top ETFs I'm Planning to Buy Hand Over Fist in 2024, Despite All the Cheap Stocks on My Radar",
    "url": "https://www.fool.com/investing/2024/01/01/3-top-etfs-im-planning-to-buy-hand-over-fist-in-20/",
    "time_published": "20240101T111700",
    "authors": [
      "CFP\u00ae",
      "Matthew Frankel"
    ],
    "summary": "I'm adding some ETFs to my retirement portfolio in 2024. here are the three I'm starting with.",
    "banner_image": "https://g.foolcdn.com/editorial/images/759690/stock-trader-2022.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.341417,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AVGO",
        "relevance_score": "0.114682",
        "ticker_sentiment_score": "0.006707",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMT",
        "relevance_score": "0.114682",
        "ticker_sentiment_score": "0.089924",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CCI",
        "relevance_score": "0.114682",
        "ticker_sentiment_score": "0.089924",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PLD",
        "relevance_score": "0.114682",
        "ticker_sentiment_score": "0.089924",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.114682",
        "ticker_sentiment_score": "0.006707",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HD",
        "relevance_score": "0.114682",
        "ticker_sentiment_score": "0.006707",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.114682",
        "ticker_sentiment_score": "0.006707",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Futures Fall As Apple Slides On Downgrade",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-apple-stock-slides-on-downgrade-tesla-deliveries/",
    "time_published": "20240102T132100",
    "authors": [
      "SCOTT LEHTONEN",
      "Investor's Business Daily"
    ],
    "summary": "Dow Jones Futures Fall 200 Points As Apple Slides On Downgrade. Tesla Deliveries Imminent Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2021/09/Stock-wallstreetflag-01-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.083282,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CALM",
        "relevance_score": "0.077719",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.192694",
        "ticker_sentiment_score": "0.068294",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CELH",
        "relevance_score": "0.154703",
        "ticker_sentiment_score": "0.120018",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.038906",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.116348",
        "ticker_sentiment_score": "-0.07792",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNOW",
        "relevance_score": "0.154703",
        "ticker_sentiment_score": "0.120635",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.038906",
        "ticker_sentiment_score": "0.008909",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.154703",
        "ticker_sentiment_score": "0.07912",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.038906",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.077719",
        "ticker_sentiment_score": "-0.148149",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.267245",
        "ticker_sentiment_score": "-0.023886",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "V",
        "relevance_score": "0.154703",
        "ticker_sentiment_score": "0.160497",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CAT",
        "relevance_score": "0.154703",
        "ticker_sentiment_score": "0.211111",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WBA",
        "relevance_score": "0.077719",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.038906",
        "ticker_sentiment_score": "-0.079072",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen Inc.  ( AMGN )  Is a Trending Stock: Facts to Know Before Betting on It",
    "url": "https://www.zacks.com/stock/news/2204932/amgen-inc-amgn-is-a-trending-stock-facts-to-know-before-betting-on-it",
    "time_published": "20240103T140006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default101.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.623304"
      }
    ],
    "overall_sentiment_score": 0.233026,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.487546",
        "ticker_sentiment_score": "0.14691",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Futures Fall Ahead Of Fed Minutes",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-fall-ahead-of-fed-minutes-coindesk-nvidia-tesla-slide/",
    "time_published": "20240103T131100",
    "authors": [
      "Investor's Business Daily",
      "SCOTT LEHTONEN"
    ],
    "summary": "Dow Jones futures dropped Wednesday morning ahead of minutes from the Federal Reserve's latest policy meeting. Meanwhile, market leaders Coindesk ( COIN ) and Nvidia ( NVDA ) , along with Tesla stock, fell sharply in early morning trading.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2022/06/Stock-jeromepowell2022-02-gov.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.014384,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.172404",
        "ticker_sentiment_score": "0.064478",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CELH",
        "relevance_score": "0.172404",
        "ticker_sentiment_score": "0.137962",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.29689",
        "ticker_sentiment_score": "-0.065662",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.29689",
        "ticker_sentiment_score": "-0.017705",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNOW",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "0.220191",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "V",
        "relevance_score": "0.172404",
        "ticker_sentiment_score": "0.172192",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CAT",
        "relevance_score": "0.214557",
        "ticker_sentiment_score": "0.136461",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.043421",
        "ticker_sentiment_score": "-0.093008",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.043421",
        "ticker_sentiment_score": "0.010974",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.172404",
        "ticker_sentiment_score": "0.127417",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Invesco Biotechnology & Genome ETF  ( PBE )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2204768/is-invesco-biotechnology-genome-etf-pbe-a-strong-etf-right-now",
    "time_published": "20240103T112007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default111.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999994"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.279971,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.116631",
        "ticker_sentiment_score": "0.066983",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.230782",
        "ticker_sentiment_score": "0.218856",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.116631",
        "ticker_sentiment_score": "0.066983",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.116631",
        "ticker_sentiment_score": "0.066983",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should SPDR Portfolio S&P 500 High Dividend ETF  ( SPYD )  Be on Your Investing Radar?",
    "url": "https://www.zacks.com/stock/news/2204769/should-spdr-portfolio-sp-500-high-dividend-etf-spyd-be-on-your-investing-radar",
    "time_published": "20240103T112006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Style Box ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default326.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.237792,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "STT",
        "relevance_score": "0.061631",
        "ticker_sentiment_score": "0.111021",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "0.068464",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PKG",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "0.068464",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STX",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "0.068464",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why the Market Dipped But Amgen  ( AMGN )  Gained Today",
    "url": "https://www.zacks.com/stock/news/2205955/why-the-market-dipped-but-amgen-amgn-gained-today",
    "time_published": "20240104T230018",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) reachead $303.17 at the closing of the latest trading day, reflecting a +0.82% change compared to its last close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default99.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.206602,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.571903",
        "ticker_sentiment_score": "0.276725",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Here's How Much a $1000 Investment in Amgen Made 10 Years Ago Would Be Worth Today",
    "url": "https://www.zacks.com/stock/news/2205532/heres-how-much-a-1000-investment-in-amgen-made-10-years-ago-would-be-worth-today",
    "time_published": "20240104T133005",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Holding on to popular or trending stocks for the long-term can make your portfolio a winner.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default100.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      }
    ],
    "overall_sentiment_score": 0.207553,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.668028",
        "ticker_sentiment_score": "0.318064",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Antibody Therapeutics Market is Expected to Reach $479.0 Billion | MarketsandMarkets.",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36487416/antibody-therapeutics-market-is-expected-to-reach-479-0-billion-marketsandmarkets",
    "time_published": "20240104T123000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Chicago, Jan. 04, 2024 ( GLOBE NEWSWIRE ) -- Antibody Therapeutics market in terms of revenue was estimated to be worth $247.3 Billion in 2023 and is poised to reach $479.0 billion by 2028, growing at a CAGR of 14.1% from 2023 to 2028 according to a latest report published by MarketsandMarkets\u2122.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.287429,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "IMNM",
        "relevance_score": "0.039745",
        "ticker_sentiment_score": "0.095935",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.079392",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.079392",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.079392",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.158",
        "ticker_sentiment_score": "0.04959",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.079392",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.079392",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.079392",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.079392",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.079392",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen  ( AMGN )  Stock Sinks As Market Gains: What You Should Know",
    "url": "https://www.zacks.com/stock/news/2206572/amgen-amgn-stock-sinks-as-market-gains-what-you-should-know",
    "time_published": "20240105T225019",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the closing of the recent trading day, Amgen (AMGN) stood at $303, denoting a -0.06% change from the preceding trading day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default285.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.241483,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.700945",
        "ticker_sentiment_score": "0.383645",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "JPMorgan Healthcare, CES Show, Bank Earnings, Inflation Data",
    "url": "https://www.investors.com/research/investing-action-plan/jpmorgan-healthcare-ces-show-bank-earnings-inflation-data-investing-action-plan/",
    "time_published": "20240105T222900",
    "authors": [
      "Investor's Business Daily",
      "IBD STAFF"
    ],
    "summary": "The big benchmarks launched the New Year by posting their first weekly slip since October. The Dow trimmed less than 1% while the Nasdaq lopped off 3%. Chips faltered, but solar stocks and auto retailers were the hardest hit industries. Big Pharma names had a good week, as Merck ( MRK ) led the ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2022/07/Stock-marketgrowth-03-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.890401"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.173993,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CELH",
        "relevance_score": "0.123526",
        "ticker_sentiment_score": "0.144722",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.123526",
        "ticker_sentiment_score": "0.144722",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WDFC",
        "relevance_score": "0.123526",
        "ticker_sentiment_score": "0.013892",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.123526",
        "ticker_sentiment_score": "0.021094",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WIT",
        "relevance_score": "0.082535",
        "ticker_sentiment_score": "0.064744",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.164188",
        "ticker_sentiment_score": "0.1163",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPOT",
        "relevance_score": "0.123526",
        "ticker_sentiment_score": "0.144722",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JPM",
        "relevance_score": "0.123526",
        "ticker_sentiment_score": "0.021094",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.123526",
        "ticker_sentiment_score": "0.144722",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BK",
        "relevance_score": "0.082535",
        "ticker_sentiment_score": "0.018562",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.082535",
        "ticker_sentiment_score": "0.133922",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.082535",
        "ticker_sentiment_score": "0.018562",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KBH",
        "relevance_score": "0.164188",
        "ticker_sentiment_score": "0.107238",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AYI",
        "relevance_score": "0.123526",
        "ticker_sentiment_score": "0.091327",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QCOM",
        "relevance_score": "0.082535",
        "ticker_sentiment_score": "0.088799",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.164188",
        "ticker_sentiment_score": "0.024866",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INTC",
        "relevance_score": "0.164188",
        "ticker_sentiment_score": "0.109444",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BBY",
        "relevance_score": "0.082535",
        "ticker_sentiment_score": "0.088799",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.082535",
        "ticker_sentiment_score": "0.133922",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INFY",
        "relevance_score": "0.082535",
        "ticker_sentiment_score": "0.064744",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LRLCF",
        "relevance_score": "0.041323",
        "ticker_sentiment_score": "0.084607",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.082535",
        "ticker_sentiment_score": "0.088799",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Looking At Amgen's Recent Unusual Options Activity - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/markets/options/24/01/36516275/looking-at-amgens-recent-unusual-options-activity",
    "time_published": "20240105T194609",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Whales with a lot of money to spend have taken a noticeably bearish stance on Amgen. Looking at options history for Amgen AMGN we detected 20 trades. If we consider the specifics of each trade, it is accurate to state that 25% of the investors opened trades with bullish expectations and 75% with ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      }
    ],
    "overall_sentiment_score": 0.125529,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.738815",
        "ticker_sentiment_score": "0.089758",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "IBD Stock Of The Day: The Buying Opportunity In Weight Loss",
    "url": "https://www.investors.com/research/ibd-stock-of-the-day/novo-nordisk-stock-lingers-in-a-buy-zone-after-snagging-two-obesity-deals/",
    "time_published": "20240105T180100",
    "authors": [
      "Investor's Business Daily",
      "ALLISON GATLIN"
    ],
    "summary": "Novo Nordisk Stock Lingers In Buy Zone After Snagging Two Obesity Deals Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/01/SOTD-1-4-2024NVO.png",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999365"
      }
    ],
    "overall_sentiment_score": 0.130124,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NVO",
        "relevance_score": "0.404098",
        "ticker_sentiment_score": "0.232614",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.350564",
        "ticker_sentiment_score": "0.141762",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.120431",
        "ticker_sentiment_score": "0.032569",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.120431",
        "ticker_sentiment_score": "0.032569",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OMGA",
        "relevance_score": "0.120431",
        "ticker_sentiment_score": "0.106572",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.120431",
        "ticker_sentiment_score": "0.032569",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.060388",
        "ticker_sentiment_score": "0.337437",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "It's Been An Abysmal Two Years. But Biotech Is Looking Up.",
    "url": "https://www.investors.com/news/technology/biotech-stocks-pharma-heat-up-in-2024-as-buyouts-obesity-ai-drive-excitement/",
    "time_published": "20240105T140000",
    "authors": [
      "Investor's Business Daily",
      "ALLISON GATLIN"
    ],
    "summary": "Biotech Stocks, Pharma Heat Up In 2024 As Buyouts, Obesity And AI Drive Excitement Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/01/A1-010824-biotech-Gash.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.12567,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NVO",
        "relevance_score": "0.035679",
        "ticker_sentiment_score": "0.069333",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NBIX",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.14181",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KRTX",
        "relevance_score": "0.035679",
        "ticker_sentiment_score": "0.037838",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IONS",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.084592",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RYZB",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARWR",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALEC",
        "relevance_score": "0.09495",
        "ticker_sentiment_score": "0.150269",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.153696",
        "ticker_sentiment_score": "0.053027",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VERV",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.006781",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OMGA",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.079056",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NTLA",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "-0.008781",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BHVN",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "-0.001871",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.067127",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.035679",
        "ticker_sentiment_score": "0.017905",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CPRX",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.14181",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BEAM",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.057997",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GRCL",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CLNN",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "-0.020246",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GPCR",
        "relevance_score": "0.035679",
        "ticker_sentiment_score": "0.08972",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMPH",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.14181",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARGX",
        "relevance_score": "0.011896",
        "ticker_sentiment_score": "-0.115274",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.067127",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "-0.042606",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ESALF",
        "relevance_score": "0.035679",
        "ticker_sentiment_score": "0.064761",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.059429",
        "ticker_sentiment_score": "0.106048",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Futures Fall Ahead Of Imminent Jobs Report",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-jobs-report-ai-leader-palantir-dives-on-downgrade/",
    "time_published": "20240105T131500",
    "authors": [
      "Investor's Business Daily",
      "SCOTT LEHTONEN"
    ],
    "summary": "Stocks jeopardized their weekly winning streak Friday as Dow Jones futures and other major indexes fell Friday morning ahead of the Labor Department's pivotal December jobs report. Meanwhile, artificial intelligence leader Palantir Technologies ( AI ) tumbled on a PLTR stock analyst's downgrade.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2017/03/stock-wallstreet-031317-shutter.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.07923,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.101869",
        "ticker_sentiment_score": "0.027297",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.135538",
        "ticker_sentiment_score": "0.156142",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CELH",
        "relevance_score": "0.168963",
        "ticker_sentiment_score": "0.174777",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.234846",
        "ticker_sentiment_score": "0.039966",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.135538",
        "ticker_sentiment_score": "0.030941",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.234846",
        "ticker_sentiment_score": "0.043689",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNOW",
        "relevance_score": "0.135538",
        "ticker_sentiment_score": "0.070193",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "V",
        "relevance_score": "0.135538",
        "ticker_sentiment_score": "0.096049",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAT",
        "relevance_score": "0.168963",
        "ticker_sentiment_score": "0.202744",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.034039",
        "ticker_sentiment_score": "0.010787",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.135538",
        "ticker_sentiment_score": "0.182724",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PLTR",
        "relevance_score": "0.068016",
        "ticker_sentiment_score": "-0.056409",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Dogs Of The Dow 2024: 10 Blue-Chip Dividend Payers",
    "url": "https://www.forbes.com/sites/brettowens/2024/01/07/dogs-of-the-dow-2024-10-blue-chip-dividend-payers/",
    "time_published": "20240107T121500",
    "authors": [
      "Brett Owens"
    ],
    "summary": "The 2024 Dogs of the Dow are particularly homely hounds-which means we're talking big dividends. This year's Dogs yield more than three-times the broader market's paltry payout. So, should we hold our noses and buy? Let's grab some peanut butter treats and investigate.",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/5e0e14c60bf81b00072e5836/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.882182"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.917436"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.195231,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CSCO",
        "relevance_score": "0.077156",
        "ticker_sentiment_score": "0.156862",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.115509",
        "ticker_sentiment_score": "0.073793",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.077156",
        "ticker_sentiment_score": "-0.095558",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.096361",
        "ticker_sentiment_score": "0.106898",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IBM",
        "relevance_score": "0.096361",
        "ticker_sentiment_score": "0.003278",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.115509",
        "ticker_sentiment_score": "0.087575",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WBA",
        "relevance_score": "0.057907",
        "ticker_sentiment_score": "0.155125",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KVUE",
        "relevance_score": "0.038623",
        "ticker_sentiment_score": "0.1006",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPLK",
        "relevance_score": "0.038623",
        "ticker_sentiment_score": "0.25476",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.038623",
        "ticker_sentiment_score": "0.068065",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.096361",
        "ticker_sentiment_score": "0.107227",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DOW",
        "relevance_score": "0.038623",
        "ticker_sentiment_score": "0.106423",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Futures: Magnificent Seven Stocks Lead Market Rally",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-magnificent-seven-stocks-rally-nvidia-breaks-out-past-buy-point/",
    "time_published": "20240108T215500",
    "authors": [
      "SCOTT LEHTONEN",
      "Investor's Business Daily"
    ],
    "summary": "Dow Jones Futures: Magnificent Seven Stocks Rally. Nvidia Breaks Out Past Buy Point Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2023/02/Stock-Chip-glows-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.208919,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.155184",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.076971",
        "ticker_sentiment_score": "0.086006",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.153226",
        "ticker_sentiment_score": "0.122934",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.228073",
        "ticker_sentiment_score": "0.270391",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "C",
        "relevance_score": "0.076971",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.076971",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JPM",
        "relevance_score": "0.076971",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.153226",
        "ticker_sentiment_score": "0.202159",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.153226",
        "ticker_sentiment_score": "0.123387",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.228073",
        "ticker_sentiment_score": "0.154061",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.153226",
        "ticker_sentiment_score": "0.113992",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.076971",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "V",
        "relevance_score": "0.153226",
        "ticker_sentiment_score": "0.155683",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CAT",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.220472",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.190868",
        "ticker_sentiment_score": "0.251625",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.014102",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Nvidia dives deeper into AI drug development with Amgen, Recursion partnerships",
    "url": "https://www.marketwatch.com/story/nvidia-dives-deeper-into-ai-drug-development-with-amgen-recursion-partnerships-de481c8b",
    "time_published": "20240108T180000",
    "authors": [
      "Eleanor Laise"
    ],
    "summary": "Nvidia is doubling down on artificial-intelligence-powered drug discovery and development, announcing expanded partnerships with Amgen and Recursion Pharmaceuticals.",
    "banner_image": "https://images.mktw.net/im-608401/social",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.106715,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.545493",
        "ticker_sentiment_score": "0.144731",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RXRX",
        "relevance_score": "0.132004",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.26042",
        "ticker_sentiment_score": "0.185456",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JPM",
        "relevance_score": "0.132004",
        "ticker_sentiment_score": "0.105235",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.132004",
        "ticker_sentiment_score": "0.123084",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Investigating Amgen's Standing In Biotechnology Industry Compared To Competitors - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/news/24/01/36537225/investigating-amgens-standing-in-biotechnology-industry-compared-to-competitors",
    "time_published": "20240108T160038",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Amidst today's fast-paced and highly competitive business environment, it is crucial for investors and industry enthusiasts to conduct comprehensive company evaluations. In this article, we will delve into an extensive industry comparison, evaluating Amgen AMGN in comparison to its major ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.917436"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      }
    ],
    "overall_sentiment_score": 0.24958,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.480056",
        "ticker_sentiment_score": "0.175875",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Futures Mixed As Boeing Dives On Groundings",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-boeing-dives-on-groundings-coinbase-rallies-on-price-target-hike/",
    "time_published": "20240108T130900",
    "authors": [
      "SCOTT LEHTONEN",
      "Investor's Business Daily"
    ],
    "summary": "Dow Jones Futures Fall As Boeing Dives On Groundings. Coinbase Rallies On Price Hike Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2017/10/stock-WallStreet-03-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.119998,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.141935",
        "ticker_sentiment_score": "0.115667",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.245693",
        "ticker_sentiment_score": "0.107766",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.141935",
        "ticker_sentiment_score": "0.080304",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.071251",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.071251",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNOW",
        "relevance_score": "0.071251",
        "ticker_sentiment_score": "0.214688",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JPM",
        "relevance_score": "0.071251",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.141935",
        "ticker_sentiment_score": "0.225583",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.035661",
        "ticker_sentiment_score": "0.128652",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.035661",
        "ticker_sentiment_score": "0.115954",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.141935",
        "ticker_sentiment_score": "0.054607",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COIN",
        "relevance_score": "0.141935",
        "ticker_sentiment_score": "-0.02624",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DAL",
        "relevance_score": "0.071251",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.071251",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.106699",
        "ticker_sentiment_score": "0.070375",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.245693",
        "ticker_sentiment_score": "0.11348",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.071251",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "V",
        "relevance_score": "0.141935",
        "ticker_sentiment_score": "0.152618",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CAT",
        "relevance_score": "0.17689",
        "ticker_sentiment_score": "0.211943",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.106699",
        "ticker_sentiment_score": "-0.085498",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "SpringWorks Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference - SpringWorks Therapeutics  ( NASDAQ:SWTX ) ",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36529625/springworks-therapeutics-highlights-2023-accomplishments-and-anticipated-milestones-for-2024-at-th",
    "time_published": "20240108T113044",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "STAMFORD, Conn., Jan. 08, 2024 ( GLOBE NEWSWIRE ) -- SpringWorks Therapeutics, Inc. SWTX, a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, will present today at the 42nd Annual J.P. Morgan Healthcare Conference at 7:30 a.m. PT ( 10:30 a.m.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.174151,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.017394",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BGNE",
        "relevance_score": "0.017394",
        "ticker_sentiment_score": "0.002709",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.017394",
        "ticker_sentiment_score": "0.003569",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SWTX",
        "relevance_score": "0.03478",
        "ticker_sentiment_score": "-0.029057",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "SpringWorks Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference",
    "url": "https://www.globenewswire.com/news-release/2024/01/08/2805220/0/en/SpringWorks-Therapeutics-Highlights-2023-Accomplishments-and-Anticipated-Milestones-for-2024-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html",
    "time_published": "20240108T113000",
    "authors": [
      "SpringWorks Therapeutics",
      "Inc."
    ],
    "summary": "STAMFORD, Conn., Jan. 08, 2024 ( GLOBE NEWSWIRE ) -- SpringWorks Therapeutics, Inc. ( Nasdaq: SWTX ) , a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, will present today at the 42nd Annual J.P. Morgan Healthcare Conference at 7:30 a.m. PT ( 10:30 a.m.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/89f6acc3-0fc3-4af1-84a4-f5b95d218eb8",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.178849,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.017769",
        "ticker_sentiment_score": "0.053152",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BGNE",
        "relevance_score": "0.017769",
        "ticker_sentiment_score": "0.053152",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SWTX",
        "relevance_score": "0.035529",
        "ticker_sentiment_score": "0.058092",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030 - Ambrx Biopharma  ( NASDAQ:AMAM ) , Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36558906/global-oncology-cancer-drugs-market-revenue-projected-to-surpass-289-billion-by-2030",
    "time_published": "20240109T152500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "PALM BEACH, Fla., Jan. 09, 2024 ( GLOBE NEWSWIRE ) -- FN Media Group News Commentary - According to the report titled \"Aging in the United States,\" published by the Population Reference Bureau, \"the number of Americans aged 65 and older is projected to increase more than double over 95 million ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.998947"
      }
    ],
    "overall_sentiment_score": 0.103242,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "DNPUF",
        "relevance_score": "0.019474",
        "ticker_sentiment_score": "0.086828",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NKTX",
        "relevance_score": "0.077782",
        "ticker_sentiment_score": "-0.066051",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMAM",
        "relevance_score": "0.077782",
        "ticker_sentiment_score": "-0.065019",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSUMF",
        "relevance_score": "0.019474",
        "ticker_sentiment_score": "0.086828",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.058377",
        "ticker_sentiment_score": "0.166162",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ELEV",
        "relevance_score": "0.097141",
        "ticker_sentiment_score": "0.001107",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INCY",
        "relevance_score": "0.038937",
        "ticker_sentiment_score": "0.095682",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.097141",
        "ticker_sentiment_score": "-0.069713",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GLYC",
        "relevance_score": "0.019474",
        "ticker_sentiment_score": "0.133755",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Looking At Amgen's Recent Unusual Options Activity - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/markets/options/24/01/36558676/looking-at-amgens-recent-unusual-options-activity",
    "time_published": "20240109T151623",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Financial giants have made a conspicuous bearish move on Amgen. Our analysis of options history for Amgen AMGN revealed 35 unusual trades. Delving into the details, we found 37% of traders were bullish, while 62% showed bearish tendencies.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.121226,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.742397",
        "ticker_sentiment_score": "0.078821",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Futures Lower As Netflix Slides On Downgrade",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-netflix-slides-on-downgrade-nvidia-set-to-hit-more-record-highs/",
    "time_published": "20240109T131200",
    "authors": [
      "Investor's Business Daily",
      "SCOTT LEHTONEN"
    ],
    "summary": "Dow Jones Futures Fall As Netflix Slides On Downgrade. Nvidia To Hit More Record Highs Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2019/10/stock-wall-street-flags-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.125108,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.212115",
        "ticker_sentiment_score": "0.025517",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.246404",
        "ticker_sentiment_score": "0.120353",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.142355",
        "ticker_sentiment_score": "0.087329",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.142355",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.071463",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JPM",
        "relevance_score": "0.071463",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.17741",
        "ticker_sentiment_score": "0.19543",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NEOG",
        "relevance_score": "0.107016",
        "ticker_sentiment_score": "-0.03966",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "0.115999",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.17741",
        "ticker_sentiment_score": "0.125977",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.142355",
        "ticker_sentiment_score": "0.087329",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AYI",
        "relevance_score": "0.107016",
        "ticker_sentiment_score": "-0.03966",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.212115",
        "ticker_sentiment_score": "0.110013",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.071463",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "V",
        "relevance_score": "0.142355",
        "ticker_sentiment_score": "0.146672",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAT",
        "relevance_score": "0.142355",
        "ticker_sentiment_score": "0.219761",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.142355",
        "ticker_sentiment_score": "0.140471",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "How Is The Market Feeling About Amgen? - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/short-sellers/24/01/36582492/how-is-the-market-feeling-about-amgen",
    "time_published": "20240110T193022",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Amgen's AMGN short percent of float has risen 11.84% since its last report. The company recently reported that it has 9.06 million shares sold short, which is 1.7% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.11 days to cover their ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.267375,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.224903",
        "ticker_sentiment_score": "0.158881",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Futures Mixed As CPI Inflation Data Looms",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-goldman-sachs-downgraded-bitcoin-stock-coinbase-slides/",
    "time_published": "20240110T131400",
    "authors": [
      "SCOTT LEHTONEN",
      "Investor's Business Daily"
    ],
    "summary": "Dow Jones Futures Fall As Goldman Sachs Downgraded. Bitcoin Stock Coinbase Slides Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2017/08/WallStreetFinance2-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.143114,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.138265",
        "ticker_sentiment_score": "0.102157",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.206099",
        "ticker_sentiment_score": "0.088336",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.138265",
        "ticker_sentiment_score": "0.071156",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.069394",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRWD",
        "relevance_score": "0.069394",
        "ticker_sentiment_score": "0.188027",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.069394",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JPM",
        "relevance_score": "0.069394",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.172342",
        "ticker_sentiment_score": "0.184649",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.069394",
        "ticker_sentiment_score": "0.188027",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.138265",
        "ticker_sentiment_score": "-0.161588",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.03473",
        "ticker_sentiment_score": "0.115549",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.172342",
        "ticker_sentiment_score": "0.120675",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COIN",
        "relevance_score": "0.103927",
        "ticker_sentiment_score": "-0.231723",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "PSMT",
        "relevance_score": "0.103927",
        "ticker_sentiment_score": "0.12371",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KBH",
        "relevance_score": "0.103927",
        "ticker_sentiment_score": "0.12371",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.138265",
        "ticker_sentiment_score": "0.071156",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.172342",
        "ticker_sentiment_score": "0.077385",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SGH",
        "relevance_score": "0.103927",
        "ticker_sentiment_score": "0.12371",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.069394",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAT",
        "relevance_score": "0.138265",
        "ticker_sentiment_score": "0.210256",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GCT",
        "relevance_score": "0.069394",
        "ticker_sentiment_score": "0.188027",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.138265",
        "ticker_sentiment_score": "0.172429",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.103927",
        "ticker_sentiment_score": "-0.231723",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Is AI More Valuable In Advertising Than Healthcare? Jim Cramer Questions Wall Street's Preference - Amgen  ( NASDAQ:AMGN ) , Amazon.com  ( NASDAQ:AMZN ) ",
    "url": "https://www.benzinga.com/news/24/01/36572344/is-ai-more-valuable-in-advertising-than-healthcare-jim-cramer-questions-wall-streets-preference",
    "time_published": "20240110T110256",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "In a recent revelation, CNBC's Mad Money host Jim Cramer disclosed that the financial market values artificial intelligence ( AI ) technology more for advertising than for healthcare. What Happened: Cramer shared his insights while attending JPMorgan's healthcare conference, reported CNBC on ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/jim-cramer-shutterstock_1.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.317128,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MDT",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "0.175148",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "0.175148",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "0.123315",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JPM",
        "relevance_score": "0.107495",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COR",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "0.175148",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Amgen  ( AMGN )  Suffers a Larger Drop Than the General Market: Key Insights",
    "url": "https://www.zacks.com/stock/news/2209160/amgen-amgn-suffers-a-larger-drop-than-the-general-market-key-insights",
    "time_published": "20240111T225022",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) reachead $303.10 at the closing of the latest trading day, reflecting a -0.48% change compared to its last close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default3.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.875462"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.265452,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.699089",
        "ticker_sentiment_score": "0.363878",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Al Gore is officially too old to serve on Apple's board | Business",
    "url": "https://www.cnn.com/2024/01/11/tech/al-gore-is-officially-too-old-for-apple/index.html",
    "time_published": "20240111T223300",
    "authors": [
      "Ramishah Maruf"
    ],
    "summary": "Al Gore is officially too old to serve on Apple's board ...",
    "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/240111164844-al-gore-011723.jpg?c=16x9&q=w_800,c_fill",
    "source": "CNN",
    "category_within_source": "Markets",
    "source_domain": "www.cnn.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.136055,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.151539",
        "ticker_sentiment_score": "0.059806",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.151539",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Large Drugmakers Show Enthusiasm To Embrace $100B Obesity Market, Despite Novo And Lilly's Dominance - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/general/biotech/24/01/36594746/large-drugmakers-show-enthusiasm-to-embrace-100b-obesity-market-despite-novo-and-lillys-dominance",
    "time_published": "20240111T164037",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Pharmaceutical companies, including Amgen Inc AMGN and Pfizer Inc PFE, are strategically positioning themselves to tap into the burgeoning obesity market. The pursuit involves developing innovative drugs or engaging in strategic acquisitions to compete with established players such as Novo ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/11/aapharma_0.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.164763,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BAYZF",
        "relevance_score": "0.228073",
        "ticker_sentiment_score": "0.084786",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JPM",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.33628",
        "ticker_sentiment_score": "0.252282",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.33628",
        "ticker_sentiment_score": "0.252282",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ALT",
        "relevance_score": "0.228073",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.531326",
        "ticker_sentiment_score": "0.077283",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.43789",
        "ticker_sentiment_score": "0.185632",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Xeris  ( XERS )  Up on Licensing Deal With Amgen to Develop Tepezza",
    "url": "https://www.zacks.com/stock/news/2208740/xeris-xers-up-on-licensing-deal-with-amgen-to-develop-tepezza",
    "time_published": "20240111T133000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Xeris (XERS) gains 16% after signing a licensing deal with Amgen, which allows the latter to utilize the XeriJect technology to develop a subcutaneous formulation of teprotumumab in Thyroid Eye Disease.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/1076.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.928769"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.224431,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ADMA",
        "relevance_score": "0.377142",
        "ticker_sentiment_score": "0.210134",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.377142",
        "ticker_sentiment_score": "0.350647",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "PBYI",
        "relevance_score": "0.256989",
        "ticker_sentiment_score": "0.195759",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "XERS",
        "relevance_score": "0.194242",
        "ticker_sentiment_score": "0.20057",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Futures Rise Ahead Of Imminent CPI Inflation Report",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-cpi-inflation-report-nvidia-stock-set-to-hit-record-high/",
    "time_published": "20240111T132200",
    "authors": [
      "Investor's Business Daily",
      "SCOTT LEHTONEN"
    ],
    "summary": "Dow Jones futures were slightly higher in premarket trades Thursday, as Wall Street braced for a critical inflation report from the Labor Department. Among individual stocks, Nvidia stock rallied and set to hit another record high, while crypto stock Coinbase ( COIN ) jumped on SEC approval for ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2017/03/stock-wallstreet-031317-shutter.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.143159,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KBH",
        "relevance_score": "0.124809",
        "ticker_sentiment_score": "-0.031077",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.165883",
        "ticker_sentiment_score": "0.213819",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.206509",
        "ticker_sentiment_score": "0.027872",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.041755",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.206509",
        "ticker_sentiment_score": "0.210346",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CAT",
        "relevance_score": "0.165883",
        "ticker_sentiment_score": "0.230009",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.041755",
        "ticker_sentiment_score": "0.200708",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.206509",
        "ticker_sentiment_score": "0.139379",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.165883",
        "ticker_sentiment_score": "0.158303",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "COIN",
        "relevance_score": "0.124809",
        "ticker_sentiment_score": "0.078085",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.124809",
        "ticker_sentiment_score": "0.078085",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Vera Therapeutics Stock Soared by 22% This Week",
    "url": "https://www.fool.com/investing/2024/01/12/why-vera-therapeutics-stock-soared-by-22-this-week/",
    "time_published": "20240112T234415",
    "authors": [
      "Eric Volkman"
    ],
    "summary": "Executive changes and a bullish analyst take combined to boost sentiment on the company.",
    "banner_image": "https://g.foolcdn.com/editorial/images/761177/two-people-seated-at-a-lab-desk-featuring-a-pc-screen-and-microscope.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      }
    ],
    "overall_sentiment_score": 0.213119,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "DVAX",
        "relevance_score": "0.146916",
        "ticker_sentiment_score": "-0.11025",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.146916",
        "ticker_sentiment_score": "0.242507",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.146916",
        "ticker_sentiment_score": "-0.059967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VERA",
        "relevance_score": "0.421485",
        "ticker_sentiment_score": "0.465416",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Futures Lower Ahead Of Key Inflation Data",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-inflation-data-tesla-stock-dives-despite-cathie-wood-buys/",
    "time_published": "20240112T131700",
    "authors": [
      "SCOTT LEHTONEN",
      "Investor's Business Daily"
    ],
    "summary": "Dow Jones Futures Drop Ahead Of Inflation Data. Tesla Stock Dives Despite Cathie Wood Buys Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2021/09/Stock-wallstreetflag-01-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.038073,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.144491",
        "ticker_sentiment_score": "0.152901",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.03631",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.10863",
        "ticker_sentiment_score": "0.209181",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.10863",
        "ticker_sentiment_score": "0.209181",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JPM",
        "relevance_score": "0.10863",
        "ticker_sentiment_score": "0.209181",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.180056",
        "ticker_sentiment_score": "0.148814",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.03631",
        "ticker_sentiment_score": "0.010849",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.180056",
        "ticker_sentiment_score": "0.125872",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DAL",
        "relevance_score": "0.072545",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.10863",
        "ticker_sentiment_score": "-0.15628",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "MELI",
        "relevance_score": "0.144491",
        "ticker_sentiment_score": "0.147904",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.250019",
        "ticker_sentiment_score": "-0.123804",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.10863",
        "ticker_sentiment_score": "0.209181",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CAT",
        "relevance_score": "0.144491",
        "ticker_sentiment_score": "0.111375",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.144491",
        "ticker_sentiment_score": "0.141657",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "FDA Finds No Link Between Obesity Drugs and Suicidal Thoughts",
    "url": "https://www.zacks.com/stock/news/2209351/fda-finds-no-link-between-obesity-drugs-and-suicidal-thoughts",
    "time_published": "20240112T124700",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "The GLP-1 segment is an important class of drugs for multiple cardiometabolic diseases and is gaining significant popularity.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/82/41137.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.101797,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.227007",
        "ticker_sentiment_score": "0.104048",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.227007",
        "ticker_sentiment_score": "0.056869",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.171282",
        "ticker_sentiment_score": "0.110461",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.05749",
        "ticker_sentiment_score": "0.149399",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.227007",
        "ticker_sentiment_score": "0.250732",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Ozempic not linked to suicidal thoughts, FDA report finds",
    "url": "https://www.financialexpress.com/healthcare/pharma-healthcare/ozempic-not-linked-to-suicidal-thoughts-fda-report-finds/3363168/",
    "time_published": "20240112T111249",
    "authors": [
      "Bloomberg"
    ],
    "summary": "US regulators found no link between weight-loss drugs like Novo Nordisk A/S's Ozempic and suicidal thoughts, a positive sign for the popular medications as similar reviews in Europe remain ongoing.",
    "banner_image": "https://www.financialexpress.com/wp-content/uploads/2024/01/pills-384846_1280.jpg",
    "source": "The Financial Express",
    "category_within_source": "n/a",
    "source_domain": "www.financialexpress.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.082165,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.121037",
        "ticker_sentiment_score": "0.025567",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.121037",
        "ticker_sentiment_score": "0.025567",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.121037",
        "ticker_sentiment_score": "-0.009974",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick",
    "url": "https://www.zacks.com/stock/news/2210202/are-you-a-momentum-investor-this-1-stock-could-be-the-perfect-pick",
    "time_published": "20240115T145007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default59.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.40067,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.556576",
        "ticker_sentiment_score": "0.257667",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Amgen Inc.  ( AMGN )  is Attracting Investor Attention: Here is What You Should Know",
    "url": "https://www.zacks.com/stock/news/2210094/amgen-inc-amgn-is-attracting-investor-attention-here-is-what-you-should-know",
    "time_published": "20240115T140006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default261.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.235173,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.486627",
        "ticker_sentiment_score": "0.143592",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond",
    "url": "https://www.fool.com/investing/2024/01/15/5-biotech-stocks-that-could-be-big-winners-in-2024/",
    "time_published": "20240115T113000",
    "authors": [
      "George Budwell"
    ],
    "summary": "These five biotech companies could have a lot of room to run.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F761232%2Fbiotech-researcher.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.348088,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "IMVT",
        "relevance_score": "0.282234",
        "ticker_sentiment_score": "0.395991",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "BGNE",
        "relevance_score": "0.143415",
        "ticker_sentiment_score": "0.336585",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ARGX",
        "relevance_score": "0.213674",
        "ticker_sentiment_score": "0.060262",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.143415",
        "ticker_sentiment_score": "0.169678",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Eli Lilly, Novo Nordisk, Amgen and AstraZeneca",
    "url": "https://www.zacks.com/stock/news/2209905/the-zacks-analyst-blog-highlights-eli-lilly-novo-nordisk-amgen-and-astrazeneca",
    "time_published": "20240115T105000",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Eli Lilly, Novo Nordisk, Amgen and AstraZeneca are included in this Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e5/1416.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.094253,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.261117",
        "ticker_sentiment_score": "0.085906",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.261117",
        "ticker_sentiment_score": "0.040358",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.210274",
        "ticker_sentiment_score": "0.07059",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.053153",
        "ticker_sentiment_score": "0.149079",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.261117",
        "ticker_sentiment_score": "0.241559",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Osteoporosis Drugs Market is Projected to Develop at a CAGR of 3.5% from 2023 to 2033 | Persistence Market Research",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36635069/osteoporosis-drugs-market-is-projected-to-develop-at-a-cagr-of-3-5-from-2023-to-2033-persistence-m",
    "time_published": "20240116T080000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, Jan. 16, 2024 ( GLOBE NEWSWIRE ) -- Market Overview: The Osteoporosis Drugs Market is a rapidly evolving sector within the pharmaceutical industry, primarily driven by the growing aging population and the increasing prevalence of osteoporosis worldwide.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.322946,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVS",
        "relevance_score": "0.021797",
        "ticker_sentiment_score": "0.022673",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.021797",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WLDS",
        "relevance_score": "0.021797",
        "ticker_sentiment_score": "0.230828",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.021797",
        "ticker_sentiment_score": "0.044643",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen  ( AMGN )  Ascends While Market Falls: Some Facts to Note",
    "url": "https://www.zacks.com/stock/news/2211768/amgen-amgn-ascends-while-market-falls-some-facts-to-note",
    "time_published": "20240117T230017",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) closed the most recent trading day at $304.08, moving +0.2% from the previous trading session.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default74.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.972476"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.158408,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.553265",
        "ticker_sentiment_score": "0.17929",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Amgen Options Trading: A Deep Dive into Market Sentiment - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/markets/options/24/01/36666528/amgen-options-trading-a-deep-dive-into-market-sentiment",
    "time_published": "20240117T193057",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Financial giants have made a conspicuous bearish move on Amgen. Our analysis of options history for Amgen AMGN revealed 18 unusual trades. Delving into the details, we found 27% of traders were bullish, while 72% showed bearish tendencies.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.150094,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.708432",
        "ticker_sentiment_score": "0.023286",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Futures Drop Ahead Of Retail Sales",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-retail-sales-tesla-stock-slides-on-more-price-cuts/",
    "time_published": "20240117T131700",
    "authors": [
      "Investor's Business Daily",
      "SCOTT LEHTONEN"
    ],
    "summary": "Dow Jones futures sank along with other major indexes early Wednesday, as markets continued to slide after failing to gain their footing on Tuesday. Meanwhile, Tesla stock struggled below critical benchmarks after the company lowered prices on its Model Y electric vehicles in Germany.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2019/10/stock-wall-street-flags-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.059572,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.17179",
        "ticker_sentiment_score": "0.162926",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MELI",
        "relevance_score": "0.2138",
        "ticker_sentiment_score": "0.213082",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.043264",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IBKR",
        "relevance_score": "0.129284",
        "ticker_sentiment_score": "0.072138",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.295867",
        "ticker_sentiment_score": "-0.173677",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "SPOT",
        "relevance_score": "0.2138",
        "ticker_sentiment_score": "0.144712",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.17179",
        "ticker_sentiment_score": "0.174547",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CAT",
        "relevance_score": "0.17179",
        "ticker_sentiment_score": "0.081006",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SCHW",
        "relevance_score": "0.129284",
        "ticker_sentiment_score": "0.072138",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.043264",
        "ticker_sentiment_score": "0.010972",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.17179",
        "ticker_sentiment_score": "0.144019",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.17179",
        "ticker_sentiment_score": "0.185633",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Cathie Wood's Ark Invest Liquidates $15.8M Worth Of ProShares Bitcoin Strategy ETF Units - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/markets/equities/24/01/36653786/cathie-woods-ark-invest-liquidates-15-8m-worth-of-proshares-bitcoin-strategy-etf-units",
    "time_published": "20240117T033939",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "On Tuesday, Cathie Wood-led Ark Invest made a significant move by selling $15.84 million worth of ProShares Bitcoin Strategy ETF BITO units. This trade comes amidst a dynamic period in the cryptocurrency market, reflecting Ark Invest's strategic adjustments in response to evolving market ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/cathie-wood-bz-ark_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.990786"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.243933,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CRSP",
        "relevance_score": "0.224903",
        "ticker_sentiment_score": "0.579686",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.224903",
        "ticker_sentiment_score": "0.301824",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "QCOM",
        "relevance_score": "0.224903",
        "ticker_sentiment_score": "0.28065",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.224903",
        "ticker_sentiment_score": "0.439433",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.746902",
        "ticker_sentiment_score": "0.207969",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "GeminiBio Appoints Steven Sandoval, Sr. to its Board of Directors",
    "url": "https://www.prnewswire.com/news-releases/geminibio-appoints-steven-sandoval-sr-to-its-board-of-directors-302037950.html",
    "time_published": "20240118T140000",
    "authors": [
      "BelHealth Investment Partners"
    ],
    "summary": "* Senior biopharma and cell therapy engineering/operations executive with 30+ years of experience to help drive growth",
    "banner_image": "https://mma.prnewswire.com/media/959545/BelHealth_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.858979"
      }
    ],
    "overall_sentiment_score": 0.335412,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.073546",
        "ticker_sentiment_score": "0.107281",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Tech Futures Rally Ahead Of Jobless Claims",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-jobless-claims-nvidia-stock-set-to-hit-more-record-highs/",
    "time_published": "20240118T132000",
    "authors": [
      "SCOTT LEHTONEN",
      "Investor's Business Daily"
    ],
    "summary": "Dow Jones Futures Fall Ahead Of Jobless Claims. Nvidia Set To Hit More Record Highs Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2017/03/stock-wallstreet-031317-shutter.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.744043"
      }
    ],
    "overall_sentiment_score": 0.047556,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AA",
        "relevance_score": "0.12165",
        "ticker_sentiment_score": "0.057898",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.16171",
        "ticker_sentiment_score": "0.129355",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.081276",
        "ticker_sentiment_score": "0.062072",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPOT",
        "relevance_score": "0.201356",
        "ticker_sentiment_score": "0.114075",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.16171",
        "ticker_sentiment_score": "0.170372",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.040691",
        "ticker_sentiment_score": "0.117875",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.16171",
        "ticker_sentiment_score": "0.135664",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MELI",
        "relevance_score": "0.201356",
        "ticker_sentiment_score": "0.091275",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.040691",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.16171",
        "ticker_sentiment_score": "0.118043",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FAST",
        "relevance_score": "0.12165",
        "ticker_sentiment_score": "0.057898",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.16171",
        "ticker_sentiment_score": "0.111091",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KEY",
        "relevance_score": "0.12165",
        "ticker_sentiment_score": "0.057898",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here's Why Amgen  ( AMGN )  Gained But Lagged the Market Today",
    "url": "https://www.zacks.com/stock/news/2213088/heres-why-amgen-amgn-gained-but-lagged-the-market-today",
    "time_published": "20240119T225017",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) reachead $307.81 at the closing of the latest trading day, reflecting a +1.09% change compared to its last close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default328.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.95493"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      }
    ],
    "overall_sentiment_score": 0.194645,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.549988",
        "ticker_sentiment_score": "0.213311",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Liquid Biopsy in Cancer Diagnostics Global Market is Likely to Increase at a Massive Growth Rate of ~17% by 2028 | DelveInsight",
    "url": "https://www.prnewswire.com/news-releases/liquid-biopsy-in-cancer-diagnostics-global-market-is-likely-to-increase-at-a-massive-growth-rate-of-17-by-2028--delveinsight-302039144.html",
    "time_published": "20240119T220100",
    "authors": [
      "LLP",
      "DelveInsight Business Research"
    ],
    "summary": "Liquid Biopsy in Cancer Diagnostics Global Market is Likely to Increase at a Massive Growth Rate of ~17% by 2028 ... PR ...",
    "banner_image": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": -0.042033,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "A",
        "relevance_score": "0.021143",
        "ticker_sentiment_score": "0.031816",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GH",
        "relevance_score": "0.042271",
        "ticker_sentiment_score": "0.018936",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSMXF",
        "relevance_score": "0.042271",
        "ticker_sentiment_score": "0.018936",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXAS",
        "relevance_score": "0.042271",
        "ticker_sentiment_score": "0.018936",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.021143",
        "ticker_sentiment_score": "0.024956",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ILMN",
        "relevance_score": "0.021143",
        "ticker_sentiment_score": "0.031816",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SKXJF",
        "relevance_score": "0.021143",
        "ticker_sentiment_score": "-0.188371",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.021143",
        "ticker_sentiment_score": "-0.132382",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAH",
        "relevance_score": "0.021143",
        "ticker_sentiment_score": "0.024956",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSKYF",
        "relevance_score": "0.021143",
        "ticker_sentiment_score": "-0.188371",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "OCPNF",
        "relevance_score": "0.021143",
        "ticker_sentiment_score": "0.024956",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.021143",
        "ticker_sentiment_score": "-0.132382",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TECH",
        "relevance_score": "0.042271",
        "ticker_sentiment_score": "0.018936",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIOCQ",
        "relevance_score": "0.042271",
        "ticker_sentiment_score": "0.018936",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HOLX",
        "relevance_score": "0.021143",
        "ticker_sentiment_score": "0.024956",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MYGN",
        "relevance_score": "0.021143",
        "ticker_sentiment_score": "0.031816",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.021143",
        "ticker_sentiment_score": "0.031816",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BDSX",
        "relevance_score": "0.021143",
        "ticker_sentiment_score": "-0.051475",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADTX",
        "relevance_score": "0.021143",
        "ticker_sentiment_score": "0.031816",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NEO",
        "relevance_score": "0.021143",
        "ticker_sentiment_score": "0.031816",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FUJIF",
        "relevance_score": "0.021143",
        "ticker_sentiment_score": "0.024956",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QGEN",
        "relevance_score": "0.042271",
        "ticker_sentiment_score": "0.018936",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.021143",
        "ticker_sentiment_score": "0.024956",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen's Blockbuster Osteoporosis Drug Prolia Flagged With FDA Strictest Warning - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/general/biotech/24/01/36699737/amgens-blockbuster-osteoporosis-drug-prolia-flagged-with-fda-strictest-warning",
    "time_published": "20240119T182911",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "The FDA has added a serious warning to the prescribing information for Amgen Inc's AMGN drug Prolia ( denosumab ) , emphasizing an increased risk of severely low calcium levels in specific patient groups.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Amgen-Prolia.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.277814,
    "overall_sentiment_label": "Somewhat-Bearish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.414559",
        "ticker_sentiment_score": "-0.179888",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Futures Higher Ahead Of Inflation Reading",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-inflation-survey-nvidia-stock-jumps-to-record-highs/",
    "time_published": "20240119T132000",
    "authors": [
      "Investor's Business Daily",
      "SCOTT LEHTONEN"
    ],
    "summary": "Dow Jones Futures Rise Ahead Of Key Inflation Survey. Nvidia Stock Jumps To Record High Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2017/03/stock-wallstreet-031317-shutter.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.149051,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "DKNG",
        "relevance_score": "0.168785",
        "ticker_sentiment_score": "0.19166",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.210092",
        "ticker_sentiment_score": "0.059294",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPOT",
        "relevance_score": "0.210092",
        "ticker_sentiment_score": "0.163677",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ALLY",
        "relevance_score": "0.084871",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.168785",
        "ticker_sentiment_score": "0.177965",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SLB",
        "relevance_score": "0.127007",
        "ticker_sentiment_score": "0.049738",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.042496",
        "ticker_sentiment_score": "0.118454",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.168785",
        "ticker_sentiment_score": "0.139559",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MELI",
        "relevance_score": "0.210092",
        "ticker_sentiment_score": "0.169643",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "STT",
        "relevance_score": "0.127007",
        "ticker_sentiment_score": "0.049738",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.042496",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RF",
        "relevance_score": "0.127007",
        "ticker_sentiment_score": "0.049738",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CMA",
        "relevance_score": "0.127007",
        "ticker_sentiment_score": "0.049738",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.168785",
        "ticker_sentiment_score": "0.182147",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.168785",
        "ticker_sentiment_score": "0.151911",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Top Wall Street analysts pick these stocks for solid returns",
    "url": "https://www.cnbc.com/2024/01/21/top-wall-street-analysts-pick-these-stocks-for-solid-returns.html",
    "time_published": "20240121T120243",
    "authors": [
      "TipRanks.com Staff"
    ],
    "summary": "TipRanks' analyst ranking service pinpoints Wall Street's best-performing stocks, including Amazon and Nvidia.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107356885-1704913185907-gettyimages-1238626780-AFP_323G6YL.jpeg?v=1704913222&w=1920&h=1080",
    "source": "CNBC",
    "category_within_source": "Investing",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.77141"
      }
    ],
    "overall_sentiment_score": 0.351937,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.184246",
        "ticker_sentiment_score": "0.092575",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RXRX",
        "relevance_score": "0.092748",
        "ticker_sentiment_score": "0.145361",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.092748",
        "ticker_sentiment_score": "0.145361",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DASH",
        "relevance_score": "0.229149",
        "ticker_sentiment_score": "0.244616",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.316555",
        "ticker_sentiment_score": "0.295147",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JPM",
        "relevance_score": "0.092748",
        "ticker_sentiment_score": "0.005331",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Wearable Injectors Market Surges Towards US$ 19.4 Billion by 2033 with 10.2% CAGR | Persistence Market Research",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36711531/wearable-injectors-market-surges-towards-us-19-4-billion-by-2033-with-10-2-cagr-persistence-market",
    "time_published": "20240122T090000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, Jan. 22, 2024 ( GLOBE NEWSWIRE ) -- Market Overview: The Wearable Injectors Market has witnessed remarkable growth in recent years, driven by a combination of technological advancements and the growing demand for convenient and patient-centric drug delivery solutions.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.421696,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TNDM",
        "relevance_score": "0.029381",
        "ticker_sentiment_score": "0.057117",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BDX",
        "relevance_score": "0.014693",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "YPHDF",
        "relevance_score": "0.014693",
        "ticker_sentiment_score": "0.153666",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WST",
        "relevance_score": "0.014693",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PODD",
        "relevance_score": "0.029381",
        "ticker_sentiment_score": "0.207221",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.029381",
        "ticker_sentiment_score": "0.051516",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.014693",
        "ticker_sentiment_score": "0.047485",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "USD 10.40 billion growth in Vascular Endothelial Market between 2022 and 2027, The strategic alliances and ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/usd-10-40-billion-growth-in-vascular-endothelial-market-between-2022-and-2027--the-strategic-alliances-and-collaborations-are-notably-driving-market-growth-17-000-technavio-research-reports-302039609.html",
    "time_published": "20240122T043500",
    "authors": [],
    "summary": "USD 10.40 billion growth in Vascular Endothelial Market between 2022 and 2027, The strategic alliances and ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.164961,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BAYZF",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.083583",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.083583",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.083583",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.083583",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.083583",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.083583",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.083583",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VTRS",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.083583",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXEL",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.083583",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.083583",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ESALF",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.083583",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CLVSQ",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.083583",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.083583",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TAK",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.083583",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "This 1 Bullish Move by Merck Could Drive Growth for Years to Come",
    "url": "https://www.fool.com/investing/2024/01/23/this-1-bullish-move-by-merck-could-drive-growth-fo/",
    "time_published": "20240123T134500",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "It's buying a company with sophisticated biotechnology platforms that could drive lots of growth -- eventually.",
    "banner_image": "https://g.foolcdn.com/editorial/images/761793/investor-considers-screen-while-writing-on-pad.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.097895,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.043658",
        "ticker_sentiment_score": "-0.002968",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HARP",
        "relevance_score": "0.087185",
        "ticker_sentiment_score": "0.010581",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Futures Mixed After Earnings Reports",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-big-earnings-reports-magnificent-seven-stock-netflix-to-report-next/",
    "time_published": "20240123T131200",
    "authors": [
      "Investor's Business Daily",
      "SCOTT LEHTONEN"
    ],
    "summary": "Dow Jones Futures Fall On Big Earnings Reports. Magnificent Seven Stock Netflix To Report Next Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2017/04/stock-wallstreet-shutter.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.161722,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "DKNG",
        "relevance_score": "0.170576",
        "ticker_sentiment_score": "0.215034",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.170576",
        "ticker_sentiment_score": "0.08804",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.042953",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UAL",
        "relevance_score": "0.085782",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPOT",
        "relevance_score": "0.212301",
        "ticker_sentiment_score": "0.165004",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.128363",
        "ticker_sentiment_score": "0.0644",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.170576",
        "ticker_sentiment_score": "0.224647",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.085782",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.042953",
        "ticker_sentiment_score": "0.044623",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.042953",
        "ticker_sentiment_score": "0.118591",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.170576",
        "ticker_sentiment_score": "0.096618",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MELI",
        "relevance_score": "0.212301",
        "ticker_sentiment_score": "0.251407",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HAL",
        "relevance_score": "0.128363",
        "ticker_sentiment_score": "0.031178",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.042953",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.128363",
        "ticker_sentiment_score": "0.0644",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.170576",
        "ticker_sentiment_score": "0.166315",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.128363",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.170576",
        "ticker_sentiment_score": "0.150137",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GE",
        "relevance_score": "0.128363",
        "ticker_sentiment_score": "0.031178",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "5 Magnificent Dividend Growth Stocks to Buy and Hold Forever",
    "url": "https://www.fool.com/investing/2024/01/23/5-magnificent-dividend-growth-stocks-to-buy-and-ho/",
    "time_published": "20240123T114500",
    "authors": [
      "George Budwell"
    ],
    "summary": "These dividend growers ought to shine in 2024 and beyond.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F762055%2Fparabola.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.839681"
      }
    ],
    "overall_sentiment_score": 0.47811,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MO",
        "relevance_score": "0.282234",
        "ticker_sentiment_score": "0.287294",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PEP",
        "relevance_score": "0.227538",
        "ticker_sentiment_score": "0.386111",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.227538",
        "ticker_sentiment_score": "0.34713",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.171688",
        "ticker_sentiment_score": "0.380978",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.335519",
        "ticker_sentiment_score": "0.37482",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Top Research Reports for Novartis, Amgen & Palo Alto Networks",
    "url": "https://www.zacks.com/research-daily/2214881/top-research-reports-for-novartis-amgen-palo-alto-networks",
    "time_published": "20240124T191500",
    "authors": [
      "Sheraz Mian"
    ],
    "summary": "Today's Research Daily features new research reports on 16 major stocks, including Novartis AG (NVS), Amgen Inc. (AMGN) and Palo Alto Networks, Inc. (PANW).",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default268.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.2538,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.285526",
        "ticker_sentiment_score": "0.224801",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KDNY",
        "relevance_score": "0.097062",
        "ticker_sentiment_score": "0.221466",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PANW",
        "relevance_score": "0.097062",
        "ticker_sentiment_score": "0.225738",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "These Stocks Led Dow's Run to 38,000. It's Not Who You Expect.",
    "url": "https://www.investors.com/research/dow-jones-cleared-38000-thanks-to-these-stocks-aapl-lagged-msft-underperformed/",
    "time_published": "20240124T175800",
    "authors": [
      "VIDYA RAMAKRISHNAN",
      "Investor's Business Daily"
    ],
    "summary": "Dow Jones cleared 38,000 thanks to these stocks. AAPL, MSFT did not help as much Separator Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2021/02/Stock-MarketBoard-Blue42-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.977154"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.212783,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.465901",
        "ticker_sentiment_score": "0.282084",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.359014",
        "ticker_sentiment_score": "0.164414",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.244109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.244109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAT",
        "relevance_score": "0.244109",
        "ticker_sentiment_score": "0.121179",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Tech Futures Rally As Netflix Surges",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-as-netflix-surges-on-earnings-tesla-earnings-next/",
    "time_published": "20240124T131500",
    "authors": [
      "Investor's Business Daily",
      "SCOTT LEHTONEN"
    ],
    "summary": "Dow Jones Futures Rise As Netflix Surges On Earnings. Tesla Earnings Next Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2022/06/Stock-elonmusk-14-shutt.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.157042,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "DKNG",
        "relevance_score": "0.172713",
        "ticker_sentiment_score": "0.175184",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.08687",
        "ticker_sentiment_score": "0.035937",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MELI",
        "relevance_score": "0.214937",
        "ticker_sentiment_score": "0.195819",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.043499",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.08687",
        "ticker_sentiment_score": "0.053432",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPOT",
        "relevance_score": "0.214937",
        "ticker_sentiment_score": "0.096366",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNOW",
        "relevance_score": "0.172713",
        "ticker_sentiment_score": "0.04812",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.172713",
        "ticker_sentiment_score": "0.106914",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.172713",
        "ticker_sentiment_score": "0.219604",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.043499",
        "ticker_sentiment_score": "0.114787",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.172713",
        "ticker_sentiment_score": "0.111839",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "What's Going On Johnson & Johnson Stock Today? - Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/general/biotech/24/01/36755938/whats-going-on-johnson-johnson-stock-today",
    "time_published": "20240124T125416",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Tuesday, Johnson & Johnson JNJ released better-than-expected earnings for its fourth quarter of 2023. It reported quarterly adjusted earnings of $2.29 per share, up 11.7% year-over-year, beating the consensus of $2.28. Sales increased 7.3% Y/Y to $21.4 billion, beating the consensus of $20.99 ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Johnson-and-Johnson.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.917436"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.043897,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.219809",
        "ticker_sentiment_score": "0.065799",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.671304",
        "ticker_sentiment_score": "-0.079756",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen  ( AMGN )  Outperforms Broader Market: What You Need to Know",
    "url": "https://www.zacks.com/stock/news/2216157/amgen-amgn-outperforms-broader-market-what-you-need-to-know",
    "time_published": "20240125T225016",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the latest trading session, Amgen (AMGN) closed at $310.26, marking a +1.56% move from the previous day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default17.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.972476"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.225095,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.631282",
        "ticker_sentiment_score": "0.353207",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Amgen Inc.  ( AMGN )  Soars to 52-Week High, Time to Cash Out?",
    "url": "https://www.zacks.com/stock/news/2215717/amgen-inc-amgn-soars-to-52-week-high-time-to-cash-out",
    "time_published": "20240125T141504",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default243.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.99246"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      }
    ],
    "overall_sentiment_score": 0.271177,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.739411",
        "ticker_sentiment_score": "0.437982",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "PBYI",
        "relevance_score": "0.426225",
        "ticker_sentiment_score": "0.439189",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Futures Higher Ahead Of GDP, Jobless Claims; Tesla Dives",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-gdp-jobless-claims-tesla-dives-on-earnings-musk-warning/",
    "time_published": "20240125T132208",
    "authors": [
      "SCOTT LEHTONEN",
      "Investor's Business Daily"
    ],
    "summary": "Dow Jones Futures Fall Ahead of GDP, Jobless Claims. Tesla Dives On Earnings, Musk Warning Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2023/07/Stock-Tesla-RedSilo-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.998932"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.142123,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "DKNG",
        "relevance_score": "0.112709",
        "ticker_sentiment_score": "0.144311",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.037681",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPOT",
        "relevance_score": "0.149889",
        "ticker_sentiment_score": "0.114109",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNOW",
        "relevance_score": "0.149889",
        "ticker_sentiment_score": "0.080085",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.112709",
        "ticker_sentiment_score": "0.130491",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LVS",
        "relevance_score": "0.112709",
        "ticker_sentiment_score": "0.034088",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAL",
        "relevance_score": "0.112709",
        "ticker_sentiment_score": "0.034088",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.037681",
        "ticker_sentiment_score": "0.108946",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LUV",
        "relevance_score": "0.075279",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.149889",
        "ticker_sentiment_score": "0.088261",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MELI",
        "relevance_score": "0.186738",
        "ticker_sentiment_score": "0.127755",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.223179",
        "ticker_sentiment_score": "-0.095741",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NOW",
        "relevance_score": "0.075279",
        "ticker_sentiment_score": "0.031255",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LRCX",
        "relevance_score": "0.112709",
        "ticker_sentiment_score": "0.034088",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.112709",
        "ticker_sentiment_score": "0.206348",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Should Schwab U.S. Dividend Equity ETF  ( SCHD )  Be on Your Investing Radar?",
    "url": "https://www.zacks.com/stock/news/2215497/should-schwab-us-dividend-equity-etf-schd-be-on-your-investing-radar",
    "time_published": "20240125T112006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Style Box ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default70.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.230872,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SCHW",
        "relevance_score": "0.060236",
        "ticker_sentiment_score": "0.124005",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.12013",
        "ticker_sentiment_score": "0.067797",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.12013",
        "ticker_sentiment_score": "0.067797",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.12013",
        "ticker_sentiment_score": "0.067797",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the iShares Biotechnology ETF  ( IBB ) ?",
    "url": "https://www.zacks.com/stock/news/2215507/should-you-invest-in-the-ishares-biotechnology-etf-ibb",
    "time_published": "20240125T112004",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default206.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999998"
      }
    ],
    "overall_sentiment_score": 0.193755,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.034094",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.138066",
        "ticker_sentiment_score": "0.072464",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.138066",
        "ticker_sentiment_score": "0.072464",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.138066",
        "ticker_sentiment_score": "0.072464",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Novartis, Amgen, Palo Alto, Brown & Brown and Ericsson",
    "url": "https://www.zacks.com/stock/news/2215470/the-zacks-analyst-blog-highlights-novartis-amgen-palo-alto-brown-brown-and-ericsson",
    "time_published": "20240125T095800",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Novartis, Amgen, Palo Alto, Brown & Brown and Ericsson are included in this Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b7/2350.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.211029,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVS",
        "relevance_score": "0.209365",
        "ticker_sentiment_score": "0.052725",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.404563",
        "ticker_sentiment_score": "0.181316",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BRO",
        "relevance_score": "0.140485",
        "ticker_sentiment_score": "0.040143",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KDNY",
        "relevance_score": "0.070517",
        "ticker_sentiment_score": "0.210472",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PANW",
        "relevance_score": "0.276648",
        "ticker_sentiment_score": "0.183713",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Apple, Boeing, Microsoft, Alphabet And A Fed Meeting, For Starters: Investing Action Plan",
    "url": "https://www.investors.com/research/investing-action-plan/apple-boeing-microsoft-alphabet-and-a-fed-meeting-for-starters-investing-action-plan/",
    "time_published": "20240126T223200",
    "authors": [
      "Investor's Business Daily",
      "ALAN R. ELLIOTT"
    ],
    "summary": "As the stock market pushes its rally toward the end of a third straight month, some of its biggest names line up for earnings releases in the coming week. Apple ( AAPL ) , Alphabet ( GOOGL ) , Microsoft ( MSFT ) and Meta Platforms ( META ) are part of the picture.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2021/01/Stock-FlagFlying-07-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.141296,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.142777",
        "ticker_sentiment_score": "0.16668",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.142777",
        "ticker_sentiment_score": "0.073727",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.281018",
        "ticker_sentiment_score": "0.06179",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.212736",
        "ticker_sentiment_score": "-0.037429",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDNDF",
        "relevance_score": "0.035875",
        "ticker_sentiment_score": "-0.050291",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HON",
        "relevance_score": "0.071677",
        "ticker_sentiment_score": "-0.053265",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXPE",
        "relevance_score": "0.107335",
        "ticker_sentiment_score": "0.086411",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.071677",
        "ticker_sentiment_score": "0.012189",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FLS",
        "relevance_score": "0.107335",
        "ticker_sentiment_score": "0.086411",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.071677",
        "ticker_sentiment_score": "-0.053265",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.107335",
        "ticker_sentiment_score": "-0.013276",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.107335",
        "ticker_sentiment_score": "0.07479",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ANSS",
        "relevance_score": "0.035875",
        "ticker_sentiment_score": "0.075813",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.107335",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNPS",
        "relevance_score": "0.107335",
        "ticker_sentiment_score": "0.086411",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PINS",
        "relevance_score": "0.107335",
        "ticker_sentiment_score": "0.086411",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.107335",
        "ticker_sentiment_score": "-0.01194",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "P/E Ratio Insights for Amgen - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/insights/news/24/01/36808927/pe-ratio-insights-for-amgen",
    "time_published": "20240126T204514",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "In the current session, the stock is trading at $310.50, after a 0.08% spike. Over the past month, Amgen Inc. AMGN stock increased by 8.17%, and in the past year, by 23.83%.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": -0.044875,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.43852",
        "ticker_sentiment_score": "0.061083",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Regenerative Medicine Market Worth $49.0 Billion | MarketsandMarkets\u2122.",
    "url": "https://www.prnewswire.com/news-releases/regenerative-medicine-market-worth-49-0-billion--marketsandmarkets-302044495.html",
    "time_published": "20240126T153000",
    "authors": [
      "MarketsandMarkets"
    ],
    "summary": "CHICAGO, Jan. 26, 2024 /PRNewswire/ -- Regenerative Medicine Market in terms of revenue was estimated to be worth $16.0 billion in 2023 and is poised to reach $49.0 billion by 2028, growing at a CAGR of 25.1% from 2023 to 2028 according to a new report by MarketsandMarkets\u2122.",
    "banner_image": "https://mma.prnewswire.com/media/1951202/MarketsandMarkets.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.310955,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.036926",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SRPT",
        "relevance_score": "0.073773",
        "ticker_sentiment_score": "0.107998",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.073773",
        "ticker_sentiment_score": "0.107998",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.073773",
        "ticker_sentiment_score": "0.107998",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.073773",
        "ticker_sentiment_score": "0.107998",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.073773",
        "ticker_sentiment_score": "0.107998",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JCRRF",
        "relevance_score": "0.073773",
        "ticker_sentiment_score": "0.107998",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TAK",
        "relevance_score": "0.073773",
        "ticker_sentiment_score": "0.107998",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Key Takeaways From JNJ's  ( JNJ )  Q4 Earnings Presentation",
    "url": "https://www.zacks.com/stock/news/2216453/key-takeaways-from-jnjs-jnj-q4-earnings-presentation",
    "time_published": "20240126T143000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "J&J's (JNJ) Innovative Medicines as well as MedTech units outperform expectations in the fourth quarter. Here we discuss some highlights of its performance in the fourth quarter.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7d/1177.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.211414,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.114137",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.114137",
        "ticker_sentiment_score": "0.145984",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMAM",
        "relevance_score": "0.114137",
        "ticker_sentiment_score": "0.123283",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.114137",
        "ticker_sentiment_score": "0.060868",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Futures Lower Ahead Of Key Inflation Data",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-intel-plunges-on-earnings-cathie-wood-loads-up-as-tesla-dives/",
    "time_published": "20240126T131800",
    "authors": [
      "SCOTT LEHTONEN",
      "Investor's Business Daily"
    ],
    "summary": "Dow Jones Futures Fall As Intel Plunges On Earnings. Cathie Wood Loads Up As Tesla Dives Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2017/03/stock-wallstreet-031317-shutter.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      }
    ],
    "overall_sentiment_score": 0.026473,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "DKNG",
        "relevance_score": "0.135602",
        "ticker_sentiment_score": "0.12277",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MELI",
        "relevance_score": "0.135602",
        "ticker_sentiment_score": "0.11151",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.045396",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.224072",
        "ticker_sentiment_score": "-0.170472",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "SPOT",
        "relevance_score": "0.180124",
        "ticker_sentiment_score": "0.121601",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNOW",
        "relevance_score": "0.180124",
        "ticker_sentiment_score": "-0.019372",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INTC",
        "relevance_score": "0.135602",
        "ticker_sentiment_score": "-0.250998",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.135602",
        "ticker_sentiment_score": "0.144099",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WDC",
        "relevance_score": "0.045396",
        "ticker_sentiment_score": "-0.032952",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.090645",
        "ticker_sentiment_score": "-0.356882",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.045396",
        "ticker_sentiment_score": "0.034912",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.180124",
        "ticker_sentiment_score": "0.148327",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen's Planning to Take a Bite Out of Cancer. Here's What It Means for the Stock.",
    "url": "https://www.fool.com/investing/2024/01/27/amgens-planning-to-take-a-bite-out-of-cancer-heres/",
    "time_published": "20240127T140000",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "Its new approach to treating cancer is more than just a nibble around the edges.",
    "banner_image": "https://g.foolcdn.com/editorial/images/761951/chemist-team-looking-beaker-of-green-chemical.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.16657,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.425541",
        "ticker_sentiment_score": "0.270512",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HARP",
        "relevance_score": "0.063933",
        "ticker_sentiment_score": "0.129933",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Buy the Dogs of the Dow in 2024?",
    "url": "https://www.fool.com/investing/2024/01/27/should-you-buy-the-dogs-of-the-dow-in-2024/",
    "time_published": "20240127T115900",
    "authors": [
      "Jeremy Bowman"
    ],
    "summary": "The popular dividend-investing strategy has been around for years. Is it right for you?",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F762238%2Fman-holding-cash-dividends.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.989041"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.192136,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.064797",
        "ticker_sentiment_score": "0.134527",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.129168",
        "ticker_sentiment_score": "0.089459",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.064797",
        "ticker_sentiment_score": "0.134527",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.064797",
        "ticker_sentiment_score": "0.134527",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen  ( NASDAQ:AMGN )  Upgraded to Strong-Buy at StockNews.com",
    "url": "https://www.defenseworld.net/2024/01/27/amgen-nasdaqamgn-upgraded-to-strong-buy-at-stocknews-com.html",
    "time_published": "20240127T103043",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Amgen ( NASDAQ:AMGN - Get Free Report ) was upgraded by equities researchers at StockNews.com from a \"buy\" rating to a \"strong-buy\" rating in a research note issued to investors on Saturday. Other equities research analysts also recently issued reports about the company.",
    "banner_image": "https://www.marketbeat.com/logos/amgen-inc-logo-1200x675.jpg?v=20231228113741",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.986564"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.285331,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TFC",
        "relevance_score": "0.040553",
        "ticker_sentiment_score": "0.047322",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TKOMF",
        "relevance_score": "0.081001",
        "ticker_sentiment_score": "0.245498",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.040553",
        "ticker_sentiment_score": "0.047322",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.040553",
        "ticker_sentiment_score": "0.083332",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JPM",
        "relevance_score": "0.040553",
        "ticker_sentiment_score": "0.047322",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Renal Anemia Therapeutics Market to Record Growth of USD 2.08 billion from 2023 to 2028, Akebia Therapeutics Inc ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/renal-anemia-therapeutics-market-to-record-growth-of-usd-2-08-billion-from-2023-to-2028--akebia-therapeutics-inc-and-amgen-inc-to-emerge-as-some-of-the-key-companies---technavio-302045440.html",
    "time_published": "20240129T233000",
    "authors": [],
    "summary": "Renal Anemia Therapeutics Market to Record Growth of USD 2.08 billion from 2023 to 2028, Akebia Therapeutics Inc ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.242506,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TVTX",
        "relevance_score": "0.050572",
        "ticker_sentiment_score": "0.10634",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAYZF",
        "relevance_score": "0.050572",
        "ticker_sentiment_score": "0.10634",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MTLHF",
        "relevance_score": "0.050572",
        "ticker_sentiment_score": "0.10634",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALPMF",
        "relevance_score": "0.050572",
        "ticker_sentiment_score": "0.10634",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SKXJF",
        "relevance_score": "0.050572",
        "ticker_sentiment_score": "0.10634",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FGEN",
        "relevance_score": "0.050572",
        "ticker_sentiment_score": "0.10634",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KNBWF",
        "relevance_score": "0.050572",
        "ticker_sentiment_score": "0.10634",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSKYF",
        "relevance_score": "0.050572",
        "ticker_sentiment_score": "0.10634",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.100941",
        "ticker_sentiment_score": "0.114068",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.050572",
        "ticker_sentiment_score": "0.10634",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JAPAF",
        "relevance_score": "0.050572",
        "ticker_sentiment_score": "0.10634",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.050572",
        "ticker_sentiment_score": "0.10634",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AKBA",
        "relevance_score": "0.150906",
        "ticker_sentiment_score": "0.136331",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CMXHF",
        "relevance_score": "0.050572",
        "ticker_sentiment_score": "0.10634",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSBHF",
        "relevance_score": "0.050572",
        "ticker_sentiment_score": "0.10634",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Futures: Fed Meeting On Deck; AI Leader Surges Late",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-fed-meeting-on-deck-ai-stock-supermicro-surges-on-earnings-beat/",
    "time_published": "20240129T215400",
    "authors": [
      "Investor's Business Daily",
      "SCOTT LEHTONEN"
    ],
    "summary": "Dow Jones Futures: Fed Meeting On Deck. AI Stock Supermicro Surges On Earnings Beat Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2019/01/stock-FederalReserve-snow-11-shutter.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      }
    ],
    "overall_sentiment_score": 0.191332,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "DKNG",
        "relevance_score": "0.152018",
        "ticker_sentiment_score": "0.003973",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.114318",
        "ticker_sentiment_score": "0.257989",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.076358",
        "ticker_sentiment_score": "0.221211",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.226301",
        "ticker_sentiment_score": "0.147618",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPOT",
        "relevance_score": "0.114318",
        "ticker_sentiment_score": "0.087623",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNOW",
        "relevance_score": "0.114318",
        "ticker_sentiment_score": "0.042771",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.114318",
        "ticker_sentiment_score": "0.093199",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.114318",
        "ticker_sentiment_score": "0.225418",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "EXPE",
        "relevance_score": "0.114318",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.114318",
        "ticker_sentiment_score": "0.072028",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.152018",
        "ticker_sentiment_score": "0.163939",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.152018",
        "ticker_sentiment_score": "0.036316",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SHAK",
        "relevance_score": "0.076358",
        "ticker_sentiment_score": "0.014542",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.076358",
        "ticker_sentiment_score": "0.234483",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.152018",
        "ticker_sentiment_score": "0.14465",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Will Amgen  ( AMGN )  Beat Estimates Again in Its Next Earnings Report?",
    "url": "https://www.zacks.com/stock/news/2217364/will-amgen-amgn-beat-estimates-again-in-its-next-earnings-report",
    "time_published": "20240129T171011",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default266.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.99998"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.306554,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.407844",
        "ticker_sentiment_score": "0.460842",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Investors Heavily Search Amgen Inc.  ( AMGN ) : Here is What You Need to Know",
    "url": "https://www.zacks.com/stock/news/2216980/investors-heavily-search-amgen-inc-amgn-here-is-what-you-need-to-know",
    "time_published": "20240129T140006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default101.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.210853,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.490323",
        "ticker_sentiment_score": "0.104893",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Amgen a Good Dividend Stock to Buy Right Now?",
    "url": "https://www.fool.com/investing/2024/01/29/is-amgen-a-good-dividend-stock-to-buy-right-now/",
    "time_published": "20240129T133000",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "Its diverse product mix and strong fundamentals make a decent case.",
    "banner_image": "https://g.foolcdn.com/editorial/images/762667/investor-inspects-papers-on-a-couch.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.938793"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.996023"
      }
    ],
    "overall_sentiment_score": 0.135694,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.43494",
        "ticker_sentiment_score": "0.265827",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Can Amgen  ( AMGN )  Keep the Beat Streak Alive in Q4 Earnings?",
    "url": "https://www.zacks.com/stock/news/2216908/can-amgen-amgn-keep-the-beat-streak-alive-in-q4-earnings",
    "time_published": "20240129T131800",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/13/816.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.228078,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.360752",
        "ticker_sentiment_score": "0.33925",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.230454",
        "ticker_sentiment_score": "0.051738",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.230454",
        "ticker_sentiment_score": "-0.00176",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Futures Mixed Ahead Of Busy Week",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-ahead-of-busy-week-sofi-stock-surges-on-first-ever-profit/",
    "time_published": "20240129T130600",
    "authors": [
      "SCOTT LEHTONEN",
      "Investor's Business Daily"
    ],
    "summary": "Dow Jones Futures Fall Ahead Of Busy Week. SoFi Stock Surges On First Ever Profit Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2021/09/Stock-wallstreetflag-01-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.166003,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "DKNG",
        "relevance_score": "0.107817",
        "ticker_sentiment_score": "0.076704",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.107817",
        "ticker_sentiment_score": "0.225161",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.143415",
        "ticker_sentiment_score": "0.102174",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.143415",
        "ticker_sentiment_score": "0.122362",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPOT",
        "relevance_score": "0.143415",
        "ticker_sentiment_score": "0.106252",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNOW",
        "relevance_score": "0.143415",
        "ticker_sentiment_score": "0.001274",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.072",
        "ticker_sentiment_score": "0.127872",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.036037",
        "ticker_sentiment_score": "0.116113",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.143415",
        "ticker_sentiment_score": "0.073996",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.107817",
        "ticker_sentiment_score": "0.107064",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MELI",
        "relevance_score": "0.036037",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.143415",
        "ticker_sentiment_score": "0.102174",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SOFI",
        "relevance_score": "0.107817",
        "ticker_sentiment_score": "0.066126",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.072",
        "ticker_sentiment_score": "0.207777",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.072",
        "ticker_sentiment_score": "-0.040665",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "deCODE genetics: A sequence variant that increases risk of pregnancy loss",
    "url": "https://investingnews.com/decode-genetics-a-sequence-variant-that-increases-risk-of-pregnancy-loss/",
    "time_published": "20240129T110500",
    "authors": [
      "Investing News Network"
    ],
    "summary": "Scientists at deCODE genetics, a subsidiary of Amgen, and their collaborators from Iceland Denmark, and the USA published a study today in Nature Structural & Molecular Biology titled \"Variant in the synaptonemal complex protein SYCE2 associates with pregnancy loss through effects on ...",
    "banner_image": "https://mma.prnewswire.com/media/152881/amgen_logo.jpg",
    "source": "Investing News Network",
    "category_within_source": "n/a",
    "source_domain": "investingnews.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.097146,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.306963",
        "ticker_sentiment_score": "-0.154352",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "deCODE genetics: A sequence variant that increases risk of pregnancy loss - Canada NewsWire",
    "url": "https://www.newswire.ca/news-releases/decode-genetics-a-sequence-variant-that-increases-risk-of-pregnancy-loss-804766724.html",
    "time_published": "20240129T100000",
    "authors": [],
    "summary": "deCODE genetics: A sequence variant that increases risk of pregnancy loss Canada ...",
    "banner_image": null,
    "source": "Canada Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.newswire.ca",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.103983,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.303175",
        "ticker_sentiment_score": "-0.142151",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "deCODE genetics: A sequence variant that increases risk of pregnancy loss - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/decode-genetics-a-sequence-variant-that-increases-risk-of-pregnancy-loss-302043584.html",
    "time_published": "20240129T100000",
    "authors": [],
    "summary": "deCODE genetics: A sequence variant that increases risk of pregnancy loss PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.16865,
    "overall_sentiment_label": "Somewhat-Bearish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.263942",
        "ticker_sentiment_score": "-0.127168",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "deCODE genetics: Eine Sequenzvariante, die das Risiko eines Schwangerschaftsverlusts erh\u00f6ht USA - Deutsch - USA - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/decode-genetics-eine-sequenzvariante-die-das-risiko-eines-schwangerschaftsverlusts-erhoht-302044475.html",
    "time_published": "20240129T100000",
    "authors": [],
    "summary": "deCODE genetics: Eine Sequenzvariante, die das Risiko eines Schwangerschaftsverlusts erh\u00f6ht USA - Deutsch - USA PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.298702,
    "overall_sentiment_label": "Somewhat-Bearish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.231332",
        "ticker_sentiment_score": "-0.100448",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UBER",
        "relevance_score": "0.058615",
        "ticker_sentiment_score": "-0.096989",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "deCODE genetics: Una variante de secuencia que aumenta el riesgo de p\u00e9rdida del embarazo - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/decode-genetics-una-variante-de-secuencia-que-aumenta-el-riesgo-de-perdida-del-embarazo-302043800.html",
    "time_published": "20240129T100000",
    "authors": [],
    "summary": "deCODE genetics: Una variante de secuencia que aumenta el riesgo de p\u00e9rdida del embarazo PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.133814,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.199447",
        "ticker_sentiment_score": "-0.018663",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "deCODE genetics : Un variant de s\u00e9quence qui augmente le risque de fausse couche - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/decode-genetics--un-variant-de-sequence-qui-augmente-le-risque-de-fausse-couche-302044593.html",
    "time_published": "20240129T100000",
    "authors": [],
    "summary": "deCODE genetics : Un variant de s\u00e9quence qui augmente le risque de fausse couche PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.025329,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.163909",
        "ticker_sentiment_score": "0.02134",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia\u00ae and Xgeva\u00ae",
    "url": "https://www.globenewswire.com/news-release/2024/01/29/2818530/0/en/Alvotech-Announces-Positive-Top-Line-Results-from-a-Pharmacokinetic-Study-for-AVT03-a-Proposed-Biosimilar-for-Prolia-and-Xgeva.html",
    "time_published": "20240129T090000",
    "authors": [
      "Alvotech"
    ],
    "summary": "Alvotech ( NASDAQ: ALVO ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today positive top-line results from a pharmacokinetic ( PK ) study for AVT03, a biosimilar candidate to Prolia\u00ae and Xgeva\u00ae, which both ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.139843,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ALVO",
        "relevance_score": "0.513239",
        "ticker_sentiment_score": "0.189162",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.025219",
        "ticker_sentiment_score": "0.059184",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.025219",
        "ticker_sentiment_score": "0.059184",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.025219",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTUS",
        "relevance_score": "0.025219",
        "ticker_sentiment_score": "0.059184",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia\u00ae and Xgeva\u00ae",
    "url": "https://www.globenewswire.com/news-release/2024/01/29/2818535/0/en/Alvotech-Announces-Positive-Top-Line-Results-from-a-Pharmacokinetic-Study-for-AVT03-a-Proposed-Biosimilar-for-Prolia-and-Xgeva.html",
    "time_published": "20240129T090000",
    "authors": [
      "Alvotech"
    ],
    "summary": "REYKJAVIK, Iceland, Jan. 29, 2024 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today positive top-line results from a pharmacokinetic ( PK ) study for AVT03, a ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.139816,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ALVO",
        "relevance_score": "0.510497",
        "ticker_sentiment_score": "0.185412",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.02506",
        "ticker_sentiment_score": "0.059122",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.02506",
        "ticker_sentiment_score": "0.059122",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.02506",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTUS",
        "relevance_score": "0.02506",
        "ticker_sentiment_score": "0.059122",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen Options Trading: A Deep Dive into Market Sentiment - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/insights/options/24/01/36853303/amgen-options-trading-a-deep-dive-into-market-sentiment",
    "time_published": "20240130T200044",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Deep-pocketed investors have adopted a bullish approach towards Amgen AMGN, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      }
    ],
    "overall_sentiment_score": 0.108864,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.814341",
        "ticker_sentiment_score": "0.219763",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Will Amazon's  ( AMZN )  Q4 Earnings Benefit From AWS Momentum?",
    "url": "https://www.zacks.com/stock/news/2218033/will-amazons-amzn-q4-earnings-benefit-from-aws-momentum",
    "time_published": "20240130T151400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amazon's (AMZN) fourth-quarter results are likely to reflect benefits from AWS' expanding customer base, driven by the strong services portfolio and rising number of cloud regions.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/a4/1882.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.205573,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ANET",
        "relevance_score": "0.261117",
        "ticker_sentiment_score": "0.231748",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BKAHF",
        "relevance_score": "0.066414",
        "ticker_sentiment_score": "0.033334",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSBHF",
        "relevance_score": "0.066414",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.197413",
        "ticker_sentiment_score": "0.289785",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MUFG",
        "relevance_score": "0.066414",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.323078",
        "ticker_sentiment_score": "0.108879",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXXTF",
        "relevance_score": "0.066414",
        "ticker_sentiment_score": "-0.16746",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Amgen  ( AMGN )  Earnings Expected to Grow: What to Know Ahead of Next Week's Release",
    "url": "https://www.zacks.com/stock/news/2218010/amgen-amgn-earnings-expected-to-grow-what-to-know-ahead-of-next-weeks-release",
    "time_published": "20240130T150049",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default338.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.156171,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.258808",
        "ticker_sentiment_score": "0.216361",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.087663",
        "ticker_sentiment_score": "0.038054",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Futures Fall Ahead Of Key Economic Data",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-key-economic-data-alphabet-amd-microsoft-to-report-earnings/",
    "time_published": "20240130T132300",
    "authors": [
      "Investor's Business Daily",
      "SCOTT LEHTONEN"
    ],
    "summary": "Dow Jones futures fell slightly Tuesday morning, as Wall Street prepared for key economic data, with the early release of two housing reports, consumer confidence numbers and job openings.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2017/04/stock-wallstreet-shutter.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.111578,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "DKNG",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.04644",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.071784",
        "ticker_sentiment_score": "0.115734",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.096854",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPOT",
        "relevance_score": "0.107495",
        "ticker_sentiment_score": "0.098818",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNOW",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.027056",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GM",
        "relevance_score": "0.035929",
        "ticker_sentiment_score": "0.222658",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.107495",
        "ticker_sentiment_score": "0.078383",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.035929",
        "ticker_sentiment_score": "0.034318",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.05936",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.035929",
        "ticker_sentiment_score": "0.222658",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.111156",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.096854",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PHM",
        "relevance_score": "0.035929",
        "ticker_sentiment_score": "0.222658",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMD",
        "relevance_score": "0.071784",
        "ticker_sentiment_score": "0.112764",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.128408",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen  ( AMGN )  Stock Moves -0.11%: What You Should Know",
    "url": "https://www.zacks.com/stock/news/2219074/amgen-amgn-stock-moves--011-what-you-should-know",
    "time_published": "20240131T225018",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) reachead $314.26 at the closing of the latest trading day, reflecting a -0.11% change compared to its last close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default210.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.160326,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.575407",
        "ticker_sentiment_score": "0.179308",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly  ( LLY )  to Report Q4 Earnings: What's in the Cards?",
    "url": "https://www.zacks.com/stock/news/2218932/eli-lilly-lly-to-report-q4-earnings-whats-in-the-cards",
    "time_published": "20240131T164800",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "On Eli Lilly's (LLY) fourth-quarter conference call, investor focus is likely to be on the sales performance of its tirzepatide medicines, Mounjaro and Zepbound.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/39/612.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.99998"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      }
    ],
    "overall_sentiment_score": 0.138198,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.400691",
        "ticker_sentiment_score": "0.13284",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.207216",
        "ticker_sentiment_score": "0.058657",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.207216",
        "ticker_sentiment_score": "0.047535",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.207216",
        "ticker_sentiment_score": "-0.001617",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Regeneron  ( REGN )  to Report Q4 Earnings: What's in the Cards?",
    "url": "https://www.zacks.com/stock/news/2218887/regeneron-regn-to-report-q4-earnings-whats-in-the-cards",
    "time_published": "20240131T162000",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when Regeneron (REGN) reports its fourth-quarter 2023 results.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/29/44156.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999989"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.224321,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "REGN",
        "relevance_score": "0.303175",
        "ticker_sentiment_score": "0.274645",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.17618",
        "ticker_sentiment_score": "0.122537",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SRPT",
        "relevance_score": "0.132611",
        "ticker_sentiment_score": "0.12814",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAYZF",
        "relevance_score": "0.044386",
        "ticker_sentiment_score": "0.072604",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.343875",
        "ticker_sentiment_score": "0.245908",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Futures Mixed Ahead Of Fed Decision, Powell",
    "url": "https://www.investors.com/market-trend/stock-market-today/tech-falls-dow-jones-futures-rise-ahead-of-fed-decision-amd-google-microsoft-tesla-slide/",
    "time_published": "20240131T132100",
    "authors": [
      "SCOTT LEHTONEN",
      "Investor's Business Daily"
    ],
    "summary": "Dow Jones Futures Rise Ahead Of Today's Fed Decision, Powell. Google, Microsoft, Tesla Slide Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2022/06/Stock-jeromepowell2022-05-gov.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.067028,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "DKNG",
        "relevance_score": "0.216473",
        "ticker_sentiment_score": "0.0821",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.043818",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNOW",
        "relevance_score": "0.173958",
        "ticker_sentiment_score": "0.119702",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.130926",
        "ticker_sentiment_score": "0.136821",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.043818",
        "ticker_sentiment_score": "0.034852",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.173958",
        "ticker_sentiment_score": "0.12846",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.130926",
        "ticker_sentiment_score": "0.15035",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.173958",
        "ticker_sentiment_score": "-0.05982",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MA",
        "relevance_score": "0.043818",
        "ticker_sentiment_score": "-0.02796",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SBUX",
        "relevance_score": "0.043818",
        "ticker_sentiment_score": "-0.02796",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMD",
        "relevance_score": "0.130926",
        "ticker_sentiment_score": "0.012269",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.043818",
        "ticker_sentiment_score": "-0.02796",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.173958",
        "ticker_sentiment_score": "0.083352",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why you can count on the Dow making changes in February",
    "url": "https://www.marketwatch.com/story/why-you-can-count-on-the-dow-making-changes-in-february-6334fda9",
    "time_published": "20240201T164900",
    "authors": [
      "Tomi Kilgore"
    ],
    "summary": "Investors can count on the Dow Jones Industrial Average changing its members next month, for the first time in nearly four years, for several reasons. The question is, who's out and who's in?",
    "banner_image": "https://images.mktw.net/im-47719801/social",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.021159,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.113776",
        "ticker_sentiment_score": "0.040846",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.075995",
        "ticker_sentiment_score": "0.113263",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.075995",
        "ticker_sentiment_score": "-0.087921",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HON",
        "relevance_score": "0.075995",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.03804",
        "ticker_sentiment_score": "0.035336",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.075995",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.075995",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.075995",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.075995",
        "ticker_sentiment_score": "0.031594",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "V",
        "relevance_score": "0.075995",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RTX",
        "relevance_score": "0.075995",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WBA",
        "relevance_score": "0.075995",
        "ticker_sentiment_score": "0.031594",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.075995",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.075995",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.075995",
        "ticker_sentiment_score": "0.111234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.113776",
        "ticker_sentiment_score": "-0.057467",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Futures Rebound Ahead Of Jobless Claims",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-jobless-claims-amazon-apple-to-report/",
    "time_published": "20240201T143300",
    "authors": [
      "SCOTT LEHTONEN",
      "Investor's Business Daily"
    ],
    "summary": "Dow Jones Rises On Surprise Jobless Claims. Amazon, Apple To Report Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2019/10/stock-wall-street-flags-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.12074,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "DKNG",
        "relevance_score": "0.218423",
        "ticker_sentiment_score": "0.023672",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.044222",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.175539",
        "ticker_sentiment_score": "0.1099",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNOW",
        "relevance_score": "0.175539",
        "ticker_sentiment_score": "0.151815",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.132125",
        "ticker_sentiment_score": "0.125522",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.044222",
        "ticker_sentiment_score": "0.201665",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSCO",
        "relevance_score": "0.044222",
        "ticker_sentiment_score": "0.088953",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.175539",
        "ticker_sentiment_score": "0.136375",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.044222",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QCOM",
        "relevance_score": "0.044222",
        "ticker_sentiment_score": "0.088953",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RCL",
        "relevance_score": "0.044222",
        "ticker_sentiment_score": "0.088953",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.175539",
        "ticker_sentiment_score": "0.1099",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NXT(EXP20091224)",
        "relevance_score": "0.044222",
        "ticker_sentiment_score": "0.088953",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.175539",
        "ticker_sentiment_score": "0.092629",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Unlocking Q4 Potential of Amgen  ( AMGN ) : Exploring Wall Street Estimates for Key Metrics",
    "url": "https://www.zacks.com/stock/news/2219395/unlocking-q4-potential-of-amgen-amgn-exploring-wall-street-estimates-for-key-metrics",
    "time_published": "20240201T141521",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Get a deeper insight into the potential performance of Amgen (AMGN) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default345.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.986564"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.11103,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.349575",
        "ticker_sentiment_score": "0.19197",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Is Amgen Stock a Buy Now?",
    "url": "https://www.fool.com/investing/2024/02/01/is-amgen-stock-a-buy-now/",
    "time_published": "20240201T121500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "The biotech has an excellent track record, but that isn't enough to make its shares attractive.",
    "banner_image": "https://media.ycharts.com/charts/ab9f69f99bc0bdaf75981f43e8df629b.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.215565,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.70166",
        "ticker_sentiment_score": "0.260005",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.063763",
        "ticker_sentiment_score": "0.091345",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is iShares Biotechnology ETF  ( IBB )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2219196/is-ishares-biotechnology-etf-ibb-a-strong-etf-right-now",
    "time_published": "20240201T112006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default34.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999892"
      }
    ],
    "overall_sentiment_score": 0.253936,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.061631",
        "ticker_sentiment_score": "0.10902",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "0.06159",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "0.06159",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "0.06159",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Disney, Caterpillar, McDonald's, Ford: Investing Action Plan",
    "url": "https://www.investors.com/research/investing-action-plan/disney-stock-caterpillar-mcdonalds-ford-investing-action-plan/",
    "time_published": "20240202T230000",
    "authors": [
      "ALAN R. ELLIOTT",
      "Investor's Business Daily"
    ],
    "summary": "Disney Stock, Caterpillar, McDonald's, Ford: Investing Action Plan Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2019/01/stock-NYSE-05-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.998356"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.115657,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "PYPL",
        "relevance_score": "0.053931",
        "ticker_sentiment_score": "-0.065969",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TENB",
        "relevance_score": "0.080819",
        "ticker_sentiment_score": "0.021495",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDNDF",
        "relevance_score": "0.026981",
        "ticker_sentiment_score": "0.028291",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GM",
        "relevance_score": "0.053931",
        "ticker_sentiment_score": "0.094",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ILMN",
        "relevance_score": "0.053931",
        "ticker_sentiment_score": "-0.017985",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NXPI",
        "relevance_score": "0.053931",
        "ticker_sentiment_score": "0.070764",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDB",
        "relevance_score": "0.080819",
        "ticker_sentiment_score": "0.098148",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPG",
        "relevance_score": "0.080819",
        "ticker_sentiment_score": "0.065573",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.053931",
        "ticker_sentiment_score": "0.030931",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LITE",
        "relevance_score": "0.053931",
        "ticker_sentiment_score": "-0.046811",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "URI",
        "relevance_score": "0.080819",
        "ticker_sentiment_score": "0.091947",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LEN",
        "relevance_score": "0.080819",
        "ticker_sentiment_score": "0.098148",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MCK",
        "relevance_score": "0.053931",
        "ticker_sentiment_score": "0.141",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FTNT",
        "relevance_score": "0.053931",
        "ticker_sentiment_score": "0.020982",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ORLY",
        "relevance_score": "0.080819",
        "ticker_sentiment_score": "0.007181",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAT",
        "relevance_score": "0.134289",
        "ticker_sentiment_score": "0.074545",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ENB",
        "relevance_score": "0.080819",
        "ticker_sentiment_score": "0.027839",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.080819",
        "ticker_sentiment_score": "0.0255",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNPS",
        "relevance_score": "0.080819",
        "ticker_sentiment_score": "0.098148",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GLOB",
        "relevance_score": "0.080819",
        "ticker_sentiment_score": "0.098148",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.053931",
        "ticker_sentiment_score": "0.11074",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TTWO",
        "relevance_score": "0.053931",
        "ticker_sentiment_score": "0.05579",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Q4 Earnings Beat, Raises Sales View for Key Drugs",
    "url": "https://www.zacks.com/stock/news/2220511/abbvie-abbv-q4-earnings-beat-raises-sales-view-for-key-drugs",
    "time_published": "20240202T180400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie???s (ABBV) fourth-quarter earnings and sales beat estimates. Management hikes the 2027 forecast for new immunology drugs to more than $27 billion.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d5/8276.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.998645"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.12283,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CHRS",
        "relevance_score": "0.036926",
        "ticker_sentiment_score": "-0.026577",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CERE",
        "relevance_score": "0.036926",
        "ticker_sentiment_score": "0.126273",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.288893",
        "ticker_sentiment_score": "0.265849",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.146916",
        "ticker_sentiment_score": "0.01294",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GMAB",
        "relevance_score": "0.073773",
        "ticker_sentiment_score": "0.26213",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.073773",
        "ticker_sentiment_score": "0.131161",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Amgen's Weight-Loss News Just Sent Lilly To A Record High",
    "url": "https://www.investors.com/news/technology/amgen-stock-slumps-as-it-looks-to-take-on-weight-loss-drugs-leaders-lilly-novo/",
    "time_published": "20240205T180800",
    "authors": [
      "Investor's Business Daily",
      "ALLISON GATLIN"
    ],
    "summary": "Amgen Stock Slumps As It Looks To Take On Weight-Loss Drugs Leaders Lilly, Novo Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2022/11/Stock-amgen-08-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99977"
      }
    ],
    "overall_sentiment_score": 0.125806,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.459624",
        "ticker_sentiment_score": "0.267818",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.081276",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.524949",
        "ticker_sentiment_score": "0.07163",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.316846",
        "ticker_sentiment_score": "0.262422",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.316846",
        "ticker_sentiment_score": "0.087971",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AMGN: AMGN Earnings Spotlight: Analyzing Potential Gains",
    "url": "https://stocknews.com/news/amgn-incy-otsky-cort-amgn-earnings-spotlight-analyzing-potential-gains/",
    "time_published": "20240205T165415",
    "authors": [
      "StockNews.com Staff"
    ],
    "summary": "Boasting a strong market cap of $172.96 billion, Amgen Inc. ( AMGN ) specializes in the discovery, development, manufacturing, and distribution of human therapeutics worldwide. The company's extensive product portfolio is dedicated to addressing diverse medical needs, spanning oncology, ...",
    "banner_image": "https://stocknews.com/wp-content/uploads/2023/06/Anushka-Mukherjee_Headshot-2.jpg",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "stocknews.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.99793"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.998356"
      }
    ],
    "overall_sentiment_score": 0.278018,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.714306",
        "ticker_sentiment_score": "0.46284",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "CORT",
        "relevance_score": "0.085022",
        "ticker_sentiment_score": "0.128358",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INCY",
        "relevance_score": "0.085022",
        "ticker_sentiment_score": "0.128358",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Drug, Biotech Stocks' Q4 Earnings Due on Feb 6: AMGN, LLY & More",
    "url": "https://www.zacks.com/stock/news/2221113/drug-biotech-stocks-q4-earnings-due-on-feb-6-amgn-lly-more",
    "time_published": "20240205T150900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Let's take a look at four biotech, drug companies, AMGN, LLY, GILD and EXEL, slated to release quarterly results on Feb 6.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/49/1007.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.090594,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.313674",
        "ticker_sentiment_score": "0.01809",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXEL",
        "relevance_score": "0.270773",
        "ticker_sentiment_score": "-0.072387",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.046006",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.182506",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.313674",
        "ticker_sentiment_score": "0.14336",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.046006",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Weight Loss Drug's New Entrant: Amgen To Compete With Novo Nordisk, Eli Lilly, As Investigational Weight Loss Drug Shows Encouraging Early Data - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/general/biotech/24/02/36934096/weight-loss-drugs-new-entrant-amgen-to-compete-with-novo-nordisk-eli-lilly-as-investigational-wei",
    "time_published": "20240205T150541",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Amgen Inc AMGN has the data from animal and early-stage human trials of its experimental obesity drug AMG 133 ( maridebart cafraglutide ) published in Nature Metabolism.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/weight-loss-Photo-by-Vidmir-Rais-via-Pix.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.03589,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.520773",
        "ticker_sentiment_score": "0.100861",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Futures Lower After Caterpillar, McDonald's Earnings",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-caterpillar-mcdonalds-earnings-nvidia-stock/",
    "time_published": "20240205T131300",
    "authors": [
      "Investor's Business Daily",
      "SCOTT LEHTONEN"
    ],
    "summary": "Dow Jones Futures Fall As Caterpillar, McDonald's Report. Nvidia Surges More Record Highs Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2020/12/Stock-WallSt-Flags-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.142857"
      }
    ],
    "overall_sentiment_score": 0.179478,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.098054",
        "ticker_sentiment_score": "0.070711",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDNDF",
        "relevance_score": "0.098054",
        "ticker_sentiment_score": "0.015979",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "F",
        "relevance_score": "0.098054",
        "ticker_sentiment_score": "-0.182475",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "NXPI",
        "relevance_score": "0.098054",
        "ticker_sentiment_score": "-0.182475",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "EXPE",
        "relevance_score": "0.146618",
        "ticker_sentiment_score": "0.122593",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDB",
        "relevance_score": "0.194632",
        "ticker_sentiment_score": "0.117824",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.04912",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.04912",
        "ticker_sentiment_score": "0.124062",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.098054",
        "ticker_sentiment_score": "-0.182475",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "LEN",
        "relevance_score": "0.146618",
        "ticker_sentiment_score": "0.204298",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CAT",
        "relevance_score": "0.241924",
        "ticker_sentiment_score": "0.103513",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.04912",
        "ticker_sentiment_score": "0.061339",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.194632",
        "ticker_sentiment_score": "0.078633",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Take the Zacks Approach to Beat the Market: NVIDIA, Carrols, CyberArk in Focus",
    "url": "https://www.zacks.com/stock/news/2220779/take-the-zacks-approach-to-beat-the-market-nvidia-carrols-cyberark-in-focus",
    "time_published": "20240205T130200",
    "authors": [
      "Abhinab Dasgupta"
    ],
    "summary": "Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/93/534.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.977154"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.990678"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.215489,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SHOP",
        "relevance_score": "0.069094",
        "ticker_sentiment_score": "0.089311",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.069094",
        "ticker_sentiment_score": "0.089311",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.069094",
        "ticker_sentiment_score": "0.106401",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ANF",
        "relevance_score": "0.069094",
        "ticker_sentiment_score": "0.246542",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CYBR",
        "relevance_score": "0.069094",
        "ticker_sentiment_score": "0.120482",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TAST",
        "relevance_score": "0.069094",
        "ticker_sentiment_score": "0.246542",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.069094",
        "ticker_sentiment_score": "0.060365",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ETN",
        "relevance_score": "0.069094",
        "ticker_sentiment_score": "0.135577",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FICO",
        "relevance_score": "0.103479",
        "ticker_sentiment_score": "0.113822",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen  ( AMGN )  Q4 Earnings and Revenues Top Estimates",
    "url": "https://www.zacks.com/stock/news/2222064/amgen-amgn-q4-earnings-and-revenues-top-estimates",
    "time_published": "20240206T221004",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) delivered earnings and revenue surprises of 1.07% and 1%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default35.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999992"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.171018,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.405651",
        "ticker_sentiment_score": "0.209953",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LXRX",
        "relevance_score": "0.20997",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stocks Shrug Off Losses, Palantir Flies; Snap Dives Late",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-stocks-wont-fall-palantir-flies-snap-crashes-late-fortinet-elf-rise/",
    "time_published": "20240206T221000",
    "authors": [
      "Investor's Business Daily",
      "ED CARSON"
    ],
    "summary": "Dow Jones Futures: Stocks Won't Fall, Palantir Flies. Snap Crashes Late While Fortinet, ELF Rise Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2022/02/Stock-snapchat-04-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.998663"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.142857"
      }
    ],
    "overall_sentiment_score": 0.15052,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BABA",
        "relevance_score": "0.103778",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ENPH",
        "relevance_score": "0.103778",
        "ticker_sentiment_score": "0.091244",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.03468",
        "ticker_sentiment_score": "-0.131376",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TENB",
        "relevance_score": "0.103778",
        "ticker_sentiment_score": "0.107777",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "F",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.183974",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "EXPE",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.150369",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRNS",
        "relevance_score": "0.138066",
        "ticker_sentiment_score": "0.067585",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.03468",
        "ticker_sentiment_score": "0.124292",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.103778",
        "ticker_sentiment_score": "0.091244",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HLT",
        "relevance_score": "0.103778",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FTNT",
        "relevance_score": "0.205807",
        "ticker_sentiment_score": "0.089326",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CMG",
        "relevance_score": "0.138066",
        "ticker_sentiment_score": "0.092417",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UBER",
        "relevance_score": "0.138066",
        "ticker_sentiment_score": "0.067613",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AFRM",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.150369",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BRBR",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "0.082251",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PLTR",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "0.220845",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Amgen's quarterly results top expectations despite Enbrel sales decline",
    "url": "https://www.marketwatch.com/story/amgens-quarterly-results-top-expectations-despite-enbrel-sales-decline-3720269d",
    "time_published": "20240206T214300",
    "authors": [
      "Eleanor Laise"
    ],
    "summary": "Amgen on Tuesday reported fourth quarter profits and sales that topped analyst expectations even as revenues dropped for one of its top-selling drugs.",
    "banner_image": "https://images.mktw.net/im-814193/social",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.023871,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.181819",
        "ticker_sentiment_score": "0.190188",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.578948",
        "ticker_sentiment_score": "0.127919",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen Dips Despite A Record-Breaking Sales Sprint For Nine Drugs",
    "url": "https://www.investors.com/news/technology/amgen-stock-amgen-earnings-q4-2023/",
    "time_published": "20240206T211600",
    "authors": [
      "Investor's Business Daily",
      "ALLISON GATLIN"
    ],
    "summary": "Amgen Stock Dipped Despite Beating Fourth-Quarter Sales Forecasts Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2018/03/stock-amgen-02-shutter.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.890401"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      }
    ],
    "overall_sentiment_score": 0.200475,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.950309",
        "ticker_sentiment_score": "0.274951",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Tech Slides, Chinese Stocks Rebound, New York Community Bancorp Tumbles: What's Driving Markets Tuesday? - Amgen  ( NASDAQ:AMGN ) , BP  ( NYSE:BP ) ",
    "url": "https://www.benzinga.com/markets/equities/24/02/36964052/tech-slides-chinese-stocks-rebound-new-york-community-bancorp-tumbles-whats-driving-markets-tues",
    "time_published": "20240206T192404",
    "authors": [
      "Piero Cingari"
    ],
    "summary": "At noon trading in New York, major equity indices on Wall Street remain directionless as traders evaluate the future course of monetary policy ahead of several speeches by Federal Reserve officials in the days ahead.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Wall-Street_4.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.132785,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "SPOT",
        "relevance_score": "0.177802",
        "ticker_sentiment_score": "0.062224",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "F",
        "relevance_score": "0.177802",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UBS",
        "relevance_score": "0.177802",
        "ticker_sentiment_score": "0.062224",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CCK",
        "relevance_score": "0.177802",
        "ticker_sentiment_score": "0.062224",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.089462",
        "ticker_sentiment_score": "0.130458",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNAP",
        "relevance_score": "0.177802",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.177802",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NYCB",
        "relevance_score": "0.177802",
        "ticker_sentiment_score": "-0.143048",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EW",
        "relevance_score": "0.177802",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FTNT",
        "relevance_score": "0.177802",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GEHC",
        "relevance_score": "0.177802",
        "ticker_sentiment_score": "0.062224",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.177802",
        "ticker_sentiment_score": "0.062224",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.177802",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CMG",
        "relevance_score": "0.177802",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FMC",
        "relevance_score": "0.177802",
        "ticker_sentiment_score": "0.062224",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PLTR",
        "relevance_score": "0.177802",
        "ticker_sentiment_score": "0.42926",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "S&P, Nasdaq Futures Point To Another Day Of Weakness: What's Going On With Stocks? - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , SPDR S&P 500  ( ARCA:SPY ) ",
    "url": "https://www.benzinga.com/news/earnings/24/02/36952531/us-stocks-brace-for-another-day-in-the-red-as-rally-loses-steam-analyst-sees-market-pullback-on-thi",
    "time_published": "20240206T123737",
    "authors": [
      "Shanthi Rexaline"
    ],
    "summary": "U.S. stocks are poised for another day of weakness, although some positive tech earnings may provide a modest lift to the sector. The market appears to be digesting information following a rally that began after the early January downturn.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/nyse-shutter_4.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99676"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.928139"
      }
    ],
    "overall_sentiment_score": -0.024063,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "DD",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSTR",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPOT",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "F",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RMBS",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "-0.208732",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.045655",
        "ticker_sentiment_score": "0.212156",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HTZ",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JJSF",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "-0.348877",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "CRUS",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EW",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CHKP",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CMA",
        "relevance_score": "0.045655",
        "ticker_sentiment_score": "-0.132222",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GEHC",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HRB",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LPLA",
        "relevance_score": "0.045655",
        "ticker_sentiment_score": "0.176076",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "YUMC",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CMG",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SQ",
        "relevance_score": "0.045655",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WU",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PLTR",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "0.309859",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development",
    "url": "https://www.globenewswire.com/news-release/2024/02/06/2824126/0/en/TScan-Therapeutics-Expands-Clinical-Team-with-the-Appointment-of-Dawn-Pinchasik-M-D-M-S-as-Vice-President-Clinical-Development.html",
    "time_published": "20240206T120000",
    "authors": [
      "TScan Therapeutics",
      "Inc."
    ],
    "summary": "WALTHAM, Mass., Feb. 06, 2024 ( GLOBE NEWSWIRE ) -- TScan Therapeutics, Inc. ( Nasdaq: TCRX ) , a clinical-stage biopharmaceutical company focused on the development of T cell receptor ( TCR ) -engineered T cell therapies ( TCR-T ) for the treatment of patients with cancer, today announced the ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/d8d2632e-0ce4-4ed2-940e-22a1c599d43f",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.451494"
      }
    ],
    "overall_sentiment_score": 0.178861,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ALRN",
        "relevance_score": "0.036926",
        "ticker_sentiment_score": "0.045711",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.036926",
        "ticker_sentiment_score": "0.045711",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TCRX",
        "relevance_score": "0.073773",
        "ticker_sentiment_score": "-0.038691",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The first Wall Street bank to make a recession call now expects a narrow landing",
    "url": "https://www.marketwatch.com/story/the-first-wall-street-bank-to-make-a-recession-call-now-expects-a-narrow-landing-660b7549",
    "time_published": "20240206T114000",
    "authors": [
      "Barbara Kollmeyer"
    ],
    "summary": "The U.S. economy will land on a \"narrow path\" this year, and avoid a recession, thanks in part to a better consumer picture, says Deutsche Bank.",
    "banner_image": "https://images.mktw.net/im-54030136?width=700&height=559",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.977154"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.067508,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BABA",
        "relevance_score": "0.087985",
        "ticker_sentiment_score": "0.138488",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPOT",
        "relevance_score": "0.04406",
        "ticker_sentiment_score": "0.047851",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.087985",
        "ticker_sentiment_score": "-0.073181",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CMG",
        "relevance_score": "0.087985",
        "ticker_sentiment_score": "-0.073181",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LRLCF",
        "relevance_score": "0.04406",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.087985",
        "ticker_sentiment_score": "-0.073181",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PLTR",
        "relevance_score": "0.087985",
        "ticker_sentiment_score": "-0.093878",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Is Amgen Stock Trading Lower Today? - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/02/36990013/investors-focus-around-amgens-obesity-drug-data-shadows-better-than-expected-q4-ear",
    "time_published": "20240207T193626",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Tuesday, Amgen Inc AMGN reported its fourth quarter 2023 adjusted net profit increased 15% to $4.71, beating the consensus of $4.62, driven by increased revenues, partially offset by higher operating expenses. For the fourth quarter, total revenues increased 20% to $8.2 billion, beating the ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Amgen-Prolia_0.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.155778,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.097457",
        "ticker_sentiment_score": "0.245227",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.459624",
        "ticker_sentiment_score": "0.473131",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Stock Market Today: Markets Rally As S&P Eyes 5,000 Level; Cathie Wood's Top Pick Surges As Alibaba Tumbles",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-nasdaq-spy-baba-stock-cathie-wood/",
    "time_published": "20240207T190000",
    "authors": [
      "VIDYA RAMAKRISHNAN",
      "Investor's Business Daily"
    ],
    "summary": "Stock Market Today: Markets Rally As S&P Eyes 5000 Level. Cathie Wood's Top Pick Surges Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/01/Stock-BullRun-AI-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.99915"
      }
    ],
    "overall_sentiment_score": 0.091817,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BABA",
        "relevance_score": "0.108794",
        "ticker_sentiment_score": "-0.077988",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.072655",
        "ticker_sentiment_score": "-0.128972",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TENB",
        "relevance_score": "0.072655",
        "ticker_sentiment_score": "-0.021417",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CSCO",
        "relevance_score": "0.072655",
        "ticker_sentiment_score": "-0.128972",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GFF",
        "relevance_score": "0.072655",
        "ticker_sentiment_score": "-0.017264",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEX",
        "relevance_score": "0.036365",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXPE",
        "relevance_score": "0.072655",
        "ticker_sentiment_score": "-0.021417",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.036365",
        "ticker_sentiment_score": "0.087048",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EMR",
        "relevance_score": "0.072655",
        "ticker_sentiment_score": "-0.018303",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.072655",
        "ticker_sentiment_score": "0.051631",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.072655",
        "ticker_sentiment_score": "0.051631",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.072655",
        "ticker_sentiment_score": "-0.128972",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "YUM",
        "relevance_score": "0.072655",
        "ticker_sentiment_score": "0.125941",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AIZ",
        "relevance_score": "0.072655",
        "ticker_sentiment_score": "-0.136047",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FTNT",
        "relevance_score": "0.072655",
        "ticker_sentiment_score": "0.025512",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RBLX",
        "relevance_score": "0.144708",
        "ticker_sentiment_score": "0.119452",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CMG",
        "relevance_score": "0.072655",
        "ticker_sentiment_score": "0.125941",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UBER",
        "relevance_score": "0.108794",
        "ticker_sentiment_score": "-0.12428",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MAS",
        "relevance_score": "0.072655",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ODFL",
        "relevance_score": "0.072655",
        "ticker_sentiment_score": "-0.158298",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "S&P 500 Flirts With 5,000 As Magnificent 7 Tops $13 Trillion, NYCB Sinks: What's Driving Markets Wednesday? - Apple  ( NASDAQ:AAPL ) ",
    "url": "https://www.benzinga.com/markets/equities/24/02/36988926/s-p-500-flirts-with-5-000-as-magnificent-7-tops-13-trillion-nycb-sinks-whats-driving-markets-wed",
    "time_published": "20240207T184042",
    "authors": [
      "Piero Cingari"
    ],
    "summary": "Wednesday is a bullish day on Wall Street, with major large-cap indices extending record highs, aided by robust corporate earnings. Despite the overall market optimism, concerns linger within segments such as regional banks, highlighting investor caution.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Bull-and-bear-stock-market-index_6.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.875462"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.133468,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CVS",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ENPH",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "0.133416",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "0.222562",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "F",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.076847",
        "ticker_sentiment_score": "0.195851",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NYCB",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "-0.034816",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "0.222562",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HLT",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "0.222562",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ORLY",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "-0.221276",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "RBLX",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CMG",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UBER",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PYPL",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "-0.221276",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "0.222562",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "0.222562",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "0.222562",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.076847",
        "ticker_sentiment_score": "-0.026095",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EMR",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNAP",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "-0.458352",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "MCK",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "-0.221276",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "FTNT",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MCO",
        "relevance_score": "0.076847",
        "ticker_sentiment_score": "-0.026095",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "0.222562",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "0.076933",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "0.128429",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Dow Jones Rallies; Cathie Wood's Top Pick Surges On Earnings Beat, Outlook",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-rallies-cathie-woods-top-pick-surges-on-earnings-beat-outlook/",
    "time_published": "20240207T160500",
    "authors": [
      "Investor's Business Daily",
      "VIDYA RAMAKRISHNAN"
    ],
    "summary": "Dow Jones Rallies. Cathie Wood's Top Pick Surges On Earnings Beat, Outlook Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/01/Stock-BullRun-AI-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.988787"
      }
    ],
    "overall_sentiment_score": 0.115463,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BABA",
        "relevance_score": "0.100308",
        "ticker_sentiment_score": "-0.010132",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.100308",
        "ticker_sentiment_score": "-0.136361",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "YUM",
        "relevance_score": "0.100308",
        "ticker_sentiment_score": "0.133145",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.100308",
        "ticker_sentiment_score": "-0.136361",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CSCO",
        "relevance_score": "0.100308",
        "ticker_sentiment_score": "-0.136361",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FTNT",
        "relevance_score": "0.100308",
        "ticker_sentiment_score": "-0.055333",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXPE",
        "relevance_score": "0.100308",
        "ticker_sentiment_score": "-0.180386",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "RBLX",
        "relevance_score": "0.199037",
        "ticker_sentiment_score": "0.100262",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CMG",
        "relevance_score": "0.100308",
        "ticker_sentiment_score": "0.133145",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.100308",
        "ticker_sentiment_score": "0.056066",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UBER",
        "relevance_score": "0.100308",
        "ticker_sentiment_score": "-0.110195",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.100308",
        "ticker_sentiment_score": "0.056066",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen  ( AMGN )  Q4 Earnings Top, Horizon Drugs Drive Sales",
    "url": "https://www.zacks.com/stock/news/2222609/amgen-amgn-q4-earnings-top-horizon-drugs-drive-sales",
    "time_published": "20240207T145500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) beats fourth-quarter estimates for earnings and sales. Horizon's products add $954 million in sales in the quarter.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.995869"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.16915,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.379051",
        "ticker_sentiment_score": "0.246235",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.130926",
        "ticker_sentiment_score": "0.255573",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CVS",
        "relevance_score": "0.026299",
        "ticker_sentiment_score": "-0.030629",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Futures: 5 Stocks Flash Buy Signals On Earnings As Snap Crashes",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-market-rally-at-highs-5-stocks-set-to-flash-buy-signals-on-earnings-as-snap-dives/",
    "time_published": "20240207T132100",
    "authors": [
      "ED CARSON",
      "Investor's Business Daily"
    ],
    "summary": "Futures: 5 Stocks Set To Flash Buy Signals As Snap Crashes Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2017/02/stock-wallStreet-1-shutter.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.972476"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": -0.055187,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BABA",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "-0.279856",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "INTA",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "-0.279856",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "QLYS",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "-0.307164",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "HLT",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "-0.279856",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "FTNT",
        "relevance_score": "0.232439",
        "ticker_sentiment_score": "0.08343",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARM",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "-0.307164",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.191522",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UBER",
        "relevance_score": "0.175433",
        "ticker_sentiment_score": "-0.147483",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "34% of the Dow Jones Industrial Average's Weighting Is Determined by Just 5 Stocks",
    "url": "https://www.fool.com/investing/2024/02/07/34-of-the-dow-jones-weighting-from-just-5-stocks/",
    "time_published": "20240207T100600",
    "authors": [
      "Sean Williams"
    ],
    "summary": "Five well-known Dow Jones components account for more than a third -- over 13,100 points -- of its value.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F764134%2Fnyse-wall-street-trading-new-york-financial-stock-market-getty.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.977154"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.211644,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.130571",
        "ticker_sentiment_score": "0.092475",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CSCO",
        "relevance_score": "0.032781",
        "ticker_sentiment_score": "-0.012545",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.032781",
        "ticker_sentiment_score": "-0.012545",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HON",
        "relevance_score": "0.032781",
        "ticker_sentiment_score": "-0.009442",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WBA",
        "relevance_score": "0.032781",
        "ticker_sentiment_score": "-0.012545",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.226402",
        "ticker_sentiment_score": "0.086611",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HD",
        "relevance_score": "0.162802",
        "ticker_sentiment_score": "0.175345",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.098121",
        "ticker_sentiment_score": "0.090874",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DOW",
        "relevance_score": "0.032781",
        "ticker_sentiment_score": "-0.012545",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HCSG",
        "relevance_score": "0.032781",
        "ticker_sentiment_score": "0.150638",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.226402",
        "ticker_sentiment_score": "0.286982",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Biotech Stock Roundup: GILD, AMGN & BMY's Q4 Results, MOR Up on NVS Deal & More",
    "url": "https://www.zacks.com/stock/news/2223529/biotech-stock-roundup-gild-amgn-bmys-q4-results-mor-up-on-nvs-deal-more",
    "time_published": "20240208T155600",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Earnings of Gilead (GILD) and Amgen (AMGN) are in focus in the biotech sector.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/52/873.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999682"
      }
    ],
    "overall_sentiment_score": 0.133625,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "INCY",
        "relevance_score": "0.07913",
        "ticker_sentiment_score": "0.080802",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RGNX",
        "relevance_score": "0.157483",
        "ticker_sentiment_score": "0.073957",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSVT",
        "relevance_score": "0.07913",
        "ticker_sentiment_score": "-0.002048",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.118452",
        "ticker_sentiment_score": "0.029003",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.196132",
        "ticker_sentiment_score": "0.04931",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AstraZeneca  ( AZN )  Q4 Earnings & Sales Miss Estimates, Stock Down",
    "url": "https://www.zacks.com/stock/news/2223459/astrazeneca-azn-q4-earnings-sales-miss-estimates-stock-down",
    "time_published": "20240208T150400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AstraZeneca (AZN) marginally misses fourth-quarter estimates for earnings and sales. It expects revenues and EPS to increase at a low double-digit to low teens percentage in 2024 at CER.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/cf/2377.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999483"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.036343,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.08761",
        "ticker_sentiment_score": "0.121543",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.417764",
        "ticker_sentiment_score": "0.188887",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GRCL",
        "relevance_score": "0.029256",
        "ticker_sentiment_score": "0.104028",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ICVX",
        "relevance_score": "0.029256",
        "ticker_sentiment_score": "0.104028",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.116631",
        "ticker_sentiment_score": "0.043481",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors",
    "url": "https://www.globenewswire.com/news-release/2024/02/08/2825819/0/en/Zymeworks-Announces-Appointment-of-Dr-Alessandra-Cesano-to-its-Board-of-Directors.html",
    "time_published": "20240208T110000",
    "authors": [
      "Zymeworks Inc."
    ],
    "summary": "VANCOUVER, British Columbia, Feb. 08, 2024 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ( Nasdaq: ZYME ) , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/de376a45-7a16-49db-8ad4-65ff45472c90",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.451494"
      }
    ],
    "overall_sentiment_score": 0.165034,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BGNE",
        "relevance_score": "0.06697",
        "ticker_sentiment_score": "0.102407",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JAZZ",
        "relevance_score": "0.033515",
        "ticker_sentiment_score": "0.097518",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PBYI",
        "relevance_score": "0.033515",
        "ticker_sentiment_score": "-0.039469",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMMT",
        "relevance_score": "0.033515",
        "ticker_sentiment_score": "-0.039469",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NSTG",
        "relevance_score": "0.033515",
        "ticker_sentiment_score": "-0.039469",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.033515",
        "ticker_sentiment_score": "-0.039469",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.06697",
        "ticker_sentiment_score": "-0.041286",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors - Zymeworks  ( NASDAQ:ZYME ) ",
    "url": "https://www.benzinga.com/pressreleases/24/02/g37002568/zymeworks-announces-appointment-of-dr-alessandra-cesano-to-its-board-of-directors",
    "time_published": "20240208T110000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "VANCOUVER, British Columbia, Feb. 08, 2024 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ZYME, a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the appointment of ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.614606"
      }
    ],
    "overall_sentiment_score": 0.157885,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BGNE",
        "relevance_score": "0.064885",
        "ticker_sentiment_score": "0.10024",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JAZZ",
        "relevance_score": "0.032469",
        "ticker_sentiment_score": "0.095163",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PBYI",
        "relevance_score": "0.032469",
        "ticker_sentiment_score": "-0.038327",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMMT",
        "relevance_score": "0.032469",
        "ticker_sentiment_score": "-0.038327",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NSTG",
        "relevance_score": "0.032469",
        "ticker_sentiment_score": "-0.038327",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.032469",
        "ticker_sentiment_score": "-0.038327",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.064885",
        "ticker_sentiment_score": "-0.04019",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen  ( NASDAQ:AMGN )  Downgraded to \"Buy\" at StockNews.com",
    "url": "https://www.defenseworld.net/2024/02/08/amgen-nasdaqamgn-downgraded-to-buy-at-stocknews-com.html",
    "time_published": "20240208T102843",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "StockNews.com downgraded shares of Amgen ( NASDAQ:AMGN - Free Report ) from a strong-buy rating to a buy rating in a report released on Wednesday. Several other research analysts also recently weighed in on the stock.",
    "banner_image": "https://www.marketbeat.com/logos/amgen-inc-logo.jpg?v=20231228113741",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.865346"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.220927,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.045224",
        "ticker_sentiment_score": "0.063966",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.045224",
        "ticker_sentiment_score": "0.053859",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.135094",
        "ticker_sentiment_score": "0.136596",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Unstoppable Stocks to Buy and Hold for 2024 and Beyond",
    "url": "https://www.fool.com/investing/2024/02/08/2-unstoppable-stocks-to-buy-and-hold-for-2024-and/",
    "time_published": "20240208T094500",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "These great businesses are persisting and thriving through challenging economic times.",
    "banner_image": "https://g.foolcdn.com/editorial/images/763811/family-planning-saving-money.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.858979"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.917436"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.305217,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSBHF",
        "relevance_score": "0.043264",
        "ticker_sentiment_score": "0.151446",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.255195",
        "ticker_sentiment_score": "0.159154",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.043264",
        "ticker_sentiment_score": "0.151446",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MUFG",
        "relevance_score": "0.043264",
        "ticker_sentiment_score": "0.151446",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.374624",
        "ticker_sentiment_score": "0.330198",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "PBYI vs. AMGN: Which Stock Should Value Investors Buy Now?",
    "url": "https://www.zacks.com/stock/news/2224255/pbyi-vs-amgn-which-stock-should-value-investors-buy-now",
    "time_published": "20240209T164009",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "PBYI vs. AMGN: Which Stock Is the Better Value Option?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default347.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.890401"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.498567,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.680677",
        "ticker_sentiment_score": "0.610773",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Gilead Sciences, Bristol Myers, Amgen, Morphysys and REGENXBIO",
    "url": "https://www.zacks.com/stock/news/2223809/the-zacks-analyst-blog-highlights-gilead-sciences-bristol-myers-amgen-morphysys-and-regenxbio",
    "time_published": "20240209T084000",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Gilead Sciences, Bristol Myers, Amgen, Morphysys and REGENXBIO are included in this Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/13/816.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999682"
      }
    ],
    "overall_sentiment_score": 0.1404,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "INCY",
        "relevance_score": "0.072765",
        "ticker_sentiment_score": "0.108665",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RGNX",
        "relevance_score": "0.180595",
        "ticker_sentiment_score": "0.04607",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSVT",
        "relevance_score": "0.072765",
        "ticker_sentiment_score": "-0.002026",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.144926",
        "ticker_sentiment_score": "0.02423",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.215894",
        "ticker_sentiment_score": "0.041359",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stock Market Hits Highs As AI Plays Skyrocket: Weekly Review",
    "url": "https://www.investors.com/news/stock-market-hits-highs-as-arm-palantir-cloudflare-skyrocket/",
    "time_published": "20240209T001300",
    "authors": [
      "IBD STAFF",
      "Investor's Business Daily"
    ],
    "summary": "The stock market rally generally advanced with the S&P 500 hitting 5,000 for the first time and the Nasdaq at its best levels in over two years. The Dow Jones held just below its all-time highs while the Russell 2000 rebounded back above key levels.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/01/Stock-colorfullightbulb-generatedai-01-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.088082,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MDNDF",
        "relevance_score": "0.017902",
        "ticker_sentiment_score": "-0.147329",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEX",
        "relevance_score": "0.053669",
        "ticker_sentiment_score": "0.066999",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NBIX",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "0.051683",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RPD",
        "relevance_score": "0.053669",
        "ticker_sentiment_score": "-0.012012",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXPE",
        "relevance_score": "0.053669",
        "ticker_sentiment_score": "0.049042",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVGI",
        "relevance_score": "0.017902",
        "ticker_sentiment_score": "0.067321",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.071517",
        "ticker_sentiment_score": "0.053795",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARCB",
        "relevance_score": "0.071517",
        "ticker_sentiment_score": "0.054344",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DT",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "-0.078802",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "0.069261",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QLYS",
        "relevance_score": "0.053669",
        "ticker_sentiment_score": "-0.004005",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HLT",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "0.048215",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRUS",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "0.09861",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ORLY",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "-0.129876",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.089328",
        "ticker_sentiment_score": "0.118465",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AOSL",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "0.09861",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CYBR",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "-0.101404",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RBLX",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PINS",
        "relevance_score": "0.053669",
        "ticker_sentiment_score": "-0.224249",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "CMG",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "-0.158803",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "UBER",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "-0.016619",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HMC",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "0.072035",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BABA",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "-0.07722",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PYPL",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "0.037818",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPOT",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GM",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "0.072035",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NXPI",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "0.09861",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "0.051683",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RMBS",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "0.09861",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INTA",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "-0.151575",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "YUM",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "-0.158803",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "FTNT",
        "relevance_score": "0.053669",
        "ticker_sentiment_score": "-0.074739",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PI",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "0.09861",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DIOD",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "0.09861",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "0.051683",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARM",
        "relevance_score": "0.071517",
        "ticker_sentiment_score": "0.07345",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NET",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "0.018656",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AFRM",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "0.037818",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Behind the Scenes of Amgen's Latest Options Trends - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/insights/options/24/02/37071899/behind-the-scenes-of-amgens-latest-options-trends",
    "time_published": "20240212T160052",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Financial giants have made a conspicuous bearish move on Amgen. Our analysis of options history for Amgen AMGN revealed 13 unusual trades. Delving into the details, we found 46% of traders were bullish, while 53% showed bearish tendencies.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.076363,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.156461",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.832899",
        "ticker_sentiment_score": "-0.020437",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen Inc.  ( AMGN )  Is a Trending Stock: Facts to Know Before Betting on It",
    "url": "https://www.zacks.com/stock/news/2224619/amgen-inc-amgn-is-a-trending-stock-facts-to-know-before-betting-on-it",
    "time_published": "20240212T140005",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default168.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.232747,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.482078",
        "ticker_sentiment_score": "0.118669",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the VanEck Biotech ETF  ( BBH ) ?",
    "url": "https://www.zacks.com/stock/news/2224468/should-you-invest-in-the-vaneck-biotech-etf-bbh",
    "time_published": "20240212T112005",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default115.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.138412,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.133841",
        "ticker_sentiment_score": "0.071297",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.133841",
        "ticker_sentiment_score": "0.071297",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.133841",
        "ticker_sentiment_score": "0.071297",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Gene Delivery System Market Size to Touch Around USD 10.0 billion, at a CAGR of 7.2% from 2023 to 2031: Report by Transparency Market Research, Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/02/g37096872/gene-delivery-system-market-size-to-touch-around-usd-10-0-billion-at-a-cagr-of-7-2-from-2023-to-20",
    "time_published": "20240213T152500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Feb. 13, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global gene delivery system market is estimated to flourish at a CAGR of 7.2% from 2023 to 2031.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.376665,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SGMO",
        "relevance_score": "0.03399",
        "ticker_sentiment_score": "0.267177",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.03399",
        "ticker_sentiment_score": "0.04987",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GNNSF",
        "relevance_score": "0.03399",
        "ticker_sentiment_score": "0.181458",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.03399",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.067919",
        "ticker_sentiment_score": "0.30534",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "OXBDF",
        "relevance_score": "0.168726",
        "ticker_sentiment_score": "0.322112",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.03399",
        "ticker_sentiment_score": "0.139717",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.101725",
        "ticker_sentiment_score": "0.078237",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Where Are Biotech ETFs Headed After Q4 Earnings?",
    "url": "https://www.zacks.com/stock/news/2226390/where-are-biotech-etfs-headed-after-q4-earnings",
    "time_published": "20240214T214700",
    "authors": [
      "Yashwardhan Jain"
    ],
    "summary": "Look into how Biotech ETFs performed after Q4 earnings.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5d/2633.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.96136"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999326"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.057141,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GILD",
        "relevance_score": "0.099271",
        "ticker_sentiment_score": "-0.041374",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.099271",
        "ticker_sentiment_score": "0.047997",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.148426",
        "ticker_sentiment_score": "0.104579",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.099271",
        "ticker_sentiment_score": "-0.090239",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "A top 2% fund manager crushing the S&P 500 over the last 4 years despite owning none of the 'Magnificent 7' shares 7 stocks he's betting on - and breaks down the 4 guiding principles he uses to beat the market",
    "url": "https://www.businessinsider.com/where-to-invest-how-to-pick-stocks-outperform-sp500-smead-2024-2",
    "time_published": "20240214T105500",
    "authors": [
      "William Edwards"
    ],
    "summary": "Top 3% Fund Manager Since 2009 Shares 4 Tips for Beating the Market - Business Insider ...",
    "banner_image": null,
    "source": "Business Insider",
    "category_within_source": "GoogleRSS",
    "source_domain": "www.businessinsider.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.977154"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.250595,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "OXY",
        "relevance_score": "0.122269",
        "ticker_sentiment_score": "0.067168",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MORN",
        "relevance_score": "0.061315",
        "ticker_sentiment_score": "0.078124",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.182506",
        "ticker_sentiment_score": "0.061958",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LEN",
        "relevance_score": "0.122269",
        "ticker_sentiment_score": "0.067168",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.122269",
        "ticker_sentiment_score": "0.067168",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COP",
        "relevance_score": "0.122269",
        "ticker_sentiment_score": "0.067168",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Dow Jones Dividend Stocks With Above-Average Yields to Buy Now and Hold for at Least a Decade",
    "url": "https://www.fool.com/investing/2024/02/14/2-dow-jones-dividend-stocks-with-above-average-yie/",
    "time_published": "20240214T101300",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "Investors interested in a steadily rising stream of passive income will find what they're looking for with these dividend payers.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F764969%2Fwall-street-analyst-getty.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.181633,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AWON",
        "relevance_score": "0.058188",
        "ticker_sentiment_score": "0.198003",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.229691",
        "ticker_sentiment_score": "0.151532",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.390613",
        "ticker_sentiment_score": "0.412633",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.116067",
        "ticker_sentiment_score": "0.222221",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Amgen Takes Aim at Novo Nordisk and Eli Lilly, but Is the Stock a Buy?",
    "url": "https://www.fool.com/investing/2024/02/14/amgen-takes-aim-at-novo-nordisk-and-eli-lilly-but/",
    "time_published": "20240214T075900",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "It faces both clinical and competitive barriers, but they might not matter.",
    "banner_image": "https://g.foolcdn.com/editorial/images/764673/lab-worker-women-in-stem-science-research.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.190769,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.185662",
        "ticker_sentiment_score": "0.188728",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.230892",
        "ticker_sentiment_score": "0.215529",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.046816",
        "ticker_sentiment_score": "0.062609",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.230892",
        "ticker_sentiment_score": "0.185687",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "This Is What Whales Are Betting On Amgen - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/insights/options/24/02/37164462/this-is-what-whales-are-betting-on-amgen",
    "time_published": "20240215T180048",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Financial giants have made a conspicuous bearish move on Amgen. Our analysis of options history for Amgen AMGN revealed 12 unusual trades. Delving into the details, we found 16% of traders were bullish, while 83% showed bearish tendencies.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.111769,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.078611",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.832899",
        "ticker_sentiment_score": "0.073736",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.078611",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Biosimilars Market is Projected to Surpass USD 85 billion by 2031, Growing at CAGR 15.5%- Report by Transparency Market Research, Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/02/g37159019/biosimilars-market-is-projected-to-surpass-usd-85-billion-by-2031-growing-at-cagr-15-5-report-by-t",
    "time_published": "20240215T143500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Feb. 15, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global biosimilars market is estimated to flourish at a CAGR of 15.5% from 2022 to 2031.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.400888,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.033052",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.033052",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.033052",
        "ticker_sentiment_score": "0.209881",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.09893",
        "ticker_sentiment_score": "0.137506",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.066047",
        "ticker_sentiment_score": "0.120658",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "If You Invested $20,000 in Amgen in 2014, This Is How Much You Would Have Today",
    "url": "https://www.fool.com/investing/2024/02/17/if-you-invested-20000-in-amgen-in-2014-this-is-how/",
    "time_published": "20240217T131300",
    "authors": [
      "David Jagielski"
    ],
    "summary": "Has Amgen been a market-beating stock?",
    "banner_image": "https://g.foolcdn.com/editorial/images/765089/stock-traders-looking-at-a-chart.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99977"
      }
    ],
    "overall_sentiment_score": 0.409078,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.724016",
        "ticker_sentiment_score": "0.605871",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Pediatrix's  ( MD )  Q4 Earnings Miss Due to Soft Patient Volumes",
    "url": "https://www.zacks.com/stock/news/2228770/pediatrixs-md-q4-earnings-miss-due-to-soft-patient-volumes",
    "time_published": "20240220T192200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Pediatrix's (MD) Q4 results were hit by an increase in overall cost level resulting from higher same-unit clinical compensation costs. Yet, an impressive 2024 adjusted EBITDA guidance is likely to provide relief to investors.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/79/961.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.993856"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.062023,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ITGR",
        "relevance_score": "0.127456",
        "ticker_sentiment_score": "0.090608",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.127456",
        "ticker_sentiment_score": "0.010529",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MD",
        "relevance_score": "0.25168",
        "ticker_sentiment_score": "0.032658",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MOH",
        "relevance_score": "0.169378",
        "ticker_sentiment_score": "0.086537",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "BeiGene  ( BGNE )  to Report Q4 Earnings: What's in the Cards?",
    "url": "https://www.zacks.com/stock/news/2228645/beigene-bgne-to-report-q4-earnings-whats-in-the-cards",
    "time_published": "20240220T154900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "BeiGene's (BGNE) revenues in fourth-quarter 2023 are expected to have been driven by the sales of its marketed pharmaceutical products.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/86/60216.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.252242,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.045569",
        "ticker_sentiment_score": "0.061781",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BGNE",
        "relevance_score": "0.639433",
        "ticker_sentiment_score": "0.343424",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.180798",
        "ticker_sentiment_score": "0.220865",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SRPT",
        "relevance_score": "0.136113",
        "ticker_sentiment_score": "0.111729",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication",
    "url": "https://www.prnewswire.com/news-releases/redhills-opaganib-protects-against-radiation-induced-lung-inflammation-and-fibrosis--new-publication-302065891.html",
    "time_published": "20240220T120000",
    "authors": [
      "RedHill Biopharma Ltd."
    ],
    "summary": "The data, published in the International Journal of Molecular Sciences, demonstrate that opaganib significantly improved long-term survival in an in vivo model of lung damage following exposure to ionizing radiation",
    "banner_image": "https://mma.prnewswire.com/media/1334141/RedHill_Biopharma_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.905476"
      }
    ],
    "overall_sentiment_score": 0.0,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "RDHL",
        "relevance_score": "0.125297",
        "ticker_sentiment_score": "-0.008334",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.031446",
        "ticker_sentiment_score": "-0.003789",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.031446",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.031446",
        "ticker_sentiment_score": "-0.09699",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Invesco Pharmaceuticals ETF  ( PJP )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2228267/is-invesco-pharmaceuticals-etf-pjp-a-strong-etf-right-now",
    "time_published": "20240220T112006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default91.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999999"
      }
    ],
    "overall_sentiment_score": 0.267515,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.1172",
        "ticker_sentiment_score": "0.061498",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.1172",
        "ticker_sentiment_score": "0.061498",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.231884",
        "ticker_sentiment_score": "0.267105",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.1172",
        "ticker_sentiment_score": "0.061498",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Community Health  ( CYH )  Q4 Earnings Miss, Revenues Up Y/Y",
    "url": "https://www.zacks.com/stock/news/2229593/community-health-cyh-q4-earnings-miss-revenues-up-yy",
    "time_published": "20240221T175100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Community Health (CYH) expects net operating revenues in the range of $12.3-$12.7 billion for 2024.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/49/44858.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.998932"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.04296,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CYH",
        "relevance_score": "0.23281",
        "ticker_sentiment_score": "-0.040162",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ITGR",
        "relevance_score": "0.117678",
        "ticker_sentiment_score": "0.105555",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.117678",
        "ticker_sentiment_score": "0.01016",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MOH",
        "relevance_score": "0.156461",
        "ticker_sentiment_score": "0.082101",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks",
    "url": "https://www.zacks.com/stock/news/2229192/improve-your-retirement-income-with-these-3-top-ranked-dividend-stocks",
    "time_published": "20240221T141003",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default284.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.227001,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.213988",
        "ticker_sentiment_score": "0.118854",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.054114",
        "ticker_sentiment_score": "-0.036002",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NEE",
        "relevance_score": "0.213988",
        "ticker_sentiment_score": "0.122112",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen Options Trading: A Deep Dive into Market Sentiment - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/insights/options/24/02/37290222/amgen-options-trading-a-deep-dive-into-market-sentiment",
    "time_published": "20240223T180115",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Deep-pocketed investors have adopted a bearish approach towards Amgen AMGN, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.120653,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.067727",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.765876",
        "ticker_sentiment_score": "0.114",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.067727",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Nasdaq Closes In On All-Time High; Carvana Spikes On Earnings While Nvidia Vaults Above 800",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-nasdaq-sp500-carvana-nvda-stock/",
    "time_published": "20240223T153400",
    "authors": [
      "KEN SHREVE",
      "Investor's Business Daily"
    ],
    "summary": "Nasdaq Closes In On All-Time High. Carvana Spikes On Earnings While Nvidia Vaults Above 800 Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2021/02/Stock-MarketBoard-Blue42-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      }
    ],
    "overall_sentiment_score": 0.217737,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.279015",
        "ticker_sentiment_score": "0.296559",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SNOW",
        "relevance_score": "0.113597",
        "ticker_sentiment_score": "0.080743",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.113597",
        "ticker_sentiment_score": "-0.130875",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.113597",
        "ticker_sentiment_score": "-0.138692",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NKE",
        "relevance_score": "0.169676",
        "ticker_sentiment_score": "0.05745",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.169676",
        "ticker_sentiment_score": "0.05745",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.169676",
        "ticker_sentiment_score": "0.105594",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WDAY",
        "relevance_score": "0.113597",
        "ticker_sentiment_score": "0.080743",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COLL",
        "relevance_score": "0.113597",
        "ticker_sentiment_score": "0.339019",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NTNX",
        "relevance_score": "0.113597",
        "ticker_sentiment_score": "0.080743",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVNA",
        "relevance_score": "0.169676",
        "ticker_sentiment_score": "0.142178",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ZS",
        "relevance_score": "0.113597",
        "ticker_sentiment_score": "0.039715",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BKNG",
        "relevance_score": "0.113597",
        "ticker_sentiment_score": "-0.286498",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "SQ",
        "relevance_score": "0.113597",
        "ticker_sentiment_score": "0.158811",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PANW",
        "relevance_score": "0.113597",
        "ticker_sentiment_score": "0.039715",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen Inc.  ( AMGN )  is Attracting Investor Attention: Here is What You Should Know",
    "url": "https://www.zacks.com/stock/news/2230800/amgen-inc-amgn-is-attracting-investor-attention-here-is-what-you-should-know",
    "time_published": "20240223T140010",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default271.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.219514,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.486627",
        "ticker_sentiment_score": "0.134624",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "There's A Problem With Today's Obesity Drugs - How These Companies Are Solving It",
    "url": "https://www.investors.com/news/technology/weight-loss-drugs-how-outliers-like-biohaven-regeneron-are-trying-to-squeeze-into-the-obesity-space/",
    "time_published": "20240223T133000",
    "authors": [
      "ALLISON GATLIN",
      "Investor's Business Daily"
    ],
    "summary": "Weight-Loss Drugs: How Outliers Like Biohaven, Regeneron Are Taking On The Muscle Dilemma In The Obesity Space Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/02/A1MAIN_weightloss_022324.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.905476"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": -0.012175,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "EVR",
        "relevance_score": "0.031992",
        "ticker_sentiment_score": "-0.027602",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BHVN",
        "relevance_score": "0.063933",
        "ticker_sentiment_score": "-0.03917",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARWR",
        "relevance_score": "0.031992",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CYTK",
        "relevance_score": "0.015999",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALUR",
        "relevance_score": "0.031992",
        "ticker_sentiment_score": "0.05222",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.031992",
        "ticker_sentiment_score": "-0.09668",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALNY",
        "relevance_score": "0.031992",
        "ticker_sentiment_score": "-0.061293",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.158938",
        "ticker_sentiment_score": "0.096962",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.031992",
        "ticker_sentiment_score": "0.092157",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.031992",
        "ticker_sentiment_score": "-0.025591",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.031992",
        "ticker_sentiment_score": "0.092157",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amazon's stock could lose to Walgreens' this year if the Dow jinx holds",
    "url": "https://www.marketwatch.com/story/amazons-stock-could-lose-to-walgreens-this-year-if-the-dow-jinx-holds-17720eec",
    "time_published": "20240224T124100",
    "authors": [
      "Tomi Kilgore"
    ],
    "summary": "The keepers of the Dow Jones Industrial Average have been very good at making sure the changes they make to the venerable stock market barometer are seamless to investors, but nobody's perfect.",
    "banner_image": "https://images.mktw.net/im-98682489/social",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.086957,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AAPL",
        "relevance_score": "0.196212",
        "ticker_sentiment_score": "0.145033",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JBLU",
        "relevance_score": "0.098862",
        "ticker_sentiment_score": "0.04224",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HON",
        "relevance_score": "0.098862",
        "ticker_sentiment_score": "0.034127",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WBA",
        "relevance_score": "0.098862",
        "ticker_sentiment_score": "-0.054032",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.098862",
        "ticker_sentiment_score": "0.034127",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.098862",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.098862",
        "ticker_sentiment_score": "0.034127",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UBER",
        "relevance_score": "0.098862",
        "ticker_sentiment_score": "0.04224",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.098862",
        "ticker_sentiment_score": "-0.020204",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.098862",
        "ticker_sentiment_score": "0.034127",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.098862",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.098862",
        "ticker_sentiment_score": "-0.054032",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen's Upcoming Catalysts In 2024 Set To Unlock Multi-Billion Dollar Markets, Says Goldman Sachs - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/02/37318123/amgens-upcoming-catalysts-in-2024-set-to-unlock-multi-billion-dollar-markets-says-g",
    "time_published": "20240226T182533",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Amgen Inc AMGN is expected to unveil updates on various programs this year, targeting significant markets. Despite concerns about the company's long-term growth amid exclusivity losses, Goldman Sachs notes that Amgen ( Buy rating, $350 price target ) is seen as well-positioned to capitalize on ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Autoinjector-with-Amgevita-by-Amgen-Adal.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.137255,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.19117",
        "ticker_sentiment_score": "0.082069",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.371523",
        "ticker_sentiment_score": "0.172847",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.454714",
        "ticker_sentiment_score": "0.333285",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.19117",
        "ticker_sentiment_score": "0.082069",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.19117",
        "ticker_sentiment_score": "0.082069",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Biotech Stocks to Buy and Hold for the Next 10 Years",
    "url": "https://www.fool.com/investing/2024/02/26/3-biotech-stocks-you-can-buy-and-hold-for-the-next/",
    "time_published": "20240226T135000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "There's a lot to like about these three drugmakers right now, and that shouldn't stop anytime soon.",
    "banner_image": "https://g.foolcdn.com/editorial/images/766287/doctor-with-patient-talking.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.839681"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.858979"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.236594,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.054359",
        "ticker_sentiment_score": "0.162818",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.054359",
        "ticker_sentiment_score": "-0.089059",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.414559",
        "ticker_sentiment_score": "0.252334",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JAZZ",
        "relevance_score": "0.054359",
        "ticker_sentiment_score": "0.090108",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXSM",
        "relevance_score": "0.214937",
        "ticker_sentiment_score": "0.2195",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Global Nanomedicine Market Report 2023-2028: United States Emerges as a Key Player",
    "url": "https://www.prnewswire.com/news-releases/global-nanomedicine-market-report-2023-2028-united-states-emerges-as-a-key-player-302070908.html",
    "time_published": "20240226T114500",
    "authors": [
      "Research and Markets"
    ],
    "summary": "DUBLIN, Feb. 26, 2024 /PRNewswire/ -- The \"Nanomedicine Market - Forecasts from 2023 to 2028\" report has been added to ResearchAndMarkets.com's offering. The medical application of nanotechnology is the focus of the interdisciplinary field of nanomedicine.",
    "banner_image": "https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.234378,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.088147",
        "ticker_sentiment_score": "0.109752",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.044141",
        "ticker_sentiment_score": "0.104084",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.044141",
        "ticker_sentiment_score": "0.104084",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.044141",
        "ticker_sentiment_score": "0.104084",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "CytomX  ( CTMX )  to Report Q4 Earnings: Here's What to Expect",
    "url": "https://www.zacks.com/stock/news/2232603/cytomx-ctmx-to-report-q4-earnings-heres-what-to-expect",
    "time_published": "20240227T165200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Investor focus is likely to be on CytomX Therapeutics' (CTMX) updates on key cancer immunotherapeutic candidates, CX-904 and BMS-986288, on the fourth-quarter 2023 earnings call.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/284.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999756"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.096247,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CTMX",
        "relevance_score": "0.355588",
        "ticker_sentiment_score": "-0.141497",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.218161",
        "ticker_sentiment_score": "0.122327",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SRPT",
        "relevance_score": "0.355588",
        "ticker_sentiment_score": "0.070899",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.288044",
        "ticker_sentiment_score": "-0.013155",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income",
    "url": "https://www.zacks.com/stock/news/2232329/3-top-ranked-dividend-stocks-a-smarter-way-to-boost-your-retirement-income",
    "time_published": "20240227T141003",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default221.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.155091,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.211652",
        "ticker_sentiment_score": "0.117837",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NEE",
        "relevance_score": "0.211652",
        "ticker_sentiment_score": "0.121068",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Top Research Reports for NVIDIA, Visa & Amgen",
    "url": "https://www.zacks.com/research-daily/2232860/top-research-reports-for-nvidia-visa-amgen",
    "time_published": "20240228T184200",
    "authors": [
      "Mark Vickery"
    ],
    "summary": "Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Visa Inc. (V) and Amgen Inc. (AMGN).",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/8c/1033.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      }
    ],
    "overall_sentiment_score": 0.286314,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.28442",
        "ticker_sentiment_score": "0.139319",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.096671",
        "ticker_sentiment_score": "0.138864",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "V",
        "relevance_score": "0.28442",
        "ticker_sentiment_score": "0.529986",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "This biotech ETF sees 'breakout' while U.S. small-cap technology stocks lag",
    "url": "https://www.marketwatch.com/story/this-biotech-etf-sees-breakout-while-u-s-small-cap-technology-stocks-lag-69a87d4a",
    "time_published": "20240229T234600",
    "authors": [
      "Christine Idzelis"
    ],
    "summary": "This week's ETF Wrap digs into the jump in biotech funds, as well as an \"unusual\" trend in U.S. small-cap stocks versus small-cap tech equities.",
    "banner_image": "https://images.mktw.net/im-341402/social",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.184554,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VKTX",
        "relevance_score": "0.100588",
        "ticker_sentiment_score": "-0.005415",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CYTK",
        "relevance_score": "0.067158",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STT",
        "relevance_score": "0.033609",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IOVA",
        "relevance_score": "0.067158",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.067158",
        "ticker_sentiment_score": "0.044071",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.100588",
        "ticker_sentiment_score": "0.004297",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.067158",
        "ticker_sentiment_score": "0.044071",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.067158",
        "ticker_sentiment_score": "0.044071",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.033609",
        "ticker_sentiment_score": "0.097256",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Better Dividend Growth Stock: AbbVie or Amgen?",
    "url": "https://www.fool.com/investing/2024/02/29/better-dividend-growth-stock-abbvie-or-amgen/",
    "time_published": "20240229T144500",
    "authors": [
      "George Budwell"
    ],
    "summary": "A strong case can be made for owning both of these dividend growth stocks. But one of them is the better buy.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F767246%2Fdividend-concept.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999967"
      }
    ],
    "overall_sentiment_score": 0.382731,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.457794",
        "ticker_sentiment_score": "0.560592",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.364529",
        "ticker_sentiment_score": "0.401299",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.053992",
        "ticker_sentiment_score": "0.167789",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights NVIDIA, Visa, Amgen, Chubb and PACCAR",
    "url": "https://www.zacks.com/stock/news/2233797/the-zacks-analyst-blog-highlights-nvidia-visa-amgen-chubb-and-paccar",
    "time_published": "20240229T141500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "NVIDIA, Visa, Amgen, Chubb and PACCAR are part of the Zacks top Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/af/643.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.234452,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.275867",
        "ticker_sentiment_score": "0.123077",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PCAR",
        "relevance_score": "0.140076",
        "ticker_sentiment_score": "0.038861",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.40348",
        "ticker_sentiment_score": "0.128934",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "V",
        "relevance_score": "0.40348",
        "ticker_sentiment_score": "0.372037",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "CB",
        "relevance_score": "0.140076",
        "ticker_sentiment_score": "0.038861",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Lilly Stock Could Join The 1,000 Club With $81 Billion In Obesity Sales",
    "url": "https://www.investors.com/news/technology/eli-lilly-stock-price-target-increase-weight-loss-drugs-obesity-treatment/",
    "time_published": "20240301T163500",
    "authors": [
      "ALLISON GATLIN",
      "Investor's Business Daily"
    ],
    "summary": "Eli Lilly Stock And The Road To 1,000: The $81 Billion Weight-Loss Drugs Space Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2020/10/Stock-EliLilly-Lab01-company.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99999"
      }
    ],
    "overall_sentiment_score": 0.126199,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.803345",
        "ticker_sentiment_score": "0.271135",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.120733",
        "ticker_sentiment_score": "0.019112",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IRWD",
        "relevance_score": "0.060541",
        "ticker_sentiment_score": "-0.16103",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.120733",
        "ticker_sentiment_score": "0.019112",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.180236",
        "ticker_sentiment_score": "0.087193",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Apple Sinks After Wall Street Titan Pulls Magnificent 7 Stock From Conviction List Apple Sinks After Wall Street Titan Pulls Magnificent 7 Stock From Conviction List Post-iPhone 15, Vision Pro Launches - Apple  ( NASDAQ:AAPL ) , Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37423877/apple-sinks-after-wall-street-titan-pulls-magnificent-7-stock-from-conviction-list",
    "time_published": "20240301T153958",
    "authors": [
      "Chris Katje"
    ],
    "summary": "A leading financial analyst company has removed technology giant Apple Inc AAPL from its \"Conviction List\" one month after first-quarter earnings were reported. What Happened: Apple has had several eventful months with the release of the iPhone 15 in September and the Vision Pro mixed reality ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/apple-cupertino-chart.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.947132"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.222975,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.124486",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSTK",
        "relevance_score": "0.062434",
        "ticker_sentiment_score": "0.286517",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.727186",
        "ticker_sentiment_score": "0.212187",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.566543",
        "ticker_sentiment_score": "0.371248",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.185781",
        "ticker_sentiment_score": "0.077418",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VMC",
        "relevance_score": "0.185781",
        "ticker_sentiment_score": "0.302804",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 Stocks That Could Turn $1,000 Into $2,500 in 5 Years",
    "url": "https://www.fool.com/investing/2024/03/01/2-stocks-that-could-turn-1000-into-2500-in-5-years/",
    "time_published": "20240301T123100",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "It will take a lot, but this goal isn't out of reach for these stocks.",
    "banner_image": "https://g.foolcdn.com/editorial/images/766641/patient-sitting-on-hospital-bed.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.223574,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VKTX",
        "relevance_score": "0.441059",
        "ticker_sentiment_score": "0.168395",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KRYS",
        "relevance_score": "0.303175",
        "ticker_sentiment_score": "0.132994",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.051774",
        "ticker_sentiment_score": "0.052919",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.051774",
        "ticker_sentiment_score": "0.052919",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.051774",
        "ticker_sentiment_score": "0.052919",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.051774",
        "ticker_sentiment_score": "0.052919",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.051774",
        "ticker_sentiment_score": "0.052919",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "After Soaring 222% in 1 Day, Is Janux Therapeutics Stock a Buy?",
    "url": "https://www.fool.com/investing/2024/03/02/after-soaring-222-in-1-day-is-janux-therapeutics-s/",
    "time_published": "20240302T115600",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "The biotech tantalized investors with a very promising data update.",
    "banner_image": "https://g.foolcdn.com/editorial/images/767190/scientist-holds-up-petri-dish-to-the-light.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      }
    ],
    "overall_sentiment_score": 0.116037,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.046095",
        "ticker_sentiment_score": "0.154302",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JANX",
        "relevance_score": "0.092036",
        "ticker_sentiment_score": "0.155306",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Amgen  ( AMGN )  Falls More Steeply Than Broader Market: What Investors Need to Know",
    "url": "https://www.zacks.com/stock/news/2235670/amgen-amgn-falls-more-steeply-than-broader-market-what-investors-need-to-know",
    "time_published": "20240304T225018",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the closing of the recent trading day, Amgen (AMGN) stood at $279.35, denoting a -0.35% change from the preceding trading day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default133.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.95493"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.163614,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.639942",
        "ticker_sentiment_score": "0.242212",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks",
    "url": "https://www.zacks.com/stock/news/2235233/how-to-maximize-your-retirement-portfolio-with-these-top-ranked-dividend-stocks",
    "time_published": "20240304T141003",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default36.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.222651,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.220809",
        "ticker_sentiment_score": "0.12016",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRX",
        "relevance_score": "0.220809",
        "ticker_sentiment_score": "0.198287",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.220809",
        "ticker_sentiment_score": "0.125168",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Sandoz receives FDA approval for first and only denosumab biosimilars - Sandoz Group  ( OTC:SDZNY ) ",
    "url": "https://www.benzinga.com/pressreleases/24/03/g37490234/sandoz-receives-fda-approval-for-first-and-only-denosumab-biosimilars",
    "time_published": "20240305T182408",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wyost\u00ae ( denosumab-bddz ) and Jubbonti\u00ae ( denosumab-bddz ) interchangeable with and approved by FDA for all indications of reference medicines Xgeva \u00ae* ( denosumab ) and Prolia\u00ae* ( denosumab )",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.159234,
    "overall_sentiment_label": "Somewhat-Bearish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.051961",
        "ticker_sentiment_score": "0.09393",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Sandoz receives FDA approval for first and only denosumab biosimilars",
    "url": "https://www.globenewswire.com/news-release/2024/03/05/2840809/0/en/Sandoz-receives-FDA-approval-for-first-and-only-denosumab-biosimilars.html",
    "time_published": "20240305T182400",
    "authors": [
      "Sandoz International GmbH"
    ],
    "summary": "MEDIA RELEASE ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/41ea40f9-fbb7-45d9-9136-33fdb399d0ba",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.126329,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.054154",
        "ticker_sentiment_score": "0.10476",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": " ( AMGN )  - Analyzing Amgen's Short Interest - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/insights/short-sellers/24/03/37514185/amgn-analyzing-amgens-short-interest",
    "time_published": "20240306T163025",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Amgen's AMGN short percent of float has risen 18.97% since its last report. The company recently reported that it has 11.09 million shares sold short, which is 2.07% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.7 days to cover their ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.267375,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.224903",
        "ticker_sentiment_score": "0.158881",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Here is What to Know Beyond Why Amgen Inc.  ( AMGN )  is a Trending Stock",
    "url": "https://www.zacks.com/stock/news/2236586/here-is-what-to-know-beyond-why-amgen-inc-amgn-is-a-trending-stock",
    "time_published": "20240306T140010",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default168.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.230747,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.489394",
        "ticker_sentiment_score": "0.132047",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is It Time to Buy February's 3 Worst-Performing Dow Jones Stocks?",
    "url": "https://www.fool.com/investing/2024/03/06/is-it-time-to-buy-3-worst-performing-dow-jones/",
    "time_published": "20240306T124500",
    "authors": [
      "James Brumley"
    ],
    "summary": "It's only a bargain price if it's actually worth owning.",
    "banner_image": "https://media.ycharts.com/charts/7fb30c655c00f3cdce543ba9f078e851.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.980716"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.086469,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "SPLK",
        "relevance_score": "0.073773",
        "ticker_sentiment_score": "0.094378",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CSCO",
        "relevance_score": "0.218817",
        "ticker_sentiment_score": "-0.028008",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.036926",
        "ticker_sentiment_score": "0.085291",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.218817",
        "ticker_sentiment_score": "0.112615",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.288893",
        "ticker_sentiment_score": "-0.019421",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.036926",
        "ticker_sentiment_score": "0.085291",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen  ( AMGN )  Down 6.5% Since Last Earnings Report: Can It Rebound?",
    "url": "https://www.zacks.com/stock/news/2237461/amgen-amgn-down-65-since-last-earnings-report-can-it-rebound",
    "time_published": "20240307T163103",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default99.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999813"
      }
    ],
    "overall_sentiment_score": 0.113779,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.249958",
        "ticker_sentiment_score": "0.07837",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVS",
        "relevance_score": "0.02118",
        "ticker_sentiment_score": "0.009389",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.02118",
        "ticker_sentiment_score": "0.052535",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Protein Expression Market size to grow by USD 2.45 billion from 2023 to 2027, North America accounts for 37% of ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/protein-expression-market-size-to-grow-by-usd-2-45-billion-from-2023-to-2027--north-america-accounts-for-37-of-market-growth-technavio-302083091.html",
    "time_published": "20240308T224800",
    "authors": [],
    "summary": "Protein Expression Market size to grow by USD 2.45 billion from 2023 to 2027, North America accounts for 37% of ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.265097,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "A",
        "relevance_score": "0.064885",
        "ticker_sentiment_score": "0.024012",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SUVPF",
        "relevance_score": "0.032469",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BDX",
        "relevance_score": "0.032469",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GNNSF",
        "relevance_score": "0.032469",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.032469",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIO",
        "relevance_score": "0.032469",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QGEN",
        "relevance_score": "0.032469",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.032469",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.032469",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DHR",
        "relevance_score": "0.032469",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Novo Nordisk  ( NVO )  Up on Upbeat Data From New Obesity Pill Study",
    "url": "https://www.zacks.com/stock/news/2238077/novo-nordisk-nvo-up-on-upbeat-data-from-new-obesity-pill-study",
    "time_published": "20240308T150300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Novo Nordisk (NVO) stock rises as it presents encouraging efficacy data on a new investigational oral obesity pill, amycretin, at its Capital Markets Day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.190026,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.256719",
        "ticker_sentiment_score": "0.151479",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.256719",
        "ticker_sentiment_score": "0.105076",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.155786",
        "ticker_sentiment_score": "0.01855",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.444487",
        "ticker_sentiment_score": "0.34082",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Viking  ( VKTX )  Stock Down on Novo Nordisk's Obesity Pill Data",
    "url": "https://www.zacks.com/stock/news/2237803/viking-vktx-stock-down-on-novo-nordisks-obesity-pill-data",
    "time_published": "20240308T114700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Viking Therapeutics (VKTX) falls as VK2735's placebo-adjusted mean weight loss after 13 weeks of treatment in a phase II study appears similar to Novo Nordisk's amycretin in a phase I study.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/82/41137.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.142303,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.220141",
        "ticker_sentiment_score": "0.015164",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.543935",
        "ticker_sentiment_score": "-0.052958",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.220141",
        "ticker_sentiment_score": "0.075149",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The AI Race Gets Litigious",
    "url": "https://www.fool.com/investing/2024/03/09/the-ai-race-gets-litigious/",
    "time_published": "20240309T140000",
    "authors": [
      "Motley Fool Staff"
    ],
    "summary": "We've also got a look at the role of patents in pharmaceuticals and the \"patent cliff\" looming over the next decade.",
    "banner_image": "https://g.foolcdn.com/editorial/images/767969/mfm_01.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999897"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.135271,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.011745",
        "ticker_sentiment_score": "0.024158",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.005873",
        "ticker_sentiment_score": "0.153424",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.005873",
        "ticker_sentiment_score": "0.028237",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WEN",
        "relevance_score": "0.005873",
        "ticker_sentiment_score": "0.025948",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.052814",
        "ticker_sentiment_score": "0.037995",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDNDF",
        "relevance_score": "0.005873",
        "ticker_sentiment_score": "0.000795",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.005873",
        "ticker_sentiment_score": "-0.061024",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NOK",
        "relevance_score": "0.005873",
        "ticker_sentiment_score": "0.029278",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.005873",
        "ticker_sentiment_score": "0.094025",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.011745",
        "ticker_sentiment_score": "0.054819",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.052814",
        "ticker_sentiment_score": "0.084856",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SBUX",
        "relevance_score": "0.005873",
        "ticker_sentiment_score": "0.04716",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EBAY",
        "relevance_score": "0.005873",
        "ticker_sentiment_score": "0.105535",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.005873",
        "ticker_sentiment_score": "0.145276",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UBER",
        "relevance_score": "0.011745",
        "ticker_sentiment_score": "0.011815",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PANW",
        "relevance_score": "0.011745",
        "ticker_sentiment_score": "0.02692",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why the Market Dipped But Amgen  ( AMGN )  Gained Today",
    "url": "https://www.zacks.com/stock/news/2238906/why-the-market-dipped-but-amgen-amgn-gained-today",
    "time_published": "20240311T215017",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the closing of the recent trading day, Amgen (AMGN) stood at $275.36, denoting a +0.59% change from the preceding trading day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default32.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.146832,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.588876",
        "ticker_sentiment_score": "0.15513",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks",
    "url": "https://www.zacks.com/stock/news/2238528/improve-your-retirement-income-with-these-3-top-ranked-dividend-stocks",
    "time_published": "20240311T131003",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default132.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.284931,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BRX",
        "relevance_score": "0.214462",
        "ticker_sentiment_score": "0.193868",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.214462",
        "ticker_sentiment_score": "0.122324",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.054236",
        "ticker_sentiment_score": "-0.036003",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.214462",
        "ticker_sentiment_score": "0.117428",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss",
    "url": "https://www.globenewswire.com/news-release/2024/03/12/2844447/11676/en/Veru-Announces-the-Appointment-of-Louis-Aronne-MD-as-Chief-Medical-Advisor-for-its-Enobosarm-Program-for-High-Quality-Weight-Loss.html",
    "time_published": "20240312T120000",
    "authors": [
      "Veru Inc."
    ],
    "summary": "MIAMI, March 12, 2024 ( GLOBE NEWSWIRE ) -- Veru Inc. ( NASDAQ: VERU ) , a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome ( ARDS ) , today ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/9c96f1a7-e104-47d4-8011-8c19496681c2",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.007304,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ALT",
        "relevance_score": "0.0203",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VERU",
        "relevance_score": "0.121343",
        "ticker_sentiment_score": "0.022775",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.0203",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.0203",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.0203",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen  ( NASDAQ:AMGN )  Raised to \"Buy\" at StockNews.com",
    "url": "https://www.defenseworld.net/2024/03/12/amgen-nasdaqamgn-raised-to-buy-at-stocknews-com.html",
    "time_published": "20240312T083849",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "StockNews.com upgraded shares of Amgen ( NASDAQ:AMGN - Free Report ) from a hold rating to a buy rating in a research note released on Monday.",
    "banner_image": "https://www.marketbeat.com/logos/amgen-inc-logo.jpg?v=20231228113741",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.623304"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.988787"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.251409,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TFC",
        "relevance_score": "0.050572",
        "ticker_sentiment_score": "0.101519",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RBCPF",
        "relevance_score": "0.050572",
        "ticker_sentiment_score": "0.101519",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.050572",
        "ticker_sentiment_score": "0.101519",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.817115",
        "ticker_sentiment_score": "0.430556",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "COIN",
        "relevance_score": "0.050572",
        "ticker_sentiment_score": "0.084958",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields - Medtronic  ( NYSE:MDT ) , Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/news/24/03/37651163/wall-streets-most-accurate-analysts-views-on-3-health-care-stocks-delivering-high-dividend-yields",
    "time_published": "20240313T122439",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/03/13/image42.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.135852,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.113597",
        "ticker_sentiment_score": "-0.082966",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.113597",
        "ticker_sentiment_score": "-0.077409",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OGN",
        "relevance_score": "0.113597",
        "ticker_sentiment_score": "0.371301",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Amgen  ( NASDAQ:AMGN )  Upgraded by StockNews.com to \"Buy\"",
    "url": "https://www.americanbankingnews.com/2024/03/12/amgen-nasdaqamgn-upgraded-by-stocknews-com-to-buy.html",
    "time_published": "20240313T011202",
    "authors": [
      "ABMN Staff"
    ],
    "summary": "StockNews.com upgraded shares of Amgen ( NASDAQ:AMGN - Free Report ) from a hold rating to a buy rating in a report published on Monday.",
    "banner_image": "https://www.marketbeat.com/logos/amgen-inc-logo.jpg?v=20231228113741",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.americanbankingnews.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999967"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.980509"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.268661,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "RBCPF",
        "relevance_score": "0.047749",
        "ticker_sentiment_score": "0.07617",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.047749",
        "ticker_sentiment_score": "0.07617",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.768929",
        "ticker_sentiment_score": "0.440554",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "COIN",
        "relevance_score": "0.047749",
        "ticker_sentiment_score": "0.113666",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.047749",
        "ticker_sentiment_score": "0.07617",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Looking At Amgen's Recent Unusual Options Activity - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/insights/options/24/03/37717934/looking-at-amgens-recent-unusual-options-activity",
    "time_published": "20240314T203051",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Financial giants have made a conspicuous bearish move on Amgen. Our analysis of options history for Amgen AMGN revealed 11 unusual trades. Delving into the details, we found 36% of traders were bullish, while 63% showed bearish tendencies.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      }
    ],
    "overall_sentiment_score": 0.126748,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.699089",
        "ticker_sentiment_score": "-0.09131",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Monoclonal Antibody  ( mABs )  Therapeutics Market Worth $497.5 billion | MarketsandMarkets\u2122",
    "url": "https://www.prnewswire.com/news-releases/monoclonal-antibody-mabs-therapeutics-market-worth-497-5-billion--marketsandmarkets-302090362.html",
    "time_published": "20240315T143000",
    "authors": [
      "MarketsandMarkets"
    ],
    "summary": "CHICAGO, March 15, 2024 /PRNewswire/ -- Monoclonal Antibody ( mABs ) Therapeutics Market in terms of revenue was estimated to be worth $252.6 billion in 2024 and is poised to reach $497.5 billion by 2029, growing at a CAGR of 14.5% from 2024 to 2029 according to a new report by ...",
    "banner_image": "https://mma.prnewswire.com/media/2297424/MarketsandMarkets_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.227469,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.024372",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.04872",
        "ticker_sentiment_score": "0.078722",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.073024",
        "ticker_sentiment_score": "0.08487",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.04872",
        "ticker_sentiment_score": "0.078722",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.04872",
        "ticker_sentiment_score": "0.078722",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.04872",
        "ticker_sentiment_score": "0.064394",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.04872",
        "ticker_sentiment_score": "0.078722",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GSK",
        "relevance_score": "0.04872",
        "ticker_sentiment_score": "0.078722",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.024372",
        "ticker_sentiment_score": "0.081181",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.04872",
        "ticker_sentiment_score": "0.078722",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.04872",
        "ticker_sentiment_score": "0.078722",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TAK",
        "relevance_score": "0.04872",
        "ticker_sentiment_score": "0.078722",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Amgen  ( AMGN )  Outpaced the Stock Market Today",
    "url": "https://www.zacks.com/stock/news/2242485/why-amgen-amgn-outpaced-the-stock-market-today",
    "time_published": "20240318T220018",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the latest trading session, Amgen (AMGN) closed at $270.90, marking a +0.76% move from the previous day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default297.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.976913"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.151705,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.535653",
        "ticker_sentiment_score": "0.200965",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks",
    "url": "https://www.zacks.com/stock/news/2242023/improve-your-retirement-income-with-these-3-top-ranked-dividend-stocks",
    "time_published": "20240318T131003",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default236.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.201121,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.215894",
        "ticker_sentiment_score": "0.122965",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.054607",
        "ticker_sentiment_score": "-0.036005",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.215894",
        "ticker_sentiment_score": "0.118044",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIPC",
        "relevance_score": "0.108958",
        "ticker_sentiment_score": "0.122328",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Investors Heavily Search Amgen Inc.  ( AMGN ) : Here is What You Need to Know",
    "url": "https://www.zacks.com/stock/news/2242002/investors-heavily-search-amgen-inc-amgn-here-is-what-you-need-to-know",
    "time_published": "20240318T130011",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default215.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.208713,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.482982",
        "ticker_sentiment_score": "0.095046",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Gene therapy market size to grow by USD 4.61 billion from 2022 to 2027, North America is estimated to contribute 39 ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/gene-therapy-market-size-to-grow-by-usd-4-61-billion-from-2022-to-2027--north-america-is-estimated-to-contribute-39-to-the-growth-technavio-302090363.html",
    "time_published": "20240318T093600",
    "authors": [],
    "summary": "Gene therapy market size to grow by USD 4.61 billion from 2022 to 2027, North America is estimated to contribute 39 ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.296456,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GBIO",
        "relevance_score": "0.033562",
        "ticker_sentiment_score": "0.019119",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PSTX",
        "relevance_score": "0.033562",
        "ticker_sentiment_score": "0.019119",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADVM",
        "relevance_score": "0.033562",
        "ticker_sentiment_score": "0.019119",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BNTC",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.179328",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BLUE",
        "relevance_score": "0.033562",
        "ticker_sentiment_score": "0.019119",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VYGR",
        "relevance_score": "0.033562",
        "ticker_sentiment_score": "0.019119",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALPMF",
        "relevance_score": "0.033562",
        "ticker_sentiment_score": "0.019119",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EDIT",
        "relevance_score": "0.033562",
        "ticker_sentiment_score": "0.019119",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.033562",
        "ticker_sentiment_score": "0.019119",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AGTC",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.179328",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ADAP",
        "relevance_score": "0.033562",
        "ticker_sentiment_score": "0.019119",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.033562",
        "ticker_sentiment_score": "0.019119",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.033562",
        "ticker_sentiment_score": "0.110176",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CLLS",
        "relevance_score": "0.033562",
        "ticker_sentiment_score": "0.110176",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SGMO",
        "relevance_score": "0.033562",
        "ticker_sentiment_score": "0.019119",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GENE",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.179328",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABEO",
        "relevance_score": "0.033562",
        "ticker_sentiment_score": "0.019119",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OXBDF",
        "relevance_score": "0.033562",
        "ticker_sentiment_score": "0.119872",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.033562",
        "ticker_sentiment_score": "0.019119",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.033562",
        "ticker_sentiment_score": "0.019119",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen  ( AMGN )  Ascends But Remains Behind Market: Some Facts to Note",
    "url": "https://www.zacks.com/stock/news/2243077/amgen-amgn-ascends-but-remains-behind-market-some-facts-to-note",
    "time_published": "20240319T215020",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the closing of the recent trading day, Amgen (AMGN) stood at $271.73, denoting a +0.31% change from the preceding trading day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default278.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.976913"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.216606,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.52949",
        "ticker_sentiment_score": "0.279141",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Amgen  ( NASDAQ:AMGN )  Downgraded by StockNews.com to \"Hold\"",
    "url": "https://www.defenseworld.net/2024/03/19/amgen-nasdaqamgn-downgraded-by-stocknews-com-to-hold.html",
    "time_published": "20240319T062244",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Amgen ( NASDAQ:AMGN - Get Free Report ) was downgraded by equities research analysts at StockNews.com from a \"buy\" rating to a \"hold\" rating in a research note issued on Tuesday.",
    "banner_image": "https://www.marketbeat.com/logos/amgen-inc-logo-1200x675.jpg?v=20231228113741",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.658903"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.938793"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.255798,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TFC",
        "relevance_score": "0.050044",
        "ticker_sentiment_score": "0.031856",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.050044",
        "ticker_sentiment_score": "0.031856",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.790605",
        "ticker_sentiment_score": "0.415608",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.050044",
        "ticker_sentiment_score": "0.031856",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.050044",
        "ticker_sentiment_score": "0.088889",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update",
    "url": "https://www.globenewswire.com/news-release/2024/03/20/2849779/0/en/Alvotech-Reports-Financial-Results-for-Full-Year-2023-and-Provides-a-Business-Update.html",
    "time_published": "20240320T201500",
    "authors": [
      "Alvotech"
    ],
    "summary": "Alvotech ( NASDAQ: ALVO, or the \"Company\" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for full year 2023 and provided a summary of recent pipeline and corporate highlights.",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.839681"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.955357"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.131766,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.011791",
        "ticker_sentiment_score": "0.085539",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.011791",
        "ticker_sentiment_score": "0.085539",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTUS",
        "relevance_score": "0.011791",
        "ticker_sentiment_score": "0.053881",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.023579",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALVO",
        "relevance_score": "0.342487",
        "ticker_sentiment_score": "0.166948",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.011791",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.011791",
        "ticker_sentiment_score": "0.053881",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.011791",
        "ticker_sentiment_score": "0.053881",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.011791",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.011791",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:ISK",
        "relevance_score": "0.035363",
        "ticker_sentiment_score": "0.166852",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FOREX:SEK",
        "relevance_score": "0.023579",
        "ticker_sentiment_score": "0.137997",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.035363",
        "ticker_sentiment_score": "0.215495",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update",
    "url": "https://www.globenewswire.com/news-release/2024/03/20/2849778/0/en/Alvotech-Reports-Financial-Results-for-Full-Year-2023-and-Provides-a-Business-Update.html",
    "time_published": "20240320T201500",
    "authors": [
      "Alvotech"
    ],
    "summary": "REYKJAVIK, Iceland, March 20, 2024 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO, or the \"Company\" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for full year 2023 and provided a ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.839681"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.955357"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.129421,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.011762",
        "ticker_sentiment_score": "0.085519",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.011762",
        "ticker_sentiment_score": "0.085519",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTUS",
        "relevance_score": "0.011762",
        "ticker_sentiment_score": "0.053868",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.023521",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALVO",
        "relevance_score": "0.341699",
        "ticker_sentiment_score": "0.166635",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.011762",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.011762",
        "ticker_sentiment_score": "0.053868",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.011762",
        "ticker_sentiment_score": "0.053868",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.011762",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.011762",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:ISK",
        "relevance_score": "0.035276",
        "ticker_sentiment_score": "0.164818",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FOREX:SEK",
        "relevance_score": "0.023521",
        "ticker_sentiment_score": "0.135974",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.035276",
        "ticker_sentiment_score": "0.214421",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Is Pfizer Stock, At A Nine-Year Low, A Sell Amid The Search For Its Big Break?",
    "url": "https://www.investors.com/news/technology/pfizer-stock-buy-now/",
    "time_published": "20240320T170719",
    "authors": [
      "Investor's Business Daily",
      "ALLISON GATLIN"
    ],
    "summary": "Pfizer ( PFE ) stock is trading at its lowest point in nine years as the drugmaker looks for its next big break after developing the first Covid vaccine with Germany's BioNTech ( BNTX ) . This month, the European Commission approved Pfizer's Prevnar 20, a vaccine to help protect babies and ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2019/05/PFE-evergreen-051419-shutter.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999981"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999976"
      }
    ],
    "overall_sentiment_score": 0.120598,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NVO",
        "relevance_score": "0.061869",
        "ticker_sentiment_score": "-0.125315",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.061869",
        "ticker_sentiment_score": "-0.125315",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVAX",
        "relevance_score": "0.061869",
        "ticker_sentiment_score": "0.075008",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.061869",
        "ticker_sentiment_score": "0.075008",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.061869",
        "ticker_sentiment_score": "-0.14606",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.687052",
        "ticker_sentiment_score": "0.203831",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.061869",
        "ticker_sentiment_score": "0.059184",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BNTX",
        "relevance_score": "0.061869",
        "ticker_sentiment_score": "-0.14606",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stocks Rise Ahead Of Fed's Guidance On Rate Cuts; Nvidia, Super Micro Fall",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-sp500-nasdaq-federal-reserve-powell-nvidia-nvda-stock-ai-smci-google-stock-cathie-wood/",
    "time_published": "20240320T150826",
    "authors": [
      "VIDYA RAMAKRISHNAN",
      "Investor's Business Daily"
    ],
    "summary": "Stock Market Today: Stocks Rise Ahead Of Fed Powell. Nvidia, SMCI Fall As Cisco Rival Breaks Out Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2022/06/Stock-jeromepowell2022-04-gov.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.108013,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.049732",
        "ticker_sentiment_score": "0.227259",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.197011",
        "ticker_sentiment_score": "0.112503",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ANET",
        "relevance_score": "0.099271",
        "ticker_sentiment_score": "-0.213131",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "CSCO",
        "relevance_score": "0.099271",
        "ticker_sentiment_score": "-0.213131",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.148426",
        "ticker_sentiment_score": "0.079178",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NBIX",
        "relevance_score": "0.099271",
        "ticker_sentiment_score": "0.210983",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NKE",
        "relevance_score": "0.099271",
        "ticker_sentiment_score": "-0.148804",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.099271",
        "ticker_sentiment_score": "0.069793",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GIS",
        "relevance_score": "0.099271",
        "ticker_sentiment_score": "0.162721",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CAT",
        "relevance_score": "0.099271",
        "ticker_sentiment_score": "0.069793",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DRI",
        "relevance_score": "0.099271",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CMG",
        "relevance_score": "0.099271",
        "ticker_sentiment_score": "-0.061005",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TXRH",
        "relevance_score": "0.099271",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SQ",
        "relevance_score": "0.197011",
        "ticker_sentiment_score": "0.230707",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.099271",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.099271",
        "ticker_sentiment_score": "0.069793",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MAR",
        "relevance_score": "0.099271",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OLLI",
        "relevance_score": "0.099271",
        "ticker_sentiment_score": "0.162721",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Is Amgen Stock a Buy Now?",
    "url": "https://www.fool.com/investing/2024/03/21/is-amgen-stock-a-buy-now/",
    "time_published": "20240321T110000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "There are some worrying signs.",
    "banner_image": "https://g.foolcdn.com/editorial/images/769464/physician-giving-medicine-to-elderly-patient.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.193929,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.650245",
        "ticker_sentiment_score": "0.284532",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Pharmaceuticals Market In Germany size is set to grow by USD 21.44 bn from 2023-2027, Abbott Laboratories, AbbVie ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/pharmaceuticals-market-in-germany-size-is-set-to-grow-by-usd-21-44-bn-from-2023-2027--abbott-laboratories-abbvie-inc--amgen-inc-and-more-to-emerge-as-some-of-the-key-vendors--technavio-302096253.html",
    "time_published": "20240322T161800",
    "authors": [],
    "summary": "Pharmaceuticals Market In Germany size is set to grow by USD 21.44 bn from 2023-2027, Abbott Laboratories, AbbVie ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.244345,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BAYZF",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.099883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.099883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.099883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BLCO",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "-0.020684",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.099883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.099883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.099883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.099883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.099883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.099883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FSNUF",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.099883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.099883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.099883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.099883",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen  ( AMGN )  Ascends While Market Falls: Some Facts to Note",
    "url": "https://www.zacks.com/stock/news/2245686/amgen-amgn-ascends-while-market-falls-some-facts-to-note",
    "time_published": "20240325T215019",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the most recent trading session, Amgen (AMGN) closed at $280.82, indicating a +1.68% shift from the previous trading day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default306.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.110385,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.531019",
        "ticker_sentiment_score": "0.155924",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income",
    "url": "https://www.zacks.com/stock/news/2245413/3-top-ranked-dividend-stocks-a-smarter-way-to-boost-your-retirement-income",
    "time_published": "20240325T131003",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default237.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.197748,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.214462",
        "ticker_sentiment_score": "0.122324",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.054236",
        "ticker_sentiment_score": "-0.036003",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.214462",
        "ticker_sentiment_score": "0.117428",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIPC",
        "relevance_score": "0.108222",
        "ticker_sentiment_score": "0.122045",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Wall Street Awaits Consumer Confidence Data",
    "url": "https://www.zacks.com/stock/news/2246106/wall-street-awaits-consumer-confidence-data",
    "time_published": "20240326T142100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "U.S. stock markets saw a pullback on Monday to start a holiday-shortened week. However, Wall Street is likely to record the fifth consecutive winning month despite volatility. The AI-driven rally of the last 15 months is showing no sign of losing pace.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.097535,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMD",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "0.069557",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.248682",
        "ticker_sentiment_score": "0.080175",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INTC",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "0.069557",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "0.039322",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "-0.176937",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Should Schwab U.S. Dividend Equity ETF  ( SCHD )  Be on Your Investing Radar?",
    "url": "https://www.zacks.com/stock/news/2245789/should-schwab-us-dividend-equity-etf-schd-be-on-your-investing-radar",
    "time_published": "20240326T102007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Style Box ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default122.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.208752,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SCHW",
        "relevance_score": "0.059935",
        "ticker_sentiment_score": "0.117001",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.119532",
        "ticker_sentiment_score": "0.067655",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.119532",
        "ticker_sentiment_score": "0.067655",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.119532",
        "ticker_sentiment_score": "0.067655",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Wall Street Set to Post Fifth Winning Month Amid Volatility",
    "url": "https://www.zacks.com/stock/news/2245743/wall-street-set-to-post-fifth-winning-month-amid-volatility",
    "time_published": "20240326T063300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Wall Street is likely to record the fifth consecutive winning month despite volatility.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d3/848.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.099917,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMD",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "0.072406",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.248682",
        "ticker_sentiment_score": "0.08021",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INTC",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "0.072406",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "0.039322",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "-0.176937",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Precision BioSciences  ( DTIL )  Reports Q4 Loss, Lags Revenue Estimates",
    "url": "https://www.zacks.com/stock/news/2246468/precision-biosciences-dtil-reports-q4-loss-lags-revenue-estimates",
    "time_published": "20240327T121002",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Precision BioSciences (DTIL) delivered earnings and revenue surprises of -211.67% and 75.31%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default251.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999892"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.130697,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.138863",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DTIL",
        "relevance_score": "0.400265",
        "ticker_sentiment_score": "0.138028",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen's Diversified Portfolio To Drive Long-Term Growth, Though Uncertainties Loom, Analyst Says - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37991995/amgens-diversified-portfolio-to-drive-long-term-growth-though-uncertainties-loom-an",
    "time_published": "20240328T182836",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Raymond James has resumed coverage of Amgen Inc AMGN, noting a diversified portfolio where Amgen has a strong presence that can help drive solid, sustainable long-term growth.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Autoinjector-with-Amgevita-by-Amgen-Adal_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.349323,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.560201",
        "ticker_sentiment_score": "0.787238",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Amgen Options Trading: A Deep Dive into Market Sentiment - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/insights/options/24/03/37988114/amgen-options-trading-a-deep-dive-into-market-sentiment",
    "time_published": "20240328T160314",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Deep-pocketed investors have adopted a bullish approach towards Amgen AMGN, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.193364,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.741581",
        "ticker_sentiment_score": "0.208297",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar",
    "url": "https://www.zacks.com/stock/news/2247187/these-2-medical-stocks-could-beat-earnings-why-they-should-be-on-your-radar",
    "time_published": "20240328T125011",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default53.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999973"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.35923,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.380978",
        "ticker_sentiment_score": "0.372856",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Should You Invest in the iShares Biotechnology ETF  ( IBB ) ?",
    "url": "https://www.zacks.com/stock/news/2247086/should-you-invest-in-the-ishares-biotechnology-etf-ibb",
    "time_published": "20240328T102007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default38.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999999"
      }
    ],
    "overall_sentiment_score": 0.20999,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.068502",
        "ticker_sentiment_score": "0.034077",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.136499",
        "ticker_sentiment_score": "0.072027",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.136499",
        "ticker_sentiment_score": "0.072027",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.136499",
        "ticker_sentiment_score": "0.072027",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen Inc.  ( AMGN )  Is a Trending Stock: Facts to Know Before Betting on It",
    "url": "https://www.zacks.com/stock/news/2247853/amgen-inc-amgn-is-a-trending-stock-facts-to-know-before-betting-on-it",
    "time_published": "20240329T130010",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default228.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.206482,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.487546",
        "ticker_sentiment_score": "0.08334",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen  ( NASDAQ:AMGN )  Downgraded by StockNews.com to Hold",
    "url": "https://www.defenseworld.net/2024/03/29/amgen-nasdaqamgn-downgraded-by-stocknews-com-to-hold-2.html",
    "time_published": "20240329T085043",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "StockNews.com lowered shares of Amgen ( NASDAQ:AMGN - Free Report ) from a buy rating to a hold rating in a research report report published on Thursday. Several other equities analysts have also weighed in on the stock.",
    "banner_image": "https://www.marketbeat.com/logos/amgen-inc-logo.jpg?v=20231228113741",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.972476"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.208912,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.05339",
        "ticker_sentiment_score": "0.071883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.05339",
        "ticker_sentiment_score": "0.11099",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FL",
        "relevance_score": "0.05339",
        "ticker_sentiment_score": "0.11099",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.05339",
        "ticker_sentiment_score": "0.071883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BOKF",
        "relevance_score": "0.05339",
        "ticker_sentiment_score": "0.129884",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen  ( AMGN )  Sees a More Significant Dip Than Broader Market: Some Facts to Know",
    "url": "https://www.zacks.com/stock/news/2248726/amgen-amgn-sees-a-more-significant-dip-than-broader-market-some-facts-to-know",
    "time_published": "20240401T220020",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) closed the most recent trading day at $283.04, moving -0.45% from the previous trading session.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default229.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.976913"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.176837,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.587278",
        "ticker_sentiment_score": "0.218683",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why Amgen  ( AMGN )  is Poised to Beat Earnings Estimates Again",
    "url": "https://www.zacks.com/stock/news/2248594/why-amgen-amgn-is-poised-to-beat-earnings-estimates-again",
    "time_published": "20240401T161015",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default132.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999953"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.307242,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.425746",
        "ticker_sentiment_score": "0.46796",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks",
    "url": "https://www.zacks.com/stock/news/2248260/how-to-maximize-your-retirement-portfolio-with-these-top-ranked-dividend-stocks",
    "time_published": "20240401T131002",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default309.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.226978,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ARE",
        "relevance_score": "0.104455",
        "ticker_sentiment_score": "0.12824",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.207127",
        "ticker_sentiment_score": "0.114283",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.207127",
        "ticker_sentiment_score": "0.119051",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the Invesco Pharmaceuticals ETF  ( PJP ) ?",
    "url": "https://www.zacks.com/stock/news/2248126/should-you-invest-in-the-invesco-pharmaceuticals-etf-pjp",
    "time_published": "20240401T102005",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default354.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.193607,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.131643",
        "ticker_sentiment_score": "0.070705",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.131643",
        "ticker_sentiment_score": "0.070705",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.259727",
        "ticker_sentiment_score": "0.149109",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.131643",
        "ticker_sentiment_score": "0.070705",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Enzyme-linked immunosorbent assay (Elisa) testing market size to Increase by USD 564.97 million between 2022 ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/enzyme-linked-immunosorbent-assay-elisa-testing-market-size-to-increase-by-usd-564-97-million-between-2022-2027--technavio-302102559.html",
    "time_published": "20240401T082400",
    "authors": [],
    "summary": "Enzyme-linked immunosorbent assay ( Elisa ) testing market size to Increase by USD 564.97 million between 2022 ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.249637,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABCZF",
        "relevance_score": "0.026386",
        "ticker_sentiment_score": "0.058925",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "A",
        "relevance_score": "0.026386",
        "ticker_sentiment_score": "0.058925",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.026386",
        "ticker_sentiment_score": "0.058925",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen Unusual Options Activity For April 02 - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/insights/options/24/04/38054803/amgen-unusual-options-activity-for-april-02",
    "time_published": "20240402T181555",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Financial giants have made a conspicuous bearish move on Amgen. Our analysis of options history for Amgen AMGN revealed 11 unusual trades. Delving into the details, we found 18% of traders were bullish, while 81% showed bearish tendencies.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.131588,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.771727",
        "ticker_sentiment_score": "0.024071",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Dow Jones Dives As Calvin Klein Parent Craters; Cathie Wood Loads Up On This Stock Amid 45% Downtrend",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-nasdaq-sp500-cathie-wood-tesla-nvidia-stock/",
    "time_published": "20240402T145200",
    "authors": [
      "Investor's Business Daily",
      "MICHAEL LARKIN"
    ],
    "summary": "Dow Jones Dives As Calvin Klein Parent Craters. Cathie Wood Loads Up On This Stock Amid 45% Downtrend Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2018/10/stock-stress-01-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.983783"
      }
    ],
    "overall_sentiment_score": 0.092005,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CVS",
        "relevance_score": "0.075397",
        "ticker_sentiment_score": "-0.275998",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.037741",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HUM",
        "relevance_score": "0.075397",
        "ticker_sentiment_score": "-0.275998",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.150122",
        "ticker_sentiment_score": "-0.095078",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.150122",
        "ticker_sentiment_score": "0.016289",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.075397",
        "ticker_sentiment_score": "-0.168999",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.037741",
        "ticker_sentiment_score": "-0.108968",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.075397",
        "ticker_sentiment_score": "0.009279",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RSG",
        "relevance_score": "0.150122",
        "ticker_sentiment_score": "0.111664",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.075397",
        "ticker_sentiment_score": "0.009279",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.075397",
        "ticker_sentiment_score": "-0.158837",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.075397",
        "ticker_sentiment_score": "-0.168999",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.223522",
        "ticker_sentiment_score": "-0.132311",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INTC",
        "relevance_score": "0.075397",
        "ticker_sentiment_score": "0.009279",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMD",
        "relevance_score": "0.075397",
        "ticker_sentiment_score": "-0.122298",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMI",
        "relevance_score": "0.112885",
        "ticker_sentiment_score": "0.102754",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ON",
        "relevance_score": "0.037741",
        "ticker_sentiment_score": "-0.116802",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here's Why Amgen  ( AMGN )  Stock is Outperforming the Industry",
    "url": "https://www.zacks.com/stock/news/2249889/heres-why-amgen-amgn-stock-is-outperforming-the-industry",
    "time_published": "20240403T151400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) expects strong sales growth of products like Tezspire, Evenity and Repatha to make up for lower revenues from oncology biosimilars and ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/595.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.96136"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.211002,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ADMA",
        "relevance_score": "0.310843",
        "ticker_sentiment_score": "0.252568",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.613875",
        "ticker_sentiment_score": "0.308004",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VNDA",
        "relevance_score": "0.261117",
        "ticker_sentiment_score": "0.079585",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen  ( AMGN )  Ascends But Remains Behind Market: Some Facts to Note",
    "url": "https://www.zacks.com/stock/news/2251464/amgen-amgn-ascends-but-remains-behind-market-some-facts-to-note",
    "time_published": "20240405T215018",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) concluded the recent trading session at $269.95, signifying a +0.69% move from its prior day's close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default171.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.976913"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      }
    ],
    "overall_sentiment_score": 0.172407,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.588876",
        "ticker_sentiment_score": "0.282706",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why A Pullback Is Bullish For IBD Stock Of The Day Novo Nordisk",
    "url": "https://www.investors.com/research/ibd-stock-of-the-day/novo-nordisk-stock-pullback-weight-loss-drugs/",
    "time_published": "20240405T163500",
    "authors": [
      "ALLISON GATLIN",
      "Investor's Business Daily"
    ],
    "summary": "Novo Nordisk ( NVO ) is Friday's IBD Stock Of The Day. After hitting a record high in March, shares have pulled back amid new developments in the weight-loss drugs frenzy. Last month, Novo said its next-generation weight-loss pill, amycretin, outperformed blockbuster Wegovy in an early-stage ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/04/SOTD-4-5-2024NVO.png",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      }
    ],
    "overall_sentiment_score": 0.21862,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.254307",
        "ticker_sentiment_score": "0.13511",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.128822",
        "ticker_sentiment_score": "0.187818",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.128822",
        "ticker_sentiment_score": "0.187818",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.064623",
        "ticker_sentiment_score": "0.294962",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GMAB",
        "relevance_score": "0.064623",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.373378",
        "ticker_sentiment_score": "0.138725",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is iShares Biotechnology ETF  ( IBB )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2250861/is-ishares-biotechnology-etf-ibb-a-strong-etf-right-now",
    "time_published": "20240405T102007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default81.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999892"
      }
    ],
    "overall_sentiment_score": 0.256572,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.061949",
        "ticker_sentiment_score": "0.11403",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.123526",
        "ticker_sentiment_score": "0.06173",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.123526",
        "ticker_sentiment_score": "0.06173",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.123526",
        "ticker_sentiment_score": "0.06173",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Stocks to Consider Adding to Your Retirement Portfolio in April",
    "url": "https://www.fool.com/investing/2024/04/05/stocks-consider-adding-retirement-portfolio/",
    "time_published": "20240405T080500",
    "authors": [
      "James Brumley"
    ],
    "summary": "Use the recent short-term weakness from these powerhouse companies' stocks to your advantage.",
    "banner_image": "https://g.foolcdn.com/editorial/images/771458/female-investor-reviewing-her-portfolio-on-a-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.193286,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MA",
        "relevance_score": "0.035661",
        "ticker_sentiment_score": "0.167621",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.279414",
        "ticker_sentiment_score": "0.17067",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SNOW",
        "relevance_score": "0.279414",
        "ticker_sentiment_score": "0.253608",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.035661",
        "ticker_sentiment_score": "0.167621",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 Biotech Stocks to Buy Hand Over Fist in April",
    "url": "https://www.fool.com/investing/2024/04/06/2-biotech-stocks-to-buy-hand-over-fist/",
    "time_published": "20240406T124500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "These drugmakers have made important moves over the past year.",
    "banner_image": "https://g.foolcdn.com/editorial/images/771546/patient-talking-with-a-physician.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      }
    ],
    "overall_sentiment_score": 0.244544,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.500753",
        "ticker_sentiment_score": "0.378904",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "SRPT",
        "relevance_score": "0.264515",
        "ticker_sentiment_score": "0.148145",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Opthea Appoints John Han, PharmD, as VP Medical Affairs",
    "url": "https://www.globenewswire.com/news-release/2024/04/08/2859653/0/en/Opthea-Appoints-John-Han-PharmD-as-VP-Medical-Affairs.html",
    "time_published": "20240408T224200",
    "authors": [
      "Opthea Limited"
    ],
    "summary": "Brings extensive experience in retinal and ophthalmology diseases Brings extensive experience in retinal and ophthalmology diseases ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/6b4960e3-b3f5-41cb-8993-66ea0b111361",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.918141"
      }
    ],
    "overall_sentiment_score": 0.219285,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "OPT",
        "relevance_score": "0.403634",
        "ticker_sentiment_score": "0.233542",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ADVM",
        "relevance_score": "0.030178",
        "ticker_sentiment_score": "0.064876",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.09036",
        "ticker_sentiment_score": "0.125642",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.060312",
        "ticker_sentiment_score": "0.126007",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAYZF",
        "relevance_score": "0.060312",
        "ticker_sentiment_score": "0.126007",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Top Dividend Stocks to Maximize Your Retirement Income",
    "url": "https://www.zacks.com/stock/news/2251803/3-top-dividend-stocks-to-maximize-your-retirement-income",
    "time_published": "20240408T131002",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default152.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.212542,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ARE",
        "relevance_score": "0.101154",
        "ticker_sentiment_score": "0.127017",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.200688",
        "ticker_sentiment_score": "0.111538",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.200688",
        "ticker_sentiment_score": "0.116195",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting - Coherus BioSciences  ( NASDAQ:CHRS ) ",
    "url": "https://www.benzinga.com/pressreleases/24/04/g38141013/coherus-presents-preclinical-data-for-chs-1000-a-novel-anti-ilt4-antibody-at-the-2024-aacr-annual-",
    "time_published": "20240408T123000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "- In preclinical studies, CHS-1000 shows a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, leading to activation of immune cells and increased cytokine secretion - - Mechanism may enhance antitumor responses with immunotherapy - - First novel immuno-oncology ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.614606"
      }
    ],
    "overall_sentiment_score": 0.086922,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CHRS",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.052797",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Biophytis  ( BPTS )  to Begin Phase II Obesity Study, Stock Up",
    "url": "https://www.zacks.com/stock/news/2252360/biophytis-bpts-to-begin-phase-ii-obesity-study-stock-up",
    "time_published": "20240409T110200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Biophytis (BPTS) rises in the after-market hours as it announces the launch of a new clinical development program for its investigational candidate, BIO101, to treat obesity in combination with GLP-1 drugs.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c8/39674.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.204153,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.21258",
        "ticker_sentiment_score": "0.193348",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BPTS",
        "relevance_score": "0.499789",
        "ticker_sentiment_score": "0.116071",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.053749",
        "ticker_sentiment_score": "0.127728",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.160277",
        "ticker_sentiment_score": "0.067045",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 High-Growth Biotech Stocks Investors Shouldn't Sleep On in April",
    "url": "https://markets.businessinsider.com/news/stocks/3-high-growth-biotech-stocks-investors-shouldnt-sleep-on-in-april-1033232893",
    "time_published": "20240409T110000",
    "authors": [
      "Chris MacDonald"
    ],
    "summary": "It's been a volatile start to the second quarter for many sectors. However, investors continue to seek out undervalued biotech stocks for robust returns over the long term. Plenty of options exist in various niches within the biotech sector.",
    "banner_image": "https://investorplace.com/wp-content/uploads/2023/03/eli-lilly-lly-stock-sign-1600-300x169.jpg",
    "source": "Business Insider",
    "category_within_source": "GoogleRSS",
    "source_domain": "markets.businessinsider.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.281774,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.048327",
        "ticker_sentiment_score": "0.092033",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.144275",
        "ticker_sentiment_score": "0.216645",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.328611",
        "ticker_sentiment_score": "0.335479",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Amgen  ( AMGN )  Laps the Stock Market: Here's Why",
    "url": "https://www.zacks.com/stock/news/2254150/amgen-amgn-laps-the-stock-market-heres-why",
    "time_published": "20240411T220018",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the most recent trading session, Amgen (AMGN) closed at $270, indicating a +1.33% shift from the previous trading day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default71.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.986564"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.203922,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.585687",
        "ticker_sentiment_score": "0.27612",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Is Amgen Stock a Buy?",
    "url": "https://www.fool.com/investing/2024/04/11/is-amgen-stock-a-buy/",
    "time_published": "20240411T120000",
    "authors": [
      "David Jagielski"
    ],
    "summary": "Amgen's stock isn't expensive, but the business does face some challenges, which could have investors thinking twice.",
    "banner_image": "https://media.ycharts.com/charts/360357f9d46961001828a9894b28d7f9.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.905476"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      }
    ],
    "overall_sentiment_score": 0.141358,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.480678",
        "ticker_sentiment_score": "0.214374",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Looking At Amgen's Recent Unusual Options Activity - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/insights/options/24/04/38224273/looking-at-amgens-recent-unusual-options-activity",
    "time_published": "20240412T163139",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Financial giants have made a conspicuous bearish move on Amgen. Our analysis of options history for Amgen AMGN revealed 13 unusual trades. Delving into the details, we found 46% of traders were bullish, while 53% showed bearish tendencies.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.119499,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.829093",
        "ticker_sentiment_score": "0.069855",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks",
    "url": "https://www.zacks.com/stock/news/2255127/how-to-maximize-your-retirement-portfolio-with-these-top-ranked-dividend-stocks",
    "time_published": "20240415T131003",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default320.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.228365,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.212115",
        "ticker_sentiment_score": "0.137449",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.212115",
        "ticker_sentiment_score": "0.143913",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen Inc.  ( AMGN )  is Attracting Investor Attention: Here is What You Should Know",
    "url": "https://www.zacks.com/stock/news/2255105/amgen-inc-amgn-is-attracting-investor-attention-here-is-what-you-should-know",
    "time_published": "20240415T130711",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default144.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.190688,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.488469",
        "ticker_sentiment_score": "0.09267",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen, Shell And More On CNBC's 'Final Trades' - Shell  ( NYSE:SHEL ) , Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/trading-ideas/long-ideas/24/04/38243330/amgen-shell-and-more-on-cnbcs-final-trades",
    "time_published": "20240415T122938",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "On CNBC's \"Halftime Report Final Trades,\" Amy Raskin of Chevy Chase Trust said Shell plc SHEL has 12% free On April 5, Shell updated its first quarter FY24 operational outlook, reflecting lower results from its liquefied natural gas ( LNG ) trading business.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/15/amgen.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.226034,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.587597",
        "ticker_sentiment_score": "0.219742",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "RYDAF",
        "relevance_score": "0.130217",
        "ticker_sentiment_score": "0.344365",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Amgen  ( AMGN )  Suffers a Larger Drop Than the General Market: Key Insights",
    "url": "https://www.zacks.com/stock/news/2257263/amgen-amgn-suffers-a-larger-drop-than-the-general-market-key-insights",
    "time_published": "20240417T220017",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) concluded the recent trading session at $264.07, signifying a -0.59% move from its prior day's close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default337.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.983783"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.068825,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.576289",
        "ticker_sentiment_score": "0.137522",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick - AstraZeneca  ( NASDAQ:AZN ) , Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38299995/amgenastrazenecas-asthma-drug-tezspire-vs-sanofiregenerons-blockbuster-dupixent-ana",
    "time_published": "20240417T183945",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Tuesday, Amgen Inc AMGN provided an update regarding the results of the Phase 2a COURSE trial for Tezspire ( tezepelumab-ekko ) in chronic obstructive pulmonary disease ( COPD ) . Tezspire is a registered trademark of Amgen and AstraZeneca Plc AZN.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Doctor-Examining-A-Lung-Radiography_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.243559,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SSTK",
        "relevance_score": "0.110462",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.421485",
        "ticker_sentiment_score": "0.01129",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.218817",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.218817",
        "ticker_sentiment_score": "-0.12096",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Visa To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday - Visa  ( NYSE:V ) ",
    "url": "https://www.benzinga.com/news/24/04/38289868/visa-to-rally-around-18-here-are-10-top-analyst-forecasts-for-wednesday",
    "time_published": "20240417T122144",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. HC Wainwright & Co. cut the price target for Unity Biotechnology, Inc. UBX from $10 to $8.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/17/visa_-_logo.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.101831,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AR",
        "relevance_score": "0.221481",
        "ticker_sentiment_score": "0.197529",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.148731",
        "ticker_sentiment_score": "0.149203",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "V",
        "relevance_score": "0.221481",
        "ticker_sentiment_score": "0.320782",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.221481",
        "ticker_sentiment_score": "-0.142427",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STRA",
        "relevance_score": "0.221481",
        "ticker_sentiment_score": "0.241633",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BK",
        "relevance_score": "0.221481",
        "ticker_sentiment_score": "-0.067578",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UBX",
        "relevance_score": "0.221481",
        "ticker_sentiment_score": "0.098335",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.221481",
        "ticker_sentiment_score": "0.012024",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNS",
        "relevance_score": "0.221481",
        "ticker_sentiment_score": "0.003591",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "URBN",
        "relevance_score": "0.221481",
        "ticker_sentiment_score": "-0.091766",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Can This High-Yield Dividend Stock Keep Beating the S&P 500?",
    "url": "https://www.fool.com/investing/2024/04/17/can-this-high-yield-dividend-stock-keep-beating-th/",
    "time_published": "20240417T113000",
    "authors": [
      "George Budwell"
    ],
    "summary": "Amgen's shares have come under pressure this year, making it a compelling bargain buy.",
    "banner_image": "https://media.ycharts.com/charts/0e266083731171e5673ec35396700324.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.723405"
      }
    ],
    "overall_sentiment_score": 0.247991,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.337197",
        "ticker_sentiment_score": "0.332844",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Got $5,000? Here Are 3 Undervalued Stocks to Buy and Hold Forever",
    "url": "https://www.fool.com/investing/2024/04/17/got-5000-undervalued-stocks-buy-and-hold/",
    "time_published": "20240417T083000",
    "authors": [
      "James Brumley"
    ],
    "summary": "Not every business in operation today is built to thrive -- or even last -- indefinitely. These are.",
    "banner_image": "https://media.ycharts.com/charts/2671fe7094aeea27052b6167d9997c78.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.998356"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.967321"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.208755,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "EADSF",
        "relevance_score": "0.032558",
        "ticker_sentiment_score": "-0.045318",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.032558",
        "ticker_sentiment_score": "0.103096",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.032558",
        "ticker_sentiment_score": "0.103096",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.12969",
        "ticker_sentiment_score": "0.084744",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.193465",
        "ticker_sentiment_score": "0.174355",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DAL",
        "relevance_score": "0.097457",
        "ticker_sentiment_score": "-0.128905",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.097457",
        "ticker_sentiment_score": "-0.014883",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Global Radioimmunoassay Market to Grow at a Minimal CAGR of ~3% by 2030 | DelveInsight",
    "url": "https://www.prnewswire.com/news-releases/global-radioimmunoassay-market-to-grow-at-a-minimal-cagr-of-3-by-2030--delveinsight-302119197.html",
    "time_published": "20240418T213100",
    "authors": [
      "DelveInsight Business Research",
      "LLP"
    ],
    "summary": "The increasing need for radioimmunoassay is mainly driven by the rising occurrence of cancer, infectious diseases, and various other health conditions, along with a growing number of epidemics and pandemics and increasing health awareness.",
    "banner_image": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.146788,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BMXMF",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "-0.0967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "A",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "-0.0967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CNTG",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "-0.0967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXAS",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "-0.0967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EKTAY",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "-0.082191",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SKXJF",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "-0.173153",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.056741",
        "ticker_sentiment_score": "-0.035994",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSKYF",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "-0.173153",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.056741",
        "ticker_sentiment_score": "-0.035994",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.056741",
        "ticker_sentiment_score": "-0.035994",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DHR",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "0.060148",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "-0.0967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TCRT",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "0.02269",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QGEN",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "-0.0967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.056741",
        "ticker_sentiment_score": "-0.035994",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CLDX",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "0.02269",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BGNE",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "0.02269",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSMXF",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "-0.0967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAYZF",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "0.02269",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ILMN",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "-0.0967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALPMF",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "0.02269",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIO",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "-0.0967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.056741",
        "ticker_sentiment_score": "-0.035994",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.056741",
        "ticker_sentiment_score": "-0.035994",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HOLX",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "-0.0967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DGX",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "-0.0967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.056741",
        "ticker_sentiment_score": "-0.035994",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARAY",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "-0.082191",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MYGN",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "-0.0967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "-0.0967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.056741",
        "ticker_sentiment_score": "-0.035994",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly's  ( LLY )  Tirzepatide Meets Goals in Sleep Apnea Studies",
    "url": "https://www.zacks.com/stock/news/2257439/eli-lillys-lly-tirzepatide-meets-goals-in-sleep-apnea-studies",
    "time_published": "20240418T125100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Data from Eli Lilly's (LLY) SURMOUNT-OSA studies show that treatment with tirzepatide results in a mean AHI reduction of up to 63% in adults with obstructive sleep apnea and obesity.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.102534,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.378572",
        "ticker_sentiment_score": "0.135263",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.195025",
        "ticker_sentiment_score": "0.017174",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.146916",
        "ticker_sentiment_score": "0.011363",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.146916",
        "ticker_sentiment_score": "0.18079",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "How Is The Market Feeling About Amgen? - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/insights/short-sellers/24/04/38334914/how-is-the-market-feeling-about-amgen",
    "time_published": "20240419T134526",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Amgen's AMGN short percent of float has fallen 5.77% since its last report. The company recently reported that it has 10.47 million shares sold short, which is 1.96% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.83 days to cover their ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.264538,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.212115",
        "ticker_sentiment_score": "0.081887",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Amgen  ( AMGN )  Outpaced the Stock Market Today",
    "url": "https://www.zacks.com/stock/news/2259644/why-amgen-amgn-outpaced-the-stock-market-today",
    "time_published": "20240422T215017",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the most recent trading session, Amgen (AMGN) closed at $271.48, indicating a +0.95% shift from the previous trading day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default118.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.976913"
      }
    ],
    "overall_sentiment_score": 0.137977,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.63188",
        "ticker_sentiment_score": "0.276594",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks",
    "url": "https://www.zacks.com/stock/news/2259047/improve-your-retirement-income-with-these-3-top-ranked-dividend-stocks",
    "time_published": "20240422T131002",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default55.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.096154,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.219809",
        "ticker_sentiment_score": "0.119729",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.219809",
        "ticker_sentiment_score": "0.124719",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.055621",
        "ticker_sentiment_score": "-0.036012",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Better Buy: Pfizer vs. Viking Therapeutics",
    "url": "https://www.fool.com/investing/2024/04/23/better-buy-pfizer-vs-viking-therapeutics/",
    "time_published": "20240423T131500",
    "authors": [
      "George Budwell"
    ],
    "summary": "These two pharma stocks have followed distinct paths of late. Which is the better investment?",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F773859%2Fhealthcare.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.658903"
      }
    ],
    "overall_sentiment_score": 0.281154,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.058472",
        "ticker_sentiment_score": "0.003002",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.230782",
        "ticker_sentiment_score": "0.374191",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.058472",
        "ticker_sentiment_score": "0.008004",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.058472",
        "ticker_sentiment_score": "0.003002",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.44266",
        "ticker_sentiment_score": "0.561378",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "1 No-Brainer Vanguard Fund to Buy Right Now",
    "url": "https://www.fool.com/investing/2024/04/23/1-no-brainer-vanguard-fund-to-buy-right-now/",
    "time_published": "20240423T121500",
    "authors": [
      "George Budwell"
    ],
    "summary": "This Vanguard growth fund is home to some of the world's most innovative companies.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F773891%2Finnovation.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.994953"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.311772,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.066414",
        "ticker_sentiment_score": "-0.011049",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.197413",
        "ticker_sentiment_score": "0.135",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.066414",
        "ticker_sentiment_score": "-0.011049",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ANET",
        "relevance_score": "0.066414",
        "ticker_sentiment_score": "0.14636",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.066414",
        "ticker_sentiment_score": "0.11022",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.066414",
        "ticker_sentiment_score": "-0.062421",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.066414",
        "ticker_sentiment_score": "0.11022",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.066414",
        "ticker_sentiment_score": "0.11022",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.132368",
        "ticker_sentiment_score": "0.104228",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.066414",
        "ticker_sentiment_score": "0.11022",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADBE",
        "relevance_score": "0.066414",
        "ticker_sentiment_score": "0.14636",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.066414",
        "ticker_sentiment_score": "-0.011049",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PLTR",
        "relevance_score": "0.066414",
        "ticker_sentiment_score": "0.14636",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday? - Cullinan Therapeutics  ( NASDAQ:CGEM ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38413618/why-is-cullinan-therapeutics-stock-trading-higher-on-wednesday",
    "time_published": "20240424T182917",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "A recent academic case study, published on April 22, examined using Amgen Inc's AMGN Blincyto, a bispecific CD3xCD19 T-cell engager, to treat a patient with severe systemic sclerosis. The findings have implications for Cullinan Therapeutics Inc's CGEM CLN-978, a similar CD19xCD3 bispecific T-cell ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/24/laboratory-217041-1280.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.275508,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.204072",
        "ticker_sentiment_score": "0.248653",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CGEM",
        "relevance_score": "0.301933",
        "ticker_sentiment_score": "0.203167",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?",
    "url": "https://www.zacks.com/stock/news/2261491/will-healthcare-etfs-lose-momentum-as-q1-earnings-unfold",
    "time_published": "20240424T160500",
    "authors": [
      "Sweta Killa"
    ],
    "summary": "While the healthcare sector is expected to benefit from cutting-edge medicines, new drug approvals, technological advancements, and deal activities, it is expected to witness a modest earnings decline of 5.6% in the first quarter.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b3/30471.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.988915"
      }
    ],
    "overall_sentiment_score": 0.094139,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.234119",
        "ticker_sentiment_score": "0.030354",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.176717",
        "ticker_sentiment_score": "-0.00714",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.234119",
        "ticker_sentiment_score": "0.080874",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.234119",
        "ticker_sentiment_score": "0.078127",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.118354",
        "ticker_sentiment_score": "0.007886",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Coherus Announces Presentation at the 2024 American Society of Clinical Oncology  ( ASCO )  Annual Meeting",
    "url": "https://www.globenewswire.com/news-release/2024/04/24/2868756/33333/en/Coherus-Announces-Presentation-at-the-2024-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting.html",
    "time_published": "20240424T140200",
    "authors": [
      "Inc.",
      "Coherus BioSciences"
    ],
    "summary": "REDWOOD CITY, Calif., April 24, 2024 ( GLOBE NEWSWIRE ) -- Coherus BioSciences, Inc. ( Coherus, Nasdaq: CHRS ) today announced the first presentation of clinical data for CHS-114, a highly selective cytolytic anti-CCR8 antibody, at the upcoming ASCO Annual Meeting, which will be held from May 31 ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/bacb58bf-ea23-4950-a845-933265930d07",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.451494"
      }
    ],
    "overall_sentiment_score": 0.02671,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.045224",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CHRS",
        "relevance_score": "0.090304",
        "ticker_sentiment_score": "0.046557",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.045224",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Mahesh Krishnan Elected to Halozyme's Board of Directors",
    "url": "https://www.prnewswire.com/news-releases/mahesh-krishnan-elected-to-halozymes-board-of-directors-302127757.html",
    "time_published": "20240425T204500",
    "authors": [
      "Inc.",
      "Halozyme Therapeutics"
    ],
    "summary": "SAN DIEGO, April 25, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. ( NASDAQ: HALO ) ( \"Halozyme\" ) today announced the election of Mahesh Krishnan, M.D. to its Board of Directors. Dr. Krishnan has more than 20 years of experience in healthcare, biotechnology and health services.",
    "banner_image": "https://mma.prnewswire.com/media/75076/halozyme_therapeutics_logo_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.230507,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CHGCF",
        "relevance_score": "0.047465",
        "ticker_sentiment_score": "0.083841",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.047465",
        "ticker_sentiment_score": "0.083841",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABOS",
        "relevance_score": "0.047465",
        "ticker_sentiment_score": "0.083841",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARGX",
        "relevance_score": "0.047465",
        "ticker_sentiment_score": "0.083841",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.047465",
        "ticker_sentiment_score": "-0.000993",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HALO",
        "relevance_score": "0.094762",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DVA",
        "relevance_score": "0.141726",
        "ticker_sentiment_score": "-0.001252",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IDRSF",
        "relevance_score": "0.047465",
        "ticker_sentiment_score": "0.193344",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.047465",
        "ticker_sentiment_score": "0.083841",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.047465",
        "ticker_sentiment_score": "0.083841",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AstraZeneca  ( AZN )  Q1 Earnings & Sales Beat Estimates, Stock Up",
    "url": "https://www.zacks.com/stock/news/2262673/astrazeneca-azn-q1-earnings-sales-beat-estimates-stock-up",
    "time_published": "20240425T174700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AstraZeneca (AZN) beats first-quarter estimates for earnings and sales, driven by increased demand for its key oncology and rare disease drugs.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.99737"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.135032,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.380235",
        "ticker_sentiment_score": "0.195217",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GRCL",
        "relevance_score": "0.030446",
        "ticker_sentiment_score": "0.069682",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SKXJF",
        "relevance_score": "0.030446",
        "ticker_sentiment_score": "0.126377",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FUSN",
        "relevance_score": "0.030446",
        "ticker_sentiment_score": "0.069682",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSKYF",
        "relevance_score": "0.030446",
        "ticker_sentiment_score": "0.126377",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.121343",
        "ticker_sentiment_score": "0.151441",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "0.060045",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Analysts Estimate Amgen  ( AMGN )  to Report a Decline in Earnings: What to Look Out for",
    "url": "https://www.zacks.com/stock/news/2262340/analysts-estimate-amgen-amgn-to-report-a-decline-in-earnings-what-to-look-out-for",
    "time_published": "20240425T140205",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default107.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.128643,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.257895",
        "ticker_sentiment_score": "0.007922",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SRPT",
        "relevance_score": "0.173645",
        "ticker_sentiment_score": "0.022459",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Apple, Amazon, Big Pharma And The Fed: Investing Action Plan",
    "url": "https://www.investors.com/research/investing-action-plan/stock-market-apple-amazon-big-pharma-the-fed/",
    "time_published": "20240426T221700",
    "authors": [
      "ALAN R. ELLIOTT",
      "Investor's Business Daily"
    ],
    "summary": "A Big Week For The Stock Market: Apple, Amazon, Big Pharma And The Fed Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/01/Stock-FedBldg-flag-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999606"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.189522,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AAPL",
        "relevance_score": "0.270149",
        "ticker_sentiment_score": "0.056371",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDNDF",
        "relevance_score": "0.03443",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.068797",
        "ticker_sentiment_score": "0.040372",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DDOG",
        "relevance_score": "0.103035",
        "ticker_sentiment_score": "0.122123",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.03443",
        "ticker_sentiment_score": "0.151018",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.170878",
        "ticker_sentiment_score": "0.032061",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.170878",
        "ticker_sentiment_score": "0.043458",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DPZ",
        "relevance_score": "0.068797",
        "ticker_sentiment_score": "0.326415",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MA",
        "relevance_score": "0.03443",
        "ticker_sentiment_score": "0.10474",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SBUX",
        "relevance_score": "0.068797",
        "ticker_sentiment_score": "0.104639",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMD",
        "relevance_score": "0.103035",
        "ticker_sentiment_score": "0.123387",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.103035",
        "ticker_sentiment_score": "0.043751",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DELL",
        "relevance_score": "0.068797",
        "ticker_sentiment_score": "0.113638",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SQ",
        "relevance_score": "0.068797",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PYPL",
        "relevance_score": "0.137083",
        "ticker_sentiment_score": "0.109307",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.068797",
        "ticker_sentiment_score": "0.067624",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.103035",
        "ticker_sentiment_score": "0.122123",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.103035",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.068797",
        "ticker_sentiment_score": "0.044114",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CCJ",
        "relevance_score": "0.103035",
        "ticker_sentiment_score": "0.122123",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DMPZF",
        "relevance_score": "0.03443",
        "ticker_sentiment_score": "0.316853",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "EBAY",
        "relevance_score": "0.137083",
        "ticker_sentiment_score": "0.109307",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ETSY",
        "relevance_score": "0.103035",
        "ticker_sentiment_score": "0.096925",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.103035",
        "ticker_sentiment_score": "0.049741",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.103035",
        "ticker_sentiment_score": "0.122123",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.03443",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "What's in the Cards for Amgen  ( AMGN )  This Earnings Season?",
    "url": "https://www.zacks.com/stock/news/2264395/whats-in-the-cards-for-amgen-amgn-this-earnings-season",
    "time_published": "20240429T163500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/39/612.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999992"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.164794,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ALNY",
        "relevance_score": "0.141171",
        "ticker_sentiment_score": "-0.057309",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXEL",
        "relevance_score": "0.277958",
        "ticker_sentiment_score": "-0.110653",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVAX",
        "relevance_score": "0.187463",
        "ticker_sentiment_score": "-0.168923",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.321873",
        "ticker_sentiment_score": "0.177607",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Dow Jones Up As Warren Buffett Stocks Eye Entries; Elon Musk Makes This AI Boast",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-nasdaq-sp500-warren-buffett-elon-musk-tesla/",
    "time_published": "20240429T144700",
    "authors": [
      "Investor's Business Daily",
      "MICHAEL LARKIN"
    ],
    "summary": "Dow Jones Up As Warren Buffett Stocks Eye Entries. Elon Musk Makes This AI Boast Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2020/07/Stock-elonmusk-03-shutt.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.95493"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.1925,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.03631",
        "ticker_sentiment_score": "0.006991",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.072545",
        "ticker_sentiment_score": "-0.055464",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.180056",
        "ticker_sentiment_score": "0.17173",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.10863",
        "ticker_sentiment_score": "0.009099",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.10863",
        "ticker_sentiment_score": "0.12193",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.072545",
        "ticker_sentiment_score": "0.068002",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.072545",
        "ticker_sentiment_score": "-0.098529",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PARA",
        "relevance_score": "0.072545",
        "ticker_sentiment_score": "0.01417",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIDU",
        "relevance_score": "0.072545",
        "ticker_sentiment_score": "0.100684",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.072545",
        "ticker_sentiment_score": "0.034184",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LRN",
        "relevance_score": "0.10863",
        "ticker_sentiment_score": "0.138123",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.072545",
        "ticker_sentiment_score": "-0.098529",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DVA",
        "relevance_score": "0.072545",
        "ticker_sentiment_score": "0.066929",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.072545",
        "ticker_sentiment_score": "-0.055464",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.250019",
        "ticker_sentiment_score": "0.145102",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INTC",
        "relevance_score": "0.072545",
        "ticker_sentiment_score": "-0.098529",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COF",
        "relevance_score": "0.03631",
        "ticker_sentiment_score": "0.105918",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HWM",
        "relevance_score": "0.10863",
        "ticker_sentiment_score": "0.202202",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Insights Into Amgen  ( AMGN )  Q1: Wall Street Projections for Key Metrics",
    "url": "https://www.zacks.com/stock/news/2263957/insights-into-amgen-amgn-q1-wall-street-projections-for-key-metrics",
    "time_published": "20240429T131600",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Get a deeper insight into the potential performance of Amgen (AMGN) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default19.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.986564"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.095157,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.354572",
        "ticker_sentiment_score": "0.1356",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income",
    "url": "https://www.zacks.com/stock/news/2263924/3-top-ranked-dividend-stocks-a-smarter-way-to-boost-your-retirement-income",
    "time_published": "20240429T131002",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default178.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999996"
      }
    ],
    "overall_sentiment_score": 0.240438,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ALIZF",
        "relevance_score": "0.108466",
        "ticker_sentiment_score": "0.080516",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.214937",
        "ticker_sentiment_score": "0.117632",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , SPDR S&P 500  ( ARCA:SPY ) ",
    "url": "https://www.benzinga.com/news/earnings/24/04/38481553/will-earnings-cheer-continue-to-buoy-markets-apple-amazon-pfizer-coinbase-lead-flurry-of-q1-reports",
    "time_published": "20240429T055121",
    "authors": [
      "Shanthi Rexaline"
    ],
    "summary": "Corporate earnings came to the market's rescue in the past week, helping to overcome rate fears. As we look ahead to the unfolding week, it remains to be seen whether the tech earnings deluge can keep the rally's momentum going.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/29/Market.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999917"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.142857"
      }
    ],
    "overall_sentiment_score": 0.260382,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "DD",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSTR",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALL",
        "relevance_score": "0.03468",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.239137",
        "ticker_sentiment_score": "0.076466",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LSCC",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LOGI",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KHC",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NOVA",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UPWK",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COIN",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.271882",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MA",
        "relevance_score": "0.03468",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NTGR",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KLIC",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QGEN",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FIVN",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "YUMC",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ED",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DKNG",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.120474",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EG",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WING",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ILMN",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MT",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BLCO",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OMI",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SANM",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RGA",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KIM",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HSY",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "YUM",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FSLR",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EBAY",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SOFI",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QRVO",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MET",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PXD",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVS",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PARA",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXPE",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRO",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.03468",
        "ticker_sentiment_score": "0.111638",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FFIV",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FLR",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PENN",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NCLH",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XPO",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "W",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "X",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ZTS",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CYBR",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "Z",
        "relevance_score": "0.03468",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BKNG",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GSK",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ON",
        "relevance_score": "0.03468",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COP",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MNST",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NXPI",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LYV",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CBOE",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ICE",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RMBS",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OPEN",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BZH",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MGM",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXL",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ETSY",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REG",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALB",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WOLF",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NET",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DVN",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.138066",
        "ticker_sentiment_score": "0.214972",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Sandoz Settles Patent Dispute With Amgen Related To Bone Disorder Drug Denosumab - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/general/biotech/24/04/38526278/sandoz-settles-patent-dispute-with-amgen-related-to-bone-disorder-drug-denosumab",
    "time_published": "20240430T155459",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Generic and biosimilar manufacturer Sandoz AG SDZNY SDZXF reached an agreement on Tuesday with Amgen Inc AMGN to resolve all patent litigation related to its U.S. denosumab biosimilars.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/30/Sandoz-Holzkirchen-Photo-via-Company.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.080693,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.443626",
        "ticker_sentiment_score": "0.089983",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?",
    "url": "https://www.zacks.com/stock/news/2265330/will-these-5-drugbiotech-stocks-beat-q1-earnings-forecast",
    "time_published": "20240430T152000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.158563,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.042953",
        "ticker_sentiment_score": "0.043835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.253426",
        "ticker_sentiment_score": "0.062112",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.042953",
        "ticker_sentiment_score": "0.043835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.293841",
        "ticker_sentiment_score": "0.13754",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.212301",
        "ticker_sentiment_score": "0.129453",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.293841",
        "ticker_sentiment_score": "0.163676",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.333444",
        "ticker_sentiment_score": "0.138141",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars - Sandoz Group  ( OTC:SDZNY ) ",
    "url": "https://www.benzinga.com/pressreleases/24/04/g38509613/sandoz-reaches-agreement-with-amgen-resolving-all-patent-litigation-related-to-its-us-denosumab-bi",
    "time_published": "20240430T050000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Agreement clears path for launch of Jubbonti\u00ae and Wyost\u00ae on May 31, 2025 or earlier under certain circumstances Jubbonti\u00ae and Wyost\u00ae are first and only FDA-approved biosimilars to and interchangeable with Prolia*\u00ae and Xgeva*\u00ae",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.123811,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.050218",
        "ticker_sentiment_score": "0.106778",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "What's Going On With CytomX Stock? - CytomX Therapeutics  ( NASDAQ:CTMX ) ",
    "url": "https://www.benzinga.com/news/24/05/38557651/whats-going-on-with-cytomx-stock",
    "time_published": "20240501T160518",
    "authors": [
      "Erica Kollmann"
    ],
    "summary": "CytomX Therapeutics, Inc. CTMX shares are racing higher Wednesday. The company said it will report first-quarter results and provide an initial CX-904 Phase 1a dose escalation update on May 8 after the close of markets. CytomX and Amgen, Inc.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/01/pharmaceuticals-therapeutics-medicine.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.967645"
      }
    ],
    "overall_sentiment_score": 0.366113,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.262522",
        "ticker_sentiment_score": "0.066739",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTMX",
        "relevance_score": "0.497391",
        "ticker_sentiment_score": "0.490262",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Amgen Reports Better-Than-Expected Q1 Results, $50M Milestone Payment - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/general/biotech/24/05/38601856/amgen-reports-better-than-expected-q1-results-50m-milestone-payment",
    "time_published": "20240502T214440",
    "authors": [
      "Erica Kollmann"
    ],
    "summary": "Amgen Inc. AMGN reported first-quarter financial results after the closing bell Thursday. Here's a look at the highlights. The Details: Amgen reported quarterly earnings of $3.96 per share, which beat the analyst consensus estimate of $3.87 by 2.33%.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/02/pharmaceutical.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.795202"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.359426,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.834645",
        "ticker_sentiment_score": "0.578511",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ARWR",
        "relevance_score": "0.271274",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RPRX",
        "relevance_score": "0.271274",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen Falls On Quarterly Beat As Obesity Space Heats Up",
    "url": "https://www.investors.com/news/technology/amgen-stock-amgen-earnings-q1-2024/",
    "time_published": "20240502T202400",
    "authors": [
      "Investor's Business Daily",
      "ALLISON GATLIN"
    ],
    "summary": "Amgen Stock Dips Despite Quarterly Beat As Investors Watch The Obesity Space Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2022/11/Stock-amgen-08-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      }
    ],
    "overall_sentiment_score": 0.24547,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MRNA",
        "relevance_score": "0.218817",
        "ticker_sentiment_score": "-0.195258",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.948158",
        "ticker_sentiment_score": "0.350538",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Amgen's Options: A Look at What the Big Money is Thinking - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/insights/options/24/05/38593218/amgens-options-a-look-at-what-the-big-money-is-thinking",
    "time_published": "20240502T173130",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bullish stance on Amgen AMGN. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      }
    ],
    "overall_sentiment_score": 0.155557,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.741707",
        "ticker_sentiment_score": "0.150979",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Nasdaq, S&P 500 Futures Rise Ahead Of Apple Earnings: What's Going On With Stock Market? - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , SPDR S&P 500  ( ARCA:SPY ) ",
    "url": "https://www.benzinga.com/news/earnings/24/05/38576979/nasdaq-s-p-500-futures-rise-ahead-of-apple-earnings-why-this-analyst-thinks-no-cut-scenario-may-not",
    "time_published": "20240502T105251",
    "authors": [
      "Shanthi Rexaline"
    ],
    "summary": "U.S. stocks look to push ahead on a positive path, now that the Federal Reserve's rate decision is in the rearview mirror. Major index futures point to a positive open on Thursday.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/02/Wall-Street.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.142857"
      }
    ],
    "overall_sentiment_score": 0.081907,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AAPL",
        "relevance_score": "0.133655",
        "ticker_sentiment_score": "-0.055256",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.097849",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXPE",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NOVA",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.020026",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UPWK",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.020026",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DASH",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.020026",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COIN",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PENN",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NTGR",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.020026",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "W",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KLIC",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.020026",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "X",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ZTS",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CYBR",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "Z",
        "relevance_score": "0.033562",
        "ticker_sentiment_score": "0.018657",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FIVN",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BKNG",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ED",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DKNG",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COP",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ILMN",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MNST",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LYV",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ICE",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RGA",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KIM",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OPEN",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FSLR",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.020026",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MGM",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.020026",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EBAY",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.020026",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ETSY",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.020026",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REG",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WOLF",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.020026",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NET",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QRVO",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.020026",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PXD",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.097849",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "0.029538",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen Delivers a Q1 Earnings Beat",
    "url": "https://www.fool.com/data-news/2024/05/03/amgen-delivers-a-q1-earnings-beat/",
    "time_published": "20240503T221927",
    "authors": [
      "JesterAI"
    ],
    "summary": "While revenue met Wall Street's expectations, earnings surpassed them.",
    "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.990893"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.213561,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.48028",
        "ticker_sentiment_score": "0.403992",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Why Amgen Stock Zoomed Nearly 12% Higher Today",
    "url": "https://www.fool.com/investing/2024/05/03/why-amgen-stock-zoomed-nearly-12-higher-today/",
    "time_published": "20240503T221534",
    "authors": [
      "Eric Volkman"
    ],
    "summary": "The company delivered solid quarterly results, but its discussion of an investigational drug is what really gave its shares a pop.",
    "banner_image": "https://g.foolcdn.com/editorial/images/775812/medical-professional-holding-dollar-sign-paperweight.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.972476"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.337486,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.129516",
        "ticker_sentiment_score": "0.231231",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.585052",
        "ticker_sentiment_score": "0.404777",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.129516",
        "ticker_sentiment_score": "0.231231",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "U.S. Markets Moved Upward Friday; Amgen Climbed Highest",
    "url": "https://www.barrons.com/amp/articles/u-s-markets-moved-upward-friday-amgen-climbed-highest-69fcf39f",
    "time_published": "20240503T201000",
    "authors": [
      "Barron's Automation"
    ],
    "summary": "U.S. Markets Moved Upward Friday. Amgen Climbed Highest ...",
    "banner_image": "https://www.barrons.com/asset/barrons/images/social_highres.jpg",
    "source": "Barrons",
    "category_within_source": "n/a",
    "source_domain": "www.barrons.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.295272,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.922387",
        "ticker_sentiment_score": "0.494088",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Stock Market Today: Stocks Soar on Apple Buyback News, Jobs Data",
    "url": "https://www.kiplinger.com/investing/stocks/stock-market-today-stocks-soar-on-apple-buyback-news-jobs-data",
    "time_published": "20240503T200830",
    "authors": [
      "Karee Venema"
    ],
    "summary": "Stocks jumped out of the gate Friday and never looked back. Sentiment got a major lift thanks to a positive reaction to Apple's ( AAPL ) quarterly earnings report and a bad-news-is-good-news jobs report.",
    "banner_image": "https://cdn.mos.cms.futurecdn.net/hwgJ7osrMtUWhk5koeVme7-320-80.png",
    "source": "Kiplinger",
    "category_within_source": "n/a",
    "source_domain": "www.kiplinger.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.996675"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.219764,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.361802",
        "ticker_sentiment_score": "0.225809",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.427425",
        "ticker_sentiment_score": "0.334369",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Stocks Rally As Jobs Report Rekindles Rate Cut Hopes, Apple Rockets, Bitcoin Soars Above $61,000: What's Driving Markets Friday? - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/markets/cryptocurrency/24/05/38621297/stocks-rally-as-jobs-report-rekindles-rate-cut-hopes-apple-rockets-bitcoin-soars-above-61-",
    "time_published": "20240503T175102",
    "authors": [
      "Piero Cingari"
    ],
    "summary": "A weaker-than-expected jobs report sparked a widespread market rally in the last session of the week, as traders increased expectations on potential interest rate cuts later this year.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/03/Wall-street-sign-in-New-York.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.253494,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AAPL",
        "relevance_score": "0.073321",
        "ticker_sentiment_score": "0.145258",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MNST",
        "relevance_score": "0.146025",
        "ticker_sentiment_score": "0.041029",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXPE",
        "relevance_score": "0.146025",
        "ticker_sentiment_score": "0.041029",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRBG",
        "relevance_score": "0.146025",
        "ticker_sentiment_score": "0.041029",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.073321",
        "ticker_sentiment_score": "0.198972",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.146025",
        "ticker_sentiment_score": "0.341047",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CBRE",
        "relevance_score": "0.146025",
        "ticker_sentiment_score": "0.041029",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COIN",
        "relevance_score": "0.146025",
        "ticker_sentiment_score": "0.041029",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HSY",
        "relevance_score": "0.146025",
        "ticker_sentiment_score": "0.041029",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MELI",
        "relevance_score": "0.146025",
        "ticker_sentiment_score": "0.041029",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FTNT",
        "relevance_score": "0.146025",
        "ticker_sentiment_score": "0.041029",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EOG",
        "relevance_score": "0.146025",
        "ticker_sentiment_score": "0.041029",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BKNG",
        "relevance_score": "0.146025",
        "ticker_sentiment_score": "0.041029",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SQ",
        "relevance_score": "0.146025",
        "ticker_sentiment_score": "0.041029",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTRA",
        "relevance_score": "0.146025",
        "ticker_sentiment_score": "0.041029",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.146025",
        "ticker_sentiment_score": "0.217961",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Stock Market Rallies On Fed, Jobs Report, Apple: Weekly Review",
    "url": "https://www.investors.com/news/stock-market-rallies-fed-jobs-report-apple/",
    "time_published": "20240503T171800",
    "authors": [
      "IBD STAFF",
      "Investor's Business Daily"
    ],
    "summary": "The stock market rallied for the week, with Friday's weaker-than-expected jobs report bolstering a relatively dovish Federal Reserve and Fed chief Jerome Powell on Wednesday. The S&P 500 and Nasdaq tested key levels. Apple ( AAPL ) soared on a record buyback and earnings that were better than ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2018/12/Stock-NYSE-09-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.996023"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.019613,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "XPEV",
        "relevance_score": "0.041004",
        "ticker_sentiment_score": "-0.021579",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WEN",
        "relevance_score": "0.041004",
        "ticker_sentiment_score": "-0.029769",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.0819",
        "ticker_sentiment_score": "0.106072",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDNDF",
        "relevance_score": "0.020509",
        "ticker_sentiment_score": "-0.027632",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.061473",
        "ticker_sentiment_score": "-0.015047",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NBIX",
        "relevance_score": "0.041004",
        "ticker_sentiment_score": "-0.122221",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.020509",
        "ticker_sentiment_score": "-0.013582",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.0819",
        "ticker_sentiment_score": "-0.015523",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DASH",
        "relevance_score": "0.041004",
        "ticker_sentiment_score": "-0.05416",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.061473",
        "ticker_sentiment_score": "-0.092699",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DTST",
        "relevance_score": "0.020509",
        "ticker_sentiment_score": "0.009351",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.102274",
        "ticker_sentiment_score": "0.10427",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MA",
        "relevance_score": "0.020509",
        "ticker_sentiment_score": "-0.059575",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SBUX",
        "relevance_score": "0.041004",
        "ticker_sentiment_score": "-0.029769",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QCOM",
        "relevance_score": "0.102274",
        "ticker_sentiment_score": "0.056179",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.102274",
        "ticker_sentiment_score": "-0.016434",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SHAK",
        "relevance_score": "0.061473",
        "ticker_sentiment_score": "-0.030166",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SFM",
        "relevance_score": "0.0819",
        "ticker_sentiment_score": "0.15427",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TXRH",
        "relevance_score": "0.061473",
        "ticker_sentiment_score": "-0.030166",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SQ",
        "relevance_score": "0.041004",
        "ticker_sentiment_score": "-0.028699",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DKNG",
        "relevance_score": "0.041004",
        "ticker_sentiment_score": "-0.056596",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PYPL",
        "relevance_score": "0.041004",
        "ticker_sentiment_score": "-0.028699",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WING",
        "relevance_score": "0.061473",
        "ticker_sentiment_score": "-0.030166",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.0819",
        "ticker_sentiment_score": "0.125874",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NXPI",
        "relevance_score": "0.041004",
        "ticker_sentiment_score": "0.009968",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QSR",
        "relevance_score": "0.041004",
        "ticker_sentiment_score": "-0.029769",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NIO",
        "relevance_score": "0.041004",
        "ticker_sentiment_score": "-0.021579",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVNA",
        "relevance_score": "0.0819",
        "ticker_sentiment_score": "0.058097",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GNRC",
        "relevance_score": "0.041004",
        "ticker_sentiment_score": "-0.010997",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QRVO",
        "relevance_score": "0.061473",
        "ticker_sentiment_score": "0.010096",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.041004",
        "ticker_sentiment_score": "-0.122221",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LI",
        "relevance_score": "0.041004",
        "ticker_sentiment_score": "-0.021579",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.0819",
        "ticker_sentiment_score": "0.087864",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen  ( AMGN )  Q1 Earnings Top, Stock Up on Obesity Drug Update",
    "url": "https://www.zacks.com/stock/news/2268117/amgen-amgn-q1-earnings-top-stock-up-on-obesity-drug-update",
    "time_published": "20240503T154800",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) beats first-quarter 2024 estimates for earnings and sales. Amgen is \"very encouraged\" by interim data from the phase II study on obesity candidate MariTide.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f4/2111.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.988787"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.178125,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.08687",
        "ticker_sentiment_score": "0.165849",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.414559",
        "ticker_sentiment_score": "0.15669",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.172713",
        "ticker_sentiment_score": "0.163419",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.057977",
        "ticker_sentiment_score": "0.197001",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Amgen Outlook Is Bright, Analyst Predict Obesity-Focused Drug Potential Will Drive Shareholder Value",
    "url": "https://markets.businessinsider.com/news/stocks/amgen-outlook-is-bright-analyst-predict-obesity-focused-drug-potential-will-drive-shareholder-value-1033327558",
    "time_published": "20240503T153342",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Amgen Inc ( NASDAQ:AMGN ) reported first-quarter ( Q1 ) earnings Thursday, touting adjusted EPS of $3.96, which beat the analyst consensus estimate of $3.87.",
    "banner_image": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2024/05/03/Amgen-stock_1.jpeg",
    "source": "Business Insider",
    "category_within_source": "GoogleRSS",
    "source_domain": "markets.businessinsider.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.176692,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.622414",
        "ticker_sentiment_score": "0.316056",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.116914",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen Outlook Is Bright, Analyst Predict Obesity-Focused Drug Potential Will Drive Shareholder Value - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38617572/amgen-outlook-is-bright-analyst-predict-obesity-focused-drug-potential-will-drive-s",
    "time_published": "20240503T152401",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Amgen Inc AMGN reported first-quarter ( Q1 ) earnings Thursday, touting adjusted EPS of $3.96, which beat the analyst consensus estimate of $3.87. Here are highlights from the release and subsequent analyst call: Sales increased 22% Y/Y to $7.45 billion, which beat the analyst consensus ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/03/Amgen-stock_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.247856,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.68732",
        "ticker_sentiment_score": "0.469778",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.114682",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Dow Jones Soars 400 Points As Amgen, Apple Surge; Nvidia Jumps Again, Tempts New Buyers",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-sp500-nasdaq-apple-amgen-aapl-amgn-stock/",
    "time_published": "20240503T144100",
    "authors": [
      "KEN SHREVE",
      "Investor's Business Daily"
    ],
    "summary": "Stock Market Today: Dow Jones Surges, Led By Amgen, Apple. Nvidia Jumps Above Key Level Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2019/01/stock-bull-20-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999981"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.232682,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "DKNG",
        "relevance_score": "0.170075",
        "ticker_sentiment_score": "0.026809",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TOL",
        "relevance_score": "0.113866",
        "ticker_sentiment_score": "0.319204",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MELI",
        "relevance_score": "0.113866",
        "ticker_sentiment_score": "0.074693",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.279653",
        "ticker_sentiment_score": "0.283304",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CEG",
        "relevance_score": "0.113866",
        "ticker_sentiment_score": "0.043073",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PHM",
        "relevance_score": "0.113866",
        "ticker_sentiment_score": "0.238609",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.113866",
        "ticker_sentiment_score": "-0.155187",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "EXPE",
        "relevance_score": "0.113866",
        "ticker_sentiment_score": "-0.088545",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.113866",
        "ticker_sentiment_score": "-0.155187",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.170075",
        "ticker_sentiment_score": "0.250183",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BKNG",
        "relevance_score": "0.113866",
        "ticker_sentiment_score": "0.228899",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SQ",
        "relevance_score": "0.113866",
        "ticker_sentiment_score": "0.140678",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen Posts Upbeat Results, Joins OneSpan, Paylocity Holding, MercadoLibre And Other Big Stocks Moving Higher On Friday - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/news/24/05/38615271/amgen-posts-upbeat-results-joins-onespan-paylocity-holding-mercadolibre-and-other-big-stocks-moving",
    "time_published": "20240503T141559",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "U.S. stocks were higher, with the Dow Jones index gaining over 400 points on Friday. Shares of Amgen Inc. AMGN rose sharply during Friday's session after the company reported better-than-expected first-quarter financial results. Also, the company announced a $50 million milestone payment from ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/03/Amgen-stock_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.142857"
      }
    ],
    "overall_sentiment_score": 0.49708,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ENPH",
        "relevance_score": "0.116631",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.116631",
        "ticker_sentiment_score": "0.338963",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TWST",
        "relevance_score": "0.116631",
        "ticker_sentiment_score": "0.264502",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "OSPN",
        "relevance_score": "0.116631",
        "ticker_sentiment_score": "0.433897",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "LOCO",
        "relevance_score": "0.116631",
        "ticker_sentiment_score": "0.281457",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.230782",
        "ticker_sentiment_score": "0.251095",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IESC",
        "relevance_score": "0.116631",
        "ticker_sentiment_score": "0.275807",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ATGE",
        "relevance_score": "0.116631",
        "ticker_sentiment_score": "0.281457",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MODV",
        "relevance_score": "0.116631",
        "ticker_sentiment_score": "0.264502",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MTZ",
        "relevance_score": "0.116631",
        "ticker_sentiment_score": "0.264502",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "RMAX",
        "relevance_score": "0.116631",
        "ticker_sentiment_score": "0.281457",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WK",
        "relevance_score": "0.116631",
        "ticker_sentiment_score": "0.581252",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "XPO",
        "relevance_score": "0.116631",
        "ticker_sentiment_score": "0.474663",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "OLED",
        "relevance_score": "0.116631",
        "ticker_sentiment_score": "0.399451",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ARDX",
        "relevance_score": "0.116631",
        "ticker_sentiment_score": "0.363669",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "CGON",
        "relevance_score": "0.116631",
        "ticker_sentiment_score": "0.384939",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "BKNG",
        "relevance_score": "0.116631",
        "ticker_sentiment_score": "0.399451",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "PCTY",
        "relevance_score": "0.116631",
        "ticker_sentiment_score": "0.362548",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "RPRX",
        "relevance_score": "0.058472",
        "ticker_sentiment_score": "0.12728",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TNDM",
        "relevance_score": "0.116631",
        "ticker_sentiment_score": "0.264502",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DBRG",
        "relevance_score": "0.058472",
        "ticker_sentiment_score": "0.096986",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MELI",
        "relevance_score": "0.116631",
        "ticker_sentiment_score": "0.264502",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ALHC",
        "relevance_score": "0.116631",
        "ticker_sentiment_score": "0.249799",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CLFD",
        "relevance_score": "0.116631",
        "ticker_sentiment_score": "0.310807",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IBRX",
        "relevance_score": "0.116631",
        "ticker_sentiment_score": "0.143501",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WOW",
        "relevance_score": "0.174167",
        "ticker_sentiment_score": "0.135576",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Nasdaq, S&P 500 Futures Signal Higher Open On Apple's Boost: Will Non-Farm Payrolls Data Play Spoilsport? - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , SPDR S&P 500  ( ARCA:SPY ) ",
    "url": "https://www.benzinga.com/news/earnings/24/05/38609896/wall-street-looks-to-feed-off-apples-post-earnings-power-but-key-jobs-data-may-upset-the-cart-analy",
    "time_published": "20240503T110332",
    "authors": [
      "Shanthi Rexaline"
    ],
    "summary": "Stocks look set to carry forward the upward momentum on Friday amid some earnings cheer, although a tinge of nervousness is evident ahead of the all-important non-farm payrolls report.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/03/Nasdaq--New-York-City.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.142857"
      }
    ],
    "overall_sentiment_score": 0.002401,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AAPL",
        "relevance_score": "0.04912",
        "ticker_sentiment_score": "0.041977",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TNDM",
        "relevance_score": "0.098054",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ILMN",
        "relevance_score": "0.098054",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXPE",
        "relevance_score": "0.098054",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LYV",
        "relevance_score": "0.098054",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CBOE",
        "relevance_score": "0.098054",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OMI",
        "relevance_score": "0.098054",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.098054",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FLR",
        "relevance_score": "0.098054",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COIN",
        "relevance_score": "0.098054",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HSY",
        "relevance_score": "0.098054",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OPEN",
        "relevance_score": "0.098054",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXL",
        "relevance_score": "0.098054",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REG",
        "relevance_score": "0.098054",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XPO",
        "relevance_score": "0.098054",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FIVN",
        "relevance_score": "0.098054",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NET",
        "relevance_score": "0.098054",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BNXYF",
        "relevance_score": "0.04912",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.098054",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen Stock Adds Good Weight After CEO's Update On Experimental Drug Rivaling Ozempic, Nixing Oral Weight-Loss Candidate - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/general/biotech/24/05/38607066/amgen-stock-adds-good-weight-after-ceos-update-on-experimental-drug-rivaling-ozempic-nixing-oral-",
    "time_published": "20240503T074522",
    "authors": [
      "Shanthi Rexaline"
    ],
    "summary": "Amgen, Inc. AMGN shares rallied over 14% in Thursday's after-hours trading after the biopharma reported a double beat and offered an update on its obesity drug pipeline. What Happened: Amgen said on the call that it was pulling the plug on AMG 786, an oral Phase 1 candidate for obesity. \"We will ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/03/Amgen-stock.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.255866,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.311631",
        "ticker_sentiment_score": "0.244574",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.063933",
        "ticker_sentiment_score": "0.107085",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Cathie Wood's Ark Invest Snaps Up $3.54M Worth Of Shares In This Biopharma Company Following Positive Obesity Pipeline Update",
    "url": "https://markets.businessinsider.com/news/etf/cathie-wood-s-ark-invest-snaps-up-3-54m-worth-of-shares-in-this-biopharma-company-following-positive-obesity-pipeline-update-1033329716",
    "time_published": "20240505T200118",
    "authors": [
      "Shanthi Rexaline"
    ],
    "summary": "Cathie Wood's Ark Invest Snaps Up $3.54M Worth Of Shares In This Biopharma Company Following Positive Obesity ... - Markets Insider ...",
    "banner_image": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2024/05/05/Ark-Invest.jpeg",
    "source": "Business Insider",
    "category_within_source": "GoogleRSS",
    "source_domain": "markets.businessinsider.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.714479"
      }
    ],
    "overall_sentiment_score": 0.189659,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.138464",
        "ticker_sentiment_score": "0.155462",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.138464",
        "ticker_sentiment_score": "-0.126163",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Cathie Wood's Ark Invest Snaps Up $3.54M Worth Of Shares In This Biopharma Company Following Positive Obesity Pipeline Update - ARK Genomic Revolution ETF  ( BATS:ARKG ) , Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/general/biotech/24/05/38633153/cathie-woods-ark-invest-snaps-up-3-54m-worth-of-shares-in-this-biopharma-company-following-positi",
    "time_published": "20240505T191631",
    "authors": [
      "Shanthi Rexaline"
    ],
    "summary": "Cathie Wood-run Ark Invest on Friday picked up shares of a biopharma company after it revealed significant progress with it weight-loss drug candidate. What Happened: Ark, through its ARK Genomic Revolution ETF ARKG, bought 11,360 shares of Amgen, Inc. AMGN, which rallied nearly 12% on Friday.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/05/Ark-Invest.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.714479"
      }
    ],
    "overall_sentiment_score": 0.215328,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.392948",
        "ticker_sentiment_score": "0.274626",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.136113",
        "ticker_sentiment_score": "-0.125025",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen  ( NASDAQ:AMGN )  Upgraded by StockNews.com to Buy",
    "url": "https://www.defenseworld.net/2024/05/05/amgen-nasdaqamgn-upgraded-by-stocknews-com-to-buy.html",
    "time_published": "20240505T151659",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Amgen ( NASDAQ:AMGN - Get Free Report ) was upgraded by analysts at StockNews.com from a \"hold\" rating to a \"buy\" rating in a note issued to investors on Friday. Other equities research analysts also recently issued reports about the stock.",
    "banner_image": "https://www.marketbeat.com/logos/amgen-inc-logo-1200x675.jpg?v=20231228113741",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.986564"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.238763,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.046907",
        "ticker_sentiment_score": "0.036596",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.046907",
        "ticker_sentiment_score": "0.084767",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Dow Jones Up As Apple Falls; Warren Buffett Stock Steady Despite This Loss",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-nasdaq-sp-500-apple-warren-buffett-berkshire-hathaway/",
    "time_published": "20240506T144100",
    "authors": [
      "MICHAEL LARKIN",
      "Investor's Business Daily"
    ],
    "summary": "Dow Jones Up As Apple Falls. Warren Buffett Stock Steady Despite This Loss Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/05/Stock-warrenbuffett-2024-01-shutt.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.96136"
      }
    ],
    "overall_sentiment_score": 0.144455,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AAPL",
        "relevance_score": "0.218817",
        "ticker_sentiment_score": "-0.036042",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.110462",
        "ticker_sentiment_score": "0.191542",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PARA",
        "relevance_score": "0.110462",
        "ticker_sentiment_score": "-0.02915",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.055364",
        "ticker_sentiment_score": "-0.041088",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.110462",
        "ticker_sentiment_score": "-0.031067",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MU",
        "relevance_score": "0.110462",
        "ticker_sentiment_score": "0.120705",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ORCL",
        "relevance_score": "0.110462",
        "ticker_sentiment_score": "0.08337",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.110462",
        "ticker_sentiment_score": "-0.002403",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "APOS",
        "relevance_score": "0.055364",
        "ticker_sentiment_score": "0.07402",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSN",
        "relevance_score": "0.110462",
        "ticker_sentiment_score": "-0.068219",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNEJF",
        "relevance_score": "0.055364",
        "ticker_sentiment_score": "0.07402",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.110462",
        "ticker_sentiment_score": "-0.068219",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAT",
        "relevance_score": "0.110462",
        "ticker_sentiment_score": "0.191542",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Check Out What Whales Are Doing With AMGN - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/insights/options/24/05/38644939/check-out-what-whales-are-doing-with-amgn",
    "time_published": "20240506T141738",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bullish stance on Amgen AMGN. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.136583,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.80274",
        "ticker_sentiment_score": "0.167294",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.068502",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.068502",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Company News for May 6, 2024",
    "url": "https://www.zacks.com/stock/news/2268675/company-news-for-may-6-2024",
    "time_published": "20240506T133500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Companies in The News Are: HSY, AMGN, MELI, ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f3/778.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.184612,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MELI",
        "relevance_score": "0.659096",
        "ticker_sentiment_score": "-0.096857",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.659096",
        "ticker_sentiment_score": "0.660904",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.659096",
        "ticker_sentiment_score": "0.160727",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HSY",
        "relevance_score": "0.659096",
        "ticker_sentiment_score": "0.40595",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "How Is The Market Feeling About Amgen? - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/insights/short-sellers/24/05/38679707/how-is-the-market-feeling-about-amgen",
    "time_published": "20240507T184514",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Amgen's AMGN short percent of float has fallen 3.57% since its last report. The company recently reported that it has 10.11 million shares sold short, which is 1.89% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.08 days to cover their ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.264538,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.212115",
        "ticker_sentiment_score": "0.081887",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Best Dow Jones Stocks To Buy Right Now? 2 For Your Watch List",
    "url": "https://stockmarket.com/featured/best-dow-jones-stocks-to-buy-right-now-2-for-your-watch-list-2024-05-07",
    "time_published": "20240507T152525",
    "authors": [
      "Josh Dylan"
    ],
    "summary": "The stock market is where investors buy and sell shares of public companies. Among the various indexes, the Dow Jones Industrial Average ( DJIA ) is one of the most recognized.",
    "banner_image": "https://u3j7m9h7.rocketcdn.me/wp-content/uploads/2021/05/cat-stock.jpg",
    "source": "StockMarket.com",
    "category_within_source": "n/a",
    "source_domain": "stockmarket.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999998"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.972756"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.162554,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.381755",
        "ticker_sentiment_score": "0.184108",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CAT",
        "relevance_score": "0.381755",
        "ticker_sentiment_score": "0.274042",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income",
    "url": "https://www.zacks.com/stock/news/2269488/3-top-ranked-dividend-stocks-a-smarter-way-to-boost-your-retirement-income",
    "time_published": "20240507T131003",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default331.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.203667,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.215415",
        "ticker_sentiment_score": "0.119475",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.215415",
        "ticker_sentiment_score": "0.119475",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PB",
        "relevance_score": "0.215415",
        "ticker_sentiment_score": "0.124388",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen Inc.  ( AMGN )  Is a Trending Stock: Facts to Know Before Betting on It",
    "url": "https://www.zacks.com/stock/news/2269435/amgen-inc-amgn-is-a-trending-stock-facts-to-know-before-betting-on-it",
    "time_published": "20240507T130010",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default9.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.206334,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.491255",
        "ticker_sentiment_score": "0.105018",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Market Whales and Their Recent Bets on AMGN Options - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/insights/options/24/05/38706598/market-whales-and-their-recent-bets-on-amgn-options",
    "time_published": "20240508T160115",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Whales with a lot of money to spend have taken a noticeably bearish stance on Amgen. Looking at options history for Amgen AMGN we detected 17 trades. If we consider the specifics of each trade, it is accurate to state that 23% of the investors opened trades with bullish expectations and 58% with ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.149666,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.714116",
        "ticker_sentiment_score": "0.05415",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Indexes Mixed As Uber Dives On Earnings; Tesla Falls On New Probe As China Ban Hits Intel",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-sp500-nasdaq-tesla-intel-stock/",
    "time_published": "20240508T145100",
    "authors": [
      "VIDYA RAMAKRISHNAN",
      "Investor's Business Daily"
    ],
    "summary": "Indexes Mixed As Uber Dives On Earnings. Tesla Falls On New Probe As China Ban Hits Intel Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/01/Stock-teslastockmarket-01-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.997902"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.917436"
      }
    ],
    "overall_sentiment_score": -0.096528,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.205807",
        "ticker_sentiment_score": "-0.139097",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CSCO",
        "relevance_score": "0.138066",
        "ticker_sentiment_score": "0.318061",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "RDDT",
        "relevance_score": "0.205807",
        "ticker_sentiment_score": "-0.180427",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.138066",
        "ticker_sentiment_score": "0.318061",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.138066",
        "ticker_sentiment_score": "0.318061",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BCO",
        "relevance_score": "0.138066",
        "ticker_sentiment_score": "-0.082678",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SHOP",
        "relevance_score": "0.205807",
        "ticker_sentiment_score": "-0.047123",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALAB",
        "relevance_score": "0.205807",
        "ticker_sentiment_score": "-0.180427",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.205807",
        "ticker_sentiment_score": "-0.099723",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INTC",
        "relevance_score": "0.272029",
        "ticker_sentiment_score": "-0.410904",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "HALO",
        "relevance_score": "0.138066",
        "ticker_sentiment_score": "-0.082678",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UBER",
        "relevance_score": "0.205807",
        "ticker_sentiment_score": "-0.180427",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "AFRM",
        "relevance_score": "0.138066",
        "ticker_sentiment_score": "-0.094326",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan - Coherus BioSciences  ( NASDAQ:CHRS ) ",
    "url": "https://www.benzinga.com/pressreleases/24/05/g38727487/coherus-announces-full-repayment-of-pharmakon-advisors-75-million-term-loan",
    "time_published": "20240509T113000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "- New $38.7 million term loan with a May 2029 maturity - - $37.5 million royalty monetization financing based on future sales of LOQTORZI\u00ae and UDENYCA\u00ae -",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.997405"
      }
    ],
    "overall_sentiment_score": 0.146385,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.0428",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CHRS",
        "relevance_score": "0.0428",
        "ticker_sentiment_score": "0.012843",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.0428",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "S&P 500, Nasdaq To Open Lower Today: What's Dragging Stock Futures? - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , SPDR S&P 500  ( ARCA:SPY ) ",
    "url": "https://www.benzinga.com/news/earnings/24/05/38727392/wall-street-stares-at-weaker-open-on-rate-anxiety-hopes-for-better-earnings-analyst-pencils-key-s-p",
    "time_published": "20240509T112700",
    "authors": [
      "Shanthi Rexaline"
    ],
    "summary": "Trading in U.S. index futures suggests stocks may be off to a lackluster start again on Thursday. Much of the negativity in the recent session was triggered by the lack of clarity on the Federal Reserve's rate trajectory. The spotlight is likely to be on another slew of earnings reports and a Fed ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/09/Wall-Street.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.995077"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.019415,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "APP",
        "relevance_score": "0.076724",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SIX",
        "relevance_score": "0.076724",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXAS",
        "relevance_score": "0.076724",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CSIQ",
        "relevance_score": "0.076724",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AKAM",
        "relevance_score": "0.076724",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DNUT",
        "relevance_score": "0.076724",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMBL",
        "relevance_score": "0.076724",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABNB",
        "relevance_score": "0.076724",
        "ticker_sentiment_score": "-0.202957",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.076724",
        "ticker_sentiment_score": "0.09409",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HBI",
        "relevance_score": "0.076724",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LGF-A",
        "relevance_score": "0.038407",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RXT",
        "relevance_score": "0.076724",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BYND",
        "relevance_score": "0.076724",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PZZA",
        "relevance_score": "0.076724",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMC",
        "relevance_score": "0.076724",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BLNK",
        "relevance_score": "0.076724",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RBLX",
        "relevance_score": "0.076724",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DBX",
        "relevance_score": "0.076724",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MARA",
        "relevance_score": "0.076724",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVTS",
        "relevance_score": "0.076724",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CEG",
        "relevance_score": "0.076724",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.038407",
        "ticker_sentiment_score": "0.22995",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SSTK",
        "relevance_score": "0.038407",
        "ticker_sentiment_score": "0.281163",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SEDG",
        "relevance_score": "0.076724",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "YELP",
        "relevance_score": "0.076724",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EQIX",
        "relevance_score": "0.076724",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "USFD",
        "relevance_score": "0.076724",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HUBS",
        "relevance_score": "0.076724",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HOOD",
        "relevance_score": "0.076724",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SYNA",
        "relevance_score": "0.076724",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.076724",
        "ticker_sentiment_score": "0.09409",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:EUR",
        "relevance_score": "0.038407",
        "ticker_sentiment_score": "-0.107251",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.076724",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "IBD Rating Upgrades: Amgen Shows Improved Technical Strength",
    "url": "https://www.investors.com/ibd-data-stories/ibd-rating-upgrades-amgen-shows-improved-technical-strength-2/",
    "time_published": "20240509T070000",
    "authors": [
      "Investor's Business Daily",
      "INVESTOR'S BUSINESS DAILY"
    ],
    "summary": "Amgen ( AMGN ) saw a positive improvement to its Relative Strength ( RS ) Rating on Thursday, rising from 62 to 75. X This proprietary rating identifies market leadership by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.313462,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.781119",
        "ticker_sentiment_score": "0.510924",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "HALO",
        "relevance_score": "0.377142",
        "ticker_sentiment_score": "0.152882",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UTHR",
        "relevance_score": "0.377142",
        "ticker_sentiment_score": "0.152882",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ALPN",
        "relevance_score": "0.377142",
        "ticker_sentiment_score": "0.152882",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "5 Stocks Driving Dow's Market-Beating Performance",
    "url": "https://www.zacks.com/stock/news/2272307/5-stocks-driving-dows-market-beating-performance",
    "time_published": "20240510T151400",
    "authors": [
      "Sweta Killa"
    ],
    "summary": "Dow Jones outperforms at the start of May as the market rally broadens and reconstruction of the index finally pays off.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/96/63046.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999756"
      }
    ],
    "overall_sentiment_score": 0.272941,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AAPL",
        "relevance_score": "0.386306",
        "ticker_sentiment_score": "0.204006",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.114682",
        "ticker_sentiment_score": "0.062091",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.227007",
        "ticker_sentiment_score": "0.144985",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.227007",
        "ticker_sentiment_score": "0.156227",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.227007",
        "ticker_sentiment_score": "0.236177",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Amgen Is Working On a Wegovy Competitor -- What It Means for Investors",
    "url": "https://www.fool.com/investing/2024/05/12/amgen-is-working-on-a-wegovy-competitor-what-it-me/",
    "time_published": "20240512T131500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "The biotech's pipeline extends far beyond this exciting weight-loss product.",
    "banner_image": "https://g.foolcdn.com/editorial/images/776246/physician-shaking-patients-hand.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.266114,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.683932",
        "ticker_sentiment_score": "0.316255",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.061473",
        "ticker_sentiment_score": "0.248247",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Is Eli Lilly Stock A Better Pick Over Amgen?",
    "url": "https://www.forbes.com/sites/greatspeculations/2024/05/13/is-eli-lilly-stock-a-better-pick-over-amgen/",
    "time_published": "20240513T123029",
    "authors": [
      "Trefis Team"
    ],
    "summary": "Given its better prospects, we believe Eli Lilly stock ( NYSE: LLY ) is a better pick than Amgen stock ( NASDAQ : AMGN ) . Both stocks have been in the limelight lately, given their focus on the lucrative weight-loss treatment market. Eli Lilly trades at a higher valuation multiple of 20.4x ...",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/664190bb712984adff6f12fe/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999606"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.30196,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.633079",
        "ticker_sentiment_score": "0.45982",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.633079",
        "ticker_sentiment_score": "0.476129",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.035983",
        "ticker_sentiment_score": "0.051342",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Best Inverse/Leveraged ETFs of Last Week",
    "url": "https://www.zacks.com/stock/news/2272571/best-inverseleveraged-etfs-of-last-week",
    "time_published": "20240513T120000",
    "authors": [
      "Sanghamitra Saha"
    ],
    "summary": "Wall Street was upbeat last week. Notably, on Friday, the Dow secured its eighth consecutive session of gains.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/1f/1145.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.938793"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.928139"
      }
    ],
    "overall_sentiment_score": 0.281388,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AAPL",
        "relevance_score": "0.209365",
        "ticker_sentiment_score": "0.114804",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.309539",
        "ticker_sentiment_score": "0.06804",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.105604",
        "ticker_sentiment_score": "0.035499",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.105604",
        "ticker_sentiment_score": "0.035499",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.105604",
        "ticker_sentiment_score": "0.035499",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Amgen, Amazon.com, Apple, Boeing and Goldman Sachs",
    "url": "https://www.zacks.com/stock/news/2272562/the-zacks-analyst-blog-highlights-amgen-amazoncom-apple-boeing-and-goldman-sachs",
    "time_published": "20240513T113600",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Amgen, Amazon.com, Apple, Boeing and Goldman Sachs are included in this Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f3/778.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999756"
      }
    ],
    "overall_sentiment_score": 0.266064,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AAPL",
        "relevance_score": "0.389636",
        "ticker_sentiment_score": "0.161706",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.151539",
        "ticker_sentiment_score": "0.041941",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.297661",
        "ticker_sentiment_score": "0.117697",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.201105",
        "ticker_sentiment_score": "0.107755",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.249873",
        "ticker_sentiment_score": "0.189428",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "4 Best ETF Areas of Last Week",
    "url": "https://www.zacks.com/stock/news/2273728/4-best-etf-areas-of-last-week",
    "time_published": "20240514T170000",
    "authors": [
      "Sanghamitra Saha"
    ],
    "summary": "Wall Street was upbeat last week with the S&P 500 adding 1.9%, the Dow Jones advancing 2.2% and the Nasdaq Composite gained 1.1%.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default217.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      }
    ],
    "overall_sentiment_score": 0.286395,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AAPL",
        "relevance_score": "0.242285",
        "ticker_sentiment_score": "0.132561",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.122581",
        "ticker_sentiment_score": "0.040957",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.122581",
        "ticker_sentiment_score": "0.040957",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.122581",
        "ticker_sentiment_score": "0.040957",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Is Writing A New Playbook For Pharma R&D. And It's Working.",
    "url": "https://www.forbes.com/sites/chasefeiger/2024/05/14/vertex-is-writing-a-new-playbook-for-pharma-rd-and-its-working/",
    "time_published": "20240514T152207",
    "authors": [
      "Chase Feiger",
      "M.D."
    ],
    "summary": "Vertex Pharmaceuticals ( NDAQ: VRTX ) stands today as a top 20 pharma company with over a $100 billion market cap. But this biotech beacon has ridden a bumpy path to its current perch and, along the way, just may have authored a new playbook for life sciences R&D.",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/66325f3276cdd5e83f3fb6b3/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.257765,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.066722",
        "ticker_sentiment_score": "0.043156",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.04451",
        "ticker_sentiment_score": "0.138607",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "S&P 500, Nasdaq 100, Dow Jones Shatter Record Highs In Unstoppable Bull Market Rally - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/markets/equities/24/05/38857144/s-p-500-nasdaq-100-dow-jones-shatter-record-highs-in-unstoppable-bull-market-rally",
    "time_published": "20240515T201822",
    "authors": [
      "Piero Cingari"
    ],
    "summary": "The S&P 500, Nasdaq 100 and Dow Jones Industrial Average indices all shattered fresh all-time highs Wednesday, driven by a benign inflation report that boosted risk sentiment among bullish investors.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/15/Bull-Wall-Street_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.319995,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TTD",
        "relevance_score": "0.224903",
        "ticker_sentiment_score": "0.128697",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.331765",
        "ticker_sentiment_score": "0.152551",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VST",
        "relevance_score": "0.224903",
        "ticker_sentiment_score": "0.111762",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IDXX",
        "relevance_score": "0.224903",
        "ticker_sentiment_score": "0.128697",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDB",
        "relevance_score": "0.224903",
        "ticker_sentiment_score": "0.128697",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HD",
        "relevance_score": "0.224903",
        "ticker_sentiment_score": "0.409165",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.113597",
        "ticker_sentiment_score": "0.262982",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.224903",
        "ticker_sentiment_score": "0.409165",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.224903",
        "ticker_sentiment_score": "0.111762",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Hold Viking Therapeutics in Your Portfolio? - Eli Lilly and Co  ( NYSE:LLY ) , Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/news/24/05/38851376/should-you-hold-viking-therapeutics-in-your-portfolio",
    "time_published": "20240515T194324",
    "authors": [
      "Zacks"
    ],
    "summary": "Viking Therapeutics VKTX, a clinical-stage company focused on developing novel therapeutics for metabolic and endocrine disorders, has been in the news, owing to updates from its obesity program. The company, with a market cap of about $8 billion, is developing its lead candidate, VK2735, a dual ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/15/kristine-wook-kizczaf0jko-unsplash.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.244896,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.142777",
        "ticker_sentiment_score": "0.113421",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.471099",
        "ticker_sentiment_score": "0.277655",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.142777",
        "ticker_sentiment_score": "0.078755",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.212736",
        "ticker_sentiment_score": "0.203603",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Should You Hold Viking Therapeutics  ( VKTX )  in Your Portfolio?",
    "url": "https://www.zacks.com/stock/news/2274279/should-you-hold-viking-therapeutics-vktx-in-your-portfolio",
    "time_published": "20240515T153600",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Viking Therapeutics' (VKTX) lead candidate for obesity, VK2735, is expected to have tremendous potential. However, existing competition from obesity drugs in the market remains a woe.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c8/39674.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.237893,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.143629",
        "ticker_sentiment_score": "0.106341",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.473582",
        "ticker_sentiment_score": "0.28118",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.143629",
        "ticker_sentiment_score": "0.075299",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.213988",
        "ticker_sentiment_score": "0.194193",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly  ( LLY )  Settles With Spa Selling Mounjaro, Zepbound Copies",
    "url": "https://www.zacks.com/stock/news/2274187/eli-lilly-lly-settles-with-spa-selling-mounjaro-zepbound-copies",
    "time_published": "20240515T135300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Eli Lilly (LLY) reaches settlement with a medical spa selling copycat versions of Mounjaro and Zepbound. The spa will make a monetary payment to Lilly.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f2/4113.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.10314,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.499789",
        "ticker_sentiment_score": "0.016118",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.160277",
        "ticker_sentiment_score": "0.071676",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.21258",
        "ticker_sentiment_score": "0.100401",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.107255",
        "ticker_sentiment_score": "0.198134",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Roche  ( RHHBY )  Posts Encouraging Phase I Obesity Drug Data",
    "url": "https://www.zacks.com/stock/news/2274860/roche-rhhby-posts-encouraging-phase-i-obesity-drug-data",
    "time_published": "20240516T134400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Data from the study shows that nearly half of the patients who received Roche's (RHHBY) subcutaneously-administered obesity drug lost more than 20% of their body weight after 24 weeks.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/82/41137.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.17509,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.272181",
        "ticker_sentiment_score": "0.159011",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.055492",
        "ticker_sentiment_score": "0.16691",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.219312",
        "ticker_sentiment_score": "0.185723",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.219312",
        "ticker_sentiment_score": "0.220203",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.219312",
        "ticker_sentiment_score": "0.164265",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Amgen Inc.  ( AMGN )  Is a Trending Stock: Facts to Know Before Betting on It",
    "url": "https://www.zacks.com/stock/news/2274596/amgen-inc-amgn-is-a-trending-stock-facts-to-know-before-betting-on-it",
    "time_published": "20240516T130015",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default172.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.22188,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.490323",
        "ticker_sentiment_score": "0.15337",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Stocks To Watch: Amgen Sees RS Rating Jump To 81",
    "url": "https://www.investors.com/ibd-data-stories/stocks-to-watch-amgen-sees-rs-rating-jump-to-81/",
    "time_published": "20240516T070000",
    "authors": [
      "INVESTOR'S BUSINESS DAILY",
      "Investor's Business Daily"
    ],
    "summary": "The Relative Strength ( RS ) Rating for Amgen ( AMGN ) climbed into a new percentile Thursday, with an increase from 77 to 81. X This exclusive rating from Investor's Business Daily tracks share price action with a 1 ( worst ) to 99 ( best ) score.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      }
    ],
    "overall_sentiment_score": 0.294968,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.358152",
        "ticker_sentiment_score": "0.142265",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.183895",
        "ticker_sentiment_score": "0.255143",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.514619",
        "ticker_sentiment_score": "0.225806",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HALO",
        "relevance_score": "0.358152",
        "ticker_sentiment_score": "0.142265",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UTHR",
        "relevance_score": "0.358152",
        "ticker_sentiment_score": "0.142265",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly - Altimmune  ( NASDAQ:ALT ) , Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/news/earnings/24/05/38897093/4-stocks-that-could-break-novo-nordisk-lillys-obesity-duopoly",
    "time_published": "20240517T192425",
    "authors": [
      "Zacks"
    ],
    "summary": "The obesity market has garnered much interest lately, ever since Novo Nordisk NVO received FDA approval for its obesity drug Wegovy in 2021. It was only after a couple of years that the market gained a second entrant - Eli Lilly's LLY Zepbound, which received FDA approval last year in November.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/17/nick-chong-n__bnvq_w18-unsplash.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.179517,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VKTX",
        "relevance_score": "0.266828",
        "ticker_sentiment_score": "0.212936",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.067919",
        "ticker_sentiment_score": "0.204913",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.101725",
        "ticker_sentiment_score": "0.09978",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALT",
        "relevance_score": "0.266828",
        "ticker_sentiment_score": "0.069335",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.067919",
        "ticker_sentiment_score": "0.121379",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.03399",
        "ticker_sentiment_score": "0.020157",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.201803",
        "ticker_sentiment_score": "0.096423",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.067919",
        "ticker_sentiment_score": "0.021146",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen Unusual Options Activity - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/insights/options/24/05/38901450/amgen-unusual-options-activity",
    "time_published": "20240517T191613",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bullish stance on Amgen AMGN. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.148365,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.776545",
        "ticker_sentiment_score": "0.165329",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.095356",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.171872",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Amgen's  ( AMGN )  Tarlatamab Receives FDA Approval for SCLC",
    "url": "https://www.zacks.com/stock/news/2275579/amgens-amgn-tarlatamab-receives-fda-approval-for-sclc",
    "time_published": "20240517T154700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen's (AMGN) Imdelltra is the first DLL3-targeting BiTE therapy that activates the patient's own T cells to attack DLL3-expressing tumor cells.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/86/1981.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.972193"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.1152,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ANIP",
        "relevance_score": "0.405651",
        "ticker_sentiment_score": "0.250031",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LGND",
        "relevance_score": "0.20997",
        "ticker_sentiment_score": "0.227261",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ANVS",
        "relevance_score": "0.277433",
        "ticker_sentiment_score": "-0.037934",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.405651",
        "ticker_sentiment_score": "-0.045425",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly",
    "url": "https://www.zacks.com/stock/news/2275514/4-stocks-that-could-break-novo-nordisk-lillys-obesity-duopoly",
    "time_published": "20240517T140400",
    "authors": [
      "Sundeep Ganoria"
    ],
    "summary": "Though obesity drugs continue to gain traction, it is currently a duopoly market. As analysts expect demand to grow at an encouraging pace, several biotech/pharma companies are rushing to enter this space.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c8/39674.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.165572,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VKTX",
        "relevance_score": "0.271274",
        "ticker_sentiment_score": "0.211874",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.069094",
        "ticker_sentiment_score": "0.17789",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.103479",
        "ticker_sentiment_score": "0.09697",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALT",
        "relevance_score": "0.271274",
        "ticker_sentiment_score": "0.070244",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.03458",
        "ticker_sentiment_score": "0.117428",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.03458",
        "ticker_sentiment_score": "0.021179",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.205225",
        "ticker_sentiment_score": "0.096103",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.03458",
        "ticker_sentiment_score": "0.021179",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "FDA Gives Accelerated Approval To Amgen's Drug For Small Cell Lung Cancer Patients - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/general/biotech/24/05/38895049/fda-gives-accelerated-approval-to-amgens-drug-for-small-cell-lung-cancer-patients",
    "time_published": "20240517T140155",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Thursday, the FDA approved Amgen Inc's AMGN Imdelltra ( tarlatamab-dlle ) for the treatment of adult patients with extensive-stage small cell lung cancer ( ES-SCLC ) with disease progression on or after platinum-based chemotherapy.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/17/Doctor-Examining-A-Lung-Radiography.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.098131,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.362505",
        "ticker_sentiment_score": "-0.075629",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSTK",
        "relevance_score": "0.124809",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Meet the GLP-1 Drug That Could Be the Biggest Concern for Eli Lilly and Novo Nordisk",
    "url": "https://www.fool.com/investing/2024/05/17/meet-the-glp-1-drug-that-could-be-the-biggest-conc/",
    "time_published": "20240517T122400",
    "authors": [
      "David Jagielski"
    ],
    "summary": "Could Amgen be the next stock to soar due to a GLP-1 drug?",
    "banner_image": "https://g.foolcdn.com/editorial/images/776990/doctor-meeting-a-salesperson.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      }
    ],
    "overall_sentiment_score": 0.268795,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.123209",
        "ticker_sentiment_score": "0.241651",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.514619",
        "ticker_sentiment_score": "0.514875",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.123209",
        "ticker_sentiment_score": "0.241651",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch",
    "url": "https://markets.businessinsider.com/news/stocks/cannabis-meets-prescription-drugs-steroids-and-ketamine-in-schedule-iii-what-it-means-key-stocks-to-watch-1033400987",
    "time_published": "20240518T141914",
    "authors": [
      "Nicol&#225;s Jose Rodriguez"
    ],
    "summary": "President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act ( CSA ) . This shift could revolutionize the cannabis industry. But what exactly is Schedule III? What other substances are produced and studied in this ...",
    "banner_image": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2024/05/17/dalle_2024-05-17_18.49.22_-_.jpeg",
    "source": "Business Insider",
    "category_within_source": "RSS",
    "source_domain": "markets.businessinsider.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.341804,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.068896",
        "ticker_sentiment_score": "0.134749",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.068896",
        "ticker_sentiment_score": "0.134749",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.068896",
        "ticker_sentiment_score": "0.134749",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JAZZ",
        "relevance_score": "0.068896",
        "ticker_sentiment_score": "0.134749",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.068896",
        "ticker_sentiment_score": "0.134749",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.068896",
        "ticker_sentiment_score": "0.134749",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch - AbbVie  ( NYSE:ABBV ) , Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/markets/cannabis/24/05/38905472/cannabis-meets-prescription-drugs-steroids-and-ketamine-in-schedule-iii-what-it-means-key-stocks",
    "time_published": "20240518T141914",
    "authors": [
      "Nicol\u00e1s Jose Rodriguez"
    ],
    "summary": "President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act ( CSA ) . This shift could revolutionize the cannabis industry. But what exactly is Schedule III? What other substances are produced and studied in this ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/17/dalle_2024-05-17_18.49.22_-_.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.327636,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.117774",
        "ticker_sentiment_score": "0.123682",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.117774",
        "ticker_sentiment_score": "0.151999",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.175859",
        "ticker_sentiment_score": "-0.080549",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JAZZ",
        "relevance_score": "0.117774",
        "ticker_sentiment_score": "0.230325",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.117774",
        "ticker_sentiment_score": "0.067245",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.117774",
        "ticker_sentiment_score": "0.19966",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Is Amgen a Threat to Eli Lilly in This Billion-Dollar Market?",
    "url": "https://www.fool.com/investing/2024/05/19/is-amgen-a-threat-to-eli-lilly-in-this-market/",
    "time_published": "20240519T101500",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Eli Lilly's biggest growth drivers today are its weight loss drugs.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F777578%2Fgettyimages-investor-works-at-computer.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.140873,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.447091",
        "ticker_sentiment_score": "0.211884",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.05257",
        "ticker_sentiment_score": "0.070167",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.208017",
        "ticker_sentiment_score": "-0.009861",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.1568",
        "ticker_sentiment_score": "0.110599",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen/AstraZeneca Say Asthma Drug Shows Activity In Another Lung Disease Across Broad Patient Population - AstraZeneca  ( NASDAQ:AZN ) , Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/general/biotech/24/05/38924821/amgenastrazeneca-say-asthma-drug-shows-activity-in-another-lung-disease-across-broad-patient-popu",
    "time_published": "20240520T183841",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Sunday, Amgen Inc AMGN and AstraZeneca Plc AZN announced the results of the Phase 2a COURSE trial of Tezspire ( tezepelumab-ekko ) for severe chronic obstructive pulmonary disease ( COPD ) with a broad range of baseline blood eosinophil counts ( BEC ) irrespective of emphysema, chronic ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/20/Doctor-Examining-A-Lung-Radiography.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.115184,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.392948",
        "ticker_sentiment_score": "-0.078788",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.392948",
        "ticker_sentiment_score": "-0.078788",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSTK",
        "relevance_score": "0.136113",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen",
    "url": "https://www.zacks.com/stock/news/2275810/the-zacks-analyst-blog-highlights-stocks-recently-featured-in-the-blog-include-novo-nordisk-eli-lillys-viking-altimmune-roche-and-amgen",
    "time_published": "20240520T104200",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen are included in this Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.167697,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VKTX",
        "relevance_score": "0.282234",
        "ticker_sentiment_score": "0.154464",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.095899",
        "ticker_sentiment_score": "0.086129",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.095899",
        "ticker_sentiment_score": "0.029675",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALT",
        "relevance_score": "0.282234",
        "ticker_sentiment_score": "0.053625",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.032035",
        "ticker_sentiment_score": "0.116226",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.032035",
        "ticker_sentiment_score": "0.020964",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.221385",
        "ticker_sentiment_score": "0.07018",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.032035",
        "ticker_sentiment_score": "0.020964",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update",
    "url": "https://www.globenewswire.com/news-release/2024/05/21/2886080/0/en/Alvotech-Reports-Financial-Results-for-First-Quarter-of-2024-and-Provides-a-Business-Update.html",
    "time_published": "20240521T211500",
    "authors": [
      "Alvotech"
    ],
    "summary": "REYKJAVIK, Iceland, May 21, 2024 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO, or the \"Company\" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported unaudited financial results for the first three months of ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999822"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.111129,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.013693",
        "ticker_sentiment_score": "0.086813",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.013693",
        "ticker_sentiment_score": "0.086813",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTUS",
        "relevance_score": "0.013693",
        "ticker_sentiment_score": "0.054711",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.027382",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALVO",
        "relevance_score": "0.405299",
        "ticker_sentiment_score": "0.22023",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.013693",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.013693",
        "ticker_sentiment_score": "0.054711",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.013693",
        "ticker_sentiment_score": "0.054711",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.013693",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.013693",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:ISK",
        "relevance_score": "0.027382",
        "ticker_sentiment_score": "0.00379",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:SEK",
        "relevance_score": "0.027382",
        "ticker_sentiment_score": "0.00379",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.013693",
        "ticker_sentiment_score": "-0.038604",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update",
    "url": "https://www.globenewswire.com/news-release/2024/05/21/2886079/0/en/Alvotech-Reports-Financial-Results-for-First-Quarter-of-2024-and-Provides-a-Business-Update.html",
    "time_published": "20240521T211400",
    "authors": [
      "Alvotech"
    ],
    "summary": "Alvotech ( NASDAQ: ALVO, or the \"Company\" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported unaudited financial results for the first three months of 2024 and provided a summary of recent corporate ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999822"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.111134,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.013732",
        "ticker_sentiment_score": "0.086839",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.013732",
        "ticker_sentiment_score": "0.086839",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTUS",
        "relevance_score": "0.013732",
        "ticker_sentiment_score": "0.054728",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.02746",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALVO",
        "relevance_score": "0.406356",
        "ticker_sentiment_score": "0.220633",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.013732",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.013732",
        "ticker_sentiment_score": "0.054728",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.013732",
        "ticker_sentiment_score": "0.054728",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.013732",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.013732",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:ISK",
        "relevance_score": "0.02746",
        "ticker_sentiment_score": "0.003792",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:SEK",
        "relevance_score": "0.02746",
        "ticker_sentiment_score": "0.003792",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.013732",
        "ticker_sentiment_score": "-0.038614",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like Ozempic - ROUNDHILL ETF TRUST  ( NASDAQ:OZEM ) ",
    "url": "https://www.benzinga.com/general/biotech/24/05/38951889/exclusive-roundhill-investments-launches-weight-loss-etf-for-exposure-to-blockbuster-drugs-like-o",
    "time_published": "20240521T203305",
    "authors": [
      "Piero Cingari"
    ],
    "summary": "What Happened: The Roundhill GLP-1 & Weight Loss ETF OZEM marks a significant milestone as the world's first GLP-1 ETF. Roundhill asserts that weight loss drugs, particularly GLP-1 agonists, are among the most revolutionary advancements in the global pharmaceuticals industry.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/21/Munich--Bavaria--Germany---March-31-2023.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.857896"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.163888,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.147818",
        "ticker_sentiment_score": "-0.024864",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.147818",
        "ticker_sentiment_score": "0.140996",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HIMS",
        "relevance_score": "0.220141",
        "ticker_sentiment_score": "-0.00176",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.220141",
        "ticker_sentiment_score": "0.059456",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.220141",
        "ticker_sentiment_score": "0.059456",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.033675",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.147818",
        "ticker_sentiment_score": "0.140996",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Alvotech and Dr. Reddy's enter into collaboration for commercialization of AVT03  ( denosumab ) , a biosimilar candidate to Prolia\u00ae & Xgeva\u00ae in the U.S., Europe and UK",
    "url": "https://www.globenewswire.com/news-release/2024/05/21/2885547/0/en/Alvotech-and-Dr-Reddy-s-enter-into-collaboration-for-commercialization-of-AVT03-denosumab-a-biosimilar-candidate-to-Prolia-Xgeva-in-the-U-S-Europe-and-UK.html",
    "time_published": "20240521T120100",
    "authors": [
      "Alvotech"
    ],
    "summary": "HYDERABAD, INDIA & REYKJAVIK, ICELAND - Alvotech ( NASDAQ: ALVO ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide ( \"Alvotech\" ) , and Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd., ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.714479"
      }
    ],
    "overall_sentiment_score": 0.181281,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CURN",
        "relevance_score": "0.015914",
        "ticker_sentiment_score": "-0.005318",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALVO",
        "relevance_score": "0.409812",
        "ticker_sentiment_score": "0.243883",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.015914",
        "ticker_sentiment_score": "0.055651",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.015914",
        "ticker_sentiment_score": "0.055651",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.047717",
        "ticker_sentiment_score": "0.173711",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LTUS",
        "relevance_score": "0.015914",
        "ticker_sentiment_score": "0.055651",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Alvotech and Dr. Reddy's enter into collaboration for commercialization of AVT03  ( denosumab ) , a biosimilar candidate to Prolia\u00ae & Xgeva\u00ae in the U.S., Europe and UK",
    "url": "https://www.globenewswire.com/news-release/2024/05/21/2885500/0/en/Alvotech-and-Dr-Reddy-s-enter-into-collaboration-for-commercialization-of-AVT03-denosumab-a-biosimilar-candidate-to-Prolia-Xgeva-in-the-U-S-Europe-and-UK.html",
    "time_published": "20240521T120000",
    "authors": [
      "Alvotech"
    ],
    "summary": "HYDERABAD, India and REYKJAVIK, Iceland, May 21, 2024 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide ( \"Alvotech\" ) , and Dr. Reddy's Laboratories SA, wholly-owned ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.178939,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CURN",
        "relevance_score": "0.015767",
        "ticker_sentiment_score": "-0.005314",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.015767",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.015767",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTUS",
        "relevance_score": "0.015767",
        "ticker_sentiment_score": "0.05559",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALVO",
        "relevance_score": "0.40638",
        "ticker_sentiment_score": "0.239851",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.015767",
        "ticker_sentiment_score": "0.05559",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.015767",
        "ticker_sentiment_score": "0.05559",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.047278",
        "ticker_sentiment_score": "0.167601",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Sandoz receives European Commission approval for Wyost\u00ae and Jubbonti\u00ae, the first and only biosimilars of denosumab in Europe",
    "url": "https://www.globenewswire.com/news-release/2024/05/22/2886160/0/en/Sandoz-receives-European-Commission-approval-for-Wyost-and-Jubbonti-the-first-and-only-biosimilars-of-denosumab-in-Europe.html",
    "time_published": "20240522T050000",
    "authors": [
      "Sandoz International GmbH"
    ],
    "summary": "Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/41ea40f9-fbb7-45d9-9136-33fdb399d0ba",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.084789,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.040348",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8  ( CCR8 )  Antibody, CHS-114, at the 2024 American Society of Clinical Oncology  ( ASCO )  Annual Meeting - Coherus BioSciences  ( NASDAQ:CHRS ) ",
    "url": "https://www.benzinga.com/pressreleases/24/05/g38995719/coherus-presents-preliminary-results-from-phase-i-dose-escalation-study-of-its-anti-chemokine-rece",
    "time_published": "20240523T215106",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "CHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities ( DLTs ) in heavily pretreated patients with solid tumors Selective depletion of peripheral CCR8+ regulatory T cells ( Tregs ) was observed and depletion was maintained over the dosing interval, establishing ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.614606"
      }
    ],
    "overall_sentiment_score": 0.087031,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.023957",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CHRS",
        "relevance_score": "0.023957",
        "ticker_sentiment_score": "-0.008327",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.023957",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8  ( CCR8 )  Antibody, CHS-114, at the 2024 American Society of Clinical Oncology  ( ASCO )  Annual Meeting",
    "url": "https://www.globenewswire.com/news-release/2024/05/23/2887728/33333/en/Coherus-Presents-Preliminary-Results-from-Phase-I-Dose-Escalation-Study-of-its-Anti-chemokine-receptor-8-CCR8-Antibody-CHS-114-at-the-2024-American-Society-of-Clinical-Oncology-ASC.html",
    "time_published": "20240523T215100",
    "authors": [
      "Inc.",
      "Coherus BioSciences"
    ],
    "summary": "CHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities ( DLTs ) in heavily pretreated patients with solid tumors ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/bacb58bf-ea23-4950-a845-933265930d07",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.451494"
      }
    ],
    "overall_sentiment_score": 0.084734,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.024724",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CHRS",
        "relevance_score": "0.049424",
        "ticker_sentiment_score": "-0.010994",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.024724",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Top Stock Reports for Apple, Mastercard & Amgen",
    "url": "https://www.zacks.com/research-daily/2277785/top-stock-reports-for-apple-mastercard-amgen",
    "time_published": "20240523T174400",
    "authors": [
      "Sheraz Mian"
    ],
    "summary": "Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Mastercard (MA) and Amgen (AMGN), as well as two micro-cap stocks Utah Medical Products, Inc. (UTMD) and Bridger Aerospace Group Holdings, Inc. (BAER).",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default310.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.986714"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.31517,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MASI",
        "relevance_score": "0.053629",
        "ticker_sentiment_score": "-0.061316",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UTMD",
        "relevance_score": "0.107016",
        "ticker_sentiment_score": "0.050254",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.107016",
        "ticker_sentiment_score": "0.200466",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MA",
        "relevance_score": "0.053629",
        "ticker_sentiment_score": "0.10801",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.107016",
        "ticker_sentiment_score": "0.1368",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Apple, Mastercard, Amgen, Utah Medical Products and Bridger Aerospace",
    "url": "https://www.zacks.com/stock/news/2278669/the-zacks-analyst-blog-highlights-apple-mastercard-amgen-utah-medical-products-and-bridger-aerospace",
    "time_published": "20240524T133500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Apple, Mastercard, Amgen, Utah Medical Products and Bridger Aerospace are part of the Zacks top Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/15/497.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.986714"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.279642,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MASI",
        "relevance_score": "0.0428",
        "ticker_sentiment_score": "-0.061",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UTMD",
        "relevance_score": "0.21156",
        "ticker_sentiment_score": "0.071637",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.21156",
        "ticker_sentiment_score": "0.158895",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BAER",
        "relevance_score": "0.127908",
        "ticker_sentiment_score": "0.047575",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MA",
        "relevance_score": "0.127908",
        "ticker_sentiment_score": "0.073999",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.21156",
        "ticker_sentiment_score": "0.127804",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "What's Going On With Mid-Cap Cancer-Focused Verastem Oncology Stock On Friday? - Verastem  ( NASDAQ:VSTM ) ",
    "url": "https://www.benzinga.com/general/biotech/24/05/39006618/whats-going-on-with-mid-cap-cancer-focused-verastem-oncology-stock-on-friday",
    "time_published": "20240524T124521",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Thursday, Verastem Oncology VSTM announced the initial interim safety and efficacy results from the ongoing RAMP 205 Phase 1/2 trial evaluating avutometinib plus defactinib in combination with gemcitabine and Nab-paclitaxel in the first-line in patients with metastatic pancreatic cancer.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/24/A-3d-Illustration-Depicting-Cancer-Cells.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.07518,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.183895",
        "ticker_sentiment_score": "0.065208",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VSTM",
        "relevance_score": "0.439026",
        "ticker_sentiment_score": "0.026275",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.183895",
        "ticker_sentiment_score": "0.065208",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen's Catching Up to Novo Nordisk and Eli Lilly. Should You Buy It?",
    "url": "https://www.fool.com/investing/2024/05/26/amgens-catching-up-to-novo-nordisk-and-eli-lilly-s/",
    "time_published": "20240526T105300",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "The gold rush for obesity medications just got a bit more intense.",
    "banner_image": "https://g.foolcdn.com/editorial/images/778155/businessmen-and-doctors-working-on-touchpad-in-a-hospital.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.235454,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.187827",
        "ticker_sentiment_score": "0.181493",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.094576",
        "ticker_sentiment_score": "0.134761",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.141448",
        "ticker_sentiment_score": "0.133015",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.187827",
        "ticker_sentiment_score": "0.181493",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Amgen Inc.  ( AMGN )  is Attracting Investor Attention: Here is What You Should Know",
    "url": "https://www.zacks.com/stock/news/2279326/amgen-inc-amgn-is-attracting-investor-attention-here-is-what-you-should-know",
    "time_published": "20240527T130010",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default185.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.241532,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.482078",
        "ticker_sentiment_score": "0.154381",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly  ( LLY )  to Ramp Up Indiana Site for Mounjaro, Zepbound",
    "url": "https://www.zacks.com/stock/news/2279236/eli-lilly-lly-to-ramp-up-indiana-site-for-mounjaro-zepbound",
    "time_published": "20240527T120200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Since 2020, Eli Lilly (LLY) has committed more than $18 billion to building new manufacturing sites as well as updating existing manufacturing facilities.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5d/2633.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.262807,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "APG",
        "relevance_score": "0.054236",
        "ticker_sentiment_score": "0.176824",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.659096",
        "ticker_sentiment_score": "0.386355",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.16171",
        "ticker_sentiment_score": "0.072099",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.214462",
        "ticker_sentiment_score": "0.101099",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.108222",
        "ticker_sentiment_score": "0.261237",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Beat the Market the Zacks Way: EverQuote, Micron, Amgen in Focus",
    "url": "https://www.zacks.com/stock/news/2279920/beat-the-market-the-zacks-way-everquote-micron-amgen-in-focus",
    "time_published": "20240528T120700",
    "authors": [
      "Abhinab Dasgupta"
    ],
    "summary": "Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/13/816.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.977154"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.972193"
      }
    ],
    "overall_sentiment_score": 0.172726,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SE",
        "relevance_score": "0.066139",
        "ticker_sentiment_score": "0.061196",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PLMR",
        "relevance_score": "0.066139",
        "ticker_sentiment_score": "0.245905",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.066139",
        "ticker_sentiment_score": "0.101176",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MU",
        "relevance_score": "0.066139",
        "ticker_sentiment_score": "0.061196",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KALU",
        "relevance_score": "0.066139",
        "ticker_sentiment_score": "0.245905",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MTD",
        "relevance_score": "0.099066",
        "ticker_sentiment_score": "0.107081",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSCO",
        "relevance_score": "0.066139",
        "ticker_sentiment_score": "0.061217",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.066139",
        "ticker_sentiment_score": "0.061217",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EVER",
        "relevance_score": "0.066139",
        "ticker_sentiment_score": "0.252957",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BMI",
        "relevance_score": "0.066139",
        "ticker_sentiment_score": "0.12425",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen Secures FDA Nod For Rare-Disease Treatment Biosimilar Based On AstraZeneca's Drug - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/general/biotech/24/05/39069397/amgen-secures-fda-nod-for-rare-disease-treatment-biosimilar-based-on-astrazenecas-drug",
    "time_published": "20240529T165129",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Tuesday, the FDA approved Amgen Inc AMGN Bkemv ( eculizumab-aeeb ) as the first interchangeable biosimilar to AstraZeneca Plc's AZN Soliris ( eculizumab ) to treat certain rare diseases. Bkemv is approved for the following treatment indications, which are also currently approved for Soliris:",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/29/Amgen-stock.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.041881,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.367865",
        "ticker_sentiment_score": "0.473421",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.250386",
        "ticker_sentiment_score": "0.416473",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks",
    "url": "https://www.zacks.com/stock/news/2280482/improve-your-retirement-income-with-these-3-top-ranked-dividend-stocks",
    "time_published": "20240529T131002",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default114.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.185865,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.216376",
        "ticker_sentiment_score": "0.119894",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSTK",
        "relevance_score": "0.216376",
        "ticker_sentiment_score": "0.124824",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.054732",
        "ticker_sentiment_score": "-0.036005",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Where Will Amgen Be in 3 Years?",
    "url": "https://www.fool.com/investing/2024/05/29/where-will-amgen-be-in-3-years/",
    "time_published": "20240529T121500",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "The Amgen of 2027 could be much be larger than some investors expect.",
    "banner_image": "https://g.foolcdn.com/editorial/images/777720/two-investors-consult-papers-and-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.259376,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.452495",
        "ticker_sentiment_score": "0.363943",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Should You Invest in the iShares Biotechnology ETF  ( IBB ) ?",
    "url": "https://www.zacks.com/stock/news/2281075/should-you-invest-in-the-ishares-biotechnology-etf-ibb",
    "time_published": "20240530T102006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default113.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.166379,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.0699",
        "ticker_sentiment_score": "0.034109",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.139265",
        "ticker_sentiment_score": "0.072803",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.139265",
        "ticker_sentiment_score": "0.072803",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.139265",
        "ticker_sentiment_score": "0.072803",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here's How Much You Would Have Made Owning Amgen Stock In The Last 20 Years - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/insights/news/24/05/39117756/heres-how-much-you-would-have-made-owning-amgen-stock-in-the-last-20-years",
    "time_published": "20240531T180045",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Amgen AMGN has outperformed the market over the past 20 years by 1.01% on an annualized basis producing an average annual return of 8.86%. Currently, Amgen has a market capitalization of $161.52 billion.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.238974,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.95919",
        "ticker_sentiment_score": "0.384695",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Amgen Hits 80-Plus Relative Strength Rating Benchmark",
    "url": "https://www.investors.com/ibd-data-stories/amgen-hits-80-plus-relative-strength-rating-benchmark-2/",
    "time_published": "20240531T070000",
    "authors": [
      "INVESTOR'S BUSINESS DAILY",
      "Investor's Business Daily"
    ],
    "summary": "On Friday, Amgen ( AMGN ) got a positive adjustment to its Relative Strength ( RS ) Rating, from 79 to 83. X IBD's proprietary RS Rating tracks technical performance by using a 1 ( worst ) to 99 ( best ) score that identifies how a stock's price performance over the last 52 weeks matches up ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      }
    ],
    "overall_sentiment_score": 0.27822,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CORT",
        "relevance_score": "0.360752",
        "ticker_sentiment_score": "0.147931",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.651499",
        "ticker_sentiment_score": "0.489124",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "HALO",
        "relevance_score": "0.360752",
        "ticker_sentiment_score": "0.147931",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UTHR",
        "relevance_score": "0.360752",
        "ticker_sentiment_score": "0.147931",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "This Is My Favorite Way To Increase Long-Term Wealth",
    "url": "https://www.forbes.com/sites/brettowens/2024/06/01/this-is-my-favorite-way-to-increase-long-term-wealth/",
    "time_published": "20240601T135800",
    "authors": [
      "Brett Owens"
    ],
    "summary": "Got some investing money you'd like to double? As in, grow it by 100% or more? Here's the surest and safest way to do it quickly. Well, before we get into getting rich, let's talk about income. Not everyone needs to grow their pile of money bigger and bigger.",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6655e83a9ab1bdc644f11e9d/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.918141"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.392909,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.213517",
        "ticker_sentiment_score": "0.132353",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PEP",
        "relevance_score": "0.16099",
        "ticker_sentiment_score": "0.315026",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Dow Jones Falls As Fed Official Says This But Nasdaq Leads; GameStop Soars Amid Roaring Kitty Bet",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-nasdaq-sp500-fed-official-neel-kashkari-gamestop-roaring-kitty-bet/",
    "time_published": "20240603T144500",
    "authors": [
      "MICHAEL LARKIN",
      "Investor's Business Daily"
    ],
    "summary": "Dow Jones Falls As Fed Official Says This But Nasdaq Leads. GameStop Soars Amid Roaring Kitty Bet Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2021/04/Stock-Gamestop-01-IBD.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.132595,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOLD",
        "relevance_score": "0.078482",
        "ticker_sentiment_score": "0.001038",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.156207",
        "ticker_sentiment_score": "0.095785",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.078482",
        "ticker_sentiment_score": "0.190207",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SKWD",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.146282",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.078482",
        "ticker_sentiment_score": "-0.201461",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "RDDT",
        "relevance_score": "0.078482",
        "ticker_sentiment_score": "0.090925",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADSK",
        "relevance_score": "0.078482",
        "ticker_sentiment_score": "0.081088",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PARA",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.083376",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.103134",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.039289",
        "ticker_sentiment_score": "0.000992",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.078482",
        "ticker_sentiment_score": "0.190207",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DOW",
        "relevance_score": "0.078482",
        "ticker_sentiment_score": "-0.201461",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.039289",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QCOM",
        "relevance_score": "0.078482",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMC",
        "relevance_score": "0.078482",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMD",
        "relevance_score": "0.078482",
        "ticker_sentiment_score": "-0.027329",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.078482",
        "ticker_sentiment_score": "0.081088",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GME",
        "relevance_score": "0.269776",
        "ticker_sentiment_score": "0.090405",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.039289",
        "ticker_sentiment_score": "0.209557",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.",
    "url": "https://www.fool.com/investing/2024/06/03/the-gold-rush-for-weight-loss-drugs-is-here-these/",
    "time_published": "20240603T130000",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "There's probably a big enough pie here for everyone to get a slice.",
    "banner_image": "https://g.foolcdn.com/editorial/images/779213/doctors-at-table.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      }
    ],
    "overall_sentiment_score": 0.157439,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VKTX",
        "relevance_score": "0.107978",
        "ticker_sentiment_score": "0.159257",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.213988",
        "ticker_sentiment_score": "0.172504",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.161349",
        "ticker_sentiment_score": "0.096811",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.107978",
        "ticker_sentiment_score": "0.094737",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen Seeks Expanded US Approval For Autoimmune Disease Drug Acquired Via $28B Horizon Deal - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/general/biotech/24/06/39192642/amgen-seeks-expanded-us-approval-for-autoimmune-disease-drug-acquired-via-28b-horizon-deal",
    "time_published": "20240605T192654",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Wednesday, Amgen Inc AMGN announced topline results from its Phase 3 trial evaluating the efficacy and safety of Uplizna ( inebilizumab-cdon ) for Immunoglobulin G4-related disease, a systemic autoimmune fibroinflammatory multiorgan disease, usually involving the pancreas.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/05/Amgen-stock.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.064899,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.454714",
        "ticker_sentiment_score": "0.233531",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MSBHF",
        "relevance_score": "0.19117",
        "ticker_sentiment_score": "0.113512",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Futures Rise Ahead Of ADP Jobs Report",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-sp500-nasdaq-adp-jobs-report-nvidia-stock-nvda/",
    "time_published": "20240605T120500",
    "authors": [
      "Investor's Business Daily",
      "SCOTT LEHTONEN"
    ],
    "summary": "Stock Market Today: Dow Jones Rises Ahead Of ADP Jobs Report. Nvidia Hits More Record Highs Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2019/10/stock-wall-street-flags-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      }
    ],
    "overall_sentiment_score": 0.162818,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.15697",
        "ticker_sentiment_score": "0.063664",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.15697",
        "ticker_sentiment_score": "0.046777",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.195498",
        "ticker_sentiment_score": "0.188324",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CRWD",
        "relevance_score": "0.118064",
        "ticker_sentiment_score": "0.050429",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPOT",
        "relevance_score": "0.195498",
        "ticker_sentiment_score": "0.089657",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DLTR",
        "relevance_score": "0.039483",
        "ticker_sentiment_score": "0.214643",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.07887",
        "ticker_sentiment_score": "-0.112709",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HPQ",
        "relevance_score": "0.039483",
        "ticker_sentiment_score": "0.214643",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.039483",
        "ticker_sentiment_score": "0.23263",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.15697",
        "ticker_sentiment_score": "0.075663",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.195498",
        "ticker_sentiment_score": "0.112397",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.118064",
        "ticker_sentiment_score": "0.25442",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HOOD",
        "relevance_score": "0.07887",
        "ticker_sentiment_score": "0.141264",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is iShares Biotechnology ETF  ( IBB )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2283696/is-ishares-biotechnology-etf-ibb-a-strong-etf-right-now",
    "time_published": "20240605T102007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default124.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999981"
      }
    ],
    "overall_sentiment_score": 0.27215,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.060541",
        "ticker_sentiment_score": "0.074",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.120733",
        "ticker_sentiment_score": "0.062256",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.120733",
        "ticker_sentiment_score": "0.062256",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.120733",
        "ticker_sentiment_score": "0.062256",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Market Whales and Their Recent Bets on AMGN Options - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/insights/options/24/06/39213010/market-whales-and-their-recent-bets-on-amgn-options",
    "time_published": "20240606T174631",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bullish stance on Amgen AMGN. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.160447,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.759059",
        "ticker_sentiment_score": "0.179514",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Biotech Stock Roundup: GSK's Litigation Update, BIIB's Drug Approval & Other Updates",
    "url": "https://www.zacks.com/stock/news/2284959/biotech-stock-roundup-gsks-litigation-update-biibs-drug-approval-other-updates",
    "time_published": "20240606T172900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "GSK and Biogen (BIIB) are in the spotlight following litigation updates and drug approval, respectively.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/57/40404.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.052698,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "IONS",
        "relevance_score": "0.034136",
        "ticker_sentiment_score": "0.18584",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.068209",
        "ticker_sentiment_score": "0.047106",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.135921",
        "ticker_sentiment_score": "0.110716",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VIR",
        "relevance_score": "0.135921",
        "ticker_sentiment_score": "0.066487",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.135921",
        "ticker_sentiment_score": "0.158882",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Amgen's  ( AMGN )  Uplizna Meets Study Goal for Rare Disease",
    "url": "https://www.zacks.com/stock/news/2284949/amgens-amgn-uplizna-meets-study-goal-for-rare-disease",
    "time_published": "20240606T155900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Data from a late-stage study shows that treatment with Amgen's (AMGN) Uplizna achieves a statistically significant reduction in the risk of flares in patients with IgG4-RD, a rare disease.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.9545"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.064791,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ARQT",
        "relevance_score": "0.249106",
        "ticker_sentiment_score": "0.100412",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.366061",
        "ticker_sentiment_score": "0.106426",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNS",
        "relevance_score": "0.249106",
        "ticker_sentiment_score": "0.047403",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HRTX",
        "relevance_score": "0.308504",
        "ticker_sentiment_score": "0.172293",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why Is Intra-Cellular  ( ITCI )  Up 1.2% Since Last Earnings Report?",
    "url": "https://www.zacks.com/stock/news/2284839/why-is-intra-cellular-itci-up-12-since-last-earnings-report",
    "time_published": "20240606T153112",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Intra-Cellular (ITCI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default329.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.904684"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      }
    ],
    "overall_sentiment_score": 0.164138,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.256989",
        "ticker_sentiment_score": "0.065987",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ITCI",
        "relevance_score": "0.130217",
        "ticker_sentiment_score": "-0.003663",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Futures Mixed Ahead Of Jobless Claims",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-sp500-nasdaq-jobless-claims-lululemon-stock-lulu/",
    "time_published": "20240606T121200",
    "authors": [
      "SCOTT LEHTONEN",
      "Investor's Business Daily"
    ],
    "summary": "Stock Market Today: Dow Jones Falls Ahead Of Jobless Claims. Lululemon Soars On Earnings Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2017/03/stock-wallstreet-031317-shutter.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      }
    ],
    "overall_sentiment_score": 0.158928,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.154703",
        "ticker_sentiment_score": "0.102043",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.154703",
        "ticker_sentiment_score": "0.048621",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.192694",
        "ticker_sentiment_score": "0.113597",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TTC",
        "relevance_score": "0.116348",
        "ticker_sentiment_score": "0.025626",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPOT",
        "relevance_score": "0.192694",
        "ticker_sentiment_score": "0.084503",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.077719",
        "ticker_sentiment_score": "-0.061741",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.038906",
        "ticker_sentiment_score": "0.223337",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.154703",
        "ticker_sentiment_score": "0.08129",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CIEN",
        "relevance_score": "0.116348",
        "ticker_sentiment_score": "0.025626",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.192694",
        "ticker_sentiment_score": "0.160937",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LULU",
        "relevance_score": "0.077719",
        "ticker_sentiment_score": "0.066593",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FIVE",
        "relevance_score": "0.116348",
        "ticker_sentiment_score": "0.025626",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.116348",
        "ticker_sentiment_score": "0.248432",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NIO",
        "relevance_score": "0.116348",
        "ticker_sentiment_score": "0.025626",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HOOD",
        "relevance_score": "0.077719",
        "ticker_sentiment_score": "0.146111",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Amgen  ( AMGN )  Dipped More Than Broader Market Today",
    "url": "https://www.zacks.com/stock/news/2285658/why-amgen-amgn-dipped-more-than-broader-market-today",
    "time_published": "20240607T215011",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) closed the most recent trading day at $305.02, moving -0.22% from the previous trading session.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default124.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.177001,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.608634",
        "ticker_sentiment_score": "0.144551",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Trending Stock Amgen Inc.  ( AMGN )  a Buy Now?",
    "url": "https://www.zacks.com/stock/news/2285201/is-trending-stock-amgen-inc-amgn-a-buy-now",
    "time_published": "20240607T130010",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default252.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.221623,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.483888",
        "ticker_sentiment_score": "0.140057",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Futures: CPI Inflation Data, Fed Meeting Loom",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-gme-stock-fed-meeting-cpi/",
    "time_published": "20240610T210300",
    "authors": [
      "Investor's Business Daily",
      "SCOTT LEHTONEN"
    ],
    "summary": "Dow Jones Futures: CPI, Fed Meeting Loom. GME Stock Plunges 50% In Two Days Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2021/09/Stock-wallstreetflag-01-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.085606,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.096477",
        "ticker_sentiment_score": "0.14663",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.144275",
        "ticker_sentiment_score": "0.171497",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.144275",
        "ticker_sentiment_score": "0.143189",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.096477",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRWD",
        "relevance_score": "0.096477",
        "ticker_sentiment_score": "-0.023731",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPOT",
        "relevance_score": "0.144275",
        "ticker_sentiment_score": "0.129058",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "V",
        "relevance_score": "0.191549",
        "ticker_sentiment_score": "0.092686",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADBE",
        "relevance_score": "0.096477",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ORCL",
        "relevance_score": "0.096477",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.144275",
        "ticker_sentiment_score": "0.090419",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HOOD",
        "relevance_score": "0.096477",
        "ticker_sentiment_score": "0.14663",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GME",
        "relevance_score": "0.144275",
        "ticker_sentiment_score": "-0.157879",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Small Biotech Crushed On Obesity Switch After Glaucoma Flop",
    "url": "https://www.investors.com/news/technology/skye-stock-glaucoma-drug-failure-obesity-treatment/",
    "time_published": "20240610T172500",
    "authors": [
      "Investor's Business Daily",
      "ALLISON GATLIN"
    ],
    "summary": "Skye Stock Plummets After Glaucoma Drug Flop. Pivots To Obesity Treatment Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2018/11/Stock-DrugPharma-04-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      }
    ],
    "overall_sentiment_score": 0.081152,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GPCR",
        "relevance_score": "0.21686",
        "ticker_sentiment_score": "0.273078",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.21686",
        "ticker_sentiment_score": "0.273078",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.109455",
        "ticker_sentiment_score": "-0.19535",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.21686",
        "ticker_sentiment_score": "0.273078",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.109455",
        "ticker_sentiment_score": "0.183192",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.109455",
        "ticker_sentiment_score": "-0.19535",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Beat the Market Like Zacks: Goldman Sachs, Micron, Amgen in Focus",
    "url": "https://www.zacks.com/stock/news/2285863/beat-the-market-like-zacks-goldman-sachs-micron-amgen-in-focus",
    "time_published": "20240610T120700",
    "authors": [
      "Abhinab Dasgupta"
    ],
    "summary": "Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/98/601.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.977154"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.972193"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.192564,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "OUST",
        "relevance_score": "0.06697",
        "ticker_sentiment_score": "0.246068",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SE",
        "relevance_score": "0.06697",
        "ticker_sentiment_score": "0.061235",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RNAZ",
        "relevance_score": "0.06697",
        "ticker_sentiment_score": "0.253127",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.06697",
        "ticker_sentiment_score": "0.06025",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MU",
        "relevance_score": "0.06697",
        "ticker_sentiment_score": "0.061235",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CL",
        "relevance_score": "0.06697",
        "ticker_sentiment_score": "0.06025",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DCTH",
        "relevance_score": "0.06697",
        "ticker_sentiment_score": "0.146414",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.06697",
        "ticker_sentiment_score": "0.120297",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MTD",
        "relevance_score": "0.06697",
        "ticker_sentiment_score": "0.106242",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.100308",
        "ticker_sentiment_score": "0.112796",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LMFA",
        "relevance_score": "0.06697",
        "ticker_sentiment_score": "0.246068",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Futures Drop As AMD Falls On Downgrade",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-sp500-nasdaq-nvidia-stock-nvda-gme-stock/",
    "time_published": "20240610T120600",
    "authors": [
      "Investor's Business Daily",
      "SCOTT LEHTONEN"
    ],
    "summary": "Stock Market Today: Dow Jones Falls As Nvidia Stock Split Takes Effect. GME Stock Rebounds Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2017/04/stock-wallstreet-shutter.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.069415,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.126951",
        "ticker_sentiment_score": "0.091605",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.126951",
        "ticker_sentiment_score": "-0.123273",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.220236",
        "ticker_sentiment_score": "0.243815",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.063678",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPOT",
        "relevance_score": "0.158311",
        "ticker_sentiment_score": "0.023307",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.031864",
        "ticker_sentiment_score": "-0.095936",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.063678",
        "ticker_sentiment_score": "-0.061024",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ORCL",
        "relevance_score": "0.063678",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.031864",
        "ticker_sentiment_score": "-0.045343",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.126951",
        "ticker_sentiment_score": "0.035323",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.158311",
        "ticker_sentiment_score": "0.229861",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.09539",
        "ticker_sentiment_score": "0.087714",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADBE",
        "relevance_score": "0.063678",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMD",
        "relevance_score": "0.09539",
        "ticker_sentiment_score": "-0.130348",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HOOD",
        "relevance_score": "0.063678",
        "ticker_sentiment_score": "0.144145",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GME",
        "relevance_score": "0.09539",
        "ticker_sentiment_score": "-0.14516",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Structure Therapeutics  ( GPCR )  Rallying on Obesity Drug Data",
    "url": "https://www.zacks.com/stock/news/2286691/structure-therapeutics-gpcr-rallying-on-obesity-drug-data",
    "time_published": "20240611T135900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Structure Therapeutics (GPCR) stock sees an upside on positive top-line data from a phase IIa obesity study as well as a capsule-to-tablet PK study on its obesity candidate, GSBR-1290.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/49/1007.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.204047,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.166935",
        "ticker_sentiment_score": "0.180748",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GPCR",
        "relevance_score": "0.425925",
        "ticker_sentiment_score": "0.171171",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.111747",
        "ticker_sentiment_score": "0.064997",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.221313",
        "ticker_sentiment_score": "0.103646",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.166935",
        "ticker_sentiment_score": "0.33006",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Futures Fall Ahead Of Fed Meeting",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-sp500-nasdaq-general-motors-stock-gm/",
    "time_published": "20240611T121400",
    "authors": [
      "SCOTT LEHTONEN",
      "Investor's Business Daily"
    ],
    "summary": "Stock Market Today: Dow Jones Fall Ahead Of Fed Meeting. GM Stock Rises On Buyback Plan Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2019/01/stock-FederalReserve-snow-11-shutter.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.118945,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.148502",
        "ticker_sentiment_score": "0.086842",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.148502",
        "ticker_sentiment_score": "0.152796",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.11166",
        "ticker_sentiment_score": "-0.007046",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.185022",
        "ticker_sentiment_score": "0.091266",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRWD",
        "relevance_score": "0.074576",
        "ticker_sentiment_score": "-0.144466",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.11166",
        "ticker_sentiment_score": "0.026201",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPOT",
        "relevance_score": "0.11166",
        "ticker_sentiment_score": "0.080745",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GM",
        "relevance_score": "0.11166",
        "ticker_sentiment_score": "0.068971",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "V",
        "relevance_score": "0.185022",
        "ticker_sentiment_score": "0.075641",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.037329",
        "ticker_sentiment_score": "0.012914",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.148502",
        "ticker_sentiment_score": "0.074427",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HOOD",
        "relevance_score": "0.074576",
        "ticker_sentiment_score": "0.140411",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Decoding Amgen's Options Activity: What's the Big Picture? - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/insights/options/24/06/39299796/decoding-amgens-options-activity-whats-the-big-picture",
    "time_published": "20240612T200222",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "High-rolling investors have positioned themselves bullish on Amgen AMGN, and it's important for retail traders to take note. \\This activity came to our attention today through Benzinga's tracking of publicly available options data.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.187019,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.744851",
        "ticker_sentiment_score": "0.200673",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why Regeneron Stock Finally Joined The 1,000-Club",
    "url": "https://www.investors.com/news/technology/regeneron-stock-dupixent-copd-treatment/",
    "time_published": "20240612T142200",
    "authors": [
      "ALLISON GATLIN",
      "Investor's Business Daily"
    ],
    "summary": "Regeneron Stock Joins The 1,000-Club As Dupixent Enthusiasm Grows Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2020/08/Stock-regeneron-01-shutt.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.193797,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MRNA",
        "relevance_score": "0.059935",
        "ticker_sentiment_score": "-0.178026",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.119532",
        "ticker_sentiment_score": "0.031471",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.119532",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.119532",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.059935",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.236396",
        "ticker_sentiment_score": "-0.019921",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Viridian  ( VRDN )  Up 10% on Clinical Updates for Eye Disease Drug",
    "url": "https://www.zacks.com/stock/news/2287309/viridian-vrdn-up-10-on-clinical-updates-for-eye-disease-drug",
    "time_published": "20240612T131100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Viridian (VRDN) intends to initiate two late-stage studies on its experimental thyroid eye disease drug this August. Top-line data from both studies are expected in ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.18927,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ARQT",
        "relevance_score": "0.197816",
        "ticker_sentiment_score": "0.05374",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.197816",
        "ticker_sentiment_score": "0.16706",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRDN",
        "relevance_score": "0.683699",
        "ticker_sentiment_score": "0.386808",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "HRTX",
        "relevance_score": "0.245835",
        "ticker_sentiment_score": "0.11248",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Futures Rise Ahead Of CPI, Powell",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-sp500-nasdaq-cpi-powell-gme-stock-gamestop/",
    "time_published": "20240612T120400",
    "authors": [
      "SCOTT LEHTONEN",
      "Investor's Business Daily"
    ],
    "summary": "Stock Market Today: Dow Jones Rises Ahead Of CPI, Powell. GME Falls After Raising $2.1 Billion Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2017/03/stock-wallstreet-031317-shutter.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.134023,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.106699",
        "ticker_sentiment_score": "0.168478",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.141935",
        "ticker_sentiment_score": "0.094525",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.106699",
        "ticker_sentiment_score": "0.12773",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.17689",
        "ticker_sentiment_score": "0.112099",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.106699",
        "ticker_sentiment_score": "0.099703",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPOT",
        "relevance_score": "0.106699",
        "ticker_sentiment_score": "0.125837",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "V",
        "relevance_score": "0.17689",
        "ticker_sentiment_score": "0.111548",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OLED",
        "relevance_score": "0.071251",
        "ticker_sentiment_score": "-0.138873",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.035661",
        "ticker_sentiment_score": "0.14237",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.141935",
        "ticker_sentiment_score": "0.111812",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HOOD",
        "relevance_score": "0.071251",
        "ticker_sentiment_score": "0.139883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GME",
        "relevance_score": "0.211498",
        "ticker_sentiment_score": "-0.046642",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly's $50 Billion View From The Weight-Loss Arena",
    "url": "https://www.investors.com/research/the-new-america/eli-lilly-stock-weight-loss-drug-expectations/",
    "time_published": "20240612T120000",
    "authors": [
      "ALLISON GATLIN",
      "Investor's Business Daily"
    ],
    "summary": "Eli Lilly Stock Runs Up 48% Amid Lofty Expectations For Weight-Loss Drug Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/06/wNAsales061724.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.839681"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      }
    ],
    "overall_sentiment_score": 0.137497,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VKTX",
        "relevance_score": "0.062761",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.031405",
        "ticker_sentiment_score": "0.092378",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.062761",
        "ticker_sentiment_score": "-0.05814",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GLDAF",
        "relevance_score": "0.062761",
        "ticker_sentiment_score": "0.029003",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.49669",
        "ticker_sentiment_score": "0.167766",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GPCR",
        "relevance_score": "0.062761",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.062761",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.062761",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.031405",
        "ticker_sentiment_score": "0.230533",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.062761",
        "ticker_sentiment_score": "0.032226",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen  ( AMGN )  Stock Sinks As Market Gains: What You Should Know",
    "url": "https://www.zacks.com/stock/news/2288123/amgen-amgn-stock-sinks-as-market-gains-what-you-should-know",
    "time_published": "20240613T215018",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The latest trading day saw Amgen (AMGN) settling at $298.50, representing a -0.86% change from its previous close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default329.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.976913"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.181097,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.592095",
        "ticker_sentiment_score": "0.222782",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Futures: S&P 500, Nasdaq Rally To New Highs",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-sp500-nvidia-stock-nvda/",
    "time_published": "20240617T211400",
    "authors": [
      "SCOTT LEHTONEN",
      "Investor's Business Daily"
    ],
    "summary": "Dow Jones Futures: S&P 500 Rallies To New Highs. Nvidia Stock Reverses Lower Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2019/10/stock-wall-street-flags-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.154075,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.138464",
        "ticker_sentiment_score": "0.23359",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.138464",
        "ticker_sentiment_score": "0.137147",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.138464",
        "ticker_sentiment_score": "-0.066451",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.138464",
        "ticker_sentiment_score": "0.25551",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LEN",
        "relevance_score": "0.092569",
        "ticker_sentiment_score": "-0.174654",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "JBL",
        "relevance_score": "0.092569",
        "ticker_sentiment_score": "0.086474",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.138464",
        "ticker_sentiment_score": "0.137147",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMX",
        "relevance_score": "0.092569",
        "ticker_sentiment_score": "0.086474",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KR",
        "relevance_score": "0.092569",
        "ticker_sentiment_score": "0.086474",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CL",
        "relevance_score": "0.092569",
        "ticker_sentiment_score": "-0.022369",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.092569",
        "ticker_sentiment_score": "0.240059",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.183895",
        "ticker_sentiment_score": "0.159798",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Top Dow Jones Stocks To Buy Today? 2 To Know",
    "url": "https://stockmarket.com/featured/top-dow-jones-stocks-to-buy-today-2-to-know-2024-06-17",
    "time_published": "20240617T140954",
    "authors": [
      "Jonathan Phillip"
    ],
    "summary": "The Dow Jones Industrial Average ( DJIA ) is a widely recognized stock market index that represents 30 large, publicly-owned companies based in the United States. These companies are leaders across diverse sectors, making the Dow a general indicator of the market's overall condition and economic ...",
    "banner_image": "https://u3j7m9h7.rocketcdn.me/wp-content/uploads/2024/06/TRV-stock-logo.jpg",
    "source": "StockMarket.com",
    "category_within_source": "n/a",
    "source_domain": "stockmarket.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99676"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.165855,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.388879",
        "ticker_sentiment_score": "0.280051",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TRV",
        "relevance_score": "0.45825",
        "ticker_sentiment_score": "0.160251",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Amgen's  ( AMGN )  Blincyto Gets FDA Nod for Consolidation Treatment",
    "url": "https://www.zacks.com/stock/news/2289221/amgens-amgn-blincyto-gets-fda-nod-for-consolidation-treatment",
    "time_published": "20240617T135400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen's (AMGN) Blincyto is now approved for the treatment of adult and pediatric patients one month and older with Philadelphia chromosome-negative B-ALL in the consolidation phase, regardless of MRD status.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/284.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.06577,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LGND",
        "relevance_score": "0.226301",
        "ticker_sentiment_score": "0.205474",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TWST",
        "relevance_score": "0.226301",
        "ticker_sentiment_score": "0.054305",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ANVS",
        "relevance_score": "0.298567",
        "ticker_sentiment_score": "-0.037861",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.368227",
        "ticker_sentiment_score": "0.267148",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Futures Mixed As Nvidia Eyes More Record Highs",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-nasdaq-sp500-nvidia-stock-nvda-record-highs/",
    "time_published": "20240617T121100",
    "authors": [
      "SCOTT LEHTONEN",
      "Investor's Business Daily"
    ],
    "summary": "Stock Market Today: Dow Jones Futures Fall. Nvidia Stock Set For More Record Highs Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2021/09/Stock-wallstreetflag-01-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.125109,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.15347",
        "ticker_sentiment_score": "0.128679",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.115416",
        "ticker_sentiment_score": "0.108838",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.115416",
        "ticker_sentiment_score": "0.173287",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SPOT",
        "relevance_score": "0.115416",
        "ticker_sentiment_score": "0.123814",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.115416",
        "ticker_sentiment_score": "0.095937",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KR",
        "relevance_score": "0.077094",
        "ticker_sentiment_score": "0.083991",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.038592",
        "ticker_sentiment_score": "0.131881",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.15347",
        "ticker_sentiment_score": "0.090103",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.15347",
        "ticker_sentiment_score": "0.210094",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.115416",
        "ticker_sentiment_score": "0.060951",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JBL",
        "relevance_score": "0.077094",
        "ticker_sentiment_score": "0.083991",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "V",
        "relevance_score": "0.19117",
        "ticker_sentiment_score": "0.092482",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMX",
        "relevance_score": "0.077094",
        "ticker_sentiment_score": "0.083991",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OLED",
        "relevance_score": "0.077094",
        "ticker_sentiment_score": "-0.080147",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Solid Power Appoints Renewables Industry Veteran Linda Heller as Chief Financial Officer - Solid Power  ( NASDAQ:SLDP ) , Solid Power  ( NASDAQ:SLDPW ) ",
    "url": "https://www.benzinga.com/pressreleases/24/06/g39354391/solid-power-appoints-renewables-industry-veteran-linda-heller-as-chief-financial-officer",
    "time_published": "20240617T120050",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "LOUISVILLE, Colo., June 17, 2024 ( GLOBE NEWSWIRE ) -- Solid Power, Inc. SLDP, a leading developer of solid-state battery technology, today announced that the board of directors has appointed Linda Heller as the company's Chief Financial Officer and Treasurer, effective immediately.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.905476"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.233772,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SLDP",
        "relevance_score": "0.461087",
        "ticker_sentiment_score": "0.288343",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.028833",
        "ticker_sentiment_score": "0.042906",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GDYMF",
        "relevance_score": "0.028833",
        "ticker_sentiment_score": "0.042906",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.028833",
        "ticker_sentiment_score": "0.042906",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Solid Power Appoints Renewables Industry Veteran Linda Heller as Chief Financial Officer",
    "url": "https://www.globenewswire.com/news-release/2024/06/17/2899618/0/en/Solid-Power-Appoints-Renewables-Industry-Veteran-Linda-Heller-as-Chief-Financial-Officer.html",
    "time_published": "20240617T120000",
    "authors": [
      "Inc.",
      "Solid Power"
    ],
    "summary": "Company reaffirms 2024 guidance Company reaffirms 2024 guidance ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/b1a2a6ec-a955-48b7-a113-70e783455de2",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.839681"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.233873,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SLDP",
        "relevance_score": "0.448513",
        "ticker_sentiment_score": "0.289083",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.029691",
        "ticker_sentiment_score": "0.043089",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GDYMF",
        "relevance_score": "0.029691",
        "ticker_sentiment_score": "0.043089",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.029691",
        "ticker_sentiment_score": "0.043089",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the VanEck Biotech ETF  ( BBH ) ?",
    "url": "https://www.zacks.com/stock/news/2288898/should-you-invest-in-the-vaneck-biotech-etf-bbh",
    "time_published": "20240617T102005",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default1.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.168003,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.134214",
        "ticker_sentiment_score": "0.071398",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.134214",
        "ticker_sentiment_score": "0.071398",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.134214",
        "ticker_sentiment_score": "0.071398",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Check Out What Whales Are Doing With AMGN - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/insights/options/24/06/39387456/check-out-what-whales-are-doing-with-amgn",
    "time_published": "20240618T184610",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Whales with a lot of money to spend have taken a noticeably bearish stance on Amgen. Looking at options history for Amgen AMGN we detected 67 trades. If we consider the specifics of each trade, it is accurate to state that 31% of the investors opened trades with bullish expectations and 49% with ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.099632,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.761431",
        "ticker_sentiment_score": "0.121945",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here is What to Know Beyond Why Amgen Inc.  ( AMGN )  is a Trending Stock",
    "url": "https://www.zacks.com/stock/news/2289679/here-is-what-to-know-beyond-why-amgen-inc-amgn-is-a-trending-stock",
    "time_published": "20240618T130010",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default9.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.203772,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.482078",
        "ticker_sentiment_score": "0.115638",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors",
    "url": "https://www.globenewswire.com/news-release/2024/06/19/2901079/0/en/Jasper-Therapeutics-Announces-Appointment-of-Svetlana-Lucas-Ph-D-to-its-Board-of-Directors.html",
    "time_published": "20240619T120000",
    "authors": [
      "Jasper Therapeutics",
      "Inc."
    ],
    "summary": "REDWOOD CITY, Calif., June 19, 2024 ( GLOBE NEWSWIRE ) -- Jasper Therapeutics, Inc. ( Nasdaq: JSPR ) ( Jasper ) , a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit ( CD117 ) to address mast cell driven diseases such as chronic ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/ed6e5311-feff-4502-874f-39486c6ba17a",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.10061,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JSPR",
        "relevance_score": "0.063509",
        "ticker_sentiment_score": "0.098367",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ATYR",
        "relevance_score": "0.03178",
        "ticker_sentiment_score": "-0.00473",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.063509",
        "ticker_sentiment_score": "-0.005012",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.03178",
        "ticker_sentiment_score": "-0.00473",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.03178",
        "ticker_sentiment_score": "-0.00473",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors - Jasper Therapeutics  ( NASDAQ:JSPR ) ",
    "url": "https://www.benzinga.com/pressreleases/24/06/g39397237/jasper-therapeutics-announces-appointment-of-svetlana-lucas-ph-d-to-its-board-of-directors",
    "time_published": "20240619T120000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "REDWOOD CITY, Calif., June 19, 2024 ( GLOBE NEWSWIRE ) -- Jasper Therapeutics, Inc.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.107548,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JSPR",
        "relevance_score": "0.090816",
        "ticker_sentiment_score": "0.082919",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ATYR",
        "relevance_score": "0.030331",
        "ticker_sentiment_score": "-0.004693",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.060617",
        "ticker_sentiment_score": "-0.005004",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.030331",
        "ticker_sentiment_score": "-0.004693",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.030331",
        "ticker_sentiment_score": "-0.004693",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen  ( AMGN )  Gains As Market Dips: What You Should Know",
    "url": "https://www.zacks.com/stock/news/2291136/amgen-amgn-gains-as-market-dips-what-you-should-know",
    "time_published": "20240620T220016",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) closed the most recent trading day at $309.89, moving +1.27% from the previous trading session.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default202.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.190857,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.527969",
        "ticker_sentiment_score": "0.22871",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Biotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News",
    "url": "https://www.zacks.com/stock/news/2291052/biotech-stock-roundup-itci-up-on-study-data-zntl-ovid-down-on-updates-more-news",
    "time_published": "20240620T153900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5d/2633.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.052902,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ITCI",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "-0.001359",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "0.095308",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "0.110367",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ZNTL",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "0.009398",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OVID",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "-0.113811",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Where Will Amgen Be in 5 Years?",
    "url": "https://www.fool.com/investing/2024/06/20/where-will-amgen-be-in-5-years/",
    "time_published": "20240620T121500",
    "authors": [
      "David Jagielski"
    ],
    "summary": "Can Amgen be a market-beating stock?",
    "banner_image": "https://g.foolcdn.com/editorial/images/780724/scientist-working-in-a-lab.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      }
    ],
    "overall_sentiment_score": 0.127651,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.53784",
        "ticker_sentiment_score": "0.28493",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.058615",
        "ticker_sentiment_score": "0.003004",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments - Gilead Sciences  ( NASDAQ:GILD ) ",
    "url": "https://www.benzinga.com/general/biotech/24/06/39435880/gilead-sciences-faces-wall-street-speculation-about-obesity-drugs-despite-focus-on-liver-treatmen",
    "time_published": "20240621T154222",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Gilead Sciences, Inc. GILD witnessed a flurry of Wall Street speculation regarding its potential involvement in the obesity drug market. But, the biotech company, renowned for its cancer and HIV treatments, has not positioned itself as a contender in this lucrative field.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/21/Doctors-And-Nurses-Walking-In-Hospital-H.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.219317,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.155451",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.155451",
        "ticker_sentiment_score": "0.180513",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.155451",
        "ticker_sentiment_score": "0.22521",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.155451",
        "ticker_sentiment_score": "0.180513",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.155451",
        "ticker_sentiment_score": "0.089516",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.078099",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.155451",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.155451",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.305058",
        "ticker_sentiment_score": "0.206652",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.155451",
        "ticker_sentiment_score": "0.22521",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Beat the Market Like Zacks: Freshpet, AudioEye, Walmart in Focus",
    "url": "https://www.zacks.com/stock/news/2292088/beat-the-market-like-zacks-freshpet-audioeye-walmart-in-focus",
    "time_published": "20240624T121000",
    "authors": [
      "Abhinab Dasgupta"
    ],
    "summary": "Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/0d/436.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.989041"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.972193"
      }
    ],
    "overall_sentiment_score": 0.192997,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.066784",
        "ticker_sentiment_score": "0.09118",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LIDR",
        "relevance_score": "0.033421",
        "ticker_sentiment_score": "0.236966",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MU",
        "relevance_score": "0.066784",
        "ticker_sentiment_score": "0.061226",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CL",
        "relevance_score": "0.066784",
        "ticker_sentiment_score": "0.061249",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PAHC",
        "relevance_score": "0.066784",
        "ticker_sentiment_score": "0.24603",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.066784",
        "ticker_sentiment_score": "0.061249",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AEYE",
        "relevance_score": "0.066784",
        "ticker_sentiment_score": "0.24603",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FICO",
        "relevance_score": "0.100029",
        "ticker_sentiment_score": "0.112709",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FRPT",
        "relevance_score": "0.066784",
        "ticker_sentiment_score": "0.124298",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SE",
        "relevance_score": "0.066784",
        "ticker_sentiment_score": "0.061226",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BW",
        "relevance_score": "0.066784",
        "ticker_sentiment_score": "0.253088",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NEXT",
        "relevance_score": "0.066784",
        "ticker_sentiment_score": "0.107234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.066784",
        "ticker_sentiment_score": "0.10623",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Future of Weight-Loss Drugs for Investors",
    "url": "https://www.kiplinger.com/investing/healthcare-stocks/the-future-of-weight-loss-drugs-for-investors",
    "time_published": "20240624T111555",
    "authors": [
      "Adam Shell"
    ],
    "summary": "Investing in shrinking waistlines might not have the wow factor of other market obsessions. But a new class of weight-loss drugs that help people shed pounds without dieting or doing cardio looks like a game-changer.",
    "banner_image": "https://cdn.mos.cms.futurecdn.net/hwgJ7osrMtUWhk5koeVme7-320-80.png",
    "source": "Kiplinger",
    "category_within_source": "n/a",
    "source_domain": "www.kiplinger.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999612"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.928769"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.215295,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.017612",
        "ticker_sentiment_score": "0.187721",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.035215",
        "ticker_sentiment_score": "0.175147",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JHG",
        "relevance_score": "0.017612",
        "ticker_sentiment_score": "0.102883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.174713",
        "ticker_sentiment_score": "0.190248",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GPCR",
        "relevance_score": "0.035215",
        "ticker_sentiment_score": "0.008654",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MORN",
        "relevance_score": "0.035215",
        "ticker_sentiment_score": "0.142129",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.017612",
        "ticker_sentiment_score": "-0.024444",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.052801",
        "ticker_sentiment_score": "0.199704",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.035215",
        "ticker_sentiment_score": "-0.099345",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Amgen  ( AMGN )  Outpaced the Stock Market Today",
    "url": "https://www.zacks.com/stock/news/2293190/why-amgen-amgn-outpaced-the-stock-market-today",
    "time_published": "20240625T215028",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) closed at $319.31 in the latest trading session, marking a +0.36% move from the prior day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default73.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.938793"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.248074,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.603594",
        "ticker_sentiment_score": "0.343719",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Top Stock Reports for Chevron, Amgen & Philip Morris",
    "url": "https://www.zacks.com/research-daily/2292698/top-stock-reports-for-chevron-amgen-philip-morris",
    "time_published": "20240625T161800",
    "authors": [
      "Sheraz Mian"
    ],
    "summary": "Today's Research Daily features new research reports on 16 major stocks, including Chevron Corporation (CVX), Amgen Inc. (AMGN) and Philip Morris International Inc. (PM), as well as two micro-cap stocks Hurco Companies, Inc. (HURC) and Perma-Pipe International Holdings, Inc. (PPIH).",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default310.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.839681"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.350809,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PPIH",
        "relevance_score": "0.104455",
        "ticker_sentiment_score": "0.205244",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.05234",
        "ticker_sentiment_score": "0.29684",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.156123",
        "ticker_sentiment_score": "0.165451",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PM",
        "relevance_score": "0.05234",
        "ticker_sentiment_score": "0.239722",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HES",
        "relevance_score": "0.05234",
        "ticker_sentiment_score": "0.29684",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Smart Money Is Betting Big In AMGN Options - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/insights/options/24/06/39484986/smart-money-is-betting-big-in-amgn-options",
    "time_published": "20240625T161630",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bearish stance on Amgen AMGN. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.132764,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.771416",
        "ticker_sentiment_score": "0.15363",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Chevron, Amgen, Philip Morris, Hurco and Perma-Pipe",
    "url": "https://www.zacks.com/stock/news/2293366/the-zacks-analyst-blog-highlights-chevron-amgen-philip-morris-hurco-and-perma-pipe",
    "time_published": "20240626T095900",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Chevron, Amgen, Philip Morris, Hurco and Perma-Pipe are included in this Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/a4/2005.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.839681"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.312455,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PPIH",
        "relevance_score": "0.208644",
        "ticker_sentiment_score": "0.187298",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.167612",
        "ticker_sentiment_score": "0.185323",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HURC",
        "relevance_score": "0.126119",
        "ticker_sentiment_score": "0.049577",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.249106",
        "ticker_sentiment_score": "0.149207",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PM",
        "relevance_score": "0.167612",
        "ticker_sentiment_score": "0.140273",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HES",
        "relevance_score": "0.042196",
        "ticker_sentiment_score": "0.294116",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Coherus BioSciences Announces Divestiture of YUSIMRY  ( adalimumab-aqvh )  in a $40 Million Upfront All Cash Transaction",
    "url": "https://www.globenewswire.com/news-release/2024/06/27/2905181/33333/en/Coherus-BioSciences-Announces-Divestiture-of-YUSIMRY-adalimumab-aqvh-in-a-40-Million-Upfront-All-Cash-Transaction.html",
    "time_published": "20240627T122600",
    "authors": [
      "Inc.",
      "Coherus BioSciences"
    ],
    "summary": "- Transaction aligns with Coherus' strategic focus on oncology - - Transaction aligns with Coherus' strategic focus on oncology ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/bacb58bf-ea23-4950-a845-933265930d07",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.451494"
      }
    ],
    "overall_sentiment_score": 0.11854,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.052918",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CHRS",
        "relevance_score": "0.105604",
        "ticker_sentiment_score": "0.035499",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Can Amgen Stock Keep Trouncing the S&P 500?",
    "url": "https://www.fool.com/investing/2024/06/27/is-amgen-stock-a-buy/",
    "time_published": "20240627T104500",
    "authors": [
      "George Budwell"
    ],
    "summary": "Amgen's market-beating ways are unlikely to evaporate any time soon.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F781748%2Fbio-lab.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.207523,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MORN",
        "relevance_score": "0.076847",
        "ticker_sentiment_score": "0.044977",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.076847",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.500477",
        "ticker_sentiment_score": "0.220545",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.076847",
        "ticker_sentiment_score": "0.044977",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Protein Expression Market size is set to grow by USD 3.40 billion from 2024-2028, Increasing advances in proteomics ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/protein-expression-market-size-is-set-to-grow-by-usd-3-40-billion-from-2024-2028--increasing-advances-in-proteomics-research-boost-the-market-technavio-302185318.html",
    "time_published": "20240628T213100",
    "authors": [],
    "summary": "Protein Expression Market size is set to grow by USD 3.40 billion from 2024-2028, Increasing advances in proteomics ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.172504,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "A",
        "relevance_score": "0.035983",
        "ticker_sentiment_score": "0.054656",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.035983",
        "ticker_sentiment_score": "0.055498",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SUVPF",
        "relevance_score": "0.035983",
        "ticker_sentiment_score": "0.054656",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BDX",
        "relevance_score": "0.035983",
        "ticker_sentiment_score": "0.054656",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GNNSF",
        "relevance_score": "0.035983",
        "ticker_sentiment_score": "0.054656",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.071892",
        "ticker_sentiment_score": "0.057587",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIO",
        "relevance_score": "0.071892",
        "ticker_sentiment_score": "0.057587",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QGEN",
        "relevance_score": "0.035983",
        "ticker_sentiment_score": "0.054656",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.035983",
        "ticker_sentiment_score": "0.054656",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.035983",
        "ticker_sentiment_score": "0.054656",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DHR",
        "relevance_score": "0.035983",
        "ticker_sentiment_score": "0.054656",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "1 Dividend Growth Stock to Buy and Hold for 10 Years",
    "url": "https://www.fool.com/investing/2024/06/29/1-dividend-growth-stock-to-buy-hold-for-10-years/",
    "time_published": "20240629T124500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "This company's payouts look safe.",
    "banner_image": "https://g.foolcdn.com/editorial/images/781533/patient-talking-with-a-physician.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.744043"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.399852,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.672864",
        "ticker_sentiment_score": "0.625513",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Futures: Tesla Surges; Powell Speech On Tap",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-tesla-stock-powell-speech/",
    "time_published": "20240701T204600",
    "authors": [
      "SCOTT LEHTONEN",
      "Investor's Business Daily"
    ],
    "summary": "Dow Jones Futures: Tesla Stock Surges Ahead Of Q2 Deliveries. Powell Speech Next Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2023/06/Stock-teslamodels-05-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.119823,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.138997",
        "ticker_sentiment_score": "0.154558",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DMPZF",
        "relevance_score": "0.046543",
        "ticker_sentiment_score": "0.128497",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.138997",
        "ticker_sentiment_score": "0.001241",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.138997",
        "ticker_sentiment_score": "0.099321",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BURL",
        "relevance_score": "0.138997",
        "ticker_sentiment_score": "0.068313",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.092927",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVNA",
        "relevance_score": "0.138997",
        "ticker_sentiment_score": "0.068313",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MFC",
        "relevance_score": "0.092927",
        "ticker_sentiment_score": "-0.022392",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.138997",
        "ticker_sentiment_score": "0.020058",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.138997",
        "ticker_sentiment_score": "0.11517",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DPZ",
        "relevance_score": "0.092927",
        "ticker_sentiment_score": "0.135858",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen Unusual Options Activity - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/insights/options/24/07/39582162/amgen-unusual-options-activity",
    "time_published": "20240701T190209",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Whales with a lot of money to spend have taken a noticeably bearish stance on Amgen. Looking at options history for Amgen AMGN we detected 10 trades. If we consider the specifics of each trade, it is accurate to state that 40% of the investors opened trades with bullish expectations and 50% with ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.097148,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.795061",
        "ticker_sentiment_score": "0.084336",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Take the Zacks Approach to Beat the Markets: NVIDIA, Seagate, Amkor in Focus",
    "url": "https://www.zacks.com/stock/news/2295818/take-the-zacks-approach-to-beat-the-markets-nvidia-seagate-amkor-in-focus",
    "time_published": "20240701T142800",
    "authors": [
      "Santanu Roy"
    ],
    "summary": "Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/a0/43171.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.977154"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.972193"
      }
    ],
    "overall_sentiment_score": 0.175103,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.065685",
        "ticker_sentiment_score": "0.089122",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.065685",
        "ticker_sentiment_score": "0.101152",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STX",
        "relevance_score": "0.065685",
        "ticker_sentiment_score": "0.252871",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CASY",
        "relevance_score": "0.065685",
        "ticker_sentiment_score": "0.089122",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.065685",
        "ticker_sentiment_score": "0.128231",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MMM",
        "relevance_score": "0.065685",
        "ticker_sentiment_score": "0.06019",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.098389",
        "ticker_sentiment_score": "0.106885",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMKR",
        "relevance_score": "0.065685",
        "ticker_sentiment_score": "0.301249",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CARE",
        "relevance_score": "0.065685",
        "ticker_sentiment_score": "0.301249",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.065685",
        "ticker_sentiment_score": "0.06019",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "What the Options Market Tells Us About Amgen - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/insights/options/24/07/39605701/what-the-options-market-tells-us-about-amgen",
    "time_published": "20240702T200145",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Financial giants have made a conspicuous bearish move on Amgen. Our analysis of options history for Amgen AMGN revealed 9 unusual trades. Delving into the details, we found 11% of traders were bullish, while 55% showed bearish tendencies.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.102617,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.769861",
        "ticker_sentiment_score": "-0.023943",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Futures Fall Ahead Of Powell Speech",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-sp500-nasdaq-tesla-stock-powell-speech/",
    "time_published": "20240702T120600",
    "authors": [
      "Investor's Business Daily",
      "SCOTT LEHTONEN"
    ],
    "summary": "Stock Market Today: Dow Jones Falls Ahead Of Powell Speech. Tesla Delivery Numbers Due Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2022/06/Stock-jeromepowell2022-03-gov.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.061699,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.104531",
        "ticker_sentiment_score": "0.032963",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.034933",
        "ticker_sentiment_score": "0.03825",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.173333",
        "ticker_sentiment_score": "0.10674",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MFC",
        "relevance_score": "0.069798",
        "ticker_sentiment_score": "-0.183052",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.034933",
        "ticker_sentiment_score": "0.010825",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.139064",
        "ticker_sentiment_score": "0.048836",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DPZ",
        "relevance_score": "0.069798",
        "ticker_sentiment_score": "0.144728",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.139064",
        "ticker_sentiment_score": "0.091789",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DMPZF",
        "relevance_score": "0.034933",
        "ticker_sentiment_score": "0.138091",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BURL",
        "relevance_score": "0.104531",
        "ticker_sentiment_score": "0.011072",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.139064",
        "ticker_sentiment_score": "-0.08584",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVNA",
        "relevance_score": "0.139064",
        "ticker_sentiment_score": "0.012643",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.173333",
        "ticker_sentiment_score": "0.067658",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "S&P 500, Nasdaq 100 Climb To Record Highs As Data Fosters Rate Cut Optimism Ahead Of Fed Minutes; Gold, Bonds Rally: What's Driving Markets Wednesday?",
    "url": "https://markets.businessinsider.com/news/etf/s-p-500-nasdaq-100-climb-to-record-highs-as-data-fosters-rate-cut-optimism-ahead-of-fed-minutes-gold-bonds-rally-what-s-driving-markets-wednesday-1033527636",
    "time_published": "20240703T172202",
    "authors": [
      "Piero Cingari"
    ],
    "summary": "S&P 500, Nasdaq 100 Climb To Record Highs As Data Fosters Rate Cut Optimism Ahead Of Fed Minutes. Gold, Bonds ... - Markets Insider ...",
    "banner_image": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2024/07/03/SP500.jpeg",
    "source": "Business Insider",
    "category_within_source": "GoogleRSS",
    "source_domain": "markets.businessinsider.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.904684"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.009782,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LCID",
        "relevance_score": "0.081001",
        "ticker_sentiment_score": "-0.01878",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.081001",
        "ticker_sentiment_score": "0.114118",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.081001",
        "ticker_sentiment_score": "-0.01878",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ACHR",
        "relevance_score": "0.081001",
        "ticker_sentiment_score": "-0.01878",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.081001",
        "ticker_sentiment_score": "-0.01878",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PARA",
        "relevance_score": "0.081001",
        "ticker_sentiment_score": "-0.01878",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.081001",
        "ticker_sentiment_score": "-0.01878",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STZ",
        "relevance_score": "0.081001",
        "ticker_sentiment_score": "-0.01878",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.081001",
        "ticker_sentiment_score": "-0.01878",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.081001",
        "ticker_sentiment_score": "-0.01878",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.16117",
        "ticker_sentiment_score": "-0.025385",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "NVO, LLY Slip After Study Links Obesity Drug Use to Vision Loss",
    "url": "https://www.zacks.com/stock/news/2296877/nvo-lly-slip-after-study-links-obesity-drug-use-to-vision-loss",
    "time_published": "20240704T121900",
    "authors": [
      "Sundeep Ganoria"
    ],
    "summary": "A new study led by investigators of a Harvard-affiliated teaching hospital found that Novo Nordisk's (NVO) GLP-1 drugs Ozempic and Wegovy could be linked to rare cases of vision loss.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/82/41137.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.080587,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.461468",
        "ticker_sentiment_score": "0.259244",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.108712",
        "ticker_sentiment_score": "0.09481",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.054483",
        "ticker_sentiment_score": "0.141808",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.267413",
        "ticker_sentiment_score": "0.17688",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.108712",
        "ticker_sentiment_score": "-0.025525",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Forget Eli Lilly: 3 Biotech Stocks to Buy Instead",
    "url": "https://www.fool.com/investing/2024/07/04/forget-eli-lilly-3-biotech-stocks-to-buy-instead/",
    "time_published": "20240704T095000",
    "authors": [
      "Keith Speights"
    ],
    "summary": "Eli Lilly is a good stock to buy, but these should be even better.",
    "banner_image": "https://g.foolcdn.com/editorial/images/782405/scientists-in-a-lab-smiling.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.795202"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.331406,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.574608",
        "ticker_sentiment_score": "0.507325",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.140216",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "-0.049168",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.43789",
        "ticker_sentiment_score": "0.424724",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "The Top-Performing Actively Managed Funds of the Last Decade",
    "url": "https://www.kiplinger.com/investing/the-top-performing-actively-managed-funds-of-the-last-decade",
    "time_published": "20240705T113044",
    "authors": [
      "Nellie S. Huang"
    ],
    "summary": "Past performance may be no guarantee of future results, but as any good detective knows, there's no such thing as a coincidence. In the same way, there's something to be said for a mutual fund with a good track record, especially over the past decade.",
    "banner_image": "https://cdn.mos.cms.futurecdn.net/hwgJ7osrMtUWhk5koeVme7-320-80.png",
    "source": "Kiplinger",
    "category_within_source": "n/a",
    "source_domain": "www.kiplinger.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.142857"
      }
    ],
    "overall_sentiment_score": 0.268954,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVMI",
        "relevance_score": "0.019978",
        "ticker_sentiment_score": "-0.024712",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TT",
        "relevance_score": "0.019978",
        "ticker_sentiment_score": "0.145413",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.049918",
        "ticker_sentiment_score": "0.177624",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.00999",
        "ticker_sentiment_score": "0.153378",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.019978",
        "ticker_sentiment_score": "0.166863",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SPOT",
        "relevance_score": "0.019978",
        "ticker_sentiment_score": "0.178619",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SYK",
        "relevance_score": "0.019978",
        "ticker_sentiment_score": "0.145413",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.019978",
        "ticker_sentiment_score": "0.083487",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.019978",
        "ticker_sentiment_score": "0.084169",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.029964",
        "ticker_sentiment_score": "0.116634",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PENN",
        "relevance_score": "0.019978",
        "ticker_sentiment_score": "-0.030932",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OXY",
        "relevance_score": "0.019978",
        "ticker_sentiment_score": "0.187244",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.039944",
        "ticker_sentiment_score": "0.078023",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CW",
        "relevance_score": "0.019978",
        "ticker_sentiment_score": "0.053824",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WCC",
        "relevance_score": "0.019978",
        "ticker_sentiment_score": "0.015839",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.019978",
        "ticker_sentiment_score": "0.187244",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MORN",
        "relevance_score": "0.049918",
        "ticker_sentiment_score": "0.089742",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DRTTF",
        "relevance_score": "0.00999",
        "ticker_sentiment_score": "-0.023081",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ENTG",
        "relevance_score": "0.019978",
        "ticker_sentiment_score": "-0.024712",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.029964",
        "ticker_sentiment_score": "0.144183",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO",
    "url": "https://markets.businessinsider.com/news/stocks/exclusive-glp-1-weight-loss-drugs-could-become-a-trillion-dollar-market-predicts-tema-etfs-ceo-1033533664",
    "time_published": "20240707T141621",
    "authors": [
      "Piero Cingari"
    ],
    "summary": "The GLP-1 drug market for obesity treatment is expected to skyrocket to $1 trillion or more, according to Maurits Pot, founder and CEO of Tema ETFs, who shared this optimistic forecast in an exclusive interview with Benzinga.",
    "banner_image": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2024/07/07/Valparaiso-In-Usa---March-21--2024-Wegov.jpeg",
    "source": "Business Insider",
    "category_within_source": "GoogleRSS",
    "source_domain": "markets.businessinsider.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.038569,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ALNY",
        "relevance_score": "0.055881",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.055881",
        "ticker_sentiment_score": "0.007019",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.055881",
        "ticker_sentiment_score": "-0.076293",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.055881",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.166551",
        "ticker_sentiment_score": "0.054044",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.055881",
        "ticker_sentiment_score": "0.007019",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen  ( AMGN )  Outpaces Stock Market Gains: What You Should Know",
    "url": "https://www.zacks.com/stock/news/2298188/amgen-amgn-outpaces-stock-market-gains-what-you-should-know",
    "time_published": "20240708T220017",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) reachead $311.46 at the closing of the latest trading day, reflecting a +0.19% change compared to its last close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default6.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.976913"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.18273,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.612033",
        "ticker_sentiment_score": "0.228753",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Beat the Market Like Zacks: Carvana, Adobe, Amgen in Focus",
    "url": "https://www.zacks.com/stock/news/2297591/beat-the-market-like-zacks-carvana-adobe-amgen-in-focus",
    "time_published": "20240708T120100",
    "authors": [
      "Abhinab Dasgupta"
    ],
    "summary": "Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5d/931.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.977154"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.972193"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.217715,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NSSC",
        "relevance_score": "0.067727",
        "ticker_sentiment_score": "0.295721",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "COST",
        "relevance_score": "0.067727",
        "ticker_sentiment_score": "0.106294",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SE",
        "relevance_score": "0.067727",
        "ticker_sentiment_score": "0.061274",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HIMS",
        "relevance_score": "0.067727",
        "ticker_sentiment_score": "0.295721",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ADBE",
        "relevance_score": "0.067727",
        "ticker_sentiment_score": "0.061274",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CL",
        "relevance_score": "0.067727",
        "ticker_sentiment_score": "0.061299",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVNA",
        "relevance_score": "0.067727",
        "ticker_sentiment_score": "0.253292",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SFM",
        "relevance_score": "0.067727",
        "ticker_sentiment_score": "0.124377",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.067727",
        "ticker_sentiment_score": "0.061299",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FICO",
        "relevance_score": "0.101439",
        "ticker_sentiment_score": "0.113155",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Study Shows Lilly's  ( LLY )  Obesity Drug More Effective Than NVO's",
    "url": "https://www.zacks.com/stock/news/2298718/study-shows-lillys-lly-obesity-drug-more-effective-than-nvos",
    "time_published": "20240709T160500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Data from a new study, also published on the JAMA website, shows that patients taking Lilly's (LLY) obesity drug are likely to lose more weight than those taking Novo's drug.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/82/41137.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.133551,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.502693",
        "ticker_sentiment_score": "0.213002",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.107978",
        "ticker_sentiment_score": "0.092408",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.054114",
        "ticker_sentiment_score": "0.141773",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.265666",
        "ticker_sentiment_score": "0.174039",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.213988",
        "ticker_sentiment_score": "0.109265",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly Rose More Than 50% So Far This Year. Can It Soar Past $1,000 in the 2nd Half?",
    "url": "https://www.fool.com/investing/2024/07/09/can-eli-lilly-surpass-1000-this-year/",
    "time_published": "20240709T091500",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "This pharma company is posting double-digit revenue growth.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F782698%2Fgettyimages-1292931102.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.976913"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.301168,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.680677",
        "ticker_sentiment_score": "0.506886",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.049629",
        "ticker_sentiment_score": "0.11247",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.049629",
        "ticker_sentiment_score": "0.062656",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.049629",
        "ticker_sentiment_score": "0.11247",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.049629",
        "ticker_sentiment_score": "0.00799",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Check Out What Whales Are Doing With AMGN - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/insights/options/24/07/39736063/check-out-what-whales-are-doing-with-amgn",
    "time_published": "20240711T173200",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bullish stance on Amgen AMGN. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.17179,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.800999",
        "ticker_sentiment_score": "0.179053",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.073098",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Novo Nordisk  ( NVO )  Soars 38% YTD: How Should You Play the Stock?",
    "url": "https://www.zacks.com/stock/news/2300219/novo-nordisk-nvo-soars-38-ytd-how-should-you-play-the-stock",
    "time_published": "20240711T160900",
    "authors": [
      "Ahan Chakraborty"
    ],
    "summary": "Novo Nordisk (NVO) is an excellent stock to retain as share prices continue to rise, driven by the stellar performance of GLP-1 drugs. New investors should look for stock price dips to make an entry.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.955357"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.988787"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.402052,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.148502",
        "ticker_sentiment_score": "0.165469",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.074576",
        "ticker_sentiment_score": "0.076649",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.037329",
        "ticker_sentiment_score": "0.137251",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.074576",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.600455",
        "ticker_sentiment_score": "0.579738",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Up 24% in a Year: Buy, Sell or Hold the Stock?",
    "url": "https://www.zacks.com/stock/news/2300044/abbvie-abbv-up-24-in-a-year-buy-sell-or-hold-the-stock",
    "time_published": "20240711T141400",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Investors who own AbbVie's (ABBV) stock may stay invested as the company has faced its biggest challenge, Humira's patent cliff- quite well and looks set to return to robust growth next year.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d5/8276.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.795202"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.650727"
      }
    ],
    "overall_sentiment_score": 0.229682,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.085629",
        "ticker_sentiment_score": "0.135983",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CERE",
        "relevance_score": "0.085629",
        "ticker_sentiment_score": "-0.084159",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.692985",
        "ticker_sentiment_score": "0.339667",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Amgen  ( AMGN )  Rises Higher Than Market: Key Facts",
    "url": "https://www.zacks.com/stock/news/2301201/amgen-amgn-rises-higher-than-market-key-facts",
    "time_published": "20240712T215017",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) reachead $330.83 at the closing of the latest trading day, reflecting a +1.77% change compared to its last close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default239.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.986564"
      }
    ],
    "overall_sentiment_score": 0.200653,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.463792",
        "ticker_sentiment_score": "0.238853",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Pfizer  ( PFE )  Moves Forward With Once-Daily Obesity Pill Study",
    "url": "https://www.zacks.com/stock/news/2300888/pfizer-pfe-moves-forward-with-once-daily-obesity-pill-study",
    "time_published": "20240712T142800",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Pfizer (PFE) is set to move forward with the development of a once-daily formulation of danuglipron, its GLP-1 candidate for obesity.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/952.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.155349,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.112532",
        "ticker_sentiment_score": "0.084185",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.112532",
        "ticker_sentiment_score": "0.062873",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.222838",
        "ticker_sentiment_score": "0.104214",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.112532",
        "ticker_sentiment_score": "0.084185",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.60415",
        "ticker_sentiment_score": "0.234469",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Small Caps Soar After Tame CPI: Weekly Review",
    "url": "https://www.investors.com/news/stock-market-shifts-small-caps-cpi-jpmorgan-tesla/",
    "time_published": "20240712T141400",
    "authors": [
      "Investor's Business Daily",
      "IBD STAFF"
    ],
    "summary": "Stock Market Shifts Toward Small Caps After Tame CPI. JPMorgan, Taiwan Semi, Tesla In Focus: Weekly Review Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2019/05/STock-NYSEstockExchange-05-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.890401"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      }
    ],
    "overall_sentiment_score": -0.041305,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.03642",
        "ticker_sentiment_score": "-0.125076",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.072765",
        "ticker_sentiment_score": "0.059364",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.072765",
        "ticker_sentiment_score": "0.059364",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.250755",
        "ticker_sentiment_score": "0.036195",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.072765",
        "ticker_sentiment_score": "0.045559",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.03642",
        "ticker_sentiment_score": "-0.028462",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.072765",
        "ticker_sentiment_score": "0.045559",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DAL",
        "relevance_score": "0.072765",
        "ticker_sentiment_score": "-0.197496",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "TSM",
        "relevance_score": "0.144926",
        "ticker_sentiment_score": "0.104804",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COST",
        "relevance_score": "0.072765",
        "ticker_sentiment_score": "0.018231",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MORF",
        "relevance_score": "0.072765",
        "ticker_sentiment_score": "0.045559",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.180595",
        "ticker_sentiment_score": "0.094905",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LNTH",
        "relevance_score": "0.108958",
        "ticker_sentiment_score": "-0.038295",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.215894",
        "ticker_sentiment_score": "0.032184",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.072765",
        "ticker_sentiment_score": "0.045559",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HUBS",
        "relevance_score": "0.072765",
        "ticker_sentiment_score": "-0.13101",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen Inc.  ( AMGN )  Is a Trending Stock: Facts to Know Before Betting on It",
    "url": "https://www.zacks.com/stock/news/2300630/amgen-inc-amgn-is-a-trending-stock-facts-to-know-before-betting-on-it",
    "time_published": "20240712T130011",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default138.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.241536,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.48028",
        "ticker_sentiment_score": "0.154018",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "This Deeply Discounted CEF Mini-Portfolio Yields 9.2%",
    "url": "https://www.forbes.com/sites/brettowens/2024/07/13/this-deeply-discounted-cef-mini-portfolio-yields-92/",
    "time_published": "20240713T114500",
    "authors": [
      "Brett Owens"
    ],
    "summary": "With the market at nosebleed valuations, where can we look for value and yield? As usual we have a handful of closed-end funds ( CEFs ) getting no love from Wall Street. This is perfect for us as we're talking about dividends up to 14% and discounts between 10% and 15%.",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/66900287d42bde63ce22ca20/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.263411,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.091743",
        "ticker_sentiment_score": "0.034847",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HESG",
        "relevance_score": "0.030641",
        "ticker_sentiment_score": "0.069507",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.061237",
        "ticker_sentiment_score": "0.2697",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.061237",
        "ticker_sentiment_score": "0.2697",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AY",
        "relevance_score": "0.061237",
        "ticker_sentiment_score": "0.115016",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MPLX",
        "relevance_score": "0.061237",
        "ticker_sentiment_score": "0.211133",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.061237",
        "ticker_sentiment_score": "0.029",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.061237",
        "ticker_sentiment_score": "0.029",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PBA",
        "relevance_score": "0.061237",
        "ticker_sentiment_score": "0.115016",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ET",
        "relevance_score": "0.061237",
        "ticker_sentiment_score": "0.211133",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NEE",
        "relevance_score": "0.061237",
        "ticker_sentiment_score": "0.115016",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.091743",
        "ticker_sentiment_score": "0.029515",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Dividend Growth Stocks to Buy and Hold",
    "url": "https://www.fool.com/investing/2024/07/14/3-dividend-growth-stocks-to-buy-and-hold/",
    "time_published": "20240714T103000",
    "authors": [
      "David Jagielski",
      "Keith Speights",
      "and Prosper Junior Bakiny"
    ],
    "summary": "What's better than a dividend? A dividend that's growing.",
    "banner_image": "https://g.foolcdn.com/editorial/images/783166/dividends-blackboard-sketch-doodle.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.928769"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99977"
      }
    ],
    "overall_sentiment_score": 0.369079,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.351184",
        "ticker_sentiment_score": "0.45701",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.351184",
        "ticker_sentiment_score": "0.184731",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.224072",
        "ticker_sentiment_score": "0.12827",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "A Closer Look at Amgen's Options Market Dynamics - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/insights/options/24/07/39780989/a-closer-look-at-amgens-options-market-dynamics",
    "time_published": "20240715T200134",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bullish stance on Amgen AMGN. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.113479,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.74841",
        "ticker_sentiment_score": "0.101524",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.076115",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Will Amgen  ( AMGN )  Beat Estimates Again in Its Next Earnings Report?",
    "url": "https://www.zacks.com/stock/news/2301907/will-amgen-amgn-beat-estimates-again-in-its-next-earnings-report",
    "time_published": "20240715T161014",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default201.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.99989"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.302836,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.421485",
        "ticker_sentiment_score": "0.462963",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Dow Reclaims 40,000 Mark, Surpasses Major Indices: ETFs to Tap",
    "url": "https://www.zacks.com/stock/news/2301739/dow-reclaims-40000-mark-surpasses-major-indices-etfs-to-tap",
    "time_published": "20240715T142300",
    "authors": [
      "Sweta Killa"
    ],
    "summary": "The Dow Jones Industrial Average has finally started to catch up with the rally of 2024 on growing expectations of Fed rates cut this year.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/a1/354.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999953"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      }
    ],
    "overall_sentiment_score": 0.171369,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "C",
        "relevance_score": "0.089797",
        "ticker_sentiment_score": "0.216455",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.089797",
        "ticker_sentiment_score": "0.216455",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CAT",
        "relevance_score": "0.089797",
        "ticker_sentiment_score": "0.160955",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CME",
        "relevance_score": "0.04497",
        "ticker_sentiment_score": "0.028861",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HD",
        "relevance_score": "0.089797",
        "ticker_sentiment_score": "0.160955",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.134339",
        "ticker_sentiment_score": "0.050403",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.089797",
        "ticker_sentiment_score": "0.160955",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings",
    "url": "https://www.zacks.com/stock/news/2301420/want-better-returns-dont-ignore-these-2-medical-stocks-set-to-beat-earnings",
    "time_published": "20240715T125010",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default94.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999855"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.41266,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.378094",
        "ticker_sentiment_score": "0.406873",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "UTHR",
        "relevance_score": "0.257668",
        "ticker_sentiment_score": "0.256882",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "What Is the Dividend Payout for Amgen Stock?",
    "url": "https://www.fool.com/investing/2024/07/15/what-is-the-dividend-payout-for-amgen-stock/",
    "time_published": "20240715T115800",
    "authors": [
      "David Moadel"
    ],
    "summary": "Amgen offers a packed pipeline and healthy dividend distributions.",
    "banner_image": "https://g.foolcdn.com/editorial/images/782853/amgen_amgn_stock_biotech_biotechnology_pharmaceutical_pharma.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.349603,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.852739",
        "ticker_sentiment_score": "0.559184",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split",
    "url": "https://www.fool.com/investing/2024/07/15/stock-split-watch-2-stocks-that-could-split/",
    "time_published": "20240715T081500",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Revenue is climbing at these two drug companies -- and the trend should continue.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F783050%2Fgettyimages-investor-uses-tablet-and-phone.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999998"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999355"
      }
    ],
    "overall_sentiment_score": 0.266356,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.045482",
        "ticker_sentiment_score": "0.205092",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.090816",
        "ticker_sentiment_score": "-0.056158",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.310283",
        "ticker_sentiment_score": "0.203449",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.090816",
        "ticker_sentiment_score": "0.37177",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "CMG",
        "relevance_score": "0.045482",
        "ticker_sentiment_score": "0.205092",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.045482",
        "ticker_sentiment_score": "0.059207",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.045482",
        "ticker_sentiment_score": "0.059207",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.045482",
        "ticker_sentiment_score": "0.059207",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.045482",
        "ticker_sentiment_score": "0.205092",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Unpacking the Latest Options Trading Trends in Amgen - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/insights/options/24/07/39797396/unpacking-the-latest-options-trading-trends-in-amgen",
    "time_published": "20240716T150132",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Financial giants have made a conspicuous bearish move on Amgen. Our analysis of options history for Amgen AMGN revealed 18 unusual trades. Delving into the details, we found 22% of traders were bullish, while 38% showed bearish tendencies.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.12863,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.787116",
        "ticker_sentiment_score": "-0.036034",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.082677",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings",
    "url": "https://www.zacks.com/stock/news/2302294/want-better-returns-dont-ignore-these-2-medical-stocks-set-to-beat-earnings",
    "time_published": "20240716T125011",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default158.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.292502,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.263942",
        "ticker_sentiment_score": "0.228078",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "RXRX",
        "relevance_score": "0.386875",
        "ticker_sentiment_score": "0.332192",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly, Novo Nordisk Fall On Rival's Weight-Loss Drug",
    "url": "https://www.investors.com/news/technology/eli-lilly-novo-nordisk-fall-roche-weight-loss-drug/",
    "time_published": "20240717T121000",
    "authors": [
      "ED CARSON",
      "Investor's Business Daily"
    ],
    "summary": "Eli Lilly ( LLY ) and Novo Nordisk ( NVO ) fell early Wednesday as Roche released positive early-stage data for its oral weight-loss drug. Roche's Genentech unit said its GLP-1 treatment CT-996 led to 6% weight loss within four weeks of a Phase 1 trial.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2020/10/Stock-EliLilly-03-shutt.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      }
    ],
    "overall_sentiment_score": -0.09579,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.7887",
        "ticker_sentiment_score": "-0.23967",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.546745",
        "ticker_sentiment_score": "-0.668568",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.546745",
        "ticker_sentiment_score": "-0.668568",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.7887",
        "ticker_sentiment_score": "-0.23967",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Amgen  ( AMGN )  Dips More Than Broader Market: What You Should Know",
    "url": "https://www.zacks.com/stock/news/2304907/amgen-amgn-dips-more-than-broader-market-what-you-should-know",
    "time_published": "20240718T220018",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the closing of the recent trading day, Amgen (AMGN) stood at $330.97, denoting a -1.4% change from the preceding trading day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default113.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.986564"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.159035,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.478198",
        "ticker_sentiment_score": "0.074463",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Q2 Earnings Season Scorecard, Economic Outlook and Analyst Reports for NVIDIA, Meta & Others",
    "url": "https://www.zacks.com/research-daily/2304617/q2-earnings-season-scorecard-economic-outlook-and-analyst-reports-for-nvidia-meta-others",
    "time_published": "20240718T170200",
    "authors": [
      "Sheraz Mian"
    ],
    "summary": "Today's Research Daily features the Q2 earnings season scorecard and fresh research reports on NVIDIA (NVDA), Meta (META), Amgen and others.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default60.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999606"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.207178,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.137148",
        "ticker_sentiment_score": "0.278446",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.091684",
        "ticker_sentiment_score": "0.125142",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.091684",
        "ticker_sentiment_score": "0.135864",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KEY",
        "relevance_score": "0.045918",
        "ticker_sentiment_score": "0.08366",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen  ( AMGN )  Ascends While Market Falls: Some Facts to Note",
    "url": "https://www.zacks.com/stock/news/2305632/amgen-amgn-ascends-while-market-falls-some-facts-to-note",
    "time_published": "20240719T215016",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) concluded the recent trading session at $331.29, signifying a +0.1% move from its prior day's close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default137.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.986564"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.133941,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.613743",
        "ticker_sentiment_score": "0.20022",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog NVIDIA, Meta and Amgen Galaxy Gaming",
    "url": "https://www.zacks.com/stock/news/2304967/the-zacks-analyst-blog-nvidia-meta-and-amgen-galaxy-gaming",
    "time_published": "20240719T084400",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "NVIDIA, Meta and Amgen Galaxy Gaming are included in this Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/93/534.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.839681"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.231553,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.247838",
        "ticker_sentiment_score": "0.144868",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.295273",
        "ticker_sentiment_score": "0.25907",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.199447",
        "ticker_sentiment_score": "0.035706",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "10 Best Dividend Growth Stocks to Buy and Hold Forever",
    "url": "https://www.fool.com/investing/2024/07/21/10-best-dividend-growth-stocks-to-buy-and-hold-for/",
    "time_published": "20240721T143000",
    "authors": [
      "George Budwell"
    ],
    "summary": "Discover 10 dividend growth powerhouses that could turbocharge your portfolio's long-term performance.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F784033%2Fdividend-bank-roll.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.803643"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.414524,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TGT",
        "relevance_score": "0.142847",
        "ticker_sentiment_score": "0.313895",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.095517",
        "ticker_sentiment_score": "0.088064",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NDSN",
        "relevance_score": "0.142847",
        "ticker_sentiment_score": "0.248651",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "V",
        "relevance_score": "0.142847",
        "ticker_sentiment_score": "0.31512",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PH",
        "relevance_score": "0.095517",
        "ticker_sentiment_score": "0.288706",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NKE",
        "relevance_score": "0.095517",
        "ticker_sentiment_score": "0.264207",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.095517",
        "ticker_sentiment_score": "0.175948",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.142847",
        "ticker_sentiment_score": "0.103087",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.142847",
        "ticker_sentiment_score": "0.189064",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "What's in Store for ADMA Biologics  ( ADMA )  in Q2 Earnings?",
    "url": "https://www.zacks.com/stock/news/2306129/whats-in-store-for-adma-biologics-adma-in-q2-earnings",
    "time_published": "20240722T143100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "On ADMA Biologics' (ADMA) second-quarter 2024 earnings call, investors are likely to focus on the sales performance of its marketed products, Bivigam, Asceniv and Nabi-HB.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/37/2337.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.224754,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ADMA",
        "relevance_score": "0.692877",
        "ticker_sentiment_score": "0.424301",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "CRSP",
        "relevance_score": "0.151858",
        "ticker_sentiment_score": "0.043085",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADVM",
        "relevance_score": "0.250386",
        "ticker_sentiment_score": "0.029307",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.298264",
        "ticker_sentiment_score": "0.07663",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Beat the Market Like Zacks: Karooooo, UnitedHealth, Amgen in Focus",
    "url": "https://www.zacks.com/stock/news/2305893/beat-the-market-like-zacks-karooooo-unitedhealth-amgen-in-focus",
    "time_published": "20240722T121000",
    "authors": [
      "Abhinab Dasgupta"
    ],
    "summary": "Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/16/2258.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.977154"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.972193"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.170338,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KARO",
        "relevance_score": "0.066139",
        "ticker_sentiment_score": "0.241876",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ELUT",
        "relevance_score": "0.066139",
        "ticker_sentiment_score": "0.252957",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SFM",
        "relevance_score": "0.066139",
        "ticker_sentiment_score": "0.12425",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MMM",
        "relevance_score": "0.066139",
        "ticker_sentiment_score": "0.061217",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.066139",
        "ticker_sentiment_score": "0.106191",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JXNFL",
        "relevance_score": "0.033098",
        "ticker_sentiment_score": "0.232757",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VIRT",
        "relevance_score": "0.066139",
        "ticker_sentiment_score": "0.089143",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HBI",
        "relevance_score": "0.066139",
        "ticker_sentiment_score": "0.201612",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.066139",
        "ticker_sentiment_score": "0.061217",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FICO",
        "relevance_score": "0.099066",
        "ticker_sentiment_score": "0.112411",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NTLA",
        "relevance_score": "0.066139",
        "ticker_sentiment_score": "0.089143",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Geron  ( GERN )  to Report Q2 Earnings: What's in the Cards?",
    "url": "https://www.zacks.com/stock/news/2307196/geron-gern-to-report-q2-earnings-whats-in-the-cards",
    "time_published": "20240723T151300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Geron (GERN) is expected to primarily provide updates regarding the launch of its newly approved hematologic malignancy drug, Rytelo, in the United States when it reports second-quarter earnings.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/86/60216.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999973"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.115312,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AGEN",
        "relevance_score": "0.230454",
        "ticker_sentiment_score": "-0.107261",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GERN",
        "relevance_score": "0.651499",
        "ticker_sentiment_score": "0.187922",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ADVM",
        "relevance_score": "0.230454",
        "ticker_sentiment_score": "0.027482",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.274834",
        "ticker_sentiment_score": "0.065725",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is a Beat in the Cards for CRISPR  ( CRSP )  in Q2 Earnings?",
    "url": "https://www.zacks.com/stock/news/2307037/is-a-beat-in-the-cards-for-crispr-crsp-in-q2-earnings",
    "time_published": "20240723T134800",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "On CRISPR Therapeutics' (CRSP) second-quarter 2024 earnings call, investors' focus is likely to be on the sales numbers of its newly approved gene therapy, Casgevy, and other pipeline updates.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999992"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.167396,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.116631",
        "ticker_sentiment_score": "0.201145",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CRSP",
        "relevance_score": "0.340134",
        "ticker_sentiment_score": "0.024504",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADVM",
        "relevance_score": "0.286193",
        "ticker_sentiment_score": "0.030376",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.340134",
        "ticker_sentiment_score": "0.1555",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Amgen Inc.  ( AMGN )  is Attracting Investor Attention: Here is What You Should Know",
    "url": "https://www.zacks.com/stock/news/2306723/amgen-inc-amgn-is-attracting-investor-attention-here-is-what-you-should-know",
    "time_published": "20240723T130011",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default81.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.235134,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.482078",
        "ticker_sentiment_score": "0.139729",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "What Lies in Store for Healthcare ETFs in Q2 Earnings?",
    "url": "https://www.zacks.com/stock/news/2308035/what-lies-in-store-for-healthcare-etfs-in-q2-earnings",
    "time_published": "20240724T150000",
    "authors": [
      "Sweta Killa"
    ],
    "summary": "The healthcare sector has gained momentum lately on market rotation, with investors rushing to buy beaten-down stocks while shunning the hot technology sector.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d7/2961.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980716"
      }
    ],
    "overall_sentiment_score": 0.169447,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.228073",
        "ticker_sentiment_score": "0.052088",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "0.016864",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.228073",
        "ticker_sentiment_score": "0.082674",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.228073",
        "ticker_sentiment_score": "0.142692",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.007802",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is a Beat in the Cards for Incyte  ( INCY )  in Q2 Earnings?",
    "url": "https://www.zacks.com/stock/news/2307992/is-a-beat-in-the-cards-for-incyte-incy-in-q2-earnings",
    "time_published": "20240724T142600",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "On Incyte's (INCY) second-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its lead drug, Jakafi, which has been facing stiff competition.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5d/2633.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999994"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.214583,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "INCY",
        "relevance_score": "0.674691",
        "ticker_sentiment_score": "0.301406",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MOR",
        "relevance_score": "0.049019",
        "ticker_sentiment_score": "0.190032",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.146321",
        "ticker_sentiment_score": "0.137649",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADVM",
        "relevance_score": "0.241444",
        "ticker_sentiment_score": "0.028468",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.287762",
        "ticker_sentiment_score": "0.142517",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "What's in Store for Structure Therapeutics  ( GPCR )  in Q2 Earnings?",
    "url": "https://www.zacks.com/stock/news/2307855/whats-in-store-for-structure-therapeutics-gpcr-in-q2-earnings",
    "time_published": "20240724T125500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Structure Therapeutics (GPCR) is expected to provide updates on the developmental pathway of its lead product candidate, GSBR-1290, for diabetes and obesity indications in the Q2 earnings release.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/cf/61649.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999973"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.078527,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AGEN",
        "relevance_score": "0.248343",
        "ticker_sentiment_score": "-0.113847",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GPCR",
        "relevance_score": "0.657566",
        "ticker_sentiment_score": "0.158758",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ADVM",
        "relevance_score": "0.248343",
        "ticker_sentiment_score": "0.029169",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.295867",
        "ticker_sentiment_score": "0.139416",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Regeneron  ( REGN )  to Report Q2 Earnings: What's in the Cards?",
    "url": "https://www.zacks.com/stock/news/2307740/regeneron-regn-to-report-q2-earnings-whats-in-the-cards",
    "time_published": "20240724T123700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when Regeneron (REGN) reports second-quarter 2024 results.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999938"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.208348,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SNDX",
        "relevance_score": "0.137409",
        "ticker_sentiment_score": "0.038014",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.355588",
        "ticker_sentiment_score": "0.368987",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.137409",
        "ticker_sentiment_score": "0.112288",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.182506",
        "ticker_sentiment_score": "0.205096",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Amgen  ( AMGN )  Stock Moves -0.39%: What You Should Know",
    "url": "https://www.zacks.com/stock/news/2309496/amgen-amgn-stock-moves--039-what-you-should-know",
    "time_published": "20240725T220016",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) closed at $334.30 in the latest trading session, marking a -0.39% move from the prior day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default183.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.986564"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.181982,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.463792",
        "ticker_sentiment_score": "0.251768",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Market Whales and Their Recent Bets on AMGN Options - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/insights/options/24/07/39962038/market-whales-and-their-recent-bets-on-amgn-options",
    "time_published": "20240725T150631",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Deep-pocketed investors have adopted a bullish approach towards Amgen AMGN, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1721919988_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.141516,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.824531",
        "ticker_sentiment_score": "0.235656",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.077094",
        "ticker_sentiment_score": "0.096168",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AstraZeneca  ( AZN )  Beats on Q2 Earnings & Sales, Ups '24 View",
    "url": "https://www.zacks.com/stock/news/2309115/astrazeneca-azn-beats-on-q2-earnings-sales-ups-24-view",
    "time_published": "20240725T130500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AstraZeneca (AZN) reports encouraging Q2 results. It also raises its financial guidance for the full year on the back of strong demand for its marketed products.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e5/1416.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.928769"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      }
    ],
    "overall_sentiment_score": 0.141945,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "SKXJF",
        "relevance_score": "0.028903",
        "ticker_sentiment_score": "0.125691",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSKYF",
        "relevance_score": "0.028903",
        "ticker_sentiment_score": "0.125691",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.148029",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.413199",
        "ticker_sentiment_score": "0.141978",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.086556",
        "ticker_sentiment_score": "0.059251",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen  ( AMGN )  Advances But Underperforms Market: Key Facts",
    "url": "https://www.zacks.com/stock/news/2310378/amgen-amgn-advances-but-underperforms-market-key-facts",
    "time_published": "20240726T215018",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the closing of the recent trading day, Amgen (AMGN) stood at $334.85, denoting a +0.16% change from the preceding trading day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default104.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.176386,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.523451",
        "ticker_sentiment_score": "0.271646",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Unpacking the Latest Options Trading Trends in Amgen - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/insights/options/24/07/39985996/unpacking-the-latest-options-trading-trends-in-amgen",
    "time_published": "20240726T143115",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Deep-pocketed investors have adopted a bearish approach towards Amgen AMGN, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1722004272_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.139928,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.706721",
        "ticker_sentiment_score": "0.099234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.076115",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Intellia  ( NTLA )  to Report Q2 Earnings: What's in the Cards?",
    "url": "https://www.zacks.com/stock/news/2310037/intellia-ntla-to-report-q2-earnings-whats-in-the-cards",
    "time_published": "20240726T135800",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "On Intellia's (NTLA) second-quarter 2024 earnings call, investors' focus is likely to be on the progress of its pipeline of genome-editing candidates.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.183146,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KRYS",
        "relevance_score": "0.280938",
        "ticker_sentiment_score": "-0.050712",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.170878",
        "ticker_sentiment_score": "0.289102",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.280938",
        "ticker_sentiment_score": "0.153896",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NTLA",
        "relevance_score": "0.778678",
        "ticker_sentiment_score": "0.336578",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Ginkgo  ( DNA )  to Report Q2 Earnings: What's in the Cards?",
    "url": "https://www.zacks.com/stock/news/2309891/ginkgo-dna-to-report-q2-earnings-whats-in-the-cards",
    "time_published": "20240726T133200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Ginkgo's (DNA) total revenues are likely to have declined in the second quarter, owing to the expected ramp-down of the company's K-12 COVID testing services.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999998"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.02615,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KRYS",
        "relevance_score": "0.313218",
        "ticker_sentiment_score": "-0.055258",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADVM",
        "relevance_score": "0.313218",
        "ticker_sentiment_score": "0.034982",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.371523",
        "ticker_sentiment_score": "0.173609",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DNA",
        "relevance_score": "0.252987",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "What Awaits Biogen  ( BIIB )  in Q2 Earnings Post Leqembi Setback?",
    "url": "https://www.zacks.com/stock/news/2311049/what-awaits-biogen-biib-in-q2-earnings-post-leqembi-setback",
    "time_published": "20240729T143300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Biogen's (BIIB) sales in the second quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have been hurt by increased competition.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.99989"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.101129,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AGEN",
        "relevance_score": "0.197735",
        "ticker_sentiment_score": "-0.095196",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SAGE",
        "relevance_score": "0.079788",
        "ticker_sentiment_score": "0.063067",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.236205",
        "ticker_sentiment_score": "0.058071",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ESALF",
        "relevance_score": "0.236205",
        "ticker_sentiment_score": "0.027936",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.452161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Affimed  ( AFMD )  to Report Q2 Earnings: What's in the Cards?",
    "url": "https://www.zacks.com/stock/news/2310924/affimed-afmd-to-report-q2-earnings-whats-in-the-cards",
    "time_published": "20240729T134800",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "On Affimed's (AFMD) second-quarter 2024 earnings call, investors' focus is likely to be on the progress of its pipeline candidates being developed for various cancer indications.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999997"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.004799,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.288893",
        "ticker_sentiment_score": "0.157371",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AFMD",
        "relevance_score": "0.232996",
        "ticker_sentiment_score": "0.048466",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KRYS",
        "relevance_score": "0.343279",
        "ticker_sentiment_score": "-0.051622",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Bristol Myers, Johnson & Johnson, AbbVie, AstraZeneca Expect Minimal Impact From Upcoming Medicare Price Negotiations - AstraZeneca  ( NASDAQ:AZN ) , Johnson & Johnson  ( NYSE:JNJ ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/07/40047654/bristol-myers-johnson-johnson-abbvie-astrazeneca-expect-minimal-impact-from-upcoming-medicare-pri",
    "time_published": "20240730T181215",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Four major pharmaceutical companies involved in the first U.S. negotiations over Medicare drug prices expect limited business impact despite anticipated price cuts.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/30/BristolMeyersSquibb-Courtesyof-02-LVL-Ex.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.047931,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.346884",
        "ticker_sentiment_score": "0.130231",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.177802",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.263942",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.177802",
        "ticker_sentiment_score": "0.307811",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.177802",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.177802",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "$100 Invested In This Stock 20 Years Ago Would Be Worth $600 Today - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/insights/news/24/07/40046129/100-invested-in-this-stock-20-years-ago-would-be-worth-600-today",
    "time_published": "20240730T170327",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Amgen AMGN has outperformed the market over the past 20 years by 1.11% on an annualized basis producing an average annual return of 9.55%. Currently, Amgen has a market capitalization of $179.00 billion.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1722359004_0.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.238974,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.95919",
        "ticker_sentiment_score": "0.384695",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Amgen  ( AMGN )  Expected to Beat Earnings Estimates: Should You Buy?",
    "url": "https://www.zacks.com/stock/news/2312017/amgen-amgn-expected-to-beat-earnings-estimates-should-you-buy",
    "time_published": "20240730T140117",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default200.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.153888,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TNGX",
        "relevance_score": "0.173645",
        "ticker_sentiment_score": "-0.002833",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.257895",
        "ticker_sentiment_score": "0.16312",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Should You Invest in the iShares Biotechnology ETF? - First Trust Amex Biotech Index Fund  ( ARCA:FBT ) , Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/general/biotech/24/07/40064786/should-you-invest-in-the-ishares-biotechnology-etf",
    "time_published": "20240731T174834",
    "authors": [
      "Zacks"
    ],
    "summary": "Designed to provide broad exposure to the Healthcare - Biotech segment of the equity market, the iShares Biotechnology ETF IBB is a passively managed exchange traded fund launched on 02/05/2001.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/31/louis-reed-pwckf7l4-no-unsplash.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999994"
      }
    ],
    "overall_sentiment_score": 0.264116,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.072435",
        "ticker_sentiment_score": "0.034181",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.144275",
        "ticker_sentiment_score": "0.117832",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.144275",
        "ticker_sentiment_score": "0.117832",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.144275",
        "ticker_sentiment_score": "0.117832",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Can Amgen  ( AMGN )  Keep the Beat Streak Alive in Q2 Earnings?",
    "url": "https://www.zacks.com/stock/news/2312933/can-amgen-amgn-keep-the-beat-streak-alive-in-q2-earnings",
    "time_published": "20240731T133000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f4/2111.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.99998"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.115939,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "APLS",
        "relevance_score": "0.222327",
        "ticker_sentiment_score": "-0.135101",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMRN",
        "relevance_score": "0.222327",
        "ticker_sentiment_score": "-0.005121",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXEL",
        "relevance_score": "0.328091",
        "ticker_sentiment_score": "-0.187906",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.328091",
        "ticker_sentiment_score": "0.282693",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "How to Find Strong Medical Stocks Slated for Positive Earnings Surprises",
    "url": "https://www.zacks.com/stock/news/2312755/how-to-find-strong-medical-stocks-slated-for-positive-earnings-surprises",
    "time_published": "20240731T125011",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default10.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999855"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      }
    ],
    "overall_sentiment_score": 0.391247,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "RMD",
        "relevance_score": "0.313218",
        "ticker_sentiment_score": "0.262514",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.313218",
        "ticker_sentiment_score": "0.322984",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Should You Invest in the iShares Biotechnology ETF  ( IBB ) ?",
    "url": "https://www.zacks.com/stock/news/2312595/should-you-invest-in-the-ishares-biotechnology-etf-ibb",
    "time_published": "20240731T102007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default110.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.236543,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.070105",
        "ticker_sentiment_score": "0.034114",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.139669",
        "ticker_sentiment_score": "0.072917",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.139669",
        "ticker_sentiment_score": "0.072917",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.139669",
        "ticker_sentiment_score": "0.072917",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen  ( AMGN )  Advances While Market Declines: Some Information for Investors",
    "url": "https://www.zacks.com/stock/news/2314714/amgen-amgn-advances-while-market-declines-some-information-for-investors",
    "time_published": "20240801T215006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) closed at $335.53 in the latest trading session, marking a +0.92% move from the prior day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default255.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.986564"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.165584,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.472338",
        "ticker_sentiment_score": "0.125096",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Exploring Analyst Estimates for Amgen  ( AMGN )  Q2 Earnings, Beyond Revenue and EPS",
    "url": "https://www.zacks.com/stock/news/2314047/exploring-analyst-estimates-for-amgen-amgn-q2-earnings-beyond-revenue-and-eps",
    "time_published": "20240801T131524",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Amgen (AMGN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default186.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.986564"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.111124,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.354572",
        "ticker_sentiment_score": "0.118407",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should Schwab U.S. Dividend Equity ETF  ( SCHD )  Be on Your Investing Radar?",
    "url": "https://www.zacks.com/stock/news/2313767/should-schwab-us-dividend-equity-etf-schd-be-on-your-investing-radar",
    "time_published": "20240801T102006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Style Box ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default292.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.219835,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "HD",
        "relevance_score": "0.11894",
        "ticker_sentiment_score": "0.061867",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.11894",
        "ticker_sentiment_score": "0.061867",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SCHW",
        "relevance_score": "0.059636",
        "ticker_sentiment_score": "0.124001",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen's Options: A Look at What the Big Money is Thinking - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/insights/options/24/08/40140701/amgens-options-a-look-at-what-the-big-money-is-thinking",
    "time_published": "20240802T194822",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Deep-pocketed investors have adopted a bearish approach towards Amgen AMGN, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1722628100_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.102011,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.815336",
        "ticker_sentiment_score": "0.141328",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.081276",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Prediction: This Could Be Amgen's Next Massive Growth Opportunity",
    "url": "https://www.fool.com/investing/2024/08/02/prediction-this-could-be-amgen-stocks-next-massive/",
    "time_published": "20240802T120000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "The innovative biotech is looking for its next blockbuster.",
    "banner_image": "https://g.foolcdn.com/editorial/images/784305/doctor-with-patient-talking.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.332323,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.127795",
        "ticker_sentiment_score": "0.258659",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.57877",
        "ticker_sentiment_score": "0.415944",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.127795",
        "ticker_sentiment_score": "0.258659",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Is First Trust Dow 30 Equal Weight ETF  ( EDOW )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2314912/is-first-trust-dow-30-equal-weight-etf-edow-a-strong-etf-right-now",
    "time_published": "20240802T102006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default151.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999919"
      }
    ],
    "overall_sentiment_score": 0.23718,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.118064",
        "ticker_sentiment_score": "0.054927",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here are 4 things we're watching closely in the stock market this week",
    "url": "https://www.cnbc.com/2024/08/04/here-are-4-things-were-watching-closely-in-the-stock-market-this-week.html",
    "time_published": "20240804T135944",
    "authors": [],
    "summary": "Expect earnings reports, and CEO commentaries, to drive the market action.",
    "banner_image": null,
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.98396"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.947132"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.142857"
      }
    ],
    "overall_sentiment_score": 0.007224,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "APP",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MPC",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.097835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ROAD",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RIVN",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WYNN",
        "relevance_score": "0.082582",
        "ticker_sentiment_score": "0.004136",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GLW",
        "relevance_score": "0.027571",
        "ticker_sentiment_score": "0.090183",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MPW",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.094835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KVUE",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.097835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UPST",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CEG",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.097835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARRY",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.164881",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ILMN",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.027571",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BROS",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCO",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "-0.056855",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ZI",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FTNT",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VST",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.094835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FSLY",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ERJ",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HUBS",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HOOD",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CELH",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.097835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVS",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "-0.056855",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HIMS",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BLDR",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.097835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DDOG",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.094835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXON",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RKLB",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.164881",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HIMX",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.094835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "O",
        "relevance_score": "0.027571",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SG",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.164881",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BCRX",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ZTS",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.097835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ACMR",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "-0.056855",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SN",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.094835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CGC",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PLTR",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ACB",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "-0.056855",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RDDT",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "APPS",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VMC",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.097835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SEDG",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OSCR",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "-0.056855",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OGN",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.097835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GXO",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.097835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SRPT",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "-0.056855",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DNUT",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.094835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABNB",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPG",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NFE",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DT",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "-0.056855",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRON",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.094835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OXY",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VFC",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PZZA",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.094835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMD",
        "relevance_score": "0.027571",
        "ticker_sentiment_score": "0.054424",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FIVN",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.164881",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "YUMC",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CLSK",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.164881",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MNKD",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "-0.056855",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMR",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EMR",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "-0.056855",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PLUG",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.094835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ASPN",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSN",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ET",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNEJF",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "-0.056855",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "YUM",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.097835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAR",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WYNMF",
        "relevance_score": "0.027571",
        "ticker_sentiment_score": "0.004759",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAT",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.097835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.027571",
        "ticker_sentiment_score": "0.054424",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PARA",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.164881",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TTD",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.164881",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LUMN",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXSM",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BNTX",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SHOP",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "-0.056855",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TDC",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SOUN",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.164881",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "OC",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.097835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NKLA",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.082582",
        "ticker_sentiment_score": "0.090235",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DUK",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.097835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVAX",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.094835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UBER",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.097835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KRYS",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PLNT",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.097835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CSX",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FRPT",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LCID",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MGNI",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAX",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.097835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CPNG",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GCT",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.164881",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DVN",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:GBP",
        "relevance_score": "0.027571",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?",
    "url": "https://www.zacks.com/stock/news/2316241/will-these-5-medical-stocks-surpass-q2-earnings-forecasts",
    "time_published": "20240805T153600",
    "authors": [
      "Kanishka Das"
    ],
    "summary": "Let's look at five biotech and drug companies, AMGN, GILD, LLY, VTRS & NVO, due to release their second-quarter 2024 results this week.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e6/2070.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.203258,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.035555",
        "ticker_sentiment_score": "0.023124",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.244987",
        "ticker_sentiment_score": "0.038677",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VTRS",
        "relevance_score": "0.278618",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.210884",
        "ticker_sentiment_score": "0.050423",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.035555",
        "ticker_sentiment_score": "0.023124",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.244987",
        "ticker_sentiment_score": "-0.009196",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.244987",
        "ticker_sentiment_score": "0.126514",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.035555",
        "ticker_sentiment_score": "0.023124",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the Invesco Pharmaceuticals ETF  ( PJP ) ?",
    "url": "https://www.zacks.com/stock/news/2315688/should-you-invest-in-the-invesco-pharmaceuticals-etf-pjp",
    "time_published": "20240805T102007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default265.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.196134,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.129866",
        "ticker_sentiment_score": "0.070234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.193723",
        "ticker_sentiment_score": "0.118569",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.129866",
        "ticker_sentiment_score": "0.070234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.129866",
        "ticker_sentiment_score": "0.070234",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Good Stocks, Strategic Options, and a 4.5% Yield: There's a Lot to Like About This Unique ETF",
    "url": "https://www.fool.com/investing/2024/08/05/good-stocks-options-45-yield-etf-divo-amplify/",
    "time_published": "20240805T081000",
    "authors": [
      "Reuben Gregg Brewer"
    ],
    "summary": "Covered calls can generate income from an investment portfolio but can be complex. This Amplify ETF is a simple solution.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F785306%2F22_12_26-a-happy-person-with-money-raining-down-around-them-_mf-dload.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.383209,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "HD",
        "relevance_score": "0.041682",
        "ticker_sentiment_score": "0.121165",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.041682",
        "ticker_sentiment_score": "0.121165",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.041682",
        "ticker_sentiment_score": "0.121165",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "V",
        "relevance_score": "0.083251",
        "ticker_sentiment_score": "0.199504",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CAT",
        "relevance_score": "0.041682",
        "ticker_sentiment_score": "0.121165",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen  ( AMGN )  Q2 Earnings and Revenues Beat Estimates",
    "url": "https://www.zacks.com/stock/news/2317350/amgen-amgn-q2-earnings-and-revenues-beat-estimates",
    "time_published": "20240806T211511",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) delivered earnings and revenue surprises of 0.81% and 0.98%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default28.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999992"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.171016,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.40348",
        "ticker_sentiment_score": "0.209175",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TCRX",
        "relevance_score": "0.208764",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Wall Street Rebounds After Selloff, VIX Falls, Dollar Surges Against Yen: What's Driving Markets Tuesday? - Airbnb  ( NASDAQ:ABNB ) ",
    "url": "https://www.benzinga.com/markets/cryptocurrency/24/08/40199294/wall-street-rebounds-after-selloff-vix-falls-dollar-surges-against-yen-whats-driving-marke",
    "time_published": "20240806T182926",
    "authors": [
      "Piero Cingari"
    ],
    "summary": "U.S. stock markets saw a strong recovery on Tuesday, with both the S&P 500 and the Nasdaq 100 climbing over 2%, nearly offsetting Monday's losses. Investors took advantage of recent volatility to buy the dip, showing continued confidence in the U.S. economy's ability to avoid a recession.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/06/Wall-Street.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.988915"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.142857"
      }
    ],
    "overall_sentiment_score": 0.115637,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "TAP",
        "relevance_score": "0.127795",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TRIP",
        "relevance_score": "0.127795",
        "ticker_sentiment_score": "-0.049883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADTN",
        "relevance_score": "0.127795",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXPD",
        "relevance_score": "0.127795",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GPRO",
        "relevance_score": "0.127795",
        "ticker_sentiment_score": "-0.049883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RIVN",
        "relevance_score": "0.127795",
        "ticker_sentiment_score": "-0.049883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WYNN",
        "relevance_score": "0.127795",
        "ticker_sentiment_score": "-0.049883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABNB",
        "relevance_score": "0.127795",
        "ticker_sentiment_score": "-0.049883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.064104",
        "ticker_sentiment_score": "0.248578",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.127795",
        "ticker_sentiment_score": "-0.049883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRUS",
        "relevance_score": "0.127795",
        "ticker_sentiment_score": "-0.049883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TDC",
        "relevance_score": "0.127795",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PLTR",
        "relevance_score": "0.127795",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.127795",
        "ticker_sentiment_score": "0.303026",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.127795",
        "ticker_sentiment_score": "-0.074652",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CEG",
        "relevance_score": "0.127795",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RDDT",
        "relevance_score": "0.127795",
        "ticker_sentiment_score": "-0.049883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ILMN",
        "relevance_score": "0.127795",
        "ticker_sentiment_score": "-0.049883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.127795",
        "ticker_sentiment_score": "-0.049883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BOX",
        "relevance_score": "0.064104",
        "ticker_sentiment_score": "-0.043018",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RUN",
        "relevance_score": "0.127795",
        "ticker_sentiment_score": "-0.049883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ZI",
        "relevance_score": "0.127795",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FTNT",
        "relevance_score": "0.127795",
        "ticker_sentiment_score": "-0.049883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CPNG",
        "relevance_score": "0.127795",
        "ticker_sentiment_score": "-0.049883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXEL",
        "relevance_score": "0.127795",
        "ticker_sentiment_score": "-0.049883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DVN",
        "relevance_score": "0.127795",
        "ticker_sentiment_score": "-0.049883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JACK",
        "relevance_score": "0.127795",
        "ticker_sentiment_score": "-0.049883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:JPY",
        "relevance_score": "0.064104",
        "ticker_sentiment_score": "-0.109358",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.190667",
        "ticker_sentiment_score": "-0.186823",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.127795",
        "ticker_sentiment_score": "-0.186908",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Amgen Gears Up For Q2 Print; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/news/earnings/24/08/40194812/amgen-gears-up-for-q2-print-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call",
    "time_published": "20240806T154211",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "Amgen Inc. AMGN is expected to release earnings results for its second quarter, after the closing bell on Tuesday, Aug. 6. Analysts expect the Thousand Oaks, California-based company to report quarterly earnings at $5.01 per share, up slightly from $5.00 per share in the year-ago quarter.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/06/Amgen-stock.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.197117,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.575055",
        "ticker_sentiment_score": "0.258469",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.126784",
        "ticker_sentiment_score": "-0.083396",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.126784",
        "ticker_sentiment_score": "0.17451",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why Nasdaq, S&P 500 Futures Are Ripping Higher - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , SPDR S&P 500  ( ARCA:SPY ) ",
    "url": "https://www.benzinga.com/news/earnings/24/08/40183965/us-stocks-set-to-open-higher-after-mondays-crash-vix-plummets-analyst-says-would-have-worried-if-ma",
    "time_published": "20240806T111859",
    "authors": [
      "Shanthi Rexaline"
    ],
    "summary": "U.S. stocks look to bounce back on Tuesday following an across-the-board sell-off in the previous session. Strategists say all the yen carry trades haven't been unwound yet, which raises the specter of incremental weakness. That said, positive reactions to earnings from tech players such as ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/06/bulls-ai.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.972756"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.055549,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "TAP",
        "relevance_score": "0.084722",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TRIP",
        "relevance_score": "0.084722",
        "ticker_sentiment_score": "-0.043987",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADTN",
        "relevance_score": "0.084722",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXPD",
        "relevance_score": "0.084722",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GPRO",
        "relevance_score": "0.084722",
        "ticker_sentiment_score": "-0.043987",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KLG",
        "relevance_score": "0.084722",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "H",
        "relevance_score": "0.084722",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RIVN",
        "relevance_score": "0.084722",
        "ticker_sentiment_score": "-0.043987",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WYNN",
        "relevance_score": "0.084722",
        "ticker_sentiment_score": "-0.043987",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABNB",
        "relevance_score": "0.084722",
        "ticker_sentiment_score": "-0.043987",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.084722",
        "ticker_sentiment_score": "-0.043987",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRUS",
        "relevance_score": "0.084722",
        "ticker_sentiment_score": "-0.043987",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TDC",
        "relevance_score": "0.084722",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GFS",
        "relevance_score": "0.084722",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DUK",
        "relevance_score": "0.084722",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "YUMC",
        "relevance_score": "0.084722",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UBER",
        "relevance_score": "0.084722",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WT",
        "relevance_score": "0.042421",
        "ticker_sentiment_score": "0.015921",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PLTR",
        "relevance_score": "0.084722",
        "ticker_sentiment_score": "0.067485",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVTS",
        "relevance_score": "0.126784",
        "ticker_sentiment_score": "0.042229",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CEG",
        "relevance_score": "0.084722",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RDDT",
        "relevance_score": "0.084722",
        "ticker_sentiment_score": "-0.043987",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ILMN",
        "relevance_score": "0.084722",
        "ticker_sentiment_score": "-0.043987",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.084722",
        "ticker_sentiment_score": "-0.043987",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BOX",
        "relevance_score": "0.042421",
        "ticker_sentiment_score": "-0.041758",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RUN",
        "relevance_score": "0.084722",
        "ticker_sentiment_score": "-0.043987",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOX",
        "relevance_score": "0.042421",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ZI",
        "relevance_score": "0.084722",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "YUM",
        "relevance_score": "0.084722",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LCID",
        "relevance_score": "0.084722",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FTNT",
        "relevance_score": "0.084722",
        "ticker_sentiment_score": "-0.043987",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAT",
        "relevance_score": "0.084722",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CPNG",
        "relevance_score": "0.084722",
        "ticker_sentiment_score": "-0.043987",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXEL",
        "relevance_score": "0.084722",
        "ticker_sentiment_score": "-0.043987",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DVN",
        "relevance_score": "0.084722",
        "ticker_sentiment_score": "-0.043987",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JACK",
        "relevance_score": "0.084722",
        "ticker_sentiment_score": "-0.043987",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:JPY",
        "relevance_score": "0.042421",
        "ticker_sentiment_score": "0.064239",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.084722",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Invesco Large Cap Value ETF  ( PWV )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2316605/is-invesco-large-cap-value-etf-pwv-a-strong-etf-right-now",
    "time_published": "20240806T102007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default63.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999996"
      }
    ],
    "overall_sentiment_score": 0.319842,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.115509",
        "ticker_sentiment_score": "0.066729",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.115509",
        "ticker_sentiment_score": "0.066729",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.172507",
        "ticker_sentiment_score": "0.277231",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.115509",
        "ticker_sentiment_score": "0.066729",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Does Pfizer's Next 35% Rally Begin Today?",
    "url": "https://moneymorning.com/2024/08/07/does-pfizers-next-35-rally-begin-today/",
    "time_published": "20240807T185855",
    "authors": [
      "Nick Riso"
    ],
    "summary": "The market began strong this morning... and by this afternoon, we flipped into the red zone. Will it be sustained? Who knows... and honestly, who cares. There'll be enough money to make in the stock market ( or crypto, bonds, options, forex, or futures ) every day, whether we're up 20% or down ...",
    "banner_image": "",
    "source": "Money Morning",
    "category_within_source": "RSS",
    "source_domain": "moneymorning.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.294504,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SU",
        "relevance_score": "0.229149",
        "ticker_sentiment_score": "0.203472",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CTVA",
        "relevance_score": "0.229149",
        "ticker_sentiment_score": "0.203472",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FTNT",
        "relevance_score": "0.229149",
        "ticker_sentiment_score": "0.203472",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.229149",
        "ticker_sentiment_score": "0.203472",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CTSH",
        "relevance_score": "0.229149",
        "ticker_sentiment_score": "0.203472",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ARM",
        "relevance_score": "0.337811",
        "ticker_sentiment_score": "0.271977",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.229149",
        "ticker_sentiment_score": "0.203472",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.337811",
        "ticker_sentiment_score": "0.271977",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Amgen's Mixed Q2 Results Highlight Obesity Drug Potential, Analysts Focus Shifts To Upcoming Clinical Readouts - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40229568/amgens-mixed-q2-results-highlight-obesity-drug-potential-analysts-focus-shifts-to-u",
    "time_published": "20240807T180122",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Tuesday, Amgen Inc. AMGN reported mixed second-quarter results. BMO Capital Markets writes, \"A commercially in-line quarter for Amgen underscores the importance of upcoming clinical readouts in obesity and inflammatory disease.\" The analyst keeps the Outperform rating with a price target of $362.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/07/Amgen-stock_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.196991,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.10607",
        "ticker_sentiment_score": "0.128865",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.576289",
        "ticker_sentiment_score": "0.245667",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why Amgen Stock Is Down Today Despite Solid Q2 Results",
    "url": "https://www.fool.com/investing/2024/08/07/why-amgen-stock-is-down-today-despite-solid-q2-res/",
    "time_published": "20240807T171129",
    "authors": [
      "James Brumley"
    ],
    "summary": "Shares may have been likely to fall no matter what the company reported.",
    "banner_image": "https://g.foolcdn.com/editorial/images/786319/investment-analyst.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.938793"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.095952,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.521465",
        "ticker_sentiment_score": "0.039645",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.09402",
        "ticker_sentiment_score": "-0.105542",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.09402",
        "ticker_sentiment_score": "0.138331",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen Faces Near-Term Challenges But Long-Term Growth Prospects Remain Strong: Analyst - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40222508/amgen-faces-near-term-challenges-but-long-term-growth-prospects-remain-strong-analy",
    "time_published": "20240807T140624",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Tuesday, Amgen Inc. AMGN reported second-quarter sales of $8.39 billion, up 20% year over year and beating the consensus of $8.33 billion. Product sales grew 20%, driven by 26% volume growth, partially offset by a 3% lower net selling price.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/07/Amgen-stock.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.251431,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.550532",
        "ticker_sentiment_score": "0.372594",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Amgen  ( AMGN )  Stock Down Despite Q2 Earnings & Sales Beat",
    "url": "https://www.zacks.com/stock/news/2318113/amgen-amgn-stock-down-despite-q2-earnings-sales-beat",
    "time_published": "20240807T135500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) beats second-quarter 2024 estimates for earnings and sales. It tightens its revenue and earnings guidance range for 2024. Stock falls.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/62/5473.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.972476"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.127984,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.057284",
        "ticker_sentiment_score": "0.051998",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.482178",
        "ticker_sentiment_score": "0.207457",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.142565",
        "ticker_sentiment_score": "0.266893",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.057284",
        "ticker_sentiment_score": "0.051998",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "89bio Appoints Francis Sarena as Chief Operating Officer",
    "url": "https://www.globenewswire.com/news-release/2024/08/07/2925882/0/en/89bio-Appoints-Francis-Sarena-as-Chief-Operating-Officer.html",
    "time_published": "20240807T120000",
    "authors": [
      "Inc.",
      "89bio"
    ],
    "summary": "SAN FRANCISCO, Aug. 07, 2024 ( GLOBE NEWSWIRE ) -- 89bio, Inc. ( Nasdaq: ETNB ) , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the appointment of ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/b9bcc0cc-5a8f-4148-92e4-e6a6ed503a9c",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.275299,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.042196",
        "ticker_sentiment_score": "0.017635",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PYXS",
        "relevance_score": "0.042196",
        "ticker_sentiment_score": "0.017635",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ETNB",
        "relevance_score": "0.43944",
        "ticker_sentiment_score": "0.334843",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Nasdaq, S&P 500 On Track To Extend Gains: What's Driving Futures Higher - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , SPDR S&P 500  ( ARCA:SPY ) ",
    "url": "https://www.benzinga.com/news/earnings/24/08/40217156/us-stocks-set-to-extend-gains-despite-mixed-earnings-vix-dips-back-toward-pre-sell-off-levels-analy",
    "time_published": "20240807T114533",
    "authors": [
      "Shanthi Rexaline"
    ],
    "summary": "Wall Street could go from strength to strength as the index futures point to another session in the green as investors seek to put the worst behind. Volatility continued to drop, as evidenced by another sharp slide in the CBOE Volatility Index, which is now approaching pre-sell-off levels.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/07/bull-market.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.032079,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.271274",
        "ticker_sentiment_score": "-0.175585",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.271274",
        "ticker_sentiment_score": "0.254045",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FOREX:JPY",
        "relevance_score": "0.137671",
        "ticker_sentiment_score": "-0.267789",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Amgen Options Trading: A Deep Dive into Market Sentiment - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/insights/options/24/08/40256662/amgen-options-trading-a-deep-dive-into-market-sentiment",
    "time_published": "20240808T144703",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bearish stance on Amgen AMGN. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1723128420_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.990999"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.106798,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.720006",
        "ticker_sentiment_score": "0.038538",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.06623",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here's Why Eli Lilly Stock Dropped 12% Last Month",
    "url": "https://www.fool.com/investing/2024/08/08/heres-why-eli-lilly-stock-dropped-12-last-month/",
    "time_published": "20240808T050443",
    "authors": [
      "Ryan Downie"
    ],
    "summary": "News from a competitor gave investors an unwelcome dose of reality.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F786437%2Fgettyimages-1488338820-1201x800-5b2df79.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.183467,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.502207",
        "ticker_sentiment_score": "0.171369",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.067536",
        "ticker_sentiment_score": "0.073495",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.13459",
        "ticker_sentiment_score": "0.105279",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.13459",
        "ticker_sentiment_score": "0.105279",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.200688",
        "ticker_sentiment_score": "0.069927",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.13459",
        "ticker_sentiment_score": "0.105279",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Got the Market Sell-Off Blues? Do These 3 Things Right Now",
    "url": "https://www.fool.com/investing/2024/08/11/got-the-market-sell-off-blues-do-these-3-things-ri/",
    "time_published": "20240811T112800",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "You aren't powerless in the face of what the market throws at you.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F786309%2Finvestor-expresses-regret.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.089522,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.156123",
        "ticker_sentiment_score": "0.01216",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.104455",
        "ticker_sentiment_score": "0.124987",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Smart Money Is Betting Big In AMGN Options - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/insights/options/24/08/40319223/smart-money-is-betting-big-in-amgn-options",
    "time_published": "20240812T164546",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bullish stance on Amgen AMGN. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1723481144_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.151212,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.796338",
        "ticker_sentiment_score": "0.277438",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.067536",
        "ticker_sentiment_score": "-0.179672",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Introducing Jubbonti\u00ae and Wyost\u00ae, the first denosumab biosimilars on the Canadian market - Sandoz Group  ( OTC:SDZNY ) ",
    "url": "https://www.benzinga.com/pressreleases/24/08/g40312197/introducing-jubbonti-and-wyost-the-first-denosumab-biosimilars-on-the-canadian-market",
    "time_published": "20240812T130000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "- Jubbonti\u00ae and Wyost\u00ae are first denosumab biosimilars available in Canada, reflecting the Sandoz Purpose of pioneering access for patients - Jubbonti\u00ae and Wyost\u00ae approved for all indications of respective reference medicines - Sandoz Canada has a leading biosimilars portfolio, with many more in ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/1389ce09-477d-4da8-b87a-03404d01fde6/michelrobidoux-2023-10-04-6105-f-web.jpg",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.230246,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.041975",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here's How to Play Novo Nordisk  ( NVO )  After Q2 Earnings Miss",
    "url": "https://www.zacks.com/stock/news/2321469/heres-how-to-play-novo-nordisk-nvo-after-q2-earnings-miss",
    "time_published": "20240813T153100",
    "authors": [
      "Ahan Chakraborty"
    ],
    "summary": "Novo Nordisk (NVO) is an excellent stock to buy for long-term gains, driven by the stellar performance of its GLP-1 drugs. New investors should utilize the existing opportunity to make an entry.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.9545"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.955357"
      }
    ],
    "overall_sentiment_score": 0.309532,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.147366",
        "ticker_sentiment_score": "0.228021",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.074001",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.596796",
        "ticker_sentiment_score": "0.456144",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.074001",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen Inc.  ( AMGN )  Is a Trending Stock: Facts to Know Before Betting on It",
    "url": "https://www.zacks.com/stock/news/2321173/amgen-inc-amgn-is-a-trending-stock-facts-to-know-before-betting-on-it",
    "time_published": "20240813T130012",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default123.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.222183,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.484798",
        "ticker_sentiment_score": "0.104135",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Eli Lilly  ( LLY )  a Buy Post Stellar Q2 Earnings & Raised View?",
    "url": "https://www.zacks.com/stock/news/2321929/is-eli-lilly-lly-a-buy-post-stellar-q2-earnings-raised-view",
    "time_published": "20240814T133400",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Eli Lilly (LLY) is a great stock to have in one's portfolio currently based on its strong overall financial performance and robust drug pipeline.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99793"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.996675"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.368089,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.575926",
        "ticker_sentiment_score": "0.550738",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.037504",
        "ticker_sentiment_score": "0.105947",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.074926",
        "ticker_sentiment_score": "0.111082",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.074926",
        "ticker_sentiment_score": "0.096786",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.074926",
        "ticker_sentiment_score": "0.187769",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024",
    "url": "https://www.globenewswire.com/news-release/2024/08/15/2931252/0/en/Alvotech-Reports-Record-Revenues-and-Adjusted-EBITDA-for-the-Second-Quarter-and-First-Six-Months-of-2024.html",
    "time_published": "20240815T201500",
    "authors": [
      "Alvotech"
    ],
    "summary": "Alvotech ( NASDAQ: ALVO, or the \"Company\" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported unaudited financial results for the first six months of 2024 and provided a summary of recent corporate highlights.",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999941"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.451494"
      }
    ],
    "overall_sentiment_score": 0.141571,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.011148",
        "ticker_sentiment_score": "0.0851",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.011148",
        "ticker_sentiment_score": "0.0851",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTUS",
        "relevance_score": "0.011148",
        "ticker_sentiment_score": "0.055246",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAYZF",
        "relevance_score": "0.011148",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.022295",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALVO",
        "relevance_score": "0.461321",
        "ticker_sentiment_score": "0.217177",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.011148",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.011148",
        "ticker_sentiment_score": "0.055246",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.011148",
        "ticker_sentiment_score": "0.055246",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.011148",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.011148",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:ISK",
        "relevance_score": "0.022295",
        "ticker_sentiment_score": "0.078729",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:SEK",
        "relevance_score": "0.022295",
        "ticker_sentiment_score": "0.078729",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.022295",
        "ticker_sentiment_score": "0.114565",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024",
    "url": "https://www.globenewswire.com/news-release/2024/08/15/2931251/0/en/Alvotech-Reports-Record-Revenues-and-Adjusted-EBITDA-for-the-Second-Quarter-and-First-Six-Months-of-2024.html",
    "time_published": "20240815T201500",
    "authors": [
      "Alvotech"
    ],
    "summary": "REYKJAVIK, Iceland, Aug. 15, 2024 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO, or the \"Company\" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported unaudited financial results for the first six months of ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999941"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.451494"
      }
    ],
    "overall_sentiment_score": 0.141566,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.011123",
        "ticker_sentiment_score": "0.085082",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.011123",
        "ticker_sentiment_score": "0.085082",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTUS",
        "relevance_score": "0.011123",
        "ticker_sentiment_score": "0.055234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAYZF",
        "relevance_score": "0.011123",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.022243",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALVO",
        "relevance_score": "0.460377",
        "ticker_sentiment_score": "0.21687",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.011123",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.011123",
        "ticker_sentiment_score": "0.055234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.011123",
        "ticker_sentiment_score": "0.055234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.011123",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.011123",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:ISK",
        "relevance_score": "0.022243",
        "ticker_sentiment_score": "0.078708",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:SEK",
        "relevance_score": "0.022243",
        "ticker_sentiment_score": "0.078708",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.022243",
        "ticker_sentiment_score": "0.114538",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "This Healthcare Giant Had 12 Products That Generated Double-Digit Growth Last Quarter and There's Still Many More in the Pipeline",
    "url": "https://www.fool.com/investing/2024/08/17/this-healthcare-giant-had-12-products-that-generat/",
    "time_published": "20240817T102000",
    "authors": [
      "David Jagielski"
    ],
    "summary": "Amgen has many growth opportunities ahead, and it also pays a fairly high dividend.",
    "banner_image": "https://g.foolcdn.com/editorial/images/786767/a-patient-undergoing-a-checkup-at-a-doctors-office.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.744043"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.339636,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.522854",
        "ticker_sentiment_score": "0.562048",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.056674",
        "ticker_sentiment_score": "0.117251",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Dow Jones Dividend Stocks With Above-Average Yields to Buy Now and Hold for at Least a Decade",
    "url": "https://www.fool.com/investing/2024/08/18/2-dow-jones-dividend-stocks-with-above-average-yie/",
    "time_published": "20240818T092500",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "Investors seeking reliable dividend growth want to start with these two members of the Dow Jones Industrial Average.",
    "banner_image": "https://g.foolcdn.com/editorial/images/787460/wall-street-analyst-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.223194,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AWON",
        "relevance_score": "0.057767",
        "ticker_sentiment_score": "0.064039",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.057767",
        "ticker_sentiment_score": "0.064039",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.282886",
        "ticker_sentiment_score": "0.251201",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.282886",
        "ticker_sentiment_score": "0.250221",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Autoinjectors Market Size to Hit USD 3.8 Billion Milestone by 2034 with 16.2% CAGR Growth | Exclusive Report by Transparency Market Research, Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/08/g40437290/autoinjectors-market-size-to-hit-usd-3-8-billion-milestone-by-2034-with-16-2-cagr-growth-exclusive",
    "time_published": "20240819T112542",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Transparency Market Research, Inc., Aug. 19, 2024 ( GLOBE NEWSWIRE ) -- The autoinjectors market ( \u81ea\u52d5\u6ce8\u5c04\u5668\u5e02\u5834 ) value was US$ 1.0 Billion in 2022 and is anticipated to record a CAGR of 16.2% from 2023 to 2031 and surpass US$ 3.8 Billion by the end of 2031.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/0fb3ccc8-a4d0-4b90-9df1-f10a38139af0/autoinjectors-market.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.059466,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.037155",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.111144",
        "ticker_sentiment_score": "0.062477",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MLTX",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.008095",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "YPHDF",
        "relevance_score": "0.037155",
        "ticker_sentiment_score": "0.059229",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.037155",
        "ticker_sentiment_score": "0.059229",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.037155",
        "ticker_sentiment_score": "0.059229",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.111144",
        "ticker_sentiment_score": "0.093941",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.037155",
        "ticker_sentiment_score": "0.059229",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the VanEck Biotech ETF  ( BBH ) ?",
    "url": "https://www.zacks.com/stock/news/2323511/should-you-invest-in-the-vaneck-biotech-etf-bbh",
    "time_published": "20240819T102006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default249.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.186436,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "REGN",
        "relevance_score": "0.135347",
        "ticker_sentiment_score": "0.071708",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.135347",
        "ticker_sentiment_score": "0.071708",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.135347",
        "ticker_sentiment_score": "0.071708",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Nasdaq, S&P 500 Futures Climb After 8-Session Market Rally: What's Going On - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , SPDR S&P 500  ( ARCA:SPY ) ",
    "url": "https://www.benzinga.com/news/earnings/24/08/40457537/us-stocks-may-take-a-breather-after-s-p-500s-impressive-8-session-winning-streak-strategist-says-ma",
    "time_published": "20240820T104809",
    "authors": [
      "Shanthi Rexaline"
    ],
    "summary": "The gravity-defying climb faces risk, as the index futures trade narrowly mixed in early trading on Tuesday. That said, the recent gains could keep traders wary of a potential pullback.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/20/Stocks-Watch--Shutterstock.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.142857"
      }
    ],
    "overall_sentiment_score": 0.041002,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSTR",
        "relevance_score": "0.072765",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDNDF",
        "relevance_score": "0.03642",
        "ticker_sentiment_score": "0.157502",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.03642",
        "ticker_sentiment_score": "0.167371",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.03642",
        "ticker_sentiment_score": "0.208016",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.072765",
        "ticker_sentiment_score": "0.164391",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "COIN",
        "relevance_score": "0.072765",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COTY",
        "relevance_score": "0.072765",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MCD",
        "relevance_score": "0.072765",
        "ticker_sentiment_score": "0.164391",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TOL",
        "relevance_score": "0.072765",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ZTO",
        "relevance_score": "0.072765",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LZB",
        "relevance_score": "0.072765",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INTC",
        "relevance_score": "0.072765",
        "ticker_sentiment_score": "0.164391",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.072765",
        "ticker_sentiment_score": "-0.172491",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "WT",
        "relevance_score": "0.03642",
        "ticker_sentiment_score": "0.004793",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VIPS",
        "relevance_score": "0.072765",
        "ticker_sentiment_score": "-0.172491",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "PANW",
        "relevance_score": "0.072765",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:JPY",
        "relevance_score": "0.03642",
        "ticker_sentiment_score": "-0.025413",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:EUR",
        "relevance_score": "0.03642",
        "ticker_sentiment_score": "-0.073515",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.108958",
        "ticker_sentiment_score": "-0.046629",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Lilly  ( LLY )  Up 3% on Obesity Drug Cutting Diabetes Risk",
    "url": "https://www.zacks.com/stock/news/2325158/lilly-lly-up-3-on-obesity-drug-cutting-diabetes-risk",
    "time_published": "20240821T143700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Eli Lilly (LLY) reports data from a late-stage study that found that long-term treatment with Zepbound reduces the risk of progression to type 2 diabetes by 94%.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.257592,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.414559",
        "ticker_sentiment_score": "0.259835",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.08687",
        "ticker_sentiment_score": "0.08953",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.043499",
        "ticker_sentiment_score": "0.139591",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.214937",
        "ticker_sentiment_score": "0.09473",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.129983",
        "ticker_sentiment_score": "0.274143",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Targeted Therapeutics Market is Pioneering Growth Towards a USD 118.6 Billion Milestone by 2031, with a CAGR of 6.4% - Exclusive Report by Transparency Market Research, Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/08/g40518343/targeted-therapeutics-market-is-pioneering-growth-towards-a-usd-118-6-billion-milestone-by-2031-wi",
    "time_published": "20240822T213000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Transparency Market Research Inc., Aug. 22, 2024 ( GLOBE NEWSWIRE ) -- As per the report published by Transparency Market Research, the global targeted therapeutics market ( pasar terapi yang ditargetkan ) was worth US$ 69.8 Billion in 2023 and is expected to ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/cc3ec3e6-603a-464a-9be6-73c428997497/targeted-therapeutics-market.jpg",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": -0.002437,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.037504",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.037504",
        "ticker_sentiment_score": "0.056415",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IPSC",
        "relevance_score": "0.037504",
        "ticker_sentiment_score": "0.023536",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAYZF",
        "relevance_score": "0.037504",
        "ticker_sentiment_score": "0.056415",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.037504",
        "ticker_sentiment_score": "0.056415",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.037504",
        "ticker_sentiment_score": "0.056415",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.112182",
        "ticker_sentiment_score": "0.065366",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.037504",
        "ticker_sentiment_score": "0.056415",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.074926",
        "ticker_sentiment_score": "0.023466",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.037504",
        "ticker_sentiment_score": "0.056415",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TAK",
        "relevance_score": "0.037504",
        "ticker_sentiment_score": "0.056415",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Unstoppable Dividend Stocks to Buy Right Now",
    "url": "https://www.fool.com/investing/2024/08/25/3-unstoppable-dividend-stocks-to-buy-right-now/",
    "time_published": "20240825T223000",
    "authors": [
      "and Prosper Junior Bakiny",
      "Keith Speights",
      "David Jagielski"
    ],
    "summary": "These stocks are the A-team for income investors.",
    "banner_image": "https://g.foolcdn.com/editorial/images/788183/two-people-looking-at-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.818451"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.382955,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.282777",
        "ticker_sentiment_score": "0.365654",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.282777",
        "ticker_sentiment_score": "0.335334",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.237204",
        "ticker_sentiment_score": "0.186795",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Amgen Inc.  ( AMGN )  is Attracting Investor Attention: Here is What You Should Know",
    "url": "https://www.zacks.com/stock/news/2326860/amgen-inc-amgn-is-attracting-investor-attention-here-is-what-you-should-know",
    "time_published": "20240826T130013",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default278.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.223623,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.482982",
        "ticker_sentiment_score": "0.154564",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eliem Therapeutics Announces Additions to its Leadership Team",
    "url": "https://www.globenewswire.com/news-release/2024/08/26/2935366/0/en/Eliem-Therapeutics-Announces-Additions-to-its-Leadership-Team.html",
    "time_published": "20240826T110000",
    "authors": [
      "Inc.",
      "Eliem Therapeutics"
    ],
    "summary": "Brett Kaplan, M.D. appointed Chief Operating Officer ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/7c706866-08f4-4afd-a538-faed5ea153af",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.136915,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "EVR",
        "relevance_score": "0.030918",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ELYM",
        "relevance_score": "0.123209",
        "ticker_sentiment_score": "0.095339",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.030918",
        "ticker_sentiment_score": "0.069434",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.030918",
        "ticker_sentiment_score": "0.069434",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CMPX",
        "relevance_score": "0.030918",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eliem Therapeutics Announces Additions to its Leadership Team - Eliem Therapeutics  ( NASDAQ:ELYM ) ",
    "url": "https://www.benzinga.com/pressreleases/24/08/g40548679/eliem-therapeutics-announces-additions-to-its-leadership-team",
    "time_published": "20240826T110000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "SEATTLE and CAMBRIDGE, United Kingdom, Aug. 26, 2024 ( GLOBE NEWSWIRE ) -- Eliem Therapeutics, Inc. ELYM, announced today the appointments of Brett Kaplan, M.D., as Chief Operating Officer, and Nishi Rampal, M.D., as Senior Vice President, Clinical Development.",
    "banner_image": "https://ml.globenewswire.com/media/7c706866-08f4-4afd-a538-faed5ea153af/small/elym-logo-png.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.143876,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "EVR",
        "relevance_score": "0.029802",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ELYM",
        "relevance_score": "0.148182",
        "ticker_sentiment_score": "0.102662",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.029802",
        "ticker_sentiment_score": "0.049602",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.029802",
        "ticker_sentiment_score": "0.049602",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CMPX",
        "relevance_score": "0.029802",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should Invesco Large Cap Value ETF  ( PWV )  Be on Your Investing Radar?",
    "url": "https://www.zacks.com/stock/news/2327391/should-invesco-large-cap-value-etf-pwv-be-on-your-investing-radar",
    "time_published": "20240827T102008",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Style Box ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default7.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.270237,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.123526",
        "ticker_sentiment_score": "0.068619",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.184363",
        "ticker_sentiment_score": "0.196439",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.123526",
        "ticker_sentiment_score": "0.068619",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.123526",
        "ticker_sentiment_score": "0.068619",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly Launches Discounted Versions of Obesity Drug Zepbound",
    "url": "https://www.zacks.com/stock/news/2328500/eli-lilly-launches-discounted-versions-of-obesity-drug-zepbound",
    "time_published": "20240828T171800",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "LLY's single-dose vials are priced at least 50% lower than the list price of all other GLP-1 medicines for obesity.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/58/608.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.141525,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.558244",
        "ticker_sentiment_score": "0.172408",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.152499",
        "ticker_sentiment_score": "0.080551",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.051111",
        "ticker_sentiment_score": "0.195449",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.202366",
        "ticker_sentiment_score": "-0.009469",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.152499",
        "ticker_sentiment_score": "0.056869",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Viking Therapeutics Stock Price Moved Down 6% on Tuesday",
    "url": "https://www.zacks.com/stock/news/2328479/why-viking-therapeutics-stock-price-moved-down-6-on-tuesday",
    "time_published": "20240828T154900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "VKTX's shares fell after rival Eli Lilly announced that it is launching cheaper versions of Zepbound to strengthen its presence in the obesity market.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.129667,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.43789",
        "ticker_sentiment_score": "0.174991",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.43789",
        "ticker_sentiment_score": "0.149056",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.057767",
        "ticker_sentiment_score": "0.14513",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "0.021097",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.228073",
        "ticker_sentiment_score": "0.061511",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen Unusual Options Activity For August 29 - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/insights/options/24/08/40636998/amgen-unusual-options-activity-for-august-29",
    "time_published": "20240829T194854",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bullish stance on Amgen AMGN. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1724960931_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.163162,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.755347",
        "ticker_sentiment_score": "0.175399",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.06623",
        "ticker_sentiment_score": "-0.179501",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs - Johnson & Johnson  ( NYSE:JNJ ) , Eli Lilly  ( NYSE:LLY ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/09/40694793/despite-medicare-negotiations-americans-may-still-have-to-pay-more-for-prescription-drugs",
    "time_published": "20240903T191209",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Over the weekend, the U.S. government announced first-ever negotiated prices for prescription drugs for ten drugs covered under Medicare Part D that will go into effect beginning January 1, 2026. The negotiated prices are expected to save an estimated $6 billion in net covered prescription drug ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/03/over-the-counter-pills.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.07688,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.175859",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.175859",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.175859",
        "ticker_sentiment_score": "-0.074765",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.175859",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.175859",
        "ticker_sentiment_score": "0.187219",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": " ( AMGN )  - Analyzing Amgen's Short Interest - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/insights/short-sellers/24/09/40694063/amgn-analyzing-amgens-short-interest",
    "time_published": "20240903T181523",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Amgen's AMGN short percent of float has fallen 5.49% since its last report. The company recently reported that it has 9.24 million shares sold short, which is 1.72% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.95 days to cover their ...",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1725387320_0.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.264538,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.212115",
        "ticker_sentiment_score": "0.081887",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why the Market Dipped But Amgen  ( AMGN )  Gained Today",
    "url": "https://www.zacks.com/stock/news/2331754/why-the-market-dipped-but-amgen-amgn-gained-today",
    "time_published": "20240904T215018",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the closing of the recent trading day, Amgen (AMGN) stood at $330.64, denoting a +0.04% change from the preceding trading day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default75.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.161263,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.596978",
        "ticker_sentiment_score": "0.217296",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Peptide Therapeutics Market Size is Expected to Reach USD 85.9 billion, Advancing at a CAGR of 9.6% by 2031: Transparency Market Research Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/09/g40708931/peptide-therapeutics-market-size-is-expected-to-reach-usd-85-9-billion-advancing-at-a-cagr-of-9-6-",
    "time_published": "20240904T134300",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Transparency Market Research Inc. -, Sept. 04, 2024 ( GLOBE NEWSWIRE ) -- The global peptide therapeutics market ( \u30da\u30d7\u30c1\u30c9\u6cbb\u7642\u85ac\u5e02\u5834 ) is estimated to thrive at a CAGR of 9.6% from 2023 to 2031.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/e1befc1b-ff19-4283-955e-a81478fba007/peptide-therapeutics-market.jpg",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      }
    ],
    "overall_sentiment_score": 0.35883,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.03443",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.03443",
        "ticker_sentiment_score": "0.265635",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.03443",
        "ticker_sentiment_score": "0.265635",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.03443",
        "ticker_sentiment_score": "-0.167275",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.068797",
        "ticker_sentiment_score": "0.182046",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.103035",
        "ticker_sentiment_score": "0.07323",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TAK",
        "relevance_score": "0.03443",
        "ticker_sentiment_score": "-0.167275",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Choroid Plexus Disorder Treatment Market is Expected to Reach US$ 262.3 Million by 2034 | Fact.MR Report",
    "url": "https://www.benzinga.com/pressreleases/24/09/g40702459/choroid-plexus-disorder-treatment-market-is-expected-to-reach-us-262-3-million-by-2034-fact-mr-rep",
    "time_published": "20240904T100000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Rockville, MD, Sept. 04, 2024 ( GLOBE NEWSWIRE ) -- The global choroid plexus disorder treatment market is approximated at a value of US$ 130.2 million in 2024 and is forecasted to expand at a CAGR of 7.3% from 2024 to 2034, reveals Fact.MR, a market research and competitive intelligence ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/4ace86b8-afeb-4899-a7d9-00987f27cd91/choroid-plexus-disorder-treatment-market.jpg",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.218324,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "FSNUF",
        "relevance_score": "0.039418",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.039418",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.039418",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.039418",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen  ( AMGN )  Up 5.8% Since Last Earnings Report: Can It Continue?",
    "url": "https://www.zacks.com/stock/news/2332279/amgen-amgn-up-58-since-last-earnings-report-can-it-continue",
    "time_published": "20240905T153108",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default210.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999336"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.096622,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.410584",
        "ticker_sentiment_score": "0.127239",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.101047",
        "ticker_sentiment_score": "0.037168",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen Stock Rises Almost 20% in 6 Months: Buy, Sell or Hold?",
    "url": "https://www.zacks.com/stock/news/2332203/amgen-stock-rises-almost-20-in-6-months-buy-sell-or-hold",
    "time_published": "20240905T151400",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "AMGN's reasonable valuation, an interesting pipeline and continued top-line growth are good enough reasons to stay invested for now.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/13/816.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.947132"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.22158,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.045224",
        "ticker_sentiment_score": "0.258132",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.090304",
        "ticker_sentiment_score": "0.271355",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.692648",
        "ticker_sentiment_score": "0.351172",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Stockholders Vote to Elect Madhavan Balachandran to Board of Directors - Replimune Group  ( NASDAQ:REPL ) ",
    "url": "https://www.benzinga.com/pressreleases/24/09/g40727738/stockholders-vote-to-elect-madhavan-balachandran-to-board-of-directors",
    "time_published": "20240905T120000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "WOBURN, Mass., Sept. 05, 2024 ( GLOBE NEWSWIRE ) -- Replimune Group, Inc. REPL, a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that Madhavan ( Madhu ) Balachandran was elected to Replimune's Board of Directors at ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.089164,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.096283",
        "ticker_sentiment_score": "-0.034603",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REPL",
        "relevance_score": "0.532043",
        "ticker_sentiment_score": "0.130849",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here is What to Know Beyond Why Amgen Inc.  ( AMGN )  is a Trending Stock",
    "url": "https://www.zacks.com/stock/news/2332647/here-is-what-to-know-beyond-why-amgen-inc-amgn-is-a-trending-stock",
    "time_published": "20240906T130011",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default257.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.237035,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.483888",
        "ticker_sentiment_score": "0.154745",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why Amgen  ( AMGN )  Outpaced the Stock Market Today",
    "url": "https://www.zacks.com/stock/news/2334269/why-amgen-amgn-outpaced-the-stock-market-today",
    "time_published": "20240910T215019",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) reachead $328.93 at the closing of the latest trading day, reflecting a +0.92% change compared to its last close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default41.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.976913"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.14219,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.55992",
        "ticker_sentiment_score": "0.186836",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Terns Stock Soars on Positive Data From Phase I Study of Obesity Drug - Eli Lilly  ( NYSE:LLY ) , Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/general/biotech/24/09/40799808/terns-stock-soars-on-positive-data-from-phase-i-study-of-obesity-drug",
    "time_published": "20240910T195711",
    "authors": [
      "Zacks"
    ],
    "summary": "Shares of Terns Pharmaceuticals TERN, a clinical-stage company, soared 16.8% after the company announced positive top-line data from the early-stage single and multiple-ascending dose ( SAD and MAD ) obesity study.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/charts/a9/77177.jpg?v=1148197964",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.148734,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.269776",
        "ticker_sentiment_score": "0.188828",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TERN",
        "relevance_score": "0.730167",
        "ticker_sentiment_score": "-0.00791",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.054983",
        "ticker_sentiment_score": "0.175884",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.217346",
        "ticker_sentiment_score": "0.045349",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.217346",
        "ticker_sentiment_score": "0.142324",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Terns Stock Soars on Positive Data From Phase I Study of Obesity Drug",
    "url": "https://www.zacks.com/stock/news/2334185/terns-stock-soars-on-positive-data-from-phase-i-study-of-obesity-drug",
    "time_published": "20240910T152900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "TERN stock soars on positive data from the early-stage study of TERN-601 for obesity, showing statistically significant weight reduction compared to placebo.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/82/41137.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.124879,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.280294",
        "ticker_sentiment_score": "0.182041",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TERN",
        "relevance_score": "0.749166",
        "ticker_sentiment_score": "0.01996",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.057215",
        "ticker_sentiment_score": "0.17599",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.22595",
        "ticker_sentiment_score": "0.044995",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.22595",
        "ticker_sentiment_score": "0.133934",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars - UnitedHealth Group  ( NYSE:UNH ) ",
    "url": "https://www.benzinga.com/general/biotech/24/09/40820758/unitedhealth-follows-competitors-replaces-humira-with-lower-cost-biosimilars",
    "time_published": "20240911T185913",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "UnitedHealth Group Inc. UNH reportedly announced on Tuesday that it will remove AbbVie Inc.'s ABBV blockbuster drug Humira from some of its preferred reimbursement lists starting January 1, 2025. The company will recommend lower-cost biosimilar versions instead.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/11/Konskie--Poland---January-05--2019-Unite.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.216359,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CVS",
        "relevance_score": "0.175221",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.342093",
        "ticker_sentiment_score": "0.261477",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.175221",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.175221",
        "ticker_sentiment_score": "0.1277",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.175221",
        "ticker_sentiment_score": "0.123593",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.342093",
        "ticker_sentiment_score": "0.320237",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "VRDN Stock Soars as Eye Disorder Study Meets Primary Endpoints",
    "url": "https://www.zacks.com/stock/news/2334732/vrdn-stock-soars-as-eye-disorder-study-meets-primary-endpoints",
    "time_published": "20240911T152700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The phase III THRIVE study evaluating Viridian's veligrotug for treating active thyroid eye disease meets all primary and secondary endpoints.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/37/2337.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.890401"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.220913,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KRYS",
        "relevance_score": "0.22595",
        "ticker_sentiment_score": "0.212852",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.114137",
        "ticker_sentiment_score": "0.228651",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRDN",
        "relevance_score": "0.434142",
        "ticker_sentiment_score": "0.4399",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "FULC",
        "relevance_score": "0.22595",
        "ticker_sentiment_score": "0.093142",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Gene Therapy Market Set for 19% CAGR Surge, Reaching USD 38.34 Billion by 2031 | SkyQuest Technology",
    "url": "https://www.benzinga.com/pressreleases/24/09/g40833623/gene-therapy-market-set-for-19-cagr-surge-reaching-usd-38-34-billion-by-2031-skyquest-technology",
    "time_published": "20240912T133000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Westford, USA, Sept. 12, 2024 ( GLOBE NEWSWIRE ) -- SkyQuest projects that the Global Gene Therapy Market will reach a value of USD 38.34 Billion by 2031, with a CAGR of 19% during the forecast period ( 2024-2031 ) .",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      }
    ],
    "overall_sentiment_score": 0.230526,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KRYS",
        "relevance_score": "0.039878",
        "ticker_sentiment_score": "0.026899",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BLUE",
        "relevance_score": "0.039878",
        "ticker_sentiment_score": "0.026899",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SRPT",
        "relevance_score": "0.039878",
        "ticker_sentiment_score": "0.026899",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADAP",
        "relevance_score": "0.039878",
        "ticker_sentiment_score": "0.026899",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.039878",
        "ticker_sentiment_score": "0.026899",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.039878",
        "ticker_sentiment_score": "0.026899",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QURE",
        "relevance_score": "0.039878",
        "ticker_sentiment_score": "0.026899",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SLDB",
        "relevance_score": "0.039878",
        "ticker_sentiment_score": "0.026899",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABEO",
        "relevance_score": "0.039878",
        "ticker_sentiment_score": "0.026899",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RGNX",
        "relevance_score": "0.039878",
        "ticker_sentiment_score": "0.026899",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.039878",
        "ticker_sentiment_score": "0.026899",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.039878",
        "ticker_sentiment_score": "0.026899",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NTLA",
        "relevance_score": "0.039878",
        "ticker_sentiment_score": "0.026899",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Forget Eli Lilly and Novo Nordisk: This Could Be the Best Weight Loss Stock to Buy Right Now",
    "url": "https://www.fool.com/investing/2024/09/12/forget-eli-lilly-and-novo-nordisk-this-could-be/",
    "time_published": "20240912T100000",
    "authors": [
      "David Jagielski"
    ],
    "summary": "Amgen is a decently valued stock that has an excellent business and also gives investors a way to potentially gain exposure to a lucrative weight loss market.",
    "banner_image": "https://g.foolcdn.com/editorial/images/789966/a-couple-using-a-laptop-and-reviewing-documents.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99977"
      }
    ],
    "overall_sentiment_score": 0.216204,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.585687",
        "ticker_sentiment_score": "0.251075",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.108222",
        "ticker_sentiment_score": "0.147807",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Unstoppable Growth Stocks to Buy Right Now for Less Than $500",
    "url": "https://www.fool.com/investing/2024/09/13/2-unstoppable-growth-stocks-to-buy-right-now-for/",
    "time_published": "20240913T140000",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "Growth-oriented businesses can make excellent additions to a well-diversified portfolio.",
    "banner_image": "https://g.foolcdn.com/editorial/images/790292/happy-family-on-vacation-travel-dining-outdoors.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.995077"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.990893"
      }
    ],
    "overall_sentiment_score": 0.194855,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.265859",
        "ticker_sentiment_score": "0.198993",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABNB",
        "relevance_score": "0.265859",
        "ticker_sentiment_score": "0.172297",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Amgen  ( AMGN )  Rises Higher Than Market: Key Facts",
    "url": "https://www.zacks.com/stock/news/2336834/amgen-amgn-rises-higher-than-market-key-facts",
    "time_published": "20240916T220019",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) closed the most recent trading day at $335.26, moving +0.85% from the previous trading session.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default67.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.192576,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.646507",
        "ticker_sentiment_score": "0.276313",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Amgen  ( AMGN )  Stock Dips While Market Gains: Key Facts",
    "url": "https://www.zacks.com/stock/news/2337480/amgen-amgn-stock-dips-while-market-gains-key-facts",
    "time_published": "20240917T215019",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) reachead $332.80 at the closing of the latest trading day, reflecting a -0.73% change compared to its last close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default8.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.976913"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      }
    ],
    "overall_sentiment_score": 0.20219,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.568435",
        "ticker_sentiment_score": "0.268974",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly Stock Up 21% in 6 Months: Time to Add to Your Portfolio?",
    "url": "https://www.zacks.com/stock/news/2337416/eli-lilly-stock-up-21-in-6-months-time-to-add-to-your-portfolio",
    "time_published": "20240917T190000",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Investors can buy LLY stock based on its strong overall financial performance and robust drug pipeline.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999922"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.356399,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.612033",
        "ticker_sentiment_score": "0.506143",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.04303",
        "ticker_sentiment_score": "0.070263",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.085936",
        "ticker_sentiment_score": "0.07391",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.085936",
        "ticker_sentiment_score": "0.123885",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.085936",
        "ticker_sentiment_score": "0.202159",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Investors Heavily Search Amgen Inc.  ( AMGN ) : Here is What You Need to Know",
    "url": "https://www.zacks.com/stock/news/2337032/investors-heavily-search-amgen-inc-amgn-here-is-what-you-need-to-know",
    "time_published": "20240917T130011",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default268.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.230637,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.482982",
        "ticker_sentiment_score": "0.154935",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Mental Health Market to Surpass Market Valuation of USD 544.63 Billion by 2031 | SkyQuest Technology",
    "url": "https://www.benzinga.com/pressreleases/24/09/g40897547/mental-health-market-to-surpass-market-valuation-of-usd-544-63-billion-by-2031-skyquest-technology",
    "time_published": "20240917T123000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Westford, USA, Sept. 17, 2024 ( GLOBE NEWSWIRE ) -- SkyQuest projects that the Global Mental Health Market will reach a value of USD 544.63 Billion by 2031, with a CAGR of 3.5% during the forecast period ( 2024-2031 ) .",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.102378,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.036091",
        "ticker_sentiment_score": "-0.017939",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.036091",
        "ticker_sentiment_score": "-0.017939",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WLDS",
        "relevance_score": "0.036091",
        "ticker_sentiment_score": "0.153396",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ALKS",
        "relevance_score": "0.036091",
        "ticker_sentiment_score": "-0.017939",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.036091",
        "ticker_sentiment_score": "-0.017939",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.036091",
        "ticker_sentiment_score": "-0.017939",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.036091",
        "ticker_sentiment_score": "-0.017939",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.036091",
        "ticker_sentiment_score": "-0.017939",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JAZZ",
        "relevance_score": "0.036091",
        "ticker_sentiment_score": "-0.017939",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HKMPF",
        "relevance_score": "0.036091",
        "ticker_sentiment_score": "-0.017939",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.036091",
        "ticker_sentiment_score": "-0.017939",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.036091",
        "ticker_sentiment_score": "-0.017939",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.036091",
        "ticker_sentiment_score": "-0.017939",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TAK",
        "relevance_score": "0.036091",
        "ticker_sentiment_score": "-0.017939",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Behind the Scenes of Amgen's Latest Options Trends - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/insights/options/24/09/40946352/behind-the-scenes-of-amgens-latest-options-trends",
    "time_published": "20240919T190547",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bullish stance on Amgen AMGN. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1726772744_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.142284,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.647003",
        "ticker_sentiment_score": "0.138388",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "NVO Stock Loses Around $29B in 3 Months: Buy the Dip or Steer Clear?",
    "url": "https://www.zacks.com/stock/news/2339393/nvo-stock-loses-around-29b-in-3-months-buy-the-dip-or-steer-clear",
    "time_published": "20240920T150300",
    "authors": [
      "Ahan Chakraborty"
    ],
    "summary": "Despite the current downward trend of Novo Nordisk, it is an excellent stock to buy for long-term gains, driven by the stellar performance of its GLP-1 drugs.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.993781"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.989041"
      }
    ],
    "overall_sentiment_score": 0.260764,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.150357",
        "ticker_sentiment_score": "0.11855",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.075516",
        "ticker_sentiment_score": "0.112471",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.075516",
        "ticker_sentiment_score": "0.112471",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.579577",
        "ticker_sentiment_score": "0.42745",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Where Will Amgen Be in 5 Years?",
    "url": "https://www.fool.com/investing/2024/09/20/where-will-amgen-be-in-5-years/",
    "time_published": "20240920T114500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "There are plenty of ongoing positive developments with the biotech giant.",
    "banner_image": "https://g.foolcdn.com/editorial/images/790418/doctor-and-patient-talking.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.155555,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.598368",
        "ticker_sentiment_score": "0.193591",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Amgen  ( AMGN )  Stock Declines While Market Improves: Some Information for Investors",
    "url": "https://www.zacks.com/stock/news/2340196/amgen-amgn-stock-declines-while-market-improves-some-information-for-investors",
    "time_published": "20240923T220018",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the closing of the recent trading day, Amgen (AMGN) stood at $335.61, denoting a -0.52% change from the preceding trading day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default62.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.938793"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.219624,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.535653",
        "ticker_sentiment_score": "0.275705",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "What the Options Market Tells Us About Amgen - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/insights/options/24/09/40983293/what-the-options-market-tells-us-about-amgen",
    "time_published": "20240923T144544",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Whales with a lot of money to spend have taken a noticeably bullish stance on Amgen. Looking at options history for Amgen AMGN we detected 10 trades. If we consider the specifics of each trade, it is accurate to state that 40% of the investors opened trades with bullish expectations and 40% with ...",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1727102741_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.207166,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.692465",
        "ticker_sentiment_score": "0.154077",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Amgen vs. Viking Therapeutics: What's the Better GLP-1 Stock to Buy?",
    "url": "https://www.fool.com/investing/2024/09/23/amgen-vs-viking-therapeutics-whats-the-better-glp/",
    "time_published": "20240923T113000",
    "authors": [
      "David Jagielski"
    ],
    "summary": "These two stocks could be rivals in the intense GLP-1 space in the future.",
    "banner_image": "https://g.foolcdn.com/editorial/images/791335/a-physician-using-a-scale-to-measure-a-persons-weight.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99676"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.189628,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.046633",
        "ticker_sentiment_score": "-0.093713",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.230017",
        "ticker_sentiment_score": "0.11356",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.139265",
        "ticker_sentiment_score": "0.196752",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why Is Regeneron Pharmaceuticals Stock Trading Lower On Tuesday? - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) , Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/general/biotech/24/09/41012464/why-is-regeneron-pharmaceuticals-stock-trading-lower-on-tuesday",
    "time_published": "20240924T182156",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Chief District Judge Thomas Kleeh denied Regeneron Pharmaceuticals, Inc.'s REGN effort to prevent the sale of Amgen Inc's AMGN Eylea biosimilar. Regeneron filed a notice of its appeal to the U.S. Court of Appeals for the Federal Circuit.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/24/BZ-briefs.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": -0.004869,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "REGN",
        "relevance_score": "0.355588",
        "ticker_sentiment_score": "-0.129204",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.718485",
        "ticker_sentiment_score": "-0.258598",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "VTRS",
        "relevance_score": "0.241684",
        "ticker_sentiment_score": "-0.310015",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Market Whales and Their Recent Bets on AMGN Options - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/insights/options/24/09/41012047/market-whales-and-their-recent-bets-on-amgn-options",
    "time_published": "20240924T180056",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bullish stance on Amgen AMGN. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1727200853_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      }
    ],
    "overall_sentiment_score": 0.188573,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.771416",
        "ticker_sentiment_score": "0.237938",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Regeneron Stock Down on Court Ruling for Amgen's Biosimilar of Eylea",
    "url": "https://www.zacks.com/stock/news/2340793/regeneron-stock-down-on-court-ruling-for-amgens-biosimilar-of-eylea",
    "time_published": "20240924T170900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "A federal judge rejected Regeneron's request for a preliminary injunction against Amgen in its lawsuit for Eylea's biosimilar.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/55/1135.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.087079,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "REGN",
        "relevance_score": "0.441059",
        "ticker_sentiment_score": "0.008983",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSNLF",
        "relevance_score": "0.077593",
        "ticker_sentiment_score": "0.086079",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.441059",
        "ticker_sentiment_score": "-0.021005",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Cancer Supportive Care Product Market is Set to Surge at 6.9% CAGR, to Reach US$ 68.93 Billion by 2034 | Fact.MR",
    "url": "https://www.benzinga.com/pressreleases/24/09/g40997521/cancer-supportive-care-product-market-is-set-to-surge-at-6-9-cagr-to-reach-us-68-93-billion-by-203",
    "time_published": "20240924T100000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Rockville, MD, Sept. 24, 2024 ( GLOBE NEWSWIRE ) -- In its new study, Fact.MR states that the global cancer supportive care product market is estimated to reach a value of US$ 35.47 billion in 2024 and thereafter advance at a CAGR of 6.9% from 2024 to 2034.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/4051ce21-f8ad-45c0-a815-b601fdab078e/cancer-supportive-care-product-market.jpg",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.279437,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.029618",
        "ticker_sentiment_score": "-0.013415",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAYZF",
        "relevance_score": "0.029618",
        "ticker_sentiment_score": "-0.013415",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.029618",
        "ticker_sentiment_score": "-0.013415",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAX",
        "relevance_score": "0.029618",
        "ticker_sentiment_score": "-0.013415",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.029618",
        "ticker_sentiment_score": "-0.013415",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.029618",
        "ticker_sentiment_score": "-0.013415",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WLDS",
        "relevance_score": "0.029618",
        "ticker_sentiment_score": "0.551007",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.029618",
        "ticker_sentiment_score": "-0.013415",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.029618",
        "ticker_sentiment_score": "-0.013415",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HRTX",
        "relevance_score": "0.029618",
        "ticker_sentiment_score": "-0.013415",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.029618",
        "ticker_sentiment_score": "-0.013415",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TAK",
        "relevance_score": "0.029618",
        "ticker_sentiment_score": "-0.013415",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Weight-Loss Stocks That Could Rocket Higher This Year",
    "url": "https://www.fool.com/investing/2024/09/24/2-weight-loss-stocks-that-could-rocket-higher-this/",
    "time_published": "20240924T085700",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "Upcoming clinical trial results could push these stocks through the roof before 2024 is finished.",
    "banner_image": "https://g.foolcdn.com/editorial/images/791555/coffee-shop-investor-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.181211,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.430251",
        "ticker_sentiment_score": "0.259472",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.341587",
        "ticker_sentiment_score": "0.155387",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41031132/amgens-rocatinlimab-has-commercial-potential-despite-competitive-landscape-says-gol",
    "time_published": "20240925T173000",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "In an investor update on Tuesday, Amgen Inc AMGN released data from Phase 3 trials of rocatinlimab and Uplizna ( inebilizumab ) . HORIZON Phase 3 trial evaluated rocatinlimab for atopic dermatitis ( eczema ) in 726 patients.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/25/Amgen-stock_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.260004,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.187463",
        "ticker_sentiment_score": "0.270171",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.187463",
        "ticker_sentiment_score": "0.242617",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.523202",
        "ticker_sentiment_score": "-0.042106",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.187463",
        "ticker_sentiment_score": "0.270171",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41022603/amgens-rocatinlimab-data-beats-placebo-in-atopic-dermatitis-trial-but-analyst-says-",
    "time_published": "20240925T120401",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "In an investor update on Tuesday, Amgen Inc AMGN released data from Phase 3 trials of rocatinlimab and Uplizna ( inebilizumab ) . HORIZON Phase 3 trial evaluated rocatinlimab for atopic dermatitis ( eczema ) in 726 patients.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/25/Amgen-stock.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.176266,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.332883",
        "ticker_sentiment_score": "-0.050308",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.170275",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AMGN Stock Falls Despite Upbeat Data on Immunology Drugs: Here's Why",
    "url": "https://www.zacks.com/stock/news/2342165/amgn-stock-falls-despite-upbeat-data-on-immunology-drugs-heres-why",
    "time_published": "20240926T153700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Though Amgen reported encouraging results on two immunology drugs, Wall Street expresses skepticism as the data fell short when compared to existing treatments.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/13/816.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.117514,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KNBWF",
        "relevance_score": "0.063763",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.368773",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KYKOF",
        "relevance_score": "0.063763",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.251032",
        "ticker_sentiment_score": "0.074803",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Taiwan Semiconductor, American Tower And Trane Technologies On CNBC's 'Final Trades' - Taiwan Semiconductor  ( NYSE:TSM ) ",
    "url": "https://www.benzinga.com/trading-ideas/long-ideas/24/09/41045385/taiwan-semiconductor-american-tower-trane-technologies-and-a-health-care-stock-on-cnbcs-",
    "time_published": "20240926T123209",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "On CNBC's \"Halftime Report Final Trades,\" Stephen Weiss of Short Hills Capital Partners said he still finds Taiwan Semiconductor Manufacturing Company Limited TSM cheap.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/26/TSMC-Taiwan-Semiconductor-Manufacturing-.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.196689,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMT",
        "relevance_score": "0.463792",
        "ticker_sentiment_score": "-0.089003",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TT",
        "relevance_score": "0.463792",
        "ticker_sentiment_score": "0.504822",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VRTS",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.463792",
        "ticker_sentiment_score": "0.135758",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.24289",
        "ticker_sentiment_score": "0.01135",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSM",
        "relevance_score": "0.357293",
        "ticker_sentiment_score": "-0.038016",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen  ( AMGN )  Ascends While Market Falls: Some Facts to Note",
    "url": "https://www.zacks.com/stock/news/2342983/amgen-amgn-ascends-while-market-falls-some-facts-to-note",
    "time_published": "20240927T215019",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) closed at $322.67 in the latest trading session, marking a +1.12% move from the prior day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default54.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.986564"
      }
    ],
    "overall_sentiment_score": 0.119544,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.516073",
        "ticker_sentiment_score": "0.166012",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": " ( AMGN )  - Analyzing Amgen's Short Interest - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/insights/short-sellers/24/09/41100441/amgn-analyzing-amgens-short-interest",
    "time_published": "20240930T173028",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Amgen's AMGN short percent of float has risen 6.33% since its last report. The company recently reported that it has 9.00 million shares sold short, which is 1.68% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.19 days to cover their ...",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1727717425_0.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.289997,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.212115",
        "ticker_sentiment_score": "0.151778",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Amgen Inc.  ( AMGN )  Is a Trending Stock: Facts to Know Before Betting on It",
    "url": "https://www.zacks.com/stock/news/2343927/amgen-inc-amgn-is-a-trending-stock-facts-to-know-before-betting-on-it",
    "time_published": "20241001T130010",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default91.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.211066,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.485711",
        "ticker_sentiment_score": "0.083131",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the iShares Biotechnology ETF  ( IBB ) ?",
    "url": "https://www.zacks.com/stock/news/2343780/should-you-invest-in-the-ishares-biotechnology-etf-ibb",
    "time_published": "20241001T102008",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default47.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999999"
      }
    ],
    "overall_sentiment_score": 0.210358,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.067727",
        "ticker_sentiment_score": "0.034062",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.134968",
        "ticker_sentiment_score": "0.071604",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.134968",
        "ticker_sentiment_score": "0.071604",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.134968",
        "ticker_sentiment_score": "0.071604",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Moore Law, PLLC Encourages Amgen, Inc. Investors to Contact Law Firm",
    "url": "https://www.benzinga.com/pressreleases/24/10/g41154769/moore-law-pllc-encourages-amgen-inc-investors-to-contact-law-firm",
    "time_published": "20241002T222927",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, Oct. 02, 2024 ( GLOBE NEWSWIRE ) -- Moore Law, PLLC, a securities and shareholder law firm located on Wall Street, is investigating potential claims against: Please contact fletcher@fmoorelaw.com.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": -0.121012,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.78028",
        "ticker_sentiment_score": "-0.425297",
        "ticker_sentiment_label": "Bearish"
      }
    ]
  },
  {
    "title": "Federal Judge Rules Amgen Must Face Tax Liability Lawsuit That Alleges Reckless Concealment Of $10.7B Tax Bill - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/general/biotech/24/10/41147607/federal-judge-rules-amgen-must-face-tax-liability-lawsuit-that-alleges-reckless-concealment-of-10",
    "time_published": "20241002T173434",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "A federal judge has ruled that Amgen Inc. AMGN must address a proposed class-action lawsuit accusing the company of delaying disclosures regarding its potential $10.7 billion tax liability. The case argues that shareholders were misled when Amgen allegedly concealed the risk of owing billions to ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/02/Amgen-stock.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": -0.125052,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.693563",
        "ticker_sentiment_score": "-0.467849",
        "ticker_sentiment_label": "Bearish"
      }
    ]
  },
  {
    "title": "Why Amgen  ( AMGN )  Dipped More Than Broader Market Today",
    "url": "https://www.zacks.com/stock/news/2345721/why-amgen-amgn-dipped-more-than-broader-market-today",
    "time_published": "20241003T220019",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the most recent trading session, Amgen (AMGN) closed at $317.48, indicating a -0.7% shift from the previous trading day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default135.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.928769"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.126616,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.606946",
        "ticker_sentiment_score": "0.17869",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Amgen  ( AMGN )  Increases Yet Falls Behind Market: What Investors Need to Know",
    "url": "https://www.zacks.com/stock/news/2346377/amgen-amgn-increases-yet-falls-behind-market-what-investors-need-to-know",
    "time_published": "20241004T215019",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) concluded the recent trading session at $319.66, signifying a +0.69% move from its prior day's close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default108.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.99246"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.160624,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.549988",
        "ticker_sentiment_score": "0.228811",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Should You Buy the Dip on This Top Growth Stock?",
    "url": "https://www.fool.com/investing/2024/10/05/should-you-buy-the-dip-on-this-top-growth-stock/",
    "time_published": "20241005T103000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "The biotech needs to overcome an issue most drugmakers face at some point.",
    "banner_image": "https://g.foolcdn.com/editorial/images/791914/doctor-with-patient-talking.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.181006,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "REGN",
        "relevance_score": "0.110209",
        "ticker_sentiment_score": "0.499386",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.322374",
        "ticker_sentiment_score": "-0.075135",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.110209",
        "ticker_sentiment_score": "0.098369",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Magnificent Dividend Stocks to Buy in October",
    "url": "https://www.fool.com/investing/2024/10/06/3-magnificent-dividend-stocks-to-buy-in-october/",
    "time_published": "20241006T095000",
    "authors": [
      "David Jagielski",
      "Keith Speights",
      "and Prosper Junior Bakiny"
    ],
    "summary": "These dividend stocks are great picks as the fall season gets underway.",
    "banner_image": "https://g.foolcdn.com/editorial/images/792876/retired-woman-investing-laptop-401k-ira.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.744043"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999922"
      }
    ],
    "overall_sentiment_score": 0.334621,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.364053",
        "ticker_sentiment_score": "0.389014",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.094204",
        "ticker_sentiment_score": "0.067748",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LDNXF",
        "relevance_score": "0.047185",
        "ticker_sentiment_score": "0.147599",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.277433",
        "ticker_sentiment_score": "0.354037",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.232661",
        "ticker_sentiment_score": "0.213443",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Teva Prolia\u00ae  ( Denosumab )  Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA",
    "url": "https://www.globenewswire.com/news-release/2024/10/08/2959538/0/en/Teva-Prolia-Denosumab-Biosimilar-Candidate-is-Accepted-for-Review-by-U-S-FDA-and-EU-EMA.html",
    "time_published": "20241008T110000",
    "authors": [
      "Teva Pharmaceutical Industries Ltd"
    ],
    "summary": "TEL AVIV, Israel, Oct. 08, 2024 ( GLOBE NEWSWIRE ) -- Teva Pharmaceutical Industries Ltd. ( NYSE and TASE: TEVA ) today announced that the United States ( U.S. ) Food and Drug Administration ( FDA ) has accepted, and the European Medicines Agency ( EMA ) has validated, applications for TVB-009P, ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/c2001734-949b-4cc2-8021-b4b64eda1f13",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.139014,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.032602",
        "ticker_sentiment_score": "0.054731",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.129866",
        "ticker_sentiment_score": "0.188341",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Want to Invest in the Weight Loss Boom? Consider Buying These 2 Stocks",
    "url": "https://www.fool.com/investing/2024/10/08/want-to-invest-in-the-weight-loss-boom-consider/",
    "time_published": "20241008T103000",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "Investing in the most popular players in the space isn't the only valid approach.",
    "banner_image": "https://g.foolcdn.com/editorial/images/793011/two-investors-look-at-figures.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      }
    ],
    "overall_sentiment_score": 0.114551,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.149346",
        "ticker_sentiment_score": "0.030941",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.149346",
        "ticker_sentiment_score": "0.09988",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.09989",
        "ticker_sentiment_score": "0.040995",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "MediLink Announces Global Clinical Trial Collaboration and Supply Agreement on YL201 Combination Therapy",
    "url": "https://www.benzinga.com/pressreleases/24/10/n41219617/medilink-announces-global-clinical-trial-collaboration-and-supply-agreement-on-yl201-combination-t",
    "time_published": "20241008T000000",
    "authors": [
      "PRNewswire"
    ],
    "summary": "SUZHOU, China, Oct. 7, 2024 /PRNewswire/ -- MediLink Therapeutics ( Suzhou ) Co., Ltd. ( \"MediLink\" ) , a clinical-stage biotech company, today announced a global clinical trial collaboration and supply agreement with Amgen Inc.",
    "banner_image": "https://mma.prnewswire.com/media/2245292/MediLink_Therapeutics_Logo.jpg",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.117605,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.015197",
        "ticker_sentiment_score": "0.047636",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Biotech Stocks to Buy Hand Over Fist in October",
    "url": "https://www.fool.com/investing/2024/10/09/2-biotech-stocks-to-buy-hand-over-fist-in-october/",
    "time_published": "20241009T141500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "These longtime leading biotech stocks still have plenty of upside ahead.",
    "banner_image": "https://g.foolcdn.com/editorial/images/792380/doctor-and-patient-talking.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.249476,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.208464",
        "ticker_sentiment_score": "0.272865",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.356317",
        "ticker_sentiment_score": "0.352272",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Is iShares Biotechnology ETF  ( IBB )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2347953/is-ishares-biotechnology-etf-ibb-a-strong-etf-right-now",
    "time_published": "20241009T102006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default229.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999997"
      }
    ],
    "overall_sentiment_score": 0.298096,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "REGN",
        "relevance_score": "0.122581",
        "ticker_sentiment_score": "0.068387",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.122581",
        "ticker_sentiment_score": "0.068387",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.122581",
        "ticker_sentiment_score": "0.068387",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen  ( AMGN )  Dips More Than Broader Market: What You Should Know",
    "url": "https://www.zacks.com/stock/news/2349077/amgen-amgn-dips-more-than-broader-market-what-you-should-know",
    "time_published": "20241010T220018",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the latest trading session, Amgen (AMGN) closed at $321.01, marking a -0.43% move from the previous day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default58.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.986564"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.174304,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.531019",
        "ticker_sentiment_score": "0.218649",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Deere, Amgen, Copart And More: CNBC's 'Final Trades' - Copart  ( NASDAQ:CPRT ) ",
    "url": "https://www.benzinga.com/trading-ideas/long-ideas/24/10/41270890/deere-amgen-copart-and-more-cnbcs-final-trades",
    "time_published": "20241010T124912",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "On CNBC's \"Halftime Report Final Trades,\" Jim Lebenthal of Cerity Partners named Deere & Company DE as his final trade. On Wednesday, Citigroup analyst Kyle Menges maintained Deere with a Neutral and raised the price target from $395 to $420. Jason Snipe of Odyssey Capital Advisors said Amgen ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/10/John-Deere-Shutterstock.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.300787,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CPRT",
        "relevance_score": "0.570165",
        "ticker_sentiment_score": "0.311631",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DE",
        "relevance_score": "0.570165",
        "ticker_sentiment_score": "0.173392",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.156461",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.156461",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTS",
        "relevance_score": "0.156461",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.570165",
        "ticker_sentiment_score": "0.503343",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia\u00ae and Xgeva\u00ae",
    "url": "https://www.globenewswire.com/news-release/2024/10/10/2961081/0/en/European-Medicines-Agency-Confirms-Acceptance-of-Marketing-Application-for-AVT03-a-Proposed-Biosimilar-to-Prolia-and-Xgeva.html",
    "time_published": "20241010T090100",
    "authors": [
      "Alvotech"
    ],
    "summary": "Alvotech ( NASDAQ: ALVO ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the European Medicines Agency ( EMA ) has accepted a Marketing Authorization Application for AVT03, a proposed biosimilar ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.140315,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ALVO",
        "relevance_score": "0.523638",
        "ticker_sentiment_score": "0.250206",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.023673",
        "ticker_sentiment_score": "0.061327",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.023673",
        "ticker_sentiment_score": "0.061327",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.023673",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTUS",
        "relevance_score": "0.023673",
        "ticker_sentiment_score": "0.061327",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia\u00ae and Xgeva\u00ae",
    "url": "https://www.globenewswire.com/news-release/2024/10/10/2961076/0/en/European-Medicines-Agency-Confirms-Acceptance-of-Marketing-Application-for-AVT03-a-Proposed-Biosimilar-to-Prolia-and-Xgeva.html",
    "time_published": "20241010T090000",
    "authors": [
      "Alvotech"
    ],
    "summary": "REYKJAVIK, Iceland, Oct. 10, 2024 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the European Medicines Agency ( EMA ) has accepted a Marketing ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.137919,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.023372",
        "ticker_sentiment_score": "0.0927",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.023372",
        "ticker_sentiment_score": "0.0927",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTUS",
        "relevance_score": "0.023372",
        "ticker_sentiment_score": "0.061216",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALVO",
        "relevance_score": "0.518022",
        "ticker_sentiment_score": "0.248639",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.023372",
        "ticker_sentiment_score": "0.061216",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.023372",
        "ticker_sentiment_score": "0.061216",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.023372",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41296978/novo-nordisk-eli-lilly-could-face-downward-pressure-despite-market-dominance-from-p",
    "time_published": "20241011T181110",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Novo Nordisk A/S NVO and Eli Lilly And Co LLY have dominated the obesity drug market with their leading therapies, Wegovy and Zepbound, but the next generation of treatments could shift this dynamic.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/11/Siegen--North-Rhine-Westphalia---Germany.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.277047,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SSTK",
        "relevance_score": "0.063091",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.125789",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.24847",
        "ticker_sentiment_score": "0.364435",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.307731",
        "ticker_sentiment_score": "0.439554",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ALT",
        "relevance_score": "0.187705",
        "ticker_sentiment_score": "0.045317",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MORN",
        "relevance_score": "0.063091",
        "ticker_sentiment_score": "0.107055",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.125789",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.125789",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Top Dividend Stocks to Buy Hand Over Fist Right Now",
    "url": "https://www.fool.com/investing/2024/10/11/2-top-dividend-stocks-to-buy-hand-over-fist-right/",
    "time_published": "20241011T103000",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "Income stocks can be wise additions to your portfolio in any market environment.",
    "banner_image": "https://g.foolcdn.com/editorial/images/793343/businesswoman-working-finances-1.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.692272"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.238488,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.346642",
        "ticker_sentiment_score": "0.199608",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HRL",
        "relevance_score": "0.142565",
        "ticker_sentiment_score": "0.044887",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen Inc.  ( AMGN )  is Attracting Investor Attention: Here is What You Should Know",
    "url": "https://www.zacks.com/stock/news/2349749/amgen-inc-amgn-is-attracting-investor-attention-here-is-what-you-should-know",
    "time_published": "20241014T130011",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default82.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.235274,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.488469",
        "ticker_sentiment_score": "0.101572",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen  ( AMGN )  Rises As Market Takes a Dip: Key Facts",
    "url": "https://www.zacks.com/stock/news/2351055/amgen-amgn-rises-as-market-takes-a-dip-key-facts",
    "time_published": "20241015T215019",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) closed at $325.09 in the latest trading session, marking a +0.14% move from the prior day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default275.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.983783"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.184553,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.638317",
        "ticker_sentiment_score": "0.288851",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Lilly Loses Around $14B This Week: How to Play LLY Stock",
    "url": "https://www.zacks.com/stock/news/2352659/lilly-loses-around-14b-this-week-how-to-play-lly-stock",
    "time_published": "20241017T190000",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Investors can buy LLY stock based on its strong overall financial performance and robust drug pipeline.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99977"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.857896"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.230998,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.536294",
        "ticker_sentiment_score": "0.365905",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.034381",
        "ticker_sentiment_score": "0.064274",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.068698",
        "ticker_sentiment_score": "0.068196",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.068698",
        "ticker_sentiment_score": "0.170774",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.068698",
        "ticker_sentiment_score": "0.196415",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Looking Into Amgen's Recent Short Interest - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/insights/short-sellers/24/10/41380828/looking-into-amgens-recent-short-interest",
    "time_published": "20241017T131528",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Amgen's AMGN short percent of float has risen 8.93% since its last report. The company recently reported that it has 9.81 million shares sold short, which is 1.83% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.13 days to cover their ...",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1729170925_0.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.289997,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.212115",
        "ticker_sentiment_score": "0.151778",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Is Amgen Stock a Buy?",
    "url": "https://www.fool.com/investing/2024/10/18/is-amgen-stock-a-buy/",
    "time_published": "20241018T113200",
    "authors": [
      "Dan Victor"
    ],
    "summary": "This biotech leader could be poised to rally higher.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F794114%2Famgen-stock-bullish-outlook-2025.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.986564"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.306775,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.060236",
        "ticker_sentiment_score": "0.190047",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.674081",
        "ticker_sentiment_score": "0.464583",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.060236",
        "ticker_sentiment_score": "0.190047",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.12013",
        "ticker_sentiment_score": "0.095937",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Amgen  ( AMGN )  Dipped More Than Broader Market Today",
    "url": "https://www.zacks.com/stock/news/2354400/why-amgen-amgn-dipped-more-than-broader-market-today",
    "time_published": "20241021T220018",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) reachead $316.74 at the closing of the latest trading day, reflecting a -1.53% change compared to its last close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default109.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.99246"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.154659,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.596978",
        "ticker_sentiment_score": "0.207337",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "NVO Stock Falls 5% in a Month: Should Investors Buy Now or Wait?",
    "url": "https://www.zacks.com/stock/news/2354260/nvo-stock-falls-5-in-a-month-should-investors-buy-now-or-wait",
    "time_published": "20241021T155900",
    "authors": [
      "Ahan Chakraborty"
    ],
    "summary": "Despite the current downward trend of Novo Nordisk, it is an excellent stock to buy for long-term gains, driven by the stellar performance of its GLP-1 drugs.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.976671"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99793"
      }
    ],
    "overall_sentiment_score": 0.237029,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.13459",
        "ticker_sentiment_score": "0.155985",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.067536",
        "ticker_sentiment_score": "0.111458",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.067536",
        "ticker_sentiment_score": "0.111458",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.502207",
        "ticker_sentiment_score": "0.385554",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Should You Invest in the VanEck Biotech ETF  ( BBH ) ?",
    "url": "https://www.zacks.com/stock/news/2354481/should-you-invest-in-the-vaneck-biotech-etf-bbh",
    "time_published": "20241022T102007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default166.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.186298,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.071096",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.071096",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.071096",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition - Roche Holding  ( OTC:RHHBY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/10/41505575/roches-q3-sales-surge-led-by-ocrevus-vabysmo-urges-regulators-to-block-novo-holdings-16-5b-catale",
    "time_published": "20241023T230527",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Wednesday, Roche Holdings AG RHHBY released its third-quarter sales report. Sales increased 9% year over year to 15.14 billion Swiss francs ( ~$17.5 billion ) . The company's pharmaceuticals division reported sales of 11.62 billion Swiss francs.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/23/Roche.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.052678,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VKTX",
        "relevance_score": "0.163354",
        "ticker_sentiment_score": "-0.05335",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.163354",
        "ticker_sentiment_score": "-0.05335",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.319933",
        "ticker_sentiment_score": "-0.016659",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.163354",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GPCR",
        "relevance_score": "0.163354",
        "ticker_sentiment_score": "-0.05335",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.163354",
        "ticker_sentiment_score": "-0.05335",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.163354",
        "ticker_sentiment_score": "-0.05335",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen  ( AMGN )  Dips More Than Broader Market: What You Should Know",
    "url": "https://www.zacks.com/stock/news/2356298/amgen-amgn-dips-more-than-broader-market-what-you-should-know",
    "time_published": "20241023T215020",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the closing of the recent trading day, Amgen (AMGN) stood at $314.90, denoting a -1.49% change from the preceding trading day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default266.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.95493"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.142693,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.56415",
        "ticker_sentiment_score": "0.190963",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "A Closer Look at Amgen's Options Market Dynamics - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/insights/options/24/10/41500888/a-closer-look-at-amgens-options-market-dynamics",
    "time_published": "20241023T201538",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Whales with a lot of money to spend have taken a noticeably bearish stance on Amgen. Looking at options history for Amgen AMGN we detected 28 trades. If we consider the specifics of each trade, it is accurate to state that 42% of the investors opened trades with bullish expectations and 46% with ...",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1729714534_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      }
    ],
    "overall_sentiment_score": 0.088401,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.629492",
        "ticker_sentiment_score": "-0.003648",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen Gears Up to Report Q3 Earnings: Here's What to Expect",
    "url": "https://www.zacks.com/stock/news/2356191/amgen-gears-up-to-report-q3-earnings-heres-what-to-expect",
    "time_published": "20241023T190000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Volume growth from AMGN's key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.99998"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.155403,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.25142",
        "ticker_sentiment_score": "0.162845",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.202366",
        "ticker_sentiment_score": "0.109128",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.25142",
        "ticker_sentiment_score": "-0.162269",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Amgen  ( AMGN )  Earnings Expected to Grow: What to Know Ahead of Next Week's Release",
    "url": "https://www.zacks.com/stock/news/2355940/amgen-amgn-earnings-expected-to-grow-what-to-know-ahead-of-next-weeks-release",
    "time_published": "20241023T140144",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default331.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.126118,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "RGEN",
        "relevance_score": "0.175539",
        "ticker_sentiment_score": "-0.002855",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.260652",
        "ticker_sentiment_score": "0.053512",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Kymera Therapeutics, Inc.  ( KYMR )  Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release",
    "url": "https://www.zacks.com/stock/news/2356861/kymera-therapeutics-inc-kymr-expected-to-beat-earnings-estimates-what-to-know-ahead-of-q3-release",
    "time_published": "20241024T140126",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Kymera Therapeutics (KYMR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default199.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.152025,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KYMR",
        "relevance_score": "0.260189",
        "ticker_sentiment_score": "0.172834",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.175221",
        "ticker_sentiment_score": "-0.024272",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Lilly Stock a Portfolio Must Have Ahead of its Q3 Earnings?",
    "url": "https://www.zacks.com/stock/news/2356609/is-lilly-stock-a-portfolio-must-have-ahead-of-its-q3-earnings",
    "time_published": "20241024T125000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines Mounjaro and Zepbound.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.990678"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      }
    ],
    "overall_sentiment_score": 0.289427,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.477401",
        "ticker_sentiment_score": "0.424762",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.078354",
        "ticker_sentiment_score": "0.157476",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.078354",
        "ticker_sentiment_score": "0.157476",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.078354",
        "ticker_sentiment_score": "0.157476",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.078354",
        "ticker_sentiment_score": "0.175858",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "What Lies in Store for Healthcare ETFs in Q3 Earnings?",
    "url": "https://www.zacks.com/stock/news/2357907/what-lies-in-store-for-healthcare-etfs-in-q3-earnings",
    "time_published": "20241025T150000",
    "authors": [
      "Sweta Killa"
    ],
    "summary": "Big stocks are likely to dominate the returns of the healthcare ETF going into Q3 earnings announcements.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3c/2723.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.995015"
      }
    ],
    "overall_sentiment_score": 0.15352,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.232439",
        "ticker_sentiment_score": "0.108324",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.175433",
        "ticker_sentiment_score": "-0.008537",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.232439",
        "ticker_sentiment_score": "0.02845",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.232439",
        "ticker_sentiment_score": "0.160577",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.010135",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Ahead of Amgen  ( AMGN )  Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics",
    "url": "https://www.zacks.com/stock/news/2357626/ahead-of-amgen-amgn-q3-earnings-get-ready-with-wall-street-estimates-for-key-metrics",
    "time_published": "20241025T131527",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Besides Wall Street's top -and-bottom-line estimates for Amgen (AMGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default235.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.986564"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.120234,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.359707",
        "ticker_sentiment_score": "0.191279",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Here is What to Know Beyond Why Amgen Inc.  ( AMGN )  is a Trending Stock",
    "url": "https://www.zacks.com/stock/news/2357605/here-is-what-to-know-beyond-why-amgen-inc-amgn-is-a-trending-stock",
    "time_published": "20241025T130011",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default156.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.215507,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.486627",
        "ticker_sentiment_score": "0.098367",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Reliable Dividend Stocks You Can Buy and Hold Forever",
    "url": "https://www.fool.com/investing/2024/10/26/2-reliable-dividend-stocks-you-can-buy-and-hold-fo/",
    "time_published": "20241026T083000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "There are reasons beyond the dividends to invest in these stocks.",
    "banner_image": "https://media.ycharts.com/charts/c4e5b92038861f3adbf6012ed6901edf.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      }
    ],
    "overall_sentiment_score": 0.315162,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MA",
        "relevance_score": "0.04912",
        "ticker_sentiment_score": "0.260223",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.377855",
        "ticker_sentiment_score": "0.259575",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "V",
        "relevance_score": "0.377855",
        "ticker_sentiment_score": "0.269176",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split",
    "url": "https://www.fool.com/investing/2024/10/28/stock-split-watch-2-healthcare-stocks-that-look-re/",
    "time_published": "20241028T082000",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "One of these players has split its stock in the past. The other one hasn't.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F795314%2Fgettyimages-936284004.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.918141"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.088232,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.050894",
        "ticker_sentiment_score": "-0.01898",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.201523",
        "ticker_sentiment_score": "-0.016053",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CMG",
        "relevance_score": "0.050894",
        "ticker_sentiment_score": "-0.01898",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.050894",
        "ticker_sentiment_score": "0.046987",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.101582",
        "ticker_sentiment_score": "-0.014062",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.050894",
        "ticker_sentiment_score": "0.107993",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.050894",
        "ticker_sentiment_score": "0.186747",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.050894",
        "ticker_sentiment_score": "-0.01898",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen  ( AMGN )  Beats Q3 Earnings Estimates",
    "url": "https://www.zacks.com/stock/news/2361040/amgen-amgn-beats-q3-earnings-estimates",
    "time_published": "20241030T211505",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) delivered earnings and revenue surprises of 9.20% and 0.04%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default5.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999992"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.148425,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.401331",
        "ticker_sentiment_score": "0.145825",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IGMS",
        "relevance_score": "0.207571",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights - Novartis  ( NYSE:NVS ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41634528/positive-outlook-for-novartis-as-company-capitalizes-on-growing-treatment-opportuni",
    "time_published": "20241030T191203",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Tuesday, Novartis AG NVS reported third-quarter sales of $12.823 billion, up 9% ( +10% on constant currency ) , beating the consensus of $12.76 billion. Guidance: Novartis also raised its 2024 full-year guidance again this year.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/30/Stein--Switzerland---February-18--2020-N.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.222077,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KYMR",
        "relevance_score": "0.145583",
        "ticker_sentiment_score": "0.313386",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.145583",
        "ticker_sentiment_score": "0.117188",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INCY",
        "relevance_score": "0.145583",
        "ticker_sentiment_score": "0.313386",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.21686",
        "ticker_sentiment_score": "-0.123398",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.145583",
        "ticker_sentiment_score": "0.313386",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.073098",
        "ticker_sentiment_score": "-0.114885",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.145583",
        "ticker_sentiment_score": "0.050921",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "YMAB",
        "relevance_score": "0.145583",
        "ticker_sentiment_score": "0.117188",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.145583",
        "ticker_sentiment_score": "0.050921",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.145583",
        "ticker_sentiment_score": "0.152993",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.145583",
        "ticker_sentiment_score": "0.117188",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Wall Street Mixed, Semiconductors Tumble As AMD Disappoints, Alphabet Rallies, SMCI Plummets: What's Driving Markets Wednesday? - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/markets/cryptocurrency/24/10/41632224/wall-street-mixed-semiconductors-tumble-as-amd-disappoints-alphabet-rallies-smci-plummets-",
    "time_published": "20241030T173506",
    "authors": [
      "Piero Cingari"
    ],
    "summary": "Wall Street experienced a mixed trading session on Wednesday as investors weigh a batch of corporate earnings and fresh economic data. The U.S. economy grew at an annualized rate of 2.8% in the third quarter, according to advance estimates.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/30/semiconductor.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.839681"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      }
    ],
    "overall_sentiment_score": 0.193292,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.071784",
        "ticker_sentiment_score": "0.29601",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MDLZ",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RDDT",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "-0.327517",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.071784",
        "ticker_sentiment_score": "0.383541",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "SNAP",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADP",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "0.13792",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "V",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAT",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMD",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "-0.083351",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CMG",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BKNG",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CB",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.222777",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Amgen Q3 Earnings Beat, Sales In Line, Obesity Candidate in Focus",
    "url": "https://www.zacks.com/stock/news/2361422/amgen-q3-earnings-beat-sales-in-line-obesity-candidate-in-focus",
    "time_published": "20241031T114300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AMGN beats third-quarter estimates for earnings and matches the same for sales. It slightly raises 2024 sales guidance but narrows the EPS range.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/39/612.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.972476"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.118796,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.055046",
        "ticker_sentiment_score": "0.024004",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.419298",
        "ticker_sentiment_score": "0.180918",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.137044",
        "ticker_sentiment_score": "0.261416",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.055046",
        "ticker_sentiment_score": "0.024004",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen  ( AMGN )  Q3 2024 Earnings Call Transcript",
    "url": "https://www.fool.com/earnings/call-transcripts/2024/10/30/amgen-amgn-q3-2024-earnings-call-transcript/",
    "time_published": "20241031T001513",
    "authors": [
      "Motley Fool Transcribing"
    ],
    "summary": "AMGN earnings call for the period ending September 30, 2024.",
    "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.997405"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.294818,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "EVR",
        "relevance_score": "0.004354",
        "ticker_sentiment_score": "0.17391",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.004354",
        "ticker_sentiment_score": "0.182111",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.02177",
        "ticker_sentiment_score": "0.161652",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.004354",
        "ticker_sentiment_score": "0.243911",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.004354",
        "ticker_sentiment_score": "0.182111",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.004354",
        "ticker_sentiment_score": "0.17391",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.030474",
        "ticker_sentiment_score": "0.163391",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Novo Nordisk Before Q3 Earnings: How Should Investors Play the Stock?",
    "url": "https://www.zacks.com/stock/news/2363193/novo-nordisk-before-q3-earnings-how-should-investors-play-the-stock",
    "time_published": "20241104T140600",
    "authors": [
      "Ahan Chakraborty"
    ],
    "summary": "NVO's third-quarter revenues are expected to have been driven by its diabetes and obesity care product sales, especially Wegovy, Ozempic and Rybelsus.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999996"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.296334,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.148731",
        "ticker_sentiment_score": "0.177889",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.074692",
        "ticker_sentiment_score": "0.140769",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.247493",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.074692",
        "ticker_sentiment_score": "0.140769",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.574476",
        "ticker_sentiment_score": "0.476382",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Upstream Bio Can Beat AstraZeneca Asthma Drug: Analyst - Upstream Bio  ( NASDAQ:UPB ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41756467/upstream-bio-is-new-on-nasdaq-can-potentially-beat-astrazenecas-asthma-drug-on-effi",
    "time_published": "20241105T200934",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Just two weeks ago, Upstream Bio, Inc. UPB closed its upsized initial public offering ( IPO ) of 17.25 million shares at $17 per share, with gross proceeds of approximately $293 million.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/05/UpStream-Bio.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.200371,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "REGN",
        "relevance_score": "0.186738",
        "ticker_sentiment_score": "-0.006006",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.186738",
        "ticker_sentiment_score": "0.201534",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.186738",
        "ticker_sentiment_score": "0.201534",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UPB",
        "relevance_score": "0.521465",
        "ticker_sentiment_score": "-0.121536",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.186738",
        "ticker_sentiment_score": "-0.006006",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Investors Heavily Search Amgen Inc.  ( AMGN ) : Here is What You Need to Know",
    "url": "https://www.zacks.com/stock/news/2364208/investors-heavily-search-amgen-inc-amgn-here-is-what-you-need-to-know",
    "time_published": "20241105T140012",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default10.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.231183,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.488469",
        "ticker_sentiment_score": "0.092673",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Are You a Value Investor? This 1 Stock Could Be the Perfect Pick",
    "url": "https://www.zacks.com/stock/news/2365228/are-you-a-value-investor-this-1-stock-could-be-the-perfect-pick",
    "time_published": "20241106T144013",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default153.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      }
    ],
    "overall_sentiment_score": 0.41064,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.376194",
        "ticker_sentiment_score": "0.226941",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Investors Like Certainty. Trump's Win Gave Them Some.",
    "url": "https://www.fool.com/investing/2024/11/08/investors-like-certainty-trumps-win-gave-them-some/",
    "time_published": "20241108T161200",
    "authors": [
      "Motley Fool Staff"
    ],
    "summary": "We're also talking about Super Micro, Nvidia, and weight loss.",
    "banner_image": "https://g.foolcdn.com/editorial/images/797019/mfm_06.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.998682"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.988787"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.123213,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.010238",
        "ticker_sentiment_score": "0.058789",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.152628",
        "ticker_sentiment_score": "0.08558",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.030707",
        "ticker_sentiment_score": "0.0422",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HON",
        "relevance_score": "0.010238",
        "ticker_sentiment_score": "0.021327",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.061368",
        "ticker_sentiment_score": "0.039156",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.010238",
        "ticker_sentiment_score": "-0.078472",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.010238",
        "ticker_sentiment_score": "0.021327",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COIN",
        "relevance_score": "0.010238",
        "ticker_sentiment_score": "0.066853",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.020474",
        "ticker_sentiment_score": "0.025734",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.010238",
        "ticker_sentiment_score": "0.066853",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "T",
        "relevance_score": "0.020474",
        "ticker_sentiment_score": "0.054949",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INTC",
        "relevance_score": "0.051155",
        "ticker_sentiment_score": "0.064759",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.020474",
        "ticker_sentiment_score": "0.060282",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.051155",
        "ticker_sentiment_score": "0.024997",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.010238",
        "ticker_sentiment_score": "0.021327",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.010238",
        "ticker_sentiment_score": "0.194847",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "AstraZeneca/Amgen's Asthma Drug Aces Late-Stage Study In Patients With Chronic Rhinosinusitis - AstraZeneca  ( NASDAQ:AZN ) , Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/general/biotech/24/11/41843534/astrazeneca-amgens-asthma-drug-aces-late-stage-study-in-patients-with-chronic-rhinosinusitis",
    "time_published": "20241108T134714",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "AstraZeneca Plc AZN and Amgen Inc AMGN released topline data from the Phase 3 WAYPOINT trial of Tezspire ( tezepelumab ) in patients with chronic rhinosinusitis with nasal polyps ( CRSwNP [nasal polyps] )",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.0,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.340915",
        "ticker_sentiment_score": "-0.078096",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.340915",
        "ticker_sentiment_score": "-0.078096",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly Falls More Than 10% in a Month: Buy, Sell or Hold the Stock?",
    "url": "https://www.zacks.com/stock/news/2368432/eli-lilly-falls-more-than-10-in-a-month-buy-sell-or-hold-the-stock",
    "time_published": "20241111T200000",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "One can stay invested in LLY stock as it still has growth prospects despite disappointing sales of Mounjaro and Zepbound in the third quarter.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.998356"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999162"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.206754,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.411434",
        "ticker_sentiment_score": "0.210962",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.03319",
        "ticker_sentiment_score": "0.194138",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.066322",
        "ticker_sentiment_score": "0.202645",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.099339",
        "ticker_sentiment_score": "0.04262",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.066322",
        "ticker_sentiment_score": "0.264081",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Is Invesco Biotechnology & Genome ETF  ( PBE )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2367860/is-invesco-biotechnology-genome-etf-pbe-a-strong-etf-right-now",
    "time_published": "20241111T112008",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default321.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999981"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.305602,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "IVZ",
        "relevance_score": "0.170475",
        "ticker_sentiment_score": "0.266934",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.114137",
        "ticker_sentiment_score": "0.060868",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ILMN",
        "relevance_score": "0.114137",
        "ticker_sentiment_score": "0.060868",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UTHR",
        "relevance_score": "0.114137",
        "ticker_sentiment_score": "0.060868",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AstraZeneca Beats on Q3 Earnings, Ups 2024 View, to Invest $3.5B in US",
    "url": "https://www.zacks.com/stock/news/2369187/astrazeneca-beats-on-q3-earnings-ups-2024-view-to-invest-35b-in-us",
    "time_published": "20241112T200000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AZN beats third-quarter estimates for earnings and sales. It raises its sales and profit outlook for 2024 for the second time this year.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/88/898.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.980509"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      }
    ],
    "overall_sentiment_score": 0.193919,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SKXJF",
        "relevance_score": "0.027667",
        "ticker_sentiment_score": "0.119605",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSKYF",
        "relevance_score": "0.027667",
        "ticker_sentiment_score": "0.119605",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.082867",
        "ticker_sentiment_score": "0.138777",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.467555",
        "ticker_sentiment_score": "0.230692",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.110335",
        "ticker_sentiment_score": "0.117899",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:NXC",
        "relevance_score": "0.027667",
        "ticker_sentiment_score": "-0.218647",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "AstraZeneca Beats on Q3 Earnings, Ups 2024 View, to Invest $3.5B in US",
    "url": "https://www.zacks.com/stock/news/2369187/astrazeneca-beats-on-q3-earnings-ups-2024-view-to-invest-35b-in-us",
    "time_published": "20241112T200000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AZN beats third-quarter estimates for earnings and sales. It raises its sales and profit outlook for 2024 for the second time this year.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/88/898.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.988787"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      }
    ],
    "overall_sentiment_score": 0.196262,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SKXJF",
        "relevance_score": "0.02668",
        "ticker_sentiment_score": "0.119189",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSKYF",
        "relevance_score": "0.02668",
        "ticker_sentiment_score": "0.119189",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.079921",
        "ticker_sentiment_score": "0.137817",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.474866",
        "ticker_sentiment_score": "0.22155",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.106423",
        "ticker_sentiment_score": "0.116379",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:NXC",
        "relevance_score": "0.02668",
        "ticker_sentiment_score": "-0.217802",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/general/biotech/24/11/41950871/amgen-defends-its-investigational-monthly-weight-loss-injection-after-analyst-cites-maritides-imp",
    "time_published": "20241113T185920",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Tuesday, a Cantor analyst wrote that additional data from Amgen's experimental weight loss injection, MariTide, suggests a new potential safety risk tied to the drug.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/13/Amgen-stock.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.031369,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "0.133579",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "-0.172874",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.327366",
        "ticker_sentiment_score": "0.152959",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "0.133579",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) , Sanofi  ( NASDAQ:SNY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/11/41945225/regeneron-sanofis-dupixent-approval-signals-major-treatment-breakthrough-for-smokers-lung-disease",
    "time_published": "20241113T160609",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "After years of limited advancements in chronic obstructive pulmonary disease ( COPD ) treatment, patients now have new options. Regeneron Pharmaceuticals Inc REGN and Sanofi SA's SNY Dupixent recently gained FDA approval for COPD, marking its sixth U.S. indication since its first use for ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/13/Doctor-Examining-A-Lung-Radiography.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.084004,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "SSTK",
        "relevance_score": "0.083541",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.246999",
        "ticker_sentiment_score": "0.13545",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.166169",
        "ticker_sentiment_score": "0.222167",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.166169",
        "ticker_sentiment_score": "-0.032233",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.246999",
        "ticker_sentiment_score": "0.309949",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Jim Cramer Says Eli Lilly's 'Pathetic' Stock Performance Could Get A Breather If Amgen Has Hidden Bone Risk Data After 7% Stock Drop - Eli Lilly  ( NYSE:LLY ) , Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/general/health-care/24/11/41928127/jim-cramer-says-eli-lillys-pathetic-stock-performance-could-get-a-breather-if-amgen-has-hidde",
    "time_published": "20241113T031233",
    "authors": [
      "Kaustubh Bagalkote"
    ],
    "summary": "Amgen Inc.'s AMGN stock dropped over 7% on Tuesday following revelations about bone density loss in early trials of its experimental obesity drug MariTide, while CNBC's Jim Cramer suggested the news could benefit rival Eli Lilly And Co LLY.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/12/Eli-Lilly.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      }
    ],
    "overall_sentiment_score": 0.029061,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.518022",
        "ticker_sentiment_score": "-0.056193",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.587962",
        "ticker_sentiment_score": "-0.102365",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.185306",
        "ticker_sentiment_score": "0.032978",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen Shrugs Off Bone Density Concerns Related to Obesity Candidate",
    "url": "https://www.zacks.com/stock/news/2370660/amgen-shrugs-off-bone-density-concerns-related-to-obesity-candidate",
    "time_published": "20241114T200000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AMGN says there was no connection between the administration of MariTide and bone mineral density changes.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/62/5473.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.045529,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.574608",
        "ticker_sentiment_score": "-0.082692",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.056631",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "-0.012679",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen's Options Frenzy: What You Need to Know - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/insights/options/24/11/41978876/amgens-options-frenzy-what-you-need-to-know",
    "time_published": "20241114T161547",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Deep-pocketed investors have adopted a bullish approach towards Amgen AMGN, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1731600944_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.178948,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.669433",
        "ticker_sentiment_score": "0.18381",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "C",
        "relevance_score": "0.064623",
        "ticker_sentiment_score": "0.048053",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Dividend Stocks to Buy Hand Over Fist in November",
    "url": "https://www.fool.com/investing/2024/11/14/2-dividend-stocks-to-buy-hand-over-fist-november/",
    "time_published": "20241114T151500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "These companies have solid businesses and excellent dividend growth track records.",
    "banner_image": "https://g.foolcdn.com/editorial/images/797409/pharmacist-talking-to-patient.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.938793"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.30695,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.528798",
        "ticker_sentiment_score": "0.274951",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.399734",
        "ticker_sentiment_score": "0.306577",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.052226",
        "ticker_sentiment_score": "0.023093",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Want Decades of Passive Income? Buy This Index Fund and Hold It Forever",
    "url": "https://www.fool.com/investing/2024/11/15/want-decades-of-passive-income-buy-this-index-fund/",
    "time_published": "20241115T101500",
    "authors": [
      "Justin Pope"
    ],
    "summary": "This fund could be the perfect investment for those wanting financial freedom through endlessly growing dividends.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F797289%2Fsnow.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.269551,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.056011",
        "ticker_sentiment_score": "-0.053009",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LMT",
        "relevance_score": "0.056011",
        "ticker_sentiment_score": "0.0549",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CSCO",
        "relevance_score": "0.056011",
        "ticker_sentiment_score": "0.0549",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.056011",
        "ticker_sentiment_score": "0.0549",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.056011",
        "ticker_sentiment_score": "0.0549",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UPS",
        "relevance_score": "0.111747",
        "ticker_sentiment_score": "0.060394",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TXN",
        "relevance_score": "0.056011",
        "ticker_sentiment_score": "0.0549",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HD",
        "relevance_score": "0.056011",
        "ticker_sentiment_score": "0.0549",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.056011",
        "ticker_sentiment_score": "0.0549",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.056011",
        "ticker_sentiment_score": "0.0549",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Reasons to Buy Amgen Stock, and 1 Reason to Be Cautious",
    "url": "https://www.fool.com/investing/2024/11/16/2-reasons-to-buy-amgen-and-1-reason-to-be-cautious/",
    "time_published": "20241116T134500",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "Its future is bright, but that doesn't mean it'll always be smooth sailing.",
    "banner_image": "https://g.foolcdn.com/editorial/images/797556/scientist-examines-samples-with-microscope-while-in-laboratory.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      }
    ],
    "overall_sentiment_score": 0.17095,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.284861",
        "ticker_sentiment_score": "0.173386",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.058188",
        "ticker_sentiment_score": "0.272052",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "AMGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Amgen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/pressreleases/24/11/g42021942/amgen-alert-bragar-eagel-squire-p-c-is-investigating-amgen-inc-on-behalf-of-long-term-stockholders",
    "time_published": "20241116T020000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, Nov. 15, 2024 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Amgen Inc.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.891286"
      }
    ],
    "overall_sentiment_score": -0.060181,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.894261",
        "ticker_sentiment_score": "-0.167129",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Neurogene, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session - NVIDIA  ( NASDAQ:NVDA ) ",
    "url": "https://www.benzinga.com/trading-ideas/movers/24/11/42039633/neurogene-nvidia-and-other-big-stocks-moving-lower-in-mondays-pre-market-session",
    "time_published": "20241118T151217",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "U.S. stock futures were mixed this morning, with the Dow futures falling more than 100 points on Monday. Shares of Neurogene Inc. NGNE fell sharply in today's pre-market trading after the company announced it brought its high-dose gene therapy trial to a halt after a serious adverse event in a ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/18/Nvidia-Corporation-NVDA.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.658903"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": -0.150375,
    "overall_sentiment_label": "Somewhat-Bearish",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.280615",
        "ticker_sentiment_score": "-0.35904",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "RZLV",
        "relevance_score": "0.280615",
        "ticker_sentiment_score": "-0.27346",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "CMPO",
        "relevance_score": "0.280615",
        "ticker_sentiment_score": "-0.13475",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PRQR",
        "relevance_score": "0.280615",
        "ticker_sentiment_score": "-0.13475",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KSFTF",
        "relevance_score": "0.280615",
        "ticker_sentiment_score": "0.166815",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KC",
        "relevance_score": "0.410059",
        "ticker_sentiment_score": "0.220721",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.280615",
        "ticker_sentiment_score": "-0.375617",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "LAZR",
        "relevance_score": "0.280615",
        "ticker_sentiment_score": "-0.559699",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "LUNR",
        "relevance_score": "0.280615",
        "ticker_sentiment_score": "-0.096196",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OMER",
        "relevance_score": "0.280615",
        "ticker_sentiment_score": "-0.13475",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen Inc.  ( AMGN )  Is a Trending Stock: Facts to Know Before Betting on It",
    "url": "https://www.zacks.com/stock/news/2371451/amgen-inc-amgn-is-a-trending-stock-facts-to-know-before-betting-on-it",
    "time_published": "20241118T140012",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default289.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.195256,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.482078",
        "ticker_sentiment_score": "0.082737",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Dow Tumbles Over 300 Points Following Economic Reports, Nvidia, Microsoft Decline: Fear & Greed Index Moves To 'Neutral' Zone - NVIDIA  ( NASDAQ:NVDA ) ",
    "url": "https://www.benzinga.com/24/11/42029943/dow-tumbles-over-300-points-following-economic-reports-investor-sentiment-declines-fear-greed-index-moves-to-neut",
    "time_published": "20241118T080706",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "The CNN Money Fear and Greed index showed a further decline in the overall market sentiment, with the index moving to the \"Neutral\" zone on Friday. U.S. stocks settled lower on Friday, with the Dow Jones falling more than 300 points during the session.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/18/Market-Sentiment--Fear-And-Greed-Index--.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": -0.223549,
    "overall_sentiment_label": "Somewhat-Bearish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.186738",
        "ticker_sentiment_score": "0.003279",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.186738",
        "ticker_sentiment_score": "0.003279",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRC",
        "relevance_score": "0.186738",
        "ticker_sentiment_score": "-0.164514",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.186738",
        "ticker_sentiment_score": "0.003279",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WBD",
        "relevance_score": "0.09402",
        "ticker_sentiment_score": "-0.293977",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "ACM",
        "relevance_score": "0.186738",
        "ticker_sentiment_score": "-0.164514",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.186738",
        "ticker_sentiment_score": "0.034082",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.186738",
        "ticker_sentiment_score": "0.034082",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stock Market News for Nov 18, 2024",
    "url": "https://www.zacks.com/stock/news/2371293/stock-market-news-for-nov-18-2024",
    "time_published": "20241118T080700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Wall Street continues its decline on Friday following the Fed Chairman???s hawkish statement on rate cut.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/89/447.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.890401"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.967645"
      }
    ],
    "overall_sentiment_score": -0.067292,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MRNA",
        "relevance_score": "0.105141",
        "ticker_sentiment_score": "0.030928",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.105141",
        "ticker_sentiment_score": "0.030928",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.157141",
        "ticker_sentiment_score": "0.037916",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst - Silence Therapeutics  ( NASDAQ:SLN ) ",
    "url": "https://www.benzinga.com/24/11/42073596/analyst-sees-competitive-concerns-for-silence-therapeutics-zerlasiran",
    "time_published": "20241119T203442",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Monday, Silence Therapeutics plc SLN presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran in atherosclerotic cardiovascular disease ( ASCVD ) patients with high lipoprotein ( a ) [Lp ( a ) ] levels ( \u2265125 nmol/L ) .",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/19/Soleno-Therapeutics-SLNO.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.123164,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "SLN",
        "relevance_score": "0.30569",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.206685",
        "ticker_sentiment_score": "0.180587",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Decoding Amgen's Options Activity: What's the Big Picture? - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/insights/options/24/11/42096750/decoding-amgens-options-activity-whats-the-big-picture",
    "time_published": "20241120T185022",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Financial giants have made a conspicuous bullish move on Amgen. Our analysis of options history for Amgen AMGN revealed 8 unusual trades. Delving into the details, we found 37% of traders were bullish, while 37% showed bearish tendencies.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1732128618_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      }
    ],
    "overall_sentiment_score": 0.152454,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.815958",
        "ticker_sentiment_score": "0.125759",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels",
    "url": "https://www.zacks.com/stock/news/2372893/sln-stock-down-despite-cholesterol-drug-lowering-lipoprotein-levels",
    "time_published": "20241120T160400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Silence Therapeutics stock falls despite lowering lipoprotein levels in a phase II study of zerlasiran likely due to concerns regarding its competitive profile.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ab/11156.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.019021,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ALLO",
        "relevance_score": "0.311631",
        "ticker_sentiment_score": "0.101711",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SLN",
        "relevance_score": "0.529659",
        "ticker_sentiment_score": "-0.010031",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.311631",
        "ticker_sentiment_score": "-0.097559",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.190167",
        "ticker_sentiment_score": "0.122727",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly Stock Tumbles As Kennedy Targets Weight Loss Drugs - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/24/11/42119511/eli-lilly-stock-tumbles-as-rfk-jr-targets-weight-loss-drugs-buying-opportunity",
    "time_published": "20241121T174749",
    "authors": [
      "Surbhi Jain"
    ],
    "summary": "Eli Lilly and Co. LLY has seen better days. The stock is up 26.04% for the last year but has struggled recently, falling 17.57% over the last month. Lilly stock is well below its summer highs and is trading at $746.94 at the time of writing.",
    "banner_image": "https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21061153/Screenshot-2024-11-21-at-4.40.52-PM.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.989041"
      }
    ],
    "overall_sentiment_score": 0.031875,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.468029",
        "ticker_sentiment_score": "-0.285155",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.197413",
        "ticker_sentiment_score": "-0.124465",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.197413",
        "ticker_sentiment_score": "-0.124465",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Novo Nordisk Plunges 25% in 3 Months: How to Play the Stock",
    "url": "https://www.zacks.com/stock/news/2374141/novo-nordisk-plunges-25-in-3-months-how-to-play-the-stock",
    "time_published": "20241122T162800",
    "authors": [
      "Ahan Chakraborty"
    ],
    "summary": "Despite the current downward trend of NVO, it is a good stock to retain in one's portfolio for long-term gains due to strong demand for its GLP-1 drugs.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99977"
      }
    ],
    "overall_sentiment_score": 0.262262,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.113776",
        "ticker_sentiment_score": "0.094098",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.075995",
        "ticker_sentiment_score": "0.178297",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.075995",
        "ticker_sentiment_score": "0.178297",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.495692",
        "ticker_sentiment_score": "0.339054",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Amgen Reveals Data From Closely Watched Monthly Obesity Drug, With Weight Loss Of Up To 20% At One Year And No Plateau - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/24/11/42189129/amgen-reveals-data-from-closely-watched-monthly-obesity-drug-with-weight-loss-of-up-to-20-at-one-year-and-no-plat",
    "time_published": "20241126T133656",
    "authors": [],
    "summary": "On Tuesday, Amgen Inc AMGN stock fell during the premarket session after the company released long-anticipated data from the Phase 2 study of MariTide ( maridebart cafraglutide, formerly AMG 133 ) in obese patients.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/26/Doctor-Measuring-Obese-Man-Waist-Body-Fa.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": -0.128036,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.448316",
        "ticker_sentiment_score": "-0.30497",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "AMGN Stock Down Despite Strong Data From Obesity Drug Study",
    "url": "https://www.zacks.com/stock/news/2376286/amgn-stock-down-despite-strong-data-from-obesity-drug-study",
    "time_published": "20241127T200000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Data from a phase II study shows that AMGN's obesity drug MariTide leads to sustainable weight loss, robust improvements in cardiometabolic parameters and strong HbA1c reduction.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/82/41137.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": -0.029202,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.575261",
        "ticker_sentiment_score": "0.071829",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.105836",
        "ticker_sentiment_score": "0.127685",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "LLY, NVO Stock Up as Biden Proposes Medicare Cover for Obesity Drugs",
    "url": "https://www.zacks.com/stock/news/2376034/lly-nvo-stock-up-as-biden-proposes-medicare-cover-for-obesity-drugs",
    "time_published": "20241127T144600",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "The Biden administration believes that including obesity drugs in Medicare coverage will reduce out-of-pocket costs for the drugs and make them affordable.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c8/39674.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.17319,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.405651",
        "ticker_sentiment_score": "0.277599",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.140896",
        "ticker_sentiment_score": "0.172955",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.070725",
        "ticker_sentiment_score": "0.141827",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.140896",
        "ticker_sentiment_score": "0.172955",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.465599",
        "ticker_sentiment_score": "0.310952",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why Amgen's Weight Loss Result Is a Win for Eli Lilly",
    "url": "https://www.fool.com/investing/2024/11/27/why-amgens-success-is-a-win-for-eli-lilly/",
    "time_published": "20241127T085700",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "Shares of Amgen ( NASDAQ: AMGN ) recently ticked lower despite a very positive-sounding press release regarding its weight management candidate. According to the giant drugmaker, treatment with an anti-obesity candidate called MariTide helped patients reduce their weight by up to 20% after 52 ...",
    "banner_image": "https://g.foolcdn.com/editorial/images/799133/investor-doing-stuff-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.048263,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.113597",
        "ticker_sentiment_score": "0.11535",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.746902",
        "ticker_sentiment_score": "0.067079",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Personalized Medicines Market to Surpass Valuation of USD 1352.81 Billion by 2031 | SkyQuest Technology",
    "url": "https://www.benzinga.com/pressreleases/24/11/g42205102/personalized-medicines-market-to-surpass-valuation-of-usd-1352-81-billion-by-2031-skyquest-technol",
    "time_published": "20241127T003000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Westford, USA, Nov. 26, 2024 ( GLOBE NEWSWIRE ) -- SkyQuest projects that the global personalized medicines market size will reach a value of USD 1352.81 Billion by 2031, with a CAGR of 11.40% during the forecast period ( 2024-2031 ) .",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.412525,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MOLN",
        "relevance_score": "0.043979",
        "ticker_sentiment_score": "0.029234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GH",
        "relevance_score": "0.043979",
        "ticker_sentiment_score": "0.029234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDXH",
        "relevance_score": "0.043979",
        "ticker_sentiment_score": "0.029234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PSNL",
        "relevance_score": "0.043979",
        "ticker_sentiment_score": "0.029234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXAS",
        "relevance_score": "0.043979",
        "ticker_sentiment_score": "0.029234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIO",
        "relevance_score": "0.043979",
        "ticker_sentiment_score": "0.029234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.043979",
        "ticker_sentiment_score": "0.029234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.043979",
        "ticker_sentiment_score": "0.029234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.043979",
        "ticker_sentiment_score": "0.029234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SOPH",
        "relevance_score": "0.043979",
        "ticker_sentiment_score": "0.029234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.043979",
        "ticker_sentiment_score": "0.029234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MYGN",
        "relevance_score": "0.043979",
        "ticker_sentiment_score": "0.029234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QGEN",
        "relevance_score": "0.043979",
        "ticker_sentiment_score": "0.029234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.043979",
        "ticker_sentiment_score": "0.029234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TAK",
        "relevance_score": "0.043979",
        "ticker_sentiment_score": "0.029234",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Biotech Stock Roundup: BBIO Stock Up on Drug Approval, SAVA, APLT Plunge on Setbacks & More",
    "url": "https://www.zacks.com/stock/news/2377337/biotech-stock-roundup-bbio-stock-up-on-drug-approval-sava-aplt-plunge-on-setbacks-more",
    "time_published": "20241129T185100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "SAVA and APLT tank on pipeline and regulatory setbacks.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/55/1135.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.002453,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "APLT",
        "relevance_score": "0.193078",
        "ticker_sentiment_score": "0.111458",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BBIO",
        "relevance_score": "0.240014",
        "ticker_sentiment_score": "0.19582",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.145437",
        "ticker_sentiment_score": "-0.246128",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "SAVA",
        "relevance_score": "0.145437",
        "ticker_sentiment_score": "-0.03706",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen Inc.  ( AMGN )  is Attracting Investor Attention: Here is What You Should Know",
    "url": "https://www.zacks.com/stock/news/2376951/amgen-inc-amgn-is-attracting-investor-attention-here-is-what-you-should-know",
    "time_published": "20241129T140011",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default169.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.224349,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.482982",
        "ticker_sentiment_score": "0.11005",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Amgen Stock Still a Buy After an Unexpected Reveal of Data?",
    "url": "https://www.fool.com/investing/2024/11/29/is-amgen-stock-still-a-buy-after-an-unexpected-rev/",
    "time_published": "20241129T092800",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "Shares of Amgen ( NASDAQ: AMGN ) are down by 6% in the last 30 days as I write this -- a larger-than-normal amount for a large pharma company's stock to fall, especially considering that the market rose nearly 3% in the same period.",
    "banner_image": "https://g.foolcdn.com/editorial/images/799004/three-scientists-look-at-tablet-while-worried.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.050887,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.193852",
        "ticker_sentiment_score": "-0.079802",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.048919",
        "ticker_sentiment_score": "-0.034952",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Down 12.3% at One Point in a Single Trading Session, Is Amgen Stock Still a Buy?",
    "url": "https://www.fool.com/investing/2024/11/30/down-123-at-one-point-in-a-single-trading-session/",
    "time_published": "20241130T112000",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "The market didn't appreciate Amgen's ( NASDAQ: AMGN ) latest clinical data update, with the biopharma's shares falling more than 12% at one point on Nov. 26 from the previous day's close, though they recovered to close just 4.7% down for the day.And, with shares of certain direct competitors, ...",
    "banner_image": "https://g.foolcdn.com/editorial/images/799310/concerned-investor-with-two-people-in-background.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.1415,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.209365",
        "ticker_sentiment_score": "0.25178",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.260004",
        "ticker_sentiment_score": "0.150928",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.105604",
        "ticker_sentiment_score": "0.09004",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Nephropathic Cystinosis Treatment Market Poised to Reach Over US$ 744 Million by 2034 | Transparency Market Research",
    "url": "https://www.benzinga.com/pressreleases/24/12/g42270743/nephropathic-cystinosis-treatment-market-poised-to-reach-over-us-744-million-by-2034-transparency-",
    "time_published": "20241202T163000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, Transparency Market Research Inc., Dec. 02, 2024 ( GLOBE NEWSWIRE ) -- With a market valued at US$ 332.5 million in 2023, the nephropathic cystinosis treatment market ( mercado de tratamiento de cistinosis nefrop\u00e1tica ) is projected to grow at a CAGR of 7.4% from 2024 to ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/0c888331-16ae-4bee-8338-08f5106c6bfb/nephropathic-cystinosis-treatment-market.jpg",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.347404,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.041682",
        "ticker_sentiment_score": "0.054333",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.083251",
        "ticker_sentiment_score": "0.128753",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.124593",
        "ticker_sentiment_score": "0.070498",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VTRS",
        "relevance_score": "0.083251",
        "ticker_sentiment_score": "0.20109",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "This Stock Just Dropped by 12% in 1 Day: Should You Buy the Dip?",
    "url": "https://www.fool.com/investing/2024/12/02/this-stock-just-dropped-by-12-in-1-day-should-you/",
    "time_published": "20241202T130000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "The biotech industry can be volatile even for relatively large companies. Amgen ( NASDAQ: AMGN ) , one of the more prominent names in the game, just reminded us all of that fact. On Nov. 26, the company's shares dropped by as much as 12%.",
    "banner_image": "https://g.foolcdn.com/editorial/images/799306/nurse-holding-patients-hands.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.111695,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.629492",
        "ticker_sentiment_score": "0.265059",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.059488",
        "ticker_sentiment_score": "0.180174",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo's Dominance - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly  ( NYSE:LLY ) , Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/24/12/42291702/obesity-drug-wars-heat-up-amgen-challenges-eli-lilly-novos-dominance",
    "time_published": "20241203T141616",
    "authors": [
      "Surbhi Jain"
    ],
    "summary": "Amgen's MariTide challenges Lilly and Novo but falls short on efficacy and side effect profiles. Obesity market leaders Lilly and Novo strengthen dominance with advanced drugs nearing approval, eclipsing Amgen's MariTide. Benzinga shares with you top insiders news",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/03/weight-loss-shutter.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.203705,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.624172",
        "ticker_sentiment_score": "0.29196",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.420083",
        "ticker_sentiment_score": "0.150974",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.260189",
        "ticker_sentiment_score": "0.128612",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.175221",
        "ticker_sentiment_score": "0.071417",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the iShares Biotechnology ETF  ( IBB ) ?",
    "url": "https://www.zacks.com/stock/news/2378017/should-you-invest-in-the-ishares-biotechnology-etf-ibb",
    "time_published": "20241203T112008",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default274.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999999"
      }
    ],
    "overall_sentiment_score": 0.189123,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.136499",
        "ticker_sentiment_score": "0.072027",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.136499",
        "ticker_sentiment_score": "0.072027",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.136499",
        "ticker_sentiment_score": "0.072027",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Top Stock Reports for Amgen, Eaton & Enzo Biochem",
    "url": "https://www.zacks.com/research-daily/2378713/top-stock-reports-for-amgen-eaton-enzo-biochem",
    "time_published": "20241204T212800",
    "authors": [
      "Mark Vickery"
    ],
    "summary": "Today's Research Daily features new research reports on 16 major stocks, including Amgen Inc. (AMGN), Eaton Corp. plc (ETN) and Sony Group Corp. (SONY), as well as two micro-cap stocks, Moving iMage Technologies, Inc. (MITQ) and Enzo Biochem, Inc. (ENZ).",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/604.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.153729,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ENZ",
        "relevance_score": "0.121037",
        "ticker_sentiment_score": "0.099945",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNEJF",
        "relevance_score": "0.239305",
        "ticker_sentiment_score": "0.270183",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.180685",
        "ticker_sentiment_score": "0.153211",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ETN",
        "relevance_score": "0.180685",
        "ticker_sentiment_score": "0.164712",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Amgen Stock Falls 12% in a Month: Should You Buy the Dip?",
    "url": "https://www.zacks.com/stock/news/2378700/amgen-stock-falls-12-in-a-month-should-you-buy-the-dip",
    "time_published": "20241204T132900",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "AMGN's reasonable valuation, an interesting pipeline and continued top-line growth are good enough reasons to stay invested in the stock for now.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/13/816.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.145432,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.543004",
        "ticker_sentiment_score": "0.189027",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Eli Lilly Just Got a Bundle of Good News: Time to Buy?",
    "url": "https://www.fool.com/investing/2024/12/04/eli-lilly-just-got-multiple-good-news-time-to-buy/",
    "time_published": "20241204T121000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "The magic isn't over for Eli Lilly ( NYSE: LLY ) . Though the pharmaceutical giant isn't performing as well in the second half of the year as it did in the first, it still has plenty of fuel for growth. In fact, the drugmaker recently received some welcome news that jolted its stock price.The ...",
    "banner_image": "https://media.ycharts.com/charts/113bfec7c110430bdc4e44e43050e287.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.875462"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.168048,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.580595",
        "ticker_sentiment_score": "0.279756",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.098862",
        "ticker_sentiment_score": "0.038355",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.147818",
        "ticker_sentiment_score": "0.02698",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Amgen Still a Top Dividend Stock?",
    "url": "https://www.fool.com/investing/2024/12/05/is-amgen-still-a-top-dividend-stock/",
    "time_published": "20241205T122800",
    "authors": [
      "George Budwell"
    ],
    "summary": "The relationship between interest rates and dividend stocks tends to follow a predictable pattern. When the Federal Reserve signals a shift toward monetary easing, investors often rotate toward stable, high-yielding equities that can provide both income and potential appreciation.Amgen ( NASDAQ: ...",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F799868%2Fdividends.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.289687,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.229691",
        "ticker_sentiment_score": "0.135015",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "LLY's Zepbound Outshines NVO's Wegovy in Head-to-Head Obesity Study",
    "url": "https://www.zacks.com/stock/news/2379302/llys-zepbound-outshines-nvos-wegovy-in-head-to-head-obesity-study",
    "time_published": "20241205T113200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "LLY's obesity drug, Zepbound, shows an average weight loss of 20.2%, superior to 13.7% for NVO's Wegovy in a head-to-head study.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/82/41137.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.095653,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.541766",
        "ticker_sentiment_score": "0.056698",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.130926",
        "ticker_sentiment_score": "0.172449",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.065685",
        "ticker_sentiment_score": "0.019104",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.258351",
        "ticker_sentiment_score": "0.081093",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.130926",
        "ticker_sentiment_score": "-0.004847",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "This Healthcare Stock Is a Favorite of Billionaires. But Is It a Buy?",
    "url": "https://www.fool.com/investing/2024/12/05/healthcare-stock-favorite-of-billionaire-buy-lly/",
    "time_published": "20241205T103200",
    "authors": [
      "James Brumley"
    ],
    "summary": "Unsurprisingly, these stock pickers are capitalizing on an opportunity that's only recently become addressable.",
    "banner_image": "https://media.ycharts.com/charts/67ab82d1e1ac14a9612625c544122276.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.196331,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.047371",
        "ticker_sentiment_score": "0.063746",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.047371",
        "ticker_sentiment_score": "0.063746",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.486544",
        "ticker_sentiment_score": "0.260501",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MORN",
        "relevance_score": "0.047371",
        "ticker_sentiment_score": "-0.005972",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.047371",
        "ticker_sentiment_score": "0.032464",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.094576",
        "ticker_sentiment_score": "-0.006386",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.094576",
        "ticker_sentiment_score": "-0.006386",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.094576",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Amgen, Eaton, Sony, iMage and Enzo Biochem",
    "url": "https://www.zacks.com/stock/news/2379250/the-zacks-analyst-blog-highlights-amgen-eaton-sony-image-and-enzo-biochem",
    "time_published": "20241205T100000",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Amgen, Eaton, Sony, iMage and Enzo Biochem are included in this Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d9/1183.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.148568,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ENZ",
        "relevance_score": "0.115787",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNEJF",
        "relevance_score": "0.229149",
        "ticker_sentiment_score": "0.175156",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.172919",
        "ticker_sentiment_score": "0.070475",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ETN",
        "relevance_score": "0.172919",
        "ticker_sentiment_score": "0.092282",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly to Invest $3B in Wisconsin Plant to Meet Obesity Drug Demand",
    "url": "https://www.zacks.com/stock/news/2380315/eli-lilly-to-invest-3b-in-wisconsin-plant-to-meet-obesity-drug-demand",
    "time_published": "20241206T153400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Per Lilly, this is its single-largest manufacturing investment in the country outside its home state. It plans to start construction on the expansion next year.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.151255,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.591019",
        "ticker_sentiment_score": "0.197123",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.163539",
        "ticker_sentiment_score": "0.085956",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.054857",
        "ticker_sentiment_score": "0.101003",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.269181",
        "ticker_sentiment_score": "0.143479",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.109455",
        "ticker_sentiment_score": "0.061988",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "How to Play LLY Stock as Zepbound Beats NVO's Wegovy in Obesity Study",
    "url": "https://www.zacks.com/stock/news/2380023/how-to-play-lly-stock-as-zepbound-beats-nvos-wegovy-in-obesity-study",
    "time_published": "20241206T130100",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "The latest Zepbound data bodes well for Lilly and could help establish the drug as the new standard for obesity medications.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.998356"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.166682,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.390904",
        "ticker_sentiment_score": "0.163676",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.067919",
        "ticker_sentiment_score": "0.142491",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.03399",
        "ticker_sentiment_score": "0.002902",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.135347",
        "ticker_sentiment_score": "0.017445",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?",
    "url": "https://www.fool.com/investing/2024/12/07/should-you-buy-3-highest-dow-dividend-yields/",
    "time_published": "20241207T153900",
    "authors": [
      "Anders Bylund"
    ],
    "summary": "Looking for reliable income in the stock market? You might want to consider the top Dogs of the Dow in December. Here's what you need to know about this trio of blue-chip stocks.",
    "banner_image": "https://g.foolcdn.com/editorial/images/800011/dollar-bills-and-coins-on-a-calendar.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999864"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.039166,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "SHW",
        "relevance_score": "0.097655",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.146025",
        "ticker_sentiment_score": "0.021231",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.332403",
        "ticker_sentiment_score": "0.163078",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.146025",
        "ticker_sentiment_score": "-0.104407",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is iShares Biotechnology ETF  ( IBB )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2380648/is-ishares-biotechnology-etf-ibb-a-strong-etf-right-now",
    "time_published": "20241209T112006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default87.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999981"
      }
    ],
    "overall_sentiment_score": 0.248169,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.121343",
        "ticker_sentiment_score": "0.068087",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.121343",
        "ticker_sentiment_score": "0.068087",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.121343",
        "ticker_sentiment_score": "0.068087",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 No-Brainer Dividend Stocks With Yields Over 3% to Buy in 2025 and Hold for a Decade or Longer",
    "url": "https://www.fool.com/investing/2024/12/09/2-no-brainer-dividend-stocks-with-yields-over-3-to/",
    "time_published": "20241209T093600",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "Whether you're looking for a way to beat the benchmark S&P 500 index or you just want a steady flow of passive income, dividend-paying stocks are a great way to achieve your investment goals.Once companies commit to sharing a portion of their profits with shareholders, they act in ways that tend ...",
    "banner_image": "https://g.foolcdn.com/editorial/images/800186/investment-presentation2-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.186198,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CURN",
        "relevance_score": "0.112269",
        "ticker_sentiment_score": "0.031306",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.328091",
        "ticker_sentiment_score": "0.082711",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.328091",
        "ticker_sentiment_score": "0.227036",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.056275",
        "ticker_sentiment_score": "-0.007002",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Eli Lilly, Novo Nordisk's Amgen and Viking Therapeutics",
    "url": "https://www.zacks.com/stock/news/2380599/the-zacks-analyst-blog-eli-lilly-novo-nordisks-amgen-and-viking-therapeutics",
    "time_published": "20241209T065100",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Eli Lilly, Novo Nordisk's Amgen and Viking Therapeutics are included in this Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99977"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.171024,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.395492",
        "ticker_sentiment_score": "0.148572",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.095138",
        "ticker_sentiment_score": "0.048132",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.03178",
        "ticker_sentiment_score": "0.002878",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.157896",
        "ticker_sentiment_score": "0.010733",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here is What to Know Beyond Why Amgen Inc.  ( AMGN )  is a Trending Stock",
    "url": "https://www.zacks.com/stock/news/2381420/here-is-what-to-know-beyond-why-amgen-inc-amgn-is-a-trending-stock",
    "time_published": "20241210T140011",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default112.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.213009,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.484798",
        "ticker_sentiment_score": "0.107266",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen  ( AMGN )  Stock Sinks As Market Gains: Here's Why",
    "url": "https://www.zacks.com/stock/news/2382443/amgen-amgn-stock-sinks-as-market-gains-heres-why",
    "time_published": "20241211T225017",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) reachead $273.41 at the closing of the latest trading day, reflecting a -0.85% change compared to its last close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default317.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.972476"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.18863,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.653175",
        "ticker_sentiment_score": "0.308371",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "These Are the 5 Worst-Performing Stocks in the Dow Jones Industrial Average With 2024 Almost Over",
    "url": "https://www.fool.com/investing/2024/12/12/these-are-the-5-worst-performing-stocks-in-the-dow/",
    "time_published": "20241212T192318",
    "authors": [
      "Jeremy Bowman"
    ],
    "summary": "It's been a banner year for the stock market. However, not every stock has been a winner as some sectors performed better than others. Tech and utilities soared, while others like real estate and healthcare underperformed.So what are the five worst performers on the Dow Jones Industrial Average ( ...",
    "banner_image": "https://g.foolcdn.com/editorial/images/800728/economic-crisis-stock-chart-falling-down-business-global-money-bankruptcy.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": -0.108209,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NKE",
        "relevance_score": "0.308246",
        "ticker_sentiment_score": "-0.106374",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.208464",
        "ticker_sentiment_score": "-0.175279",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "FL",
        "relevance_score": "0.105141",
        "ticker_sentiment_score": "-0.051732",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.402941",
        "ticker_sentiment_score": "-0.228311",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.208464",
        "ticker_sentiment_score": "0.086678",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Unpacking the Latest Options Trading Trends in Amgen - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/insights/options/24/12/42469838/unpacking-the-latest-options-trading-trends-in-amgen",
    "time_published": "20241212T191632",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bullish stance on Amgen AMGN. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1734030989_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.139933,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.644033",
        "ticker_sentiment_score": "0.127281",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report - AstraZeneca  ( NASDAQ:AZN ) , Johnson & Johnson  ( NYSE:JNJ ) , Merck & Co  ( NYSE:MRK ) , Exelixis  ( NASDAQ:EXEL ) ",
    "url": "https://www.benzinga.com/general/biotech/24/12/42488323/drug-price-hikes-unsupported-by-evidence-cost-us-815-million-icer-report",
    "time_published": "20241213T171507",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "The Institute for Clinical and Economic Review ( ICER ) has identified five prescription drugs whose price increases in 2023 lacked sufficient clinical evidence to justify the hikes.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/13/Stethoscope-Laying-On-Medicine-White-Pil.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.135284,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "EXEL",
        "relevance_score": "0.188193",
        "ticker_sentiment_score": "-0.205218",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.188193",
        "ticker_sentiment_score": "-0.205218",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.188193",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.188193",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.188193",
        "ticker_sentiment_score": "-0.205218",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.188193",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Epidermal Growth Factors  ( EGFs )  Market to Reach US$ 3.7 Billion by 2034 | Expanding Applications in Regenerative Medicine and Cancer Therapy Drive Growth, Latest Report by TMR",
    "url": "https://www.benzinga.com/pressreleases/24/12/g42503394/epidermal-growth-factors-egfs-market-to-reach-us-3-7-billion-by-2034-expanding-applications-in-reg",
    "time_published": "20241216T103000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, Transparency Market Research Inc. , Dec. 16, 2024 ( GLOBE NEWSWIRE ) -- The global Epidermal Growth Factors ( EGFs ) market ( March\u00e9 des Facteurs de croissance \u00e9pidermiques ( EGF ) ) was valued at US$ 1.1 Bn in 2023 and is anticipated to expand at a CAGR of 11.3% from 2024 ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/27e1d943-6840-4b94-a03f-719fb05a4273/epidermal-growth-factors-egfs-market.jpg",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.180609,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.038717",
        "ticker_sentiment_score": "0.053774",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.115787",
        "ticker_sentiment_score": "0.049244",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAYZF",
        "relevance_score": "0.038717",
        "ticker_sentiment_score": "0.170484",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.115787",
        "ticker_sentiment_score": "0.175364",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.077343",
        "ticker_sentiment_score": "0.136257",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.038717",
        "ticker_sentiment_score": "-0.254204",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.038717",
        "ticker_sentiment_score": "0.170484",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.077343",
        "ticker_sentiment_score": "0.096741",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.115787",
        "ticker_sentiment_score": "0.058068",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GSK",
        "relevance_score": "0.038717",
        "ticker_sentiment_score": "0.170484",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSOI",
        "relevance_score": "0.038717",
        "ticker_sentiment_score": "0.09193",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:NANO",
        "relevance_score": "0.038717",
        "ticker_sentiment_score": "0.031583",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amgen  ( AMGN )  Stock Moves -0.21%: What You Should Know",
    "url": "https://www.zacks.com/stock/news/2384872/amgen-amgn-stock-moves--021-what-you-should-know",
    "time_published": "20241217T225014",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the most recent trading session, Amgen (AMGN) closed at $265.95, indicating a -0.21% shift from the previous trading day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default230.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.126416,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.526455",
        "ticker_sentiment_score": "0.170499",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Dow on a Record Losing Streak: Should You Buy its ETF?",
    "url": "https://www.zacks.com/stock/news/2385358/dow-on-a-record-losing-streak-should-you-buy-its-etf",
    "time_published": "20241218T152500",
    "authors": [
      "Sweta Killa"
    ],
    "summary": "The Dow Jones has been on its worst losing streak in nearly 50 years. Should you buy its ETF for 2025?",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/84/11877.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980716"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.060657,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.254973",
        "ticker_sentiment_score": "-0.173275",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.129168",
        "ticker_sentiment_score": "-0.108157",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.129168",
        "ticker_sentiment_score": "-0.108157",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.129168",
        "ticker_sentiment_score": "-0.108157",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Can Dow Jones ETF Reverse From the Worst Losing Streak in 50 Years?",
    "url": "https://www.zacks.com/stock/news/2385942/can-dow-jones-etf-reverse-from-the-worst-losing-streak-in-50-years",
    "time_published": "20241219T180000",
    "authors": [
      "Sanghamitra Saha"
    ],
    "summary": "The Dow Jones ETF has recorded the longest losing streak since 1978. Can it reverse the trend in 2025?",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f2/1072.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.858979"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.012075,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.122581",
        "ticker_sentiment_score": "0.091318",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.410697",
        "ticker_sentiment_score": "0.03925",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.122581",
        "ticker_sentiment_score": "0.091318",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.242285",
        "ticker_sentiment_score": "0.076017",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.182967",
        "ticker_sentiment_score": "0.065664",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.122581",
        "ticker_sentiment_score": "-0.030924",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.122581",
        "ticker_sentiment_score": "-0.030924",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.122581",
        "ticker_sentiment_score": "0.091318",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.182967",
        "ticker_sentiment_score": "-0.004616",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRVL",
        "relevance_score": "0.122581",
        "ticker_sentiment_score": "0.047882",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "What's Going On With Amgen Stock On Friday? - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/24/12/42627437/whats-going-on-with-amgen-stock-on-friday",
    "time_published": "20241220T194050",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Friday, Novo Nordisk A/S NVO released headline results from the REDEFINE 1 Phase 3 trial in the global REDEFINE program.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/20/weight-loss-shutter2.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.10517,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.323078",
        "ticker_sentiment_score": "0.137397",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.421485",
        "ticker_sentiment_score": "0.072541",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here's Why Amgen  ( AMGN )  Gained But Lagged the Market Today",
    "url": "https://www.zacks.com/stock/news/2387167/heres-why-amgen-amgn-gained-but-lagged-the-market-today",
    "time_published": "20241223T225018",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The latest trading day saw Amgen (AMGN) settling at $264, representing a +0.24% change from its previous close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default208.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.181308,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.549988",
        "ticker_sentiment_score": "0.269707",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Schwab US Dividend Equity ETF Reverses In December: What's Going On? - Schwab US Dividend Equity ETF  ( ARCA:SCHD ) ",
    "url": "https://www.benzinga.com/general/biotech/24/12/42660458/schwab-us-dividend-equity-etf-reverses-in-december-whats-going-on",
    "time_published": "20241223T205355",
    "authors": [
      "Erica Kollmann"
    ],
    "summary": "The Schwab US Dividend Equity ETF SCHD has given back more than half of its one-year gains in the last month, with the ETF falling more than 7% in December. Here's a look at what may be plaguing the fund.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/23/Stock-Exchange-Trading-Data-And-Financia.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.905476"
      }
    ],
    "overall_sentiment_score": 0.179455,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.312158",
        "ticker_sentiment_score": "0.048478",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.211191",
        "ticker_sentiment_score": "-0.167084",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.312158",
        "ticker_sentiment_score": "0.048478",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Spotlight on Amgen: Analyzing the Surge in Options Activity - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/insights/options/24/12/42657861/spotlight-on-amgen-analyzing-the-surge-in-options-activity",
    "time_published": "20241223T191534",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Deep-pocketed investors have adopted a bearish approach towards Amgen AMGN, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1734981331_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      }
    ],
    "overall_sentiment_score": 0.140487,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.729067",
        "ticker_sentiment_score": "0.177712",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "NVO Stock Plunges as Obesity Drug CagriSema Misses Target in Phase III",
    "url": "https://www.zacks.com/stock/news/2386953/nvo-stock-plunges-as-obesity-drug-cagrisema-misses-target-in-phase-iii",
    "time_published": "20241223T150000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Novo Nordisk stock slumps as the 22.7% weight loss achieved with its next-gen obesity candidate, CagriSema, in a phase III study misses its guidance of 25%.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.077059,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.281692",
        "ticker_sentiment_score": "0.161712",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.095707",
        "ticker_sentiment_score": "0.107487",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.411549",
        "ticker_sentiment_score": "0.075997",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Investors Heavily Search Amgen Inc.  ( AMGN ) : Here is What You Need to Know",
    "url": "https://www.zacks.com/stock/news/2386806/investors-heavily-search-amgen-inc-amgn-here-is-what-you-need-to-know",
    "time_published": "20241223T140011",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default103.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.222051,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.482982",
        "ticker_sentiment_score": "0.107012",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Twist Bioscience  ( TWST )  Surges 9.9%: Is This an Indication of Further Gains?",
    "url": "https://www.zacks.com/stock/news/2386759/twist-bioscience-twst-surges-99-is-this-an-indication-of-further-gains",
    "time_published": "20241223T134800",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Twist Bioscience (TWST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default136.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.214311,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.455525",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TWST",
        "relevance_score": "0.551295",
        "ticker_sentiment_score": "0.28816",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Lilly's Zepbound Receives FDA Approval for Sleep Apnea",
    "url": "https://www.zacks.com/stock/news/2386725/lillys-zepbound-receives-fda-approval-for-sleep-apnea",
    "time_published": "20241223T131600",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "FDA approves LLY's obesity drug Zepbound for its second indication, moderate-to-severe obstructive sleep apnea.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/cc/389.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.129827,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.498479",
        "ticker_sentiment_score": "0.230669",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.097259",
        "ticker_sentiment_score": "0.202358",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.286082",
        "ticker_sentiment_score": "0.097459",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.193078",
        "ticker_sentiment_score": "0.071825",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Excellent Dividend Stocks to Buy on the Dip",
    "url": "https://www.fool.com/investing/2024/12/23/2-excellent-dividend-stocks-to-buy-on-the-dip/",
    "time_published": "20241223T093200",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "AbbVie ( NYSE: ABBV ) and Amgen ( NASDAQ: AMGN ) have a lot in common. They are both leading drugmakers and have strong dividend track records. Both also recently saw their shares fall significantly in one day, following unimpressive clinical data for otherwise promising candidates.Despite their ...",
    "banner_image": "https://media.ycharts.com/charts/4bcb02efb3ae79099f939b6b71ea724e.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.26662,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.512596",
        "ticker_sentiment_score": "0.31906",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.055364",
        "ticker_sentiment_score": "0.085",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.373112",
        "ticker_sentiment_score": "0.395561",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.055364",
        "ticker_sentiment_score": "0.077088",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.055364",
        "ticker_sentiment_score": "0.21904",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Novo Nordisk Stock Plunges 18% in a Week: What Should Investors Do?",
    "url": "https://www.zacks.com/stock/news/2387354/novo-nordisk-stock-plunges-18-in-a-week-what-should-investors-do",
    "time_published": "20241224T134600",
    "authors": [
      "Ahan Chakraborty"
    ],
    "summary": "NVO stock declines after a recent obesity study setback and intense competition from market rivals but offers long-term growth potential.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.658903"
      }
    ],
    "overall_sentiment_score": 0.223501,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.16594",
        "ticker_sentiment_score": "0.029716",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.066784",
        "ticker_sentiment_score": "0.176553",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.066784",
        "ticker_sentiment_score": "0.176553",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.355125",
        "ticker_sentiment_score": "0.269359",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Should You Invest in the VanEck Biotech ETF  ( BBH ) ?",
    "url": "https://www.zacks.com/stock/news/2387268/should-you-invest-in-the-vaneck-biotech-etf-bbh",
    "time_published": "20241224T112006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default63.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.161328,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.071096",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.071096",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.071096",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Looking At Amgen's Recent Unusual Options Activity - Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/insights/options/24/12/42708086/looking-at-amgens-recent-unusual-options-activity",
    "time_published": "20241227T181538",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Deep-pocketed investors have adopted a bullish approach towards Amgen AMGN, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1735323335_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      }
    ],
    "overall_sentiment_score": 0.172543,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.654522",
        "ticker_sentiment_score": "0.274665",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Amgen  ( AMGN )  Suffers a Larger Drop Than the General Market: Key Insights",
    "url": "https://www.zacks.com/stock/news/2389724/amgen-amgn-suffers-a-larger-drop-than-the-general-market-key-insights",
    "time_published": "20241230T230019",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) closed at $259.30 in the latest trading session, marking a -1.28% move from the prior day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default333.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.14047,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.527969",
        "ticker_sentiment_score": "0.249029",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Amgen  ( AMGN )  Advances While Market Declines: Some Information for Investors",
    "url": "https://www.zacks.com/stock/news/2390241/amgen-amgn-advances-while-market-declines-some-information-for-investors",
    "time_published": "20241231T225018",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amgen (AMGN) closed at $260.64 in the latest trading session, marking a +0.52% move from the prior day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default115.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.119998,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.478198",
        "ticker_sentiment_score": "0.230341",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  }
]